PREVALENCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTC

A THESIS SUBMITTED TO

BABA FARID UNIVERSITY OF HEALTH SCIENCES, FARIDKOT (PUNJAB)

IN THE PARTIAL FULFILLMENT

FOR THE AWARD OF DEGREE OF

DM

IN

CARDIOLOGY

2024

Submitted By

DR KESHAV SACHDEVA

DEPARTMENT OF CARDIOLOGY

DAYANAND MEDICAL COLLEGE AND HOSPITAL

LUDHIANA, PUNJAB

DECLARATION BY THE CANDIDATE

I hereby declare that the dissertation entitled "**PREVALENCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTC"** submitted towards partial fulfillment of the requirements for the award of **DM in Cardiology** degree to BFUHS is a compilation of original work carried out by me under the supervision of **Dr. Naved Aslam,** Professor, Department of Cardiology, **Dr. Abhishek Goyal,** Professor, Department of Cardiology and **Dr. Parshotam Lal Gautam,** Professor & Head, Department of Critical Care Medicine. No part of this thesis has formed the basis for the award of any degree previously.

_____

Dr. Keshav Sachdeva
Department of Cardiology,
Dayanand Medical College & Hospital,
Ludhiana, Punjab

Date:

Place:

CERTIFICATE OF SUPERVISORS

This is to certify that the work incorporated in this dissertation entitled **"PREVALENCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTC"** has been carried out by **Dr. Keshav Sachdeva** under our direct supervision. The data incorporated in this thesis is original and genuine and has been carried out by the candidate himself.

Signature of Supervisor

Dr. Naved Aslam
Professor
Department of Cardiology
DMC&H, Ludhiana

Signature of Co-Supervisors

Dr. Abhishek Goyal
Professor
Department of Cardiology
DMC&H, Ludhiana

Dr. Parshotam Lal Gautam
Professor & Head
Department of Critical care Medicine
DMC&H, Ludhiana

Date:

ENDORSEMENT BY THE HEAD OF THE INSTITUTE

This is to certify that the dissertation entitled **"PREVALENCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTC"** is a bonafide research work done by **Dr. Keshav Sachdeva** under the supervision of **Dr. Naved Aslam,** Professor, Department of Cardiology, **Dr. Abhishek Goyal,** Professor, Department of Cardiology and **Dr. Parshotam Lal Gautam,** Professor & Head, Department of Critical Care Medicine.

Principal

Dr. G S Wander
Principal
DMC&H, Ludhiana

Date:

COPYRIGHT

Declaration by the Candidate

I hereby declare that the Baba Farid University of Heath Sciences, Faridkot, shall have the rights to preserve & use this dissertation in print or electronic format for academic/study purpose by the research scholar/students.

Signature

Dr. KESHAV SACHDEVA
Department of Cardiology,
Dayanand Medical College & Hospital,
Ludhiana, Punjab - 141001

Date:

© Baba Farid University of Health Sciences, Faridkot

Dedicated

to my

family,

friends

& teachers

ACKNOWLEDGEMENT

My efforts in drafting this thesis would be incomplete if I do not extend my heartfelt gratitude to the people, who helped me for the last 2 years to shape this work into a successful one. First and foremost I extend my profound gratitude to my guide Dr. Naved Aslam, department of Cardiology, Hero DMC Heart Institute. His sagacious guidance, unwavering encouragement, and meticulous feedbacks have been instrumental in shaping this research

I am deeply indebted to my Co-Guide Dr. Abhishek Goyal and Dr. P.L. Gautam. Their erudite suggestions, thoughtful critiques, and generous contribution of time have substantially enhanced the quality of this thesis.

I would like to take the opportunity of this platform to thank the faculty of my department Dr. G.S. Wander, Dr. Bishav Mohan, Dr. Shibba Takkar Chhabra, Dr. Gautam Singal, Dr. Akash Batta, and Dr. Anshuman Gupta for sharing their expertise and creating a stimulating research environment.

A sincere thanks to the team of research and development, sister in-charges of the ICUs and the whole staff including nursing staff, ward boys, helpers for their constant help and support.

I am thankful for the unwavering support and camaraderie of my colleagues and peers, Dr. Raagini Gupta, Dr. Bhojraj Sharma, Dr. Sahil Bansal, Dr. Mohit Tayal, Dr. Abhishek Garg, Dr. Anil Yadav, Dr. Ankit Gulia, Dr. Sahil Sheokand, Dr. Tasleem Arif, Dr.Rishav Tohani, Dr. Himanshu Garg, Dr. Shubham Garg, Dr. Avneesh Garg, and Dr. Bharat Bhushan who helped me collect the vast data and help it organise well to make it easier for me to prepare my results.

I remain highly indebted to all my patients for their unfailing and constant cooperation. Their cooperation was one of the most essential requirements for this work.

My cherished companion, Dr. Ananta Kanwar, has been an unyielding pillar of strength, offering selfless encouragement, unwavering

patience, and unconditional love. Her presence has been a constant source of inspiration. My adorable son Prithvi, along with his cousins Viraj and Rishi have been a major stress buster and energy refill whenever I was exhausted and tense.

I would like to express love and my deepest gratitude to my family members, Jagwanti Sachdeva, Dr. Vijay Sachdeva, Ritu Sachdeva, Kartik Sachdeva, Pallavi Arora, Dr. Jagdishwar Kanwar, Dr. Kiran Kanwar, and Dr. Ajeyta Kanwar for their unwavering support, understanding, and sacrifices made during my research tenure.

It won’t be justified if I don’t thank the Eternal Deity for guiding me with a baton of light in the journey of life.

Dr Keshav Sachdeva

ABBREVIATIONS

ABPA – Allergic bronchopulmonary aspergillosis

AGE – Acute gastroenteritis

AHA – American Heart Association

AKI – Acute kidney injury

ALB – Albumin

ALF – Acute liver failure

ATT – Anti tubercular therapy

BIL – Bilirubin

CAD – Coronary artery disease

CHF – Congestive heart failure

CKD – Chronic kidney disease

CLD – Chronic liver disease

COPD – Chronic obstructive pulmonary disease

CVA – Cerebrovascular accident

DBP – Diastolic blood pressure

DCMP – Dilated cardiomyopathy

DM – Diabetes mellitus

DVT – Deep venous thrombosis

ECG – Electrocardiogram

ESRD – End stage renal disease

FDA – Food and drug administration

Hb – Hemoglobin

HCMP – Hypertrophic cardiomyopathy

hERG – Human ether-a-go-go-related gene

HIV – Human immunodeficiency virus

ICMP – Ischemic cardiomyopathy

ICSOL – Intracranial space occupying lesion

ICU – Intensive care unit

IQR – Interquartile range

LQTS – Long QT syndrome

LVEF – Left ventricular ejection fraction

LVH – Left ventricular hypertrophy

NSTEMI – Non ST elevation myocardial infarction

OSA – Obstructive sleep apnea

PAD – Peripheral arterial disease

PPCP – Peripartum cardiomyopathy

PR – Pulse rate

PTE – Pulmonary thromboembolism

RRT – Renal replacement therapy

SBP – Systolic blood pressure

SCD – Sudden cardiac death

SGOT – Serum Glutamic-Oxaloacetic Transaminase

SGPT – Serum Glutamic Pyruvic Transaminase

STEMI – ST elevation myocardial infarction

TdP – Torsades de pointes

TLC – Total leucocyte count

TSP – Total serum protein

UTI – Urinary tract infection

VT – Ventricular tachycardia

ABSTRACT

BACKGROUND: Prevalence of acquired LQTS is much more in critically ill patients having various QTc prolonging medical conditions, electrolyte abnormalities, and medications, as compared to general population. But little is known about its prognostic significance.

AIM: To define prevalence, clinical profile and in hospital outcomes of patients with prolonged QTc.

METHODS AND RESULTS: Single-center, prospective, observational study of six months duration carried out on 245 consecutive adult ICU patients. Prolonged QTc was defined as a QTc of ≥450 ms in men and ≥460 ms in women. Markedly prolonged QTc was defined as ≥500 ms. Clinical details were noted. Common co-morbidities at presentation were hypertension (N,%) (138, 56.3%), DM2 (117, 47.8%), CAD (98, 40%), AKI (88, 35.9 %), shock (88, 35.9%), ACS (80, 32.6%), surgical illness (60, 24.5%), heart failure (58, 23.7%), sepsis (62, 25.3%), LRTI (44, 18%), CKD (32, 13.1%), COPD (23, 9.4%), hypothyroidism (21, 8.6%), CVA (18, 7.3%), CLD (14, 5.7%), malignancy (6, 2.4%). Mean QTc of the study population was 479.7 ms (SD=56.9). Out of 245 patients, 173 were found to have prolonged QTc interval on the first day (mean = 502.5 ms, SD = 51.1, with prevalence of 70.6% [M=45.3%, F=25.3%]. Markedly prolonged QTc was seen in 67 (27.3%) patients. For the identification of risk factors for LQTS, patient variables were compared between LQTS and normal QTc patients by univariate and multivariate analysis. Of various medical conditions, we found statistically significant higher number of patients of heart failure [50/58 (86.2%) vs 8/58 (13.8%), p = 0.003], shock [71/88 (80.7%) vs 17/88 (19.3%), p = 0.013], LV dysfunction [mean LVEF 38.7%, SD 17.07 vs mean LVEF 45.7%, SD 14.74 (p = 0.002)] with prolonged QTc interval. Biochemical abnormalities associated with significantly higher percentage of patients with prolonged QTc interval were raised SGOT [106/136 (77.9%) vs 30/136 (22.1%), p = 0.007], raised SGPT [80/101 (79.2%) vs 21/101 (20.8%), p = 0.015], hypokalemia [34/40 (85%) vs 6/40 (15%), p = 0.029], hypocalcemia [59/73 (80.8%) vs 14/73 (19.2%), p = 0.022), hyponatremia [68/85 (80%) vs 17/85 (20%), p = 0.008], and hypoalbuminemia [86/110 (78.2%) vs 24/110 (21.8%), p = 0.008]. Drugs like amiodarone [40/47 (85.1%) vs 7/47 (14.9%), p = 0.015], levosalbutamol [79/99 (45.66%) vs 20/99 (27.78%), p = 0.001], furosemide [96/122 (78.7%) vs 26/122 (21.3%), p = 0.006], spironolactone [83/100 (83%) vs 17/100 (17%)] and haloperidol [32/35 (91.4%) vs 3/35 (8.6%), p = 0.002] were significantly associated with LQTS. The median duration of ICU stay was significantly more in the patients with prolonged QTc [median of 6.5 days (IQR 4-10) vs 5 days (IQR 2.25-7), p = 0.001], however there was no significant difference in ICU mortality between two groups [27/37 (73%) vs 10/37 (27%), (p = 0.732)]. The frequency of ventricular tachycardia was significantly higher in patients with prolonged QTc interval [16/17 (94%) vs 1/17 (6%), p = 0.004].

CONCLUSION: The LQTS is highly prevalent in critically ill patients. These patients have a higher chance of adverse outcomes in the form of increased duration of ICU stay and frequency of ventricular tachycardia however we did not find any significant difference in the ICU mortality between the two groups.

KEYWORDS: QT interval, Arrhythmia, Torsades de pointes, ICU Mortality, LQTS.

TABLE OF CONTENTS

S. NO.	TOPIC	PAGES
I	INTRODUCTION	1-2
II	AIMS AND OBJECTIVES	3
III	REVIEW OF LITERATURE	4-9
IV	MATERIALS AND METHODS	10-12
V	OBSERVATIONS AND RESULTS	13-63
VI	DISCUSSION	64-70
VIII	SUMMARY AND CONCLUSIONS	71-72
IX	BIBLIOGRAPHY	73-78
	APPENDICES – I	
	- PROFORMA	
	- MASTER CHART	
	APPENDICES – II	
	- APPROVAL LETTER OF THESIS PLAN	
	- THESIS PLAN	

LIST OF TABLES

Table no.	Title	Pages
1.	Sex distribution	13
2.	Age distribution	14
3.	Vitals on ICU admission	15
4.	Medical conditions on admission to ICU	16
5.	Endocrine co-morbidities	17
6.	Neurologic co-morbidities	18
7.	Pulmonary co-morbidities	19
8.	Cardiac co-morbidities	20
9.	GI co-morbidities	22
10.	Nephrologic co-morbidities	23
11.	Identifiable infections	24
12.	Surgical illness	25
13.	Psychiatric illness	26
14.	Laboratory parameters on ICU admission	27
15.	Laboratory abnormality	28
16.	QTc prolonging drugs and the corresponding number of patients taking them.	29
17.	Outcomes of study cohort	30

18.	Prevalence of prolonged QTc on the day of ICU admission	31
19.	mean QTc in both groups at ICU admission	32
20.	Distribution of prolonged QTc according to age and sex	33
21.	Mean age of patients in normal vs prolonged QTc group	34
22.	Prevalence of markedly prolonged QTc on the day of ICU admission	35
23.	Comparison of vital parameters of the two groups at ICU admission	37
24.	Comparison of frequency of various medical conditions according to QTc interval at admission	39
25.	Comparison of mean LVEF between two groups at ICU admission	44
26.	Comparison of hematological parameters at ICU admission	45
27.	Comparison of biochemical parameters at ICU admission	46
28.	Comparison of various drugs between the two groups	48
29.	Comparison of frequency of various ECG patterns at ICU admission	53
30.	Multivariate analyses	54
31.	Prognostic significance of prolonged QTc	56
32.	Difference in ICU mortality and VT episodes in the two groups during ICU stay	58
33.	Mortality and APACHE II score	59
34.	Comparison of APACHE II score at ICU admission	60
35.	Subgroup analysis of patients with QTc > 500 ms	62

LIST OF FIGURES

Figure no.	Title	Pages
1.	Sex distribution of study population	13
2.	Age distribution of study population.	14
3.	Vitals on ICU admission	15
4.	Medical conditions on admission to ICU	16
5.	Endocrine co-morbidities on admission to ICU	17
6.	Neurologic co-morbidities	18
7.	Pulmonary co-morbidities	19
8.	Cardiac co-morbidities	21
9.	GI co-morbidities	22
10.	Nephrologic co-morbidities	23
11.	Identifiable infections	24
12.	Surgical illness	25
13.	Psychiatric illness	26
14.	Laboratory parameters on ICU admission	27
15.	Laboratory abnormality	28
16.	QTc prolonging drugs and the corresponding percentage of patients taking them.	29

17.	Prevalence of prolonged QTc on the day of ICU admission	31
18.	Distribution of prolonged QTc according to age and sex	33
19.	Mean age of patients in normal vs prolonged QTc group	34
20.	Prevalence of markedly prolonged QTc on the day of ICU admission	35
21.	Comparison of vital parameters of the two groups at ICU admission	38
22.	Comparison of mean LVEF between two groups at ICU admission	44
23.	Prognostic significance of prolonged QTc	57
24	Difference in ICU mortality and VT episodes in the two groups during ICU stay	58
25.	Mortality and APACHE II score	59
26.	Comparison of APACHE II score at ICU admission	60

BABA FARID UNIVERSITY OF HEALTH SCIENCES
Sadiq Road, Faridkot-151203 (Pb.) INDIA
Phone No. 91-1639-256253 and Fax No. 91-1639-256234
Website: www.bfuhs.ac.in, Email: bfuhspc@gmail.com
(BFUHS – UNIVERSITY LIBRARY- Coordinator APC)

11-BFUHS (LI-PC-134)24/1370 Dated: October 28, 2024

Plagiarism Verification Certificate

Title of the thesis: **Prevalence, Clinical Profile, And In-Hospital Outcomes In Icu Patients With Prolonged QTc.**

Total Page: **73 (Seventy Three only) eFSPC** **(eFile Sent for Plagiarism Check)**

Researcher: **Keshav Sachdeva**

Supervisor: **Dr. Naved Aslam**

Research Centre: **Dayanand Medical College & Hospital, Ludhiana**

This is to report that the above thesis was scanned for similarity detection. Process and outcome is given below:

DID:	**2447314**	Software used:	**DRILLBIT**
Date:	**October 28, 2024**	Similarity Index:	**5% (Below 10 Percent)**

Total words count: **11194 (eFSPC)**

The complete report is submitted for review by the Supervisor and Co-Supervisor.

University Coordinator/
Name & Signature (Checked by)
(From University library)

The complete report of the above thesis has been reviewed by the undersigned. (Check Box)

☐ The similarity index is below accepted norms.

☐ The similarity index is above accepted norms, because of the following reasons:

1.....
2.....
3…….....
4…….....
5……

The thesis may be considered for the award of degree. (Relevant documents attached).

Research Scholar **Co-Supervisor** **Supervisor**

INTRODUCTION

QTc interval on an electrocardiogram (ECG) measures the time from the start of the Q wave to the end of the T wave. It is the measurement of the duration of cardiac depolarization and repolarization and provides crucial insights into the heart's electrical activity. QTc interval can be prolonged due to genetic as well as acquired conditions [1,2,3,4,5].

QTc interval is affected by many structural and functional factors which affect myocardial repolarization There are many known factors which can prolong the QTc interval like demographics, various comorbidities and biochemical abnormalities [1,2,3].

Acquired causes encompass electrolyte imbalances, sinus node dysfunction, high-grade atrioventricular block, myocardial ischemia and injury, and medication use, among others. Notably, the use of certain drugs is a significant cause of acquired QTc prolongation. Many commonly prescribed cardiac and non-cardiac medications can lead to QTc prolongation. This condition is linked to a significantly heightened risk of a potentially fatal cardiac arrhythmia, torsades de pointes (TdP), and also increases overall in hospital mortality[1,2,3,4,5].

In order to identify the factors linked to a prolonged QTc interval, previous research was primarily conducted on patients with specific medical disorders [6,7,8,9,10,11,12]. However, little is known regarding the occurrence of QTc interval prolongation and the factors that influence it in patients with a variety of comorbidities who are admitted to the intensive care unit. And the various available studies in ICU patients have shown very variable values of prevalences of LQTS of 24% [13], 46.6% [14], 27.9% [15], 39% [16], 61% [17] and 52% [18]. The prevalence of QTc prolongation is likely to be higher in ICU patients because usually these patients are acutely ill and often have more than one risk factors, receive multiple QTc prolonging drugs, and have multiple medical conditions.

QTc prolongation holds prognostic significance and is often an overlooked parameter in ECG readings. Hence, our study was planned

to find out the prevalence, and prognostic significance of QTc prolongation in patients admitted to the ICU of a tertiary care hospital.

Apart from this, factors causing QTc prolongation were also studied as we can prevent life-threatening arrhythmias by correcting or avoiding these factors.

Since there is a dearth of information in this area in the Indian population, we conducted this study to determine the frequency and prognostic importance of QTc prolongation in intensive care unit patients.

AIMS AND OBJECTIVES

1. To describe the clinical profile of patients with prolonged QTc in ICU settings.
2. To investigate the prevalence of LQTS in ICU patients.
3. To investigate the risk factors of LQTS in ICU patients.
4. To find out prognostic significance of prolonged QTc in terms of in-ICU mortality, duration of ICU stay, and number of VT episodes.
5. To observe and assess predictors of the clinical outcomes during ICU stay of patients with prolonged QTc.

REVIEW OF LITERATURE

Prolonged or long QT syndrome (LQTS) can be due to genetic as well as an acquired condition. Among them, common causes of acquired LQTS include certain medications, electrolyte imbalances such as hypokalemia, hypocalcemia, or hypomagnesemia, and a number of medical disorders that can trigger torsade de pointes and sudden cardiac death. In addition, some patients with acquired LQTS have an underlying "forme fruste" of congenital LQTS. LQTS is linked to a higher risk of torsades de pointes (tdp), a distinctive and potentially fatal cardiac arrhythmia [1,2,19].

Roden DM examined patients with chromosome 7 related acquired LQTS, and discovered large repolarization abnormalities. This repolarization abnormality was greatly reduced after receiving potassium [2]. Acquired QTc prolongation is much more common. Selzer and Wray first described quinidine-induced QTc prolongation that resulted in ventricular fibrillation in 1964 [20]. Two years later, Dessertenne defined torsades de pointes as a polymorphic ventricular tachycardia that resembles QRS complexes twisting sinusoidally around an isoelectric line. They stated that in an old woman with syncope and complete atrioventricular block [21]. Usually self-limiting, this polymorphic VT has the potential to degenerate into ventricular fibrillation.

It is very difficult to ascertain the incidence of LQTS. Due to their propensity to produce QTc prolongation, which can result in torsades de pointes and unexpected sudden cardiac deaths, several non-cardiovascular medications have been taken off the market. Nonetheless, noncardiac drugs often have a lower risk of torsades de pointes than antiarrhythmic drugs. Since we cannot forecast an individual's risk or the number of drug-induced episodes, LQTS is a significant concern for physicians.

Ventricular depolarization and repolarization are represented by the QT interval on the surface electrocardiogram. We average it over three to five beats in a single lead, starting from the start of the QRS complex

and ending with the T wave. Usually, precordial leads have the longest QT intervalHeart rate affects the QT interval. The RR interval that comes before the QT interval needs to be measured for rate adjustment. The QT interval can be corrected for heart rate using several formulas. The most commonly formulas are the Bazett's square root formula (QTc = QT/$\sqrt[2]{RR}$) and the Fridericia's cube root formula (QTc = QT/$\sqrt[3]{RR}$). Despite the lack of agreement over the optimal formula for QTc correction, Bazett's formula is regarded as the gold standard, despite the possibility that it overestimates the QTc interval [22,23,24]. Based on recommendations from the American Heart Association and the American College of Cardiology Foundation and other professional organizations, prolonged QTc is defined as a QTc of ≥ 450 ms in men and ≥460 ms in women [25]. Due to the proportional shortening of the QTc interval in men during adolescence, this value is smaller in them. Several other factors like ECG acquisition technique, autonomic nervous system activity activity, electrolyte imbalance, diurnal variation, as well as inter and intra-observer variability may affect the QT interval.

Each person has a unique relationship between the QT interval and heart rate. It is crucial to keep in mind that the rate correction equations could not be precise enough, particularly when evaluating the slight variations in the QTc interval brought on by medications.

Patients with LQTS usually present with symptoms like palpitations, syncope, seizures, and sudden cardiac death (SCD) [26,27]. In an individual with LQTS, usually multiple clinical risk factors are present. LQTS brought on by drugs can happen to anyone at any time. Additionally, it is frequently noted that in addition to drug exposure, the majority of patients have at least one known risk factor [28,29,30,31]. TdP is two to three times more common in women than in men, according to numerous research that have consistently demonstrated this [32,33].

Multiple studies including the study at University of British Columbia, Vancouver demonstrated significantly increased risk of cardiac

arrhythmia with QT prolonging drugs with age > 65 years [32]. Hypokalemia is also a common risk factor in drug-induced LQTS [4,34].

Number of studies in past to had tried to find out prevalence and risk factors associated with a prolonged QTc interval in selected patient populations, such as patients with myocardial infarction, pneumonia, subarachnoid hemorrhage, and alcoholic liver disease, etc [6,7,8,9]. Left ventricular hypertrophy and congestive heart failure are additional high-risk conditions that can increase the likelihood of drug-induced TdP [11,35]. Study at Winston Salem found 16.4% prevalence of QTc prolongation in patients of LVH and mortality risk was higher in patients with concomitant LVH & QTc prolongation [35]. A study of 91 congestive heart failure patients in Nigeria showed that the mean QTc was noticeably longer in the deceased than in the surviving (ODD ratio - 3) [11]. Oregeon Sudden unexplained death study showed that mean QTC was significantly greater in patients of sudden cardiac death with CAD. Diabetes and QT prolonging drugs were major predictors in this study [6]. In patients with liver cirrhosis QTc interval was significantly prolonged in patients with higher Child class and alcoholics than other etiologies and alcoholics were found to have greater hepatic venous pressure gradient [8]. Even non-alcoholic fatty liver disease was associated with higher QTc prolongation compared to general population [36]. There are studies suggestive of greater prevalence of QTc prolongation in symptomatic HIV infection compared to asymptomatic HIV patients and general population [37]. Study in elderly patients with pneumonia showed greater prevalence of QTc prolongation and mortality in these patients, with diabetes and hypoalbuminemia as additional factors to have significantly association with QTc prolongation [38]. Chronic renal failure was also found to be significantly associated with prolonged QTc and it was significantly associated with mortality in ESRD patients [10].

More than 50 Food and Drug Administration (FDA) approved medications can affect the QT interval. The most potent QT-prolonging cardiac medications are antiarrhythmic agents, particularly amiodarone, quinidine, dofetilide, and sotalol, with quinidine having the

most torsadogenic potential. Noncardiac QT prolonging medications include antibiotics (macrolides and quinolones), antipsychotics (haloperidol and phenothiazines), antidepressants (tricyclics and selective serotonin reuptake inhibitors) and antiemetics such as ondansetron. An online reference for QT prolonging medications is maintained by The Arizona Center for Research and Education on Therapeutics [4,39,40,41]. Many studies show that QT prolonging drugs are commonly prescribed in medical patients and can lead to TdP and sudden cardiac death in patients with other risk factors of QT prolongation [39,40,41].

LQTS in patients admitted in high dependency medical units have not been studied much and even lesser in surgical patients. This ECG abnormality is likely to be higher in patients admitted in high dependency medical units because acutely ill patients often have one or more of risk factors, are typically elderly with multiple comorbidities, and receive multiple drug treatments [28,29,30,31,42,43]. In a retrospective analysis done on 1558 adult patients in the emergency department, the prevalence of Bazzet corrected LQTS was 35% and 8% patients had QTc interval of > 500 ms. Prolonged QTc was defined as > 450 ms for men and > 460 ms for women. A significant number of patients with structural heart disease (39%) were included in this study [28]. In another study of 537 patients in the internal medicine ward, 22.3% had a prolonged QTc based on the Bazett formula. Patients' adjusted odds for QTc prolongation were noticeably greater in the presence of liver disease, hypokalemia and those who were taking ≥1 QT-prolonging drug at admission [29]. 33.5% of patients were taking at least one QT prolonging drug at the time of admission and the prescription of such a drug independently doubled the risk of QTc prolongation. Moreover, half of the patients who had LQTS at admission, received at least one additional QT prolonging drug during the stay or were discharged with such a drug [29]. In a prospective observational study of 1039 patients in an adult intensive care unit of a university medical center, QT prolongation was seen in 24% of patients, with Torsade de Pointes leading to 6% of in-hospital cardiac arrests. Factors associated with

LQTS were female sex, hypokalemia, hypocalcemia, QT-prolonging drugs, hyperglycemia, history of stroke, high creatinine, and hypothyroidism [30]. James E. Tisdale et al. recruited total 1159 consecutive patients admitted to two cardiac units. They excluded patients with age <18 years, ECG rhythm of complete ventricular pacing, and patient with duration of stay <24 hours. This study found prevalence of QTc interval prolongation was 27.9% on admission; 18.2% had severe QTc prolongation (>500ms). Among patients with prolonged QTc, 34.7% were administered QTc interval-prolonging drugs [31]. In study by Golzari H et al the prevalence of prolonged QTc of ≥ 450 ms was 25.2%, and the prevalence of markedly prolonged QTc of ≥ 500 ms was 3.5%. They found no significant associations between QTc intervals and admission values for any of the electrolytes [44]. Hock Heck Tan et. all conducted a systematic literature review regarding cardiovascular effects of five common antipsychotic medications, aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone. Fifty-five percent of the patients with single ingestion developed tachycardia. The only patient developed significantly prolonged QTc interval. Use of antipsychotic drugs was associated with a 1.53-fold increased risk of ventricular arrythmia and/or sudden cardiac death (SCD). Antipsychotic drugs with potential risk included clothiapine, prochlorperazine, haloperidol, quetiapine, thioridazine, olanzapine, sulpiride and risperidone. Antipsychotic drugs with hERG potassium channel blocking properties had the highest risk of ventricular arrythmia/SCD [45]. Bradley D. Freeman, collected data from 212,016 individuals over a 63-month period and found that 2.9% were receiving QTc prolonging drugs. The most frequently prescribed agents were Amiodarone (23.5%), Haloperidol (19.8%), and Levofloxacin (19.7%). Coadministration of QTc-prolonging drugs occurred in 18.6% of patients and there was higher ICU mortality rate and longer ICU stay compared to patients not receiving co-administered drugs. Acutely ill patients with prolonged QTc had longer hospital stay and nearly three times mortality than those without QT prolongation [42].

Early detection and treatment of a prolonged QTc interval can lower the risk of sudden cardiac death. Early recognition allows initiation of appropriate treatment and monitoring and prevents the unknowing prescription of QT prolonging medications when alternative medications are available. Potassium supplementation was found to be beneficial in patients of hypokalemia with prolonged QTc [46]. Study at Purdue and Indiana universities at Indianapolis incorporated electronic medical records of patients and computer alert on screen of pharmacist (CDSS) when a QTc prolonging drug was prescribed to moderate & high-risk patients. These patients were then prescribed alternate medications [47]. A Scientific Statement from the American Heart Association (AHA) recommends continuous monitoring of QTc interval if certain conditions are present. These include patients who are on a QTc-prolonging drug, patients with rhythm disturbances causing severe bradycardia or long pauses, and patients with hypomagnesemia or hypokalemia [48]. In a study of ICU patients, approximately 69% of critically ill patients had at least one of the three AHA criteria for QT-interval monitoring [13].

However, there is scarce literature about the prevalence and determinants of QTc interval prolongation in patients admitted to the ICU and the relation of QTc with multiple factors simultaneously have been very less studied. Therefore this study was planned.

MATERIALS AND METHODS

SOURCE OF DATA

The study population will consist of consecutive patients meeting the inclusion criteria from medical, surgical and cardiac ICUs .

INCLUSION CRITERIA

1. All ICU patients above 18 years of age admitted in medical, surgical and cardiac ICUs during a period of six months.

EXCLUSION CRTERIA

1. Patients with tachyarrhythmias like permanent atrial fibrillation, QRS complex wide than >120 ms, or baseline ECG with unidentifiable T waves.

STUDY DESIGN

Single-center, prospective, observational study carried out on patients with different illnesses recruited from medical, surgical and cardiac ICUs in Dayanand Medical College and Hospital, and Hero DMC Heart Institute, a tertiary care hospital in Ludhiana, Punjab.

METHODOLOGY

After admission to the ICU each patient was evaluated and following parameters were recorded in a predesigned proforma:

- Demographic data, clinical history & physical examination findings,
- Past history of a prolonged QTc interval, VT, TdP, or cardiac arrest, CAD, left ventricular systolic dysfunction.
- Any other underlying and/or concomitant diseases,
- Main diagnostic categories leading to emergency medical services admission,
- APACHE-II score
- Left ventricular ejection fraction
- 12 lead ECG,
- Arterial blood gas,
- Hemogram (Hb, TLC, and platelet count),

- Random blood sugar, serum electrolytes (Potassium, Sodium, Calcium, Magnesium, Phosphorus)
- Renal function test (blood urea / creatinine),
- Liver function test (SGOT, SGPT, total protein, albumin, total and indirect bilirubin),
- The medications that were provided at the time of admission or while the patient was in the hospital and had the potential to lengthen the QTc interval were noted. The list of medications known to cause or contribute to QTc interval prolongation was taken from the Arizona Center for Education and Research on Therapeutics, Tucson, Arizona (www.qtdrugs.org).
- Any occurrence of VT, TdP.
- Total duration of ICU stay and whether the patient survived or not.

Hyponatremia was defined as serum sodium < 135 mEq/l, hypernatremia as serum sodium > 145 mEq/l, hypomagnesemia as magnesium level < 1.7 mg/dl, hypermagnesemia as serum magnesium > 2.8 mg/dl, hypokalemia as a serum potassium level of <3.5 mEq/l, hyperkalemia as serum potassium >5 mEq/l, hypophosphatemia as serum phosphate < 2.7 mg/dl, hyperphosphatemia as serum phosphate > 4.5 mg/dl, hypocalcemia as calcium level< 8.6mg/dl, hypercalcemia as serum calcium > 10.2 mg/dl, hypoalbuminemia as serum albumin < 3.5 g/dl and raised serum creatinine as a creatinine level of > 1.2 mg/dl.

Sinus tachycardia was defined as heart rate > 100/minute, bradycardia as heart rate < 60/minute. LVH was defined according to Sokolow-Lyon criteria.

Measurement of the QTc Interval:

Within 24 hours of being admitted to the intensive care unit, the investigator manually assessed the RR and QT intervals from the 12-lead ECG. Since Lead II or V5 provide the most accurate approximation of the longest QT interval, they were utilized for QTc measurement. Bazett's formula (QTc = $QT/\sqrt[2]{RR}$) was applied for correction of QT intervals for heart rate. Even though there are many

formulas for QT interval correction, we specifically have chosen this formula as this is the most widely used formula. The U wave was not included if it was distinct from and smaller than 50 percent of the T wave. According to guidelines from the American Heart Association and the American College of Cardiology Foundation, a QTc of ≥ 450 ms for males and > 460 ms for women was considered prolonged. In both sexes, a QTc interval of more than 500 ms was deemed noticeably prolonged since it has been linked to a dramatically increased risk of TdP. At the end of the study, prevalence, clinical profile and in ICU outcomes of patients with prolonged QTc were studied.

STATISTICAL ANALYSIS

Data was maintained on Microsoft excel sheet and descriptive statistics were used. The measurable data was subjected to one sample Kolmogrov-smirnov test for normality of the data. The measure of central tendency and dispersion of data was calculated by using mean and standard deviation or median and interquartile range (IQR) depending upon the normality of data. Normally distributed data was presented by means and standard deviation and skewed data was presented by median and IQR. Qualitative variables were presented in the form of numbers and percentages. Prevalence of prolonged QTc among ICU patients was calculated. For comparison of various characteristics among patients with and without prolonged QTc interval, student-t test was used for continuous variables with normal distribution and Mann-Whitney U-test was used for non-normally distributed variables. Chi-square test (or Fisher's exact test) was used to compare categorical variables. Multivariate binary logistic regression analysis was used for the covariates that obtained a p value of < 0.05 in univariate analysis. A probability value (p value) less than 0.05 was considered statistically significant.

OBSERVATIONS AND RESULTS

This prospective observational study included 245 patients of various illnesses admitted in medical, surgical, and cardiac ICUs of a tertiary care hospital during study duration of six months from June 2023 to November 2023. There were 159 (64.9%) males and 86 (35.1%) females in study cohort. Mean age of study cohort was 62.93 ± 14.40 years with minimum age of 19 years and maximum age of 99 years. Detailed distribution of age groups and gender in study cohort has been depicted in tables – 1,2 and figures – 1,2 .

Table – 1 Sex distribution

SEX	No. of cases	Percentage
F	86	35.1%
M	159	64.9%
Total	245	100.0%

Figure – 1 Sex distribution of study population



Table – 2 Age distribution		
AGE GROUP	No. of cases	Percentage
< 30	8	3.3%
31-50	36	14.7%
51-70	123	50.2%
> 70	78	31.8%
Total	245	100.0%

Figure – 2 Age distribution of study population.



VITALS ON ICU ADMISSION

Vitals of patients at the time of ICU admission, like systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate (PR), temperature, and APACHE-II score are given in table – 3 and figure – 3.

Table – 3 Vitals on ICU admission

	Mean	Std. Deviation
SBP	120.70	27.00
DBP	70.77	13.34
PR	99.69	28.40
TEMPERATURE	98.64	1.31
APACHE II SCORE	16.13	7.52

Figure – 3 Vitals on ICU admission



MEDICAL CONDITIONS AT ICU ADMISSION

Various co-morbidities on admission to the ICU were hypertension in 138 (56.3%), endocrine in 127 (51.8%), neurologic in 34 (13.9%), pulmonary in 75 (30.6%), cardiac in 196 (80%), gastrointestinal (GI) in 47 (19.2%), nephrologic in 132 (53.9%), sepsis in 62 (25.3%), infections in 32 (13.1%), malignancy in 6 (2.4%), surgical illness in 60 (24.5%), shock in 88 (35.9%) and psychiatric illness in 39 (15.9%) patients. Further details of distribution of medical conditions among study subjects is provided in table – 4 and figure – 4.

Table – 4 Medical conditions on admission to ICU

	No. of cases	Percentage
HYPERTENSION	138	56.3%
ENDOCRINE	127	51.8%
NEUROLOGIC	34	13.9%
PULMONARY	75	30.6%
CARDIAC	196	80.0%
GASTRO-INTESTINAL	47	19.2%
NEPHRO	132	53.9%
SEPSIS	62	25.3%
INFECTIONS	32	13.1%
MALIGNANCY	6	2.4%
SURGICAL ILLNESS	60	24.5%
SHOCK	88	35.9%
PSYCHIATRIC	39	15.9%

Figure – 4 Medical conditions on admission to ICU



Common endocrine co-morbidities were hypothyroidism in 21 (8.6%), and diabetes mellitus type 2 in 117 (47.8%) patients (table – 5, figure – 5).

Table – 5 Endocrine co-morbidities		
	No. of cases	Percentage
HYPOTHYROID	21	8.6%
DM1	1	0.4%
DM2	117	47.8%

Figure – 5 Endocrine co-morbidities on admission to ICU



Common neurologic co-morbidities were hemorrhagic CVA in 3 (1.2%), ischemic CVA in 15 (6.1%), seizures in 11 (4.5%), intracranial space occupying lesion (ICSOL) in 1 (0.4%), and Parkinson disease in 6 (2.4%) (table – 6, figure – 6).

Table – 6 Neurologic co-morbidities		
	No. of cases	Percentage
HEMORRHAGIC CVA	3	1.2%
ISCHAEMIC CVA	15	6.1%
SEIZURE	11	4.5%
ICSOL	1	0.4%
Parkinson disease	6	2.4%

Figure – 6 Neurologic co-morbidities



Common pulmonary co-morbidities were pneumonia in 44 (18%), COPD in 23 (9.4%), pleural effusion in 11 (4.5%), pneumothorax in 3 (1.2%), allergic bronchopulmonary aspergillosis (ABPA) in 1 (0.4%), pulmonary thromboembolism (PTE) in 8 (3.2%), and obstructive sleep apnea in 1 (0.4%) patients (table – 7, figure – 7).

Table – 7 Pulmonary co-morbidities

	No. of cases	Percentage
PNEUMONIA	44	18.0%
COPD	23	9.4%
PLEURAL EFFUSION	11	4.5%
PNEUMOTHORAX	3	1.2%
ABPA	1	0.4%
PTE	8	3.2%
OSA	1	0.4%

Figure – 7 Pulmonary co-morbidities



Various cardiac co-morbidities were ST elevation myocardial infarction (STEMI) in 44 (18%), non ST elevation myocardial infarction (NSTEMI) in 31 (12.7%), unstable angina in 5 (2%), coronary artery disease in 98 (40%), congenital heart disease in 2 (0.8%), congestive heart failure in 58 (23.7%), arrythmia in 59 (24%), dilated cardiomyopathy (DCMP) in 17 (6.9%), ischemic cardiomyopathy (ICMP) in 7 (2.9%), hypertrophic cardiomyopathy (HCMP) in 2 (0.8%), peripartum cardiomyopathy (PPCM) in 1 (0.4%), valvular heart disease including both primary and secondary valvular stenotic and regurgitant lesions in 66 (26.9%), pericardial effusion in 10 (4.1%), deep venous thrombosis (DVT) in 4 (1.6 %), myocarditis in 1 (0.4%), peripheral arterial disease (PAD) in 3 (1.2%) patients (table – 8, figure – 8).

Table – 8 Cardiac co-morbidities

	No. of cases	Percentage
STEMI	44	18.0%
NSTEMI	31	12.7%
UNSTABLE ANGINA	5	2.0%
CAD	98	40%
CONGENITAL HEART DISEASE	2	0.8%
CHF	58	23.7%
Arrythmia	59	24%
DCMP	17	6.9%
ICMP	7	2.9%
HCMP	2	0.8%
PPCM	1	0.4%
Valvular heart disease	66	26.9%
Pericardial effusion	10	4.1%
DVT	4	1.6%
Myocarditis	4	1.6%
PAD	3	1.2%

Figure – 8 Cardiac co-morbidities



Various GI co-morbidities were chronic liver disease (CLD) in 14 (5.7%), hepatitis in 7 (2.9%), acute liver failure (ALF) in 4 (1.6%), pancreatitis in 6 (2.4%), cholecystitis in 10 (4.1%), esophageal ulcer in 1 (0.4%), acute gastroenteritis (AGE) in 4 (1.6%), celiac disease in 1 (0.4%), and hepatic encephalitis in 3 (1.2%) patients (table – 9, figure – 9)

Table – 9 GI co-morbidities

	No. of cases	Percentage
CLD	14	5.7%
HEPATITIS	7	2.9%
ALF	4	1.6%
PANCREATITIS	6	2.4%
CHOLECYSTITIS	10	4.1%
Esophageal ulcer	1	0.4%
AGE	4	1.6%
Celiac disease	1	0.4%
Hepatic encephalitis	3	1.2%

Figure – 9 GI co-morbidities



Various nephrologic co-morbidities were acute kidney injury (AKI) in 88 (35.9%), chronic kidney disease (CKD) in 32 (13.1%), obstructive uropathy in 5 (2%), urinary tract infection (UTI) in 41 (16.7%), nephritic syndrome in 1 (0.4%) patients (table – 10, figure – 10). A total of 23 (9.4%) patients underwent renal replacement therapy (RRT).

Table – 10 Nephrologic co-morbidities

	No. of cases	Percentage
AKI	88	35.9%
CKD	32	13.1%
NEPHRITIC	1	0.4%
OBSTRUCTIVE UROPATHY	5	2.0%
UTI	41	16.7%
USE OF RRT	23	9.4%

Figure – 10 Nephrologic co-morbidities



Common identifiable infections were tuberculosis in 7 (2.9%), dengue in 10 (4.1%), COVID-19 in 4 (1.6%), and H1N1 in 11 (4.5%) patients (table – 11, figure – 11).

Table – 11 Identifiable infections

	No. of cases	Percentage
TB	7	2.9%
DENGUE	10	4.1%
COVID	4	1.6%
H1N1	11	4.5%

Figure – 11 Identifiable infections



A total of 73 patients underwent surgery. Among various surgeries, 23 (9.4%) were related to GI system, 15 (6.1%) orthopedic, 5 (2%) neurosurgery, 8 (3.3%) urology, 7 (2.9%) obstetrics and gynecology, 3 (1.2%) plastic surgery, 7 (2.9%) cardio-thoracic, and 5 (2%) related to trauma (table – 12, figure – 12).

Table – 12 Surgical illness

	No. of cases	Percentage
GI	23	9.4%
ORTHOPEDIC	15	6.1%
NEUROSURGERY	5	2.0%
UROLOGY	8	3.3%
OBG	7	2.9%
PLASTIC SURGERY	3	1.2%
TRAUMA	5	2.0%
CTVS	7	2.9%

Figure – 12 Surgical illness



Among psychiatric illnesses, common ones were depression in 11 (4.5%), anxiety in 4 (1.6%), psychosis in 10 (4.1%), delirium in 7 (2.9%), schizophrenia in 1 (0.4%), and withdrawal symptoms in 7 (2.9%) patients (table – 13, figure – 13).

Table – 13 Psychiatric illness

	No. of cases	Percentage
DEPRESSION	11	4.5%
ANXIETY	4	1.6%
PSYCHOSIS	10	4.1%
DELIRIUM	7	2.9%
SCHIZOPHRENIA	1	0.4%
WITHDRAWAL	7	2.9%

Figure – 13 Psychiatric illness



LABORATORY PARAMETERS OF STUDY COHORT AT BASELINE

Mean Hb of study cohort was 11.63 ± 2.39 gm/dl and mean TLC was (13.26 ± 10.01) x $10^3/cm^3$. This along with mean values of other laboratory parameters are given in table – 14 and figure – 14.

Table – 14 Laboratory parameters on ICU admission		
	Mean	Std. Deviation
RBS	167.46	95.78
HB	11.63	2.39
TLC	13.26	10.01
PLATELET	236.08	118.38
PH	7.39	0.11
HCO3	21.47	5.06
LACTATE	2.11	2.24
K	4.34	0.83
CA	8.79	0.76
MG	2.29	0.46
PO4	3.75	1.34
Na	135.73	5.76
UREA	59.91	54.65
CREATININE	1.60	1.53
BIL	1.17	2.19
TSP	6.62	0.79
ALB	3.52	0.62
LVEF	40.65	16.55

Figure – 14 Laboratory parameters on ICU admission



A significant number of patients were found to have one or more biochemical abnormalities as shown in table – 15. 119 (48.6%) and 136 (55.5%) patients had deranged renal function (RFT) and liver function (LFT) tests respectively. Hypoalbuminemia was seen in 110 (44.9%) patients. Magnitude of other electrolyte abnormalities are shown in table – 15 and figure – 15.

Table – 15 Laboratory abnormality

	No. of patients	Percentage
Deranged RFT	119	48.6%
Deranged LFT	136	55.5%
Hypoalbuminemia	110	44.9%
Hyponatremia	85	34.7%
Hypernatremia	12	4.9%
Hypokalemia	40	16.3%
Hyperkalemia	51	20.8%
Hypocalcemia	73	29.8%
Hypercalcemia	2	0.8%
Hypomagnesemia	28	11.4%
Hypermagnesemia	43	17.5%
Hypophosphatemia	41	16.7%
Hyperphosphatemia	49	20%

Figure – 15 Laboratory abnormality



QTc PROLONGING DRUGS

Out of the total 245 patients, many were on the drugs known to cause QTc prolongation. In table – 16 and figure – 16, we have the information about common QTc prolonging drugs and the corresponding number of patients taking them.

Table – 16 QTc prolonging drugs and the corresponding number of patients taking them.

	No. of patients	Percentage
Amiodarone	47	19.2%
Macrolides	89	36.3%
Fluoroquinolones	9	3.7%
Clindamycin	10	4.1%
ATT	4	1.6%
Metronidazole	29	11.8%
Antifungals	13	5.3%
Antivirals	15	6.1%
Antipsychotics	38	15.5%
Antidepressants	11	4.5%
Tramadol	8	3.3%
Antineoplastic (imatinib)	1	0.4%
Bronchodilators	100	40.8%
Diuretics	155	63.3%
Antacids and antiemetics	238	97.1%
Massive blood transfusion (citrate)	5	2%
Ranolazine	3	1.2%
Inotropes	134	54.7%
Antiepileptics	24	9.8%

Figure – 16 QTc prolonging drugs and the corresponding percentage of patients taking them.



OUTCOMES OF STUDY COHORT

Mean duration of ICU stay of study cohort was 7.19 ± 5.26 days. Out of 245 patients, 208 (84.9%) patients were shifted out from ICU after stabilization, and 37 (15.1%) patients died as depicted in table – 17. Out of 245 patients, 17 patients developed ventricular tachycardia during the period of ICU stay. Out of them, 5 patients could not survive the event.

Table – 17 Outcomes of study cohort	
Mean duration of ICU stay	7.19 ± 5.26 days
Total no. of patients discharged from ICU	208 (84.9%)
Total no. of patients died	37 (15.1%)
Total no. of patients who had VT	17

PREVALANCE OF QTc PROLONGATION

Our study aim was to find out prevalence of QTc prolongation in ICU patients and prognostic significance of same, if any. A total of 173 patients were found to have QTc prolongation on the day of ICU admission with prevalence of 70.6% (table – 18, figure – 17). Mean QTc in the LQTS group was 502.56 ± 51.19 mm and in the normal QTc group was 424.82 ± 21.41 mm (p = 0.001) (table – 19).

After three days, the prevalence prolonged QTc was 59.2 %. Distribution of prolonged QTc interval was not significantly different in different age groups as depicted in table – 20 and figure – 18. Out of the total 173 patients with prolonged QTc, 111 (64.2%) were male and 62 (35.8%) were female (table – 20, figure – 18). Mean age of patients with normal QTc interval was 65.36 ± 13.57 years and of patients with prolonged QTc was 61.92 ± 14.65 years (table – 21, figure – 19). Out of total 245, 67 patients (27.3%) were found to have markedly prolonged QTc interval of > 500ms (table – 22, figure – 20).

Table – 18 Prevalence of prolonged QTc on the day of ICU admission

QTc INTERVAL	No. of cases	Percentage
Normal	72	29.4%
Prolonged	173	70.6%
Total	245	100.0%

Figure – 17 Prevalence of prolonged QTc on the day of ICU admission



Table – 19 mean QTc in both groups at ICU admission										
	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
QTC INTERVAL	424.82	21.41	430.00	413-441.75	502.56	51.19	492.00	470.5-518	-12.259	**0.001**

Table – 20 Distribution of prolonged QTc according to age and sex								
		Normal QTc (n=72)		Prolonged QTc (n=173)		Total	Chi-square value	p-value
		No. of cases	Percentage	No. of cases	Percentage			
AGE GROUP	< 30	0	0.0%	8	4.6%	8	5.815	0.121
	31-50	13	18.1%	23	13.3%	36		
	51-70	32	44.4%	91	52.6%	123		
	> 70	27	37.5%	51	29.5%	78		
SEX	F	24	33.3%	62	35.8%	86	0.140	0.708
	M	48	66.7%	111	64.2%	159		

Figure – 18 Distribution of prolonged QTc according to age and sex



Table – 21 Mean age of patients in normal vs prolonged QTc group										
	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
AGE	65.36	13.57	67.50	58.25-75	61.92	14.65	64.00	54-72.5	-1.679	0.093

Figure – 19 Mean age of patients in normal vs prolonged QTc group



Table – 22 Prevalence of markedly prolonged QTc on the day of ICU admission		
QTC INTERVAL GROUP	No. of cases	Percentage
Normal	72	29.4%
Prolonged but < 500 ms	106	43.3%
Pronged and > 500 ms	67	27.3%
Total	245	100.0%

Figure – 20 Prevalence of markedly prolonged QTc on the day of ICU admission



Out of 245 patients, a total of 25 (10.2%) patients had a history of syncope either in the past or in the current admission. Out of those, 17 had prolonged QTc. Out of these 17 patients, 7 had markedly prolonged QTc. Out of 25 patients with history of syncope, 10 patients also had history of VT either in the past or in the current admission and all of them had prolonged QTc. Four patients were found to have family history of sudden cardiac death. QTc interval in those were 461 ms, 510 ms, 512 ms, and 447 ms respectively.

QTc prolongation in patients with history of syncope:


25 (10.2%) Patients had history of syncope
17 had prolonged QTc
8 had normal QTc
7 had QTc >500 ms
10 had QTc <500 ms
No History of VT
5 had history of VT
5 had history of VT

For the identification of risk factors for long QTc syndrome (LQTS), patient variables were compared between LQTS and normal QTc patients by univariate and multivariate analysis.

On comparing the vital parameters of the two groups (table – 23, figure – 21) we found that the mean SBP was 122.29 ± 23.10 mm Hg in patients with normal QTc vs 120.04 ± 28.52 mm Hg (p = 0.713) in those with a prolonged QTc. Similarly, there was no statistically significant difference in the mean DBP of the two groups. Mean heart rate in the normal QTc group was 92 ± 26.04 vs 102.9 ± 28.79 in the LQTS group (p = 0.002), and the mean temperature was 98.44 ± 1.14-degree Fahrenheit vs 98.72 ± 1.37 degree Fahrenheit (p = 0.005) in the groups respectively.

Table – 23 Comparison of vital parameters of the two groups at ICU admission

	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
SBP	122.29	23.10	120.00	110-130	120.04	28.52	120.00	100-140	-0.368	0.713
DBP	71.00	10.65	70.00	60-80	70.67	14.35	70.00	60-80	-0.001	0.999
PR	92.00	26.04	88.50	72-109.25	102.90	28.79	101.00	81.5-120	-3.048	**0.002**
TEMPERATURE	98.44	1.14	98.00	98-98.675	98.72	1.37	98.40	98-99.4	-2.806	**0.005**

Figure – 21 Comparison of vital parameters of the two groups at ICU admission



Of various medical conditions, we found statistically significant higher number of patients of heart failure [50/58 (86.2%) vs 8/58 (13.8%), p = 0.003], shock [71/88 (80.7%) vs 17/88 (19.3%), p = 0.013], LV dysfunction [mean LVEF 38.7%, SD 17.07 vs mean LVEF 45.7%, SD 14.74 (p = 0.002)] with prolonged QTc interval. A detailed comparison of all other medical and surgical conditions is shown in table – 24,25 and figure – 22.

Table – 24 Comparison of frequency of various medical conditions according to QTc interval at admission

	Normal QTc (n=72)		Prolonged QTc (n=173)		Total	Chi-square value	p-value
	No. of cases	Percentage	No. of cases	Percentage			
HYPERTENSION	39	28.26%	99	71.74%	138	0.193	0.660
HYPOTHYROID	10	47.62%	11	52.38%	21	3.679	0.055
DM1	1	100.00%	0	0.00%	1	2.413	0.120
DM2	33	28.21%	84	71.79%	117	0.151	0.698
HEMORRHAGIC CVA	0	0.00%	3	100.00%	3	1.264	0.261
ISCHAEMIC CVA	2	13.33%	13	86.67%	15	1.985	0.159
SEIZURE	5	45.45%	6	54.55%	11	1.433	0.231
PNEUMONIA	15	34.09%	29	65.91%	44	0.572	0.450
COPD	7	30.43%	16	69.57%	23	0.013	0.908

PLEURAL EFFUSION	1	9.09%	10	90.91%	11	2.286	0.131
PNEUMOTHORAX	0	0.00%	3	100.00%	3	1.264	0.261
PTE	2	25.00%	6	75.00%	8	0.076	0.782
STEMI	13	29.55%	31	70.45%	44	0.001	0.980
NSTEMI	10	32.26%	21	67.74%	31	0.141	0.679
UNSTABLE ANGINA	1	20.00%	4	80.00%	5	0.217	0.642
CAD	26	26.53%	72	73.47%	98	0.639	0.424
CONGENITAL HEART DISEASE	0	0.00%	2	100.00%	2	0.839	0.360
CHF	8	13.79%	50	86.21%	58	8.905	**0.003**
AF	9	26.47%	25	73.53%	34	0.162	0.687
AFL	0	0.00%	2	100.00%	2	0.839	0.360
VT	1	5.88%	16	94.12%	17	4.864	**0.027**
DCMP	2	11.76%	15	88.24%	17	2.734	0.165
ICMP	1	14.29%	6	85.71%	7	0.792	0.374
HCMP	1	50.00%	1	50.00%	2	0.413	0.521
VALVULAR HEART DISEASE	11	22.00%	39	78.00%	50	1.652	0.199

PERICARDIAL EFFUSION	2	20.00%	8	80.00%	10	0.443	0.728
CLD	1	7.14%	13	92.86%	14	3.541	0.072
HEPATITIS	3	42.86%	4	57.14%	7	0.630	0.427
ALF	1	25.00%	3	75.00%	4	0.038	0.846
PANCREATITIS	1	16.67%	5	83.33%	6	0.480	0.674
CHOLECYSTITIS	5	50.00%	5	50.00%	10	2.135	0.164
AKI	20	22.73%	68	77.27%	88	2.936	0.108
CKD	7	21.88%	25	78.13%	32	1.001	0.407
NEPHRITIC	1	100.00%	0	0.00%	1	2.413	0.294
OBSTRUCTIVE UROPATHY	1	20.00%	4	80.00%	5	0.217	0.642
UTI	11	26.83%	30	73.17%	41	0.155	0.693
USE OF RRT	5	21.74%	18	78.26%	23	0.716	0.478
SEPSIS	17	27.42%	45	72.58%	62	0.155	0.694
TB	1	14.29%	6	85.71%	7	0.792	0.677
DENGUE	2	20.00%	8	80.00%	10	0.443	0.728
COVID	0	0.00%	4	100.00%	4	1.692	0.193

H1N1	7	63.64%	4	36.36%	11	6.510	0.017
MALIGNANCY	1	16.67%	5	83.33%	6	0.477	0.489
DEPRESSION	4	36.36%	7	63.64%	11	0.270	0.736
ANXIETY	3	75.00%	1	25.00%	4	4.077	0.077
PSYCHOSIS	1	10.00%	9	90.00%	10	1.888	0.289
DELIRIUM	1	14.29%	6	85.71%	7	0.792	0.677
SCHIZOPHRENIA	0	0.00%	1	100.00%	1	0.418	0.518
GI surgery	6	26.09%	17	73.91%	23	0.133	0.814
ORTHOPEDIC surgery	3	20.00%	12	80.00%	15	0.679	0.563
NEURO surgery	0	0.00%	5	100.00%	5	2.124	0.325
URO surgery	3	37.50%	5	62.50%	8	0.262	0.696
OBG surgery	0	0.00%	7	100.00%	7	2.999	0.109
PLASTIC surgery	0	0.00%	3	100.00%	3	1.264	0.558
TRAUMA	0	0.00%	5	100.00%	5	2.124	0.325
CTV surgery	4	57.14%	3	42.86%	7	2.675	0.199
SHOCK	17	19.32%	71	80.68%	88	6.710	**0.013**

SYNCOPE	8	32.00%	17	68.00%	25	0.092	0.762
CARDIAC ARREST	1	14.29%	6	85.71%	7	0.792	0.374
FAMILY HISTORY OF PREMATURE SUDDEN DEATH (<40 YRS)	2	50.00%	2	50.00%	4	0.829	0.363
MYOCARDITIS	0	0.00%	4	100.00%	4	1.692	0.324
ENCEPHALITIS	4	30.77%	9	69.23%	13	0.013	0.911
STARVATION	2	50.00%	2	50.00%	4	0.833	0.362
LIQUID PROTEIN DIET	0	0.00%	6	100.00%	6	2.560	0.184
CELIAC DISEASE	0	0.00%	1	100.00%	1	0.418	0.518
HYPOTHERMIA	1	16.67%	5	83.33%	6	0.480	0.489

Table – 25 Comparison of mean LVEF between two groups at ICU admission										
	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
LVEF	45.67	14.74	49.00	34-60	38.66	17.07	35.00	25-60	-3.054	**0.002**

Figure – 22 Comparison of mean LVEF between two groups at ICU admission



Various laboratory parameters were compared between two groups with or without prolonged QTc interval. Among hematological parameters, mean hemoglobin level was significantly different in two groups. It was 12.18 ± 2.27 in patients with normal QTc vs 11.39 ± 2.40 in patients with prolonged QTc (p = 0.019). However, there was no significant difference in total leucocyte and platelet counts (table – 26).

Table – 26 Comparison of hematological parameters at ICU admission

	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
HB	12.18	2.27	12.30	10.775-13.5	11.39	2.40	11.40	9.6-13.1	-2.346	**0.019**
TLC	11.81	7.31	9.50	7.725-14.25	13.86	10.90	11.50	8.1-16.25	-1.633	0.103
PLATELET	216.57	108.89	218.50	134-260.5	244.20	121.49	221.00	152-305.5	-1.566	0.117

Biochemical abnormalities associated with significantly higher percentage of patients with prolonged QTc interval were raised SGOT [106/136 (77.9%) vs 30/136 (22.1%), p = 0.007], raised SGPT [80/101 (79.2%) vs 21/101 (20.8%), p = 0.015], hypokalemia [34/40 (85%) vs 6/40 (15%), p = 0.029], hypocalcemia [59/73 (80.8%) vs 14/73 (19.2%), p = 0.022), hyponatremia [68/85 (80%) vs 17/85 (20%), p = 0.008], and hypoalbuminemia [86/110 (78.2%) vs 24/110 (21.8%), p = 0.008]. This and other frequently encountered biochemical abnormalities are shown in table – 27.

Table – 27 Comparison of biochemical parameters at ICU admission

	Normal QTc	Prolonged QTc	P value
Raised creatinine	34/119 (28.6%)	85/119 (71.4%)	0.785
Hyperuricemia	22/101 (21.8%)	79/101 (78.2%)	0.051
Hyperbilirubinemia	10/53 (18.9%)	43/53 (81.1%)	0.062
Raised SGOT	30/136 (22.1%)	106/136 (77.9%)	**0.007**
Raised SGPT	21/101 (20.8%)	80/101 (79.2%)	**0.015**
Raised ALP	16/70 (22.2%)	54/70 (31.2%)	0.337
Hypoalbuminemia	24/110 (21.8%)	86/110 (78.2%)	**0.008**

Hyponatremia	17/85 (20%)	68/85 (80%)	**0.008**
Hypernatremia	1/12 (8.3%)	11/12 (91.7%)	0.101
Hypokalemia	6/40 (15%)	34/40 (85%)	**0.029**
Hyperkalemia	12/51 (23.5%)	39/51 (76.5%)	0.203
Hypocalcemia	14/73 (19.2%)	59/73 (80.8%)	**0.022**
Hypercalcemia	2/2 (100%)	0/2 (0%)	0.028
Hypomagnesemia	7/28 (25%)	21/28 (75%)	0.588
Hypermagnesemia	14/43 (32.5%)	29/43 (67.5%)	0.805
Hypophosphatemia	17/41 (41.5%)	24/41 (58.5%)	0.063
Hyperphosphatemia	13/49 (26.5%)	36/49 (73.5%)	0.624

Out of the total 245 patients, many were on the drugs known to cause QTc prolongation (table – 16). Drugs like amiodarone [40/47 (85.1%) vs 7/47 (14.9%), p = 0.015], levosalbutamol [79/99 (45.66%) vs 20/99 (27.78%), p = 0.001], furosemide [96/122 (78.7%) vs 26/122 (21.3%), p = 0.006], spironolactone [83/100 (83%) vs 17/100 (17%)] and haloperidol [32/35 (91.4%) vs 3/35 (8.6%), p = 0.002] were significantly associated with LQTS. This and comparison of other commonly used drugs is shown in table – 28.

Table – 28 Comparison of various drugs between the two groups

	Normal QTc (n=72)		Prolonged QTc (n=173)		Total	Chi-square value	p-value
	No. of cases	Percentage	No. of cases	Percentage			
AMIODARONE	7	14.89%	40	85.11%	47	5.88	**0.015**
MACROLIDES	11	29.73%	26	70.27%	37	0.002	0.96
FLUOROQUINOLONES	3	33.33%	6	66.67%	9	0.07	0.791
CLINDAMYCIN	1	10.00%	9	90.00%	10	1.888	0.289
ATT	0	0.00%	4	100.00%	4	1.692	0.193
METRONIDAZOLE	7	24.14%	22	75.86%	29	0.437	0.509
ANTIFUNGAL	4	30.77%	9	69.23%	13	0.013	0.911

ANTIVIRAL	9	60.00%	6	40.00%	15	7.216	0.007
HALOPERIDOL	3	8.57%	32	91.43%	35	8.527	**0.002**
QUETIAPINE	0	0.00%	1	100.00%	1	0.418	0.518
RISPERIDONE	1	33.33%	2	66.67%	3	0.023	0.88
ESCITALOPRAM	2	33.33%	4	66.67%	6	0.046	0.83
FLUOXETINE	0	0.00%	1	100.00%	1	0.418	0.518
SERTRALINE	1	50.00%	1	50.00%	2	0.413	0.502
AMITRYPTILINE	0	0.00%	1	100.00%	1	0.18	0.518
NORTRYPTILINE	1	100.00%	0	0.00%	1	2.413	0.294
ANTIHISTAMINES	0	0.00%	1	100.00%	1	0.418	0.518
FENTANYL	10	17.86%	46	82.14%	56	4.632	0.0314
MORPHINE	3	60.00%	2	40.00%	5	2.295	0.129

TRAMADOL	2	25.00%	6	75.00%	8	0.076	0.782
CLONAZEPAM	14	23.33%	46	76.67%	60	1.397	0.237
DIAZEPAM	3	60.00%	2	40.00%	5	2.295	0.129
LORAZEPAM	0	0.00%	3	100.00%	3	1.258	0.262
MIDAZOLAM	10	23.26%	33	76.74%	43	0.941	0.332
IMATINIB	0	0.00%	1	100.00%	1	0.418	0.518
FORMETROL	0	0.00%	1	100.00%	1	0.418	0.518
SALMETROL	0	0.00%	1	100.00%	1	0.418	0.518
LEVOSALBUTAMOL	20	20.20%	79	79.80%	99	6.727	**0.009**
FUROSEMIDE	26	21.31%	96	78.69%	122	7.638	**0.006**
TORSEMIDE	5	33.33%	10	66.67%	15	0.12	0.729
METOLAZONE	4	16.67%	20	83.33%	24	2.075	0.237

SPIRONOLACTONE	17	17.00%	83	83.00%	100	12.495	**0.001**
CTD	1	50.00%	1	50.00%	2	0.413	0.502
ONDANSETRON	13	30.23%	30	69.77%	43	0.018	0.893
DOMPERIDONE	4	23.53%	13	76.47%	17	0.302	0.784
METOCLOPRAMIDE	1	33.33%	2	66.67%	3	0.023	0.88
PANTOPRAZOLE	57	28.64%	142	71.36%	199	0.283	0.595
ESOMEPRAZOLE	12	27.91%	31	72.09%	43	0.055	0.814
LEVOSULPRIDE	1	33.33%	2	66.67%	3	0.023	0.88
TAMSULOSIN	8	29.63%	19	70.37%	27	0.001	0.977
SILODOSIN	1	20.00%	4	80.00%	5	0.217	0.642
CITRATE (MASSIVE BT)	1	20.00%	4	80.00%	5	0.217	0.642
RANOLAZINE	2	66.67%	1	33.33%	3	2.034	0.154

NOREPINEPHRINE	23	17.16%	111	82.84%	134	21.296	**0.001**
EPINEPHRINE	2	11.11%	16	88.89%	18	3.127	0.106
DOPAMINE	12	13.64%	76	86.36%	88	16.419	**0.001**
DOBUTAMINE	0	0.00%	1	100.00%	1	0.418	0.518
VASOPRESSIN	7	18.92%	30	81.08%	37	2.302	0.129
LEVETIRACITAM	5	27.78%	13	72.22%	18	0.024	0.876
PHENYTOIN	0	0.00%	3	100.00%	3	1.259	0.262
VALPROATE	1	100.00%	0	0.00%	1	2.403	0.121

Various ECG patterns were studied and compared between the two groups and no significant difference was observed. Details of various ECG abnormalities is provided in table – 29.

Table – 29 Comparison of frequency of various ECG patterns at ICU admission

QTC INTERVAL	Normal QTc (n=72)		Prolonged QTc (n=173)		Total	Chi-square value	p-value
	No. of cases	%	No. of cases	%			
U WAVE	0	0.00%	4	2.30%	4	1.692	0.324
ST ELEVATION	12	16.70%	34	19.70%	46	0.297	0.72
ST DEPRESSION	11	15.30%	30	17.30%	41	0.155	0.851
LVH	2	2.80%	6	3.50%	8	0.077	0.782
RVH	0	0.00%	1	0.60%	1	0.418	0.518
POOR R PROGRESSION	4	5.60%	20	11.60%	24	2.075	0.237

MULTIVARIATE ANALYSIS

Covariates obtaining a P value <0.05 in the univariate analyses were included in the multivariate binary logistic regression analyses. After multivariate analysis, congestive heart failure [OR = 3.4 (95% CI 1.2-9.2), p = 0.015], and drugs like amiodarone [OR = 2.9 (95% CI 1.08-7.9), p = 0.033] and haloperidol [OR = 4.7 (95% CI 1.2-17.8), p = 0.023] were significantly associated with prolonged QTc. None of the electrolyte abnormality was significantly associated (table – 30).

Table – 30 Multivariate analyses

	p-value	Odd ratio	95% C.I.for Odd ratio	
			Lower	Upper
PR	0.488	1.004	0.992	1.017
TEMPERATURE	0.617	1.068	0.824	1.384
CHF	**0.015**	3.417	1.268	9.204
SHOCK	0.517	0.708	0.248	2.016
SGOT	0.281	1.449	0.738	2.846
ALB	0.723	1.141	0.549	2.371
NA	0.115	1.797	0.866	3.730
HYPOKALEMIA	0.248	1.873	0.645	5.438
HYPOCALCEMIA	0.414	1.399	0.626	3.128

AMIODARONE	**0.033**	2.942	1.089	7.950
HALOPERIDOL	**0.023**	4.710	1.242	17.859
LEVOSALBUTAMOL	0.803	1.099	0.523	2.309
FUROSEMIDE	0.622	0.820	0.372	1.808
SPIRONOLACTONE	0.360	1.454	0.652	3.241
NOREPINEPHRINE	0.153	2.184	0.748	6.379
DOPAMINE	0.148	2.135	0.764	5.963

PROGNOSTIC SIGNIFICANCE OF PROLONGED QTc INTERVAL

Outcome was assessed in the form of duration of ICU stay, ICU mortality and episodes of in ICU ventricular tachycardia. The median duration of ICU stay was significantly more in the patients with prolonged QTc [median of 6.5 days (IQR 4-10) vs 5 days (IQR 2.25-7), p = 0.001] (table – 31, figure – 23), however there was no significant difference in ICU mortality between two groups [27/37 (73%) vs 10/37 (27%), (p = 0.732)], although numerically there were more deaths in the LQTS group (table – 32, figure – 24). ICU mortality also co-related with APACHE II score (table – 33, figure – 25). Mean APACHE II score in the patients who died was 22.73 ± 7.88 vs 14.96 ± 6.84 in the patients who survived (p = 0.001). And the mean APACHE II score was significantly more in patients with prolonged QTc (17.43 ± 7.32 vs 13.01 ± 7.13, p = 0.001) (table – 34, figure – 26). The number of patients who had ventricular tachycardia were significantly higher in the prolonged QTc interval group [16/17 (94%) vs 1/17 (6%), p = 0.004] (table – 32).

Table – 31 Prognostic significance of prolonged QTc

	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
DURATION OF ICU STAY	5.78	4.33	5.00	2.25-7	7.78	5.51	6.50	4-10	-3.189	**0.001**

Figure – 23 Prognostic significance of prolonged QTc



Table – 32 Difference in ICU mortality and VT episodes in the two groups during ICU stay								
		Normal QTc (n=72)		Prolonged QTc (n=173)		Total	Chi-square value	p-value
		No. of cases	Percentage	No. of cases	Percentage			
DEATH	No	62	86.10%	146	84.40%	208	0.117	0.732
	Yes	10	13.90%	27	15.60%	37		
VT	No	71	98.60%	157	90.80%	228	4.864	**0.027**
	Yes	1	1.40%	16	9.20%	17		

Figure – 24 Difference in ICU mortality and VT episodes in the two groups during ICU stay



Table – 33 Mortality and APACHE II score										
	ALIVE				DIED				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
APACHE II SCORE	14.96	6.84	15.00	10-20.0	22.73	7.88	24.00	16.5-29.5	-6.221	**0.001**

Figure – 25 Mortality and APACHE II score



Table – 34 Comparison of APACHE II score at ICU admission										
	Normal QTc				Prolonged QTc				Z	p-value
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
APACHE II SCORE	13.01	7.13	12.00	9-16.0	17.43	7.32	18.00	12-23.0	-4.707	**0.001**

Figure – 26 Comparison of APACHE II score at ICU admission



SUBGROUP ANALYSIS OF PATIENTS WITH MARKEDLY PROLONGED QTc INTERVAL (> 500 ms)

Total 67 (27.3%) patients were found to have markedly prolonged QTc interval (QTc > 500 ms). There were 23 male and 44 female patients. The mean age of patients in this subgroup was 62.40 ± 15.98 years. Among vital parameters the mean pulse rate was 103.03 ± 31.65 per min. Mean systolic and diastolic blood pressures were 116.41 ± 28.69 mm Hg and 68.75 ± 15.99 mmHg respectively.

On univariate analysis, lab abnormality found to be significantly associated with markedly prolonged QTc was hypomagnesemia [14/28 (50%) vs 14/28 (50%), p = 0.007]. Significantly associated medical conditions were ischemic stroke [9/15 (60%) vs 6/15 (40%), p = 0.006], dilated cardiomyopathy [9/17 (52.9%) vs 8/17 (47.1%), p = 0.022], LV dysfunction [mean EF of 34.86% ± 16.48 vs 42.81% ± 16.10, p = 0.001], and hypothermia [4/6 (66.7%) vs 2/6 (33.3%), p = 0.049]. Among various drugs, haloperidol was significantly associated with markedly prolonged QTc [18/35 (51.4%) vs 17/35 (48.6%), p = 0.002].

Patients with markedly prolonged QTc were sicker (mean APACHE II score 18.46 ± 6.04 vs 15.25 ± 7.85, p = 0.003) and had a longer duration of ICU stay [median of 8 days (IQR 4-11) vs 5 days (IQR 3-9), p = 0.001], and had significantly higher frequency of VT episodes [9/17 (52.9%) vs 8/17 (47.1%), p = 0.022]. That is why there was significantly more usage of drugs like oral mexiletine [10/12 (83.3%) vs 2/12 (16.7%), p = 0.001] and IV xylocaine [13/21 (61.9%) vs 8/21 (38.1%), p = 0.001] in these patients. However, mortality was not significantly different in the two groups (table – 35).

Table – 35 Subgroup analysis of patients with QTc > 500 ms			
Variables	QTc <500 ms	QTc >500 ms	P value
Age in years (Mean±SD)	*63.13 ± 13.80*	62.40 ± 15.98	0.726
SBP in mmHg (Mean±SD)	*122.30 ± 26.24*	116.41 ± 28.69	0.136
DBP in mmHg (Mean±SD)	*71.52 ± 12.18*	68.75 ± 15.99	0.156
PR/min (Mean±SD)	*98.44 ± 27.07*	103.03 ± 31.65	0.260
APACHE II (Mean±SD)	*15.25 ± 7.85*	18.46 ± 6.04	**0.003**
Lab parameters, N(%) Hypomagnesemia	*14/28 (50%)*	14/28 (50%)	**0.007**
Medical conditions, N(%) Ischemic stroke	*6/15 (40%)*	9/15 (60%)	**0.006**
DCMP	*8/17 (47.1%)*	9/17 (52.9%)	**0.022**
Hypothermia	*2/6 (33.3%)*	4/6 (66.7%)	**0.049**

LV dysfunction (mean EF ± SD)	*42.81% ± 16.10*	34.86% ± 16.48	**0.001**
Drugs, N(%) Haloperidol	*17/35 (48.6%)*	18/35 (51.4)	**0.002**
Outcome, N(%) VT	*8/17 (47.1%)*	9/17 (52.9%)	**0.022**
Mortality	*25/37 (67.6%)*	12/37 (32.4%)	0.432
Duration of stay (median, IQR)	*8 (4-11)*	5 (3-9)	**0.001**

After multivariate analysis, LV dysfunction [OR = 0.9 (95% CI 0.95-0.99), p = 0.007], hypomagnesemia [OR = 2.8 (95% CI 1.1-7.1), p = 0.021] and use of haloperidol [OR = 3 (95% CI 1.2-7), p = 0.012] were significantly associated with markedly prolonged QTc.

DISCUSSION

Life-threatening arrhythmias such as Torsades de Pointes/ventricular tachycardia can result from an extended QTc interval. Prior research on the prevalence and prognostic importance of a prolonged QTc interval has typically focused on a few specific medical disorders like intracranial hemorrhage, liver cirrhosis, CAD, HIV, etc but little is known about its significance in non-selective ICU patients. This study was done to determine the prevalence of prolonged QTc intervals in ICU patients, identify predisposing factors, and assess its prognostic significance regarding hospital stay duration, ventricular tachycardia incidence, and ICU mortality rates.

Our study showed a very high prevalence of QTc prolongation in patients of various illnesses at the time of ICU admission. It is highest among the previous studies which showed varying prevalence of LQTS of 24% [13], 46.6% [14], 27.9% [15], 39% [16], 61% [17] and 52% [18]. The inclusion of critically ill patients with various illnesses in our study probably contributed to the higher prevalence of QTc prolongation and many of them had one or more risk factors for QT prolongation.

In our study, QTc interval was numerically higher in males as compared to females. This finding aligned with the findings of a study by Pasquier et al. in which the odds ratio for men was 1.4 [29]. Although most of the previous studies including a study in patients on psychotropics in British University of Columbia, Vancouver [32], a study in Serbian diabetic patients [49] and an Indian study [43] suggested that QTc prolongation was more common in female patients. Sex hormones are thought to have an impact on cardiac repolarization. Testosterone, by increasing IKr, shortens the QTc interval and reduces the risk of TdP. The elevated frequency of QTc prolongation in male patients in our study can be explained by the convergence of several possible risk factors for QTc prolongation in comparison to female patients.

On comparison of vital parameters, our study found that the patients with prolonged QTc had significantly faster heart rate. Typically, QTc prolongation is associated with slower heart rates, but this finding can

be attributed to the higher severity of illness in these patients (as indicated by a higher APACHE II score). Patients with prolonged QTc had significantly higher mean temperatures than those with normal QTc (98.72 ± 1.37 degree Fahrenheit vs 98.44 ± 1.14-degree Fahrenheit) (p = 0.005). Even though the numerical difference between these two mean values seems very less, the p value may have come significant because of very small standard deviations. Both the heart rate and temperature differences were not significant in multivariate analysis.

Of various medical conditions, QT interval was significantly prolonged in patients of heart failure [50/58 (86.2%) vs 8/58 (13.8%), p = 0.003], shock [71/88 (80.7%) vs 17/88 (19.3%), p = 0.013], LV dysfunction [mean LVEF 38.7%, SD 17.07 vs mean LVEF 45.7%, SD 14.74 (p = 0.002)]. According to a study on CHF patients in Nigeria, QTc prolongation is highly prevalent in these patients and is linked to a bad prognosis [11]. This may be attributed to cardiac structural abnormalities and dyselectrolemia as a secondary effect of diuretic therapy. In non-selective medical patients, retrospective study by Seftchick MW et al [28] reported that structural cardiac disease was substantially linked to QTc prolongation. Cardiogenic shock is characterized by significantly reduced cardiac output and impaired myocardial contractility. This can lead to decreased perfusion of myocardium, which may exacerbate the electrical instability seen in LQTS. The combination of low blood flow and prolonged QTc intervals increases the risk of arrhythmias, particularly Torsades de Pointes. Shock often leads to metabolic derangements, including electrolyte imbalances such as hypokalemia and hypomagnesemia. These imbalances can further prolong the QTc interval and increase the likelihood of arrhythmias [50]. The physiological response to shock includes activation of the sympathetic nervous system. This can lead to increased heart rate and myocardial oxygen demand, which may worsen ischemia and further destabilize cardiac rhythm in patients with LQTS. The stress response can also provoke arrhythmic events in susceptible individuals. In managing shock, certain medications that may be used (such as antiarrhythmics

or vasopressors) can have QT-prolonging effects themselves. This can make treating patients with LQTS more difficult because these medications may make the underlying problem worse. Also, patients with CVA, chronic kidney disease, liver cirrhosis were found to have numerically (although not significantly) more frequent occurrence of LQTS. Cirrhotic cardiomyopathy involves abnormalities in the β-adrenergic signaling pathway, changes in cardiomyocyte membrane fluidity, myocardial hypertrophy, and ion channel defects, which lead to repolarization abnormalities and prolonged QTc [8]. In patients with chronic kidney disease (CKD), it is hypothesized that structural alterations such as left ventricular hypertrophy (LVH) and cardiomyopathy, along with ion channel defects resulting from dyselectrolemia, lead to repolarization abnormalities and diastolic dysfunction [10]. In CVA patients, QTc can be prolonged due to autonomic dysfunction, electrolyte imbalances, and ischemic injury [12].

Among various hematological parameters, the mean hemoglobin level was notably lower in patients exhibiting a prolonged QTc interval. Notably, a study conducted in Serbia involving chronic anemia patients without comorbidities also observed a significant prolongation of the QT interval in these individuals [51]. However, we believe that LQTS in patients with low hemoglobin can be attributed to multiple comorbidities such as chronic liver disease (CLD), chronic kidney disease (CKD), and chronic inflammatory conditions. Low hemoglobin often coexist with these comorbidities and can be linked to prolonged QTc intervals.

Biochemical issues linked to a significantly higher number of patients with a prolonged QTc interval were hypokalemia [34/40 (85%) vs 6/40 (15%), p = 0.029], hypocalcemia [59/73 (80.8%) vs 14/73 (19.2%), p = 0.022), hyponatremia [68/85 (80%) vs 17/85 (20%), p = 0.008], and hypoalbuminemia [86/110 (78.2%) vs 24/110 (21.8%), p = 0.008]. Hypokalemia induces QTc prolongation by paradoxically diminishing IKr through enhanced activation or exaggerated competitive block by sodium. Seftchick et al [28] and the QTIP study also reported that hypokalemia is a risk factor for prolonged QTc [30]. Hypocalcemia causes QTc prolongation primarily through mechanisms related to

impaired calcium handling in cardiac myocytes, leading to delayed repolarization and increased risk for arrhythmias. There is also a role of Calcium-Dependent Inactivation (CDI) of L-Type Calcium Channels and genetic polymorphisms in calmodulin, a calcium-binding protein that plays a role in intracellular calcium handling. In prior research, including a study conducted by Seftchick MW et al. [28] among emergency medical patients, there is evidence indicating a prolongation of the QT interval associated with hypocalcemia. Hyponatremia can potentially lead to prolonged QT intervals, although the relationship is less direct compared to other electrolyte imbalances like hypokalemia or hypocalcemia. Low sodium levels can disrupt normal cardiac function and contribute to arrhythmias. Severe hyponatremia can lead to neurohormonal changes, including elevated sympathetic nervous system activity. This heightened sympathetic tone can alter heart rate and myocardial oxygen demand, which may indirectly affect the QT interval. However, on multivariate analysis, none of the electrolyte abnormality was significantly associated with prolonged QTc. Study in medical inpatients [29] and study in elderly Pneumonia patients [38] did not show any association of hypo or hypercalcemia with QTc interval. In a study by Golzari et al. [44], No meaningful correlation was found between prolonged QTc intervals and any of the measured electrolyte levels (potassium, magnesium, calcium) after considering various factors such as age, gender, comorbidities, ECG abnormalities, and medications. A study published in the Internal Medicine Journal [52] found that in individuals with chronic renal disease and coronary artery disease, decreased serum albumin concentrations were substantially linked to an increased risk of QTc prolongation. The mechanism could involve indirect effects on electrolyte balance, as albumin binds to calcium and helps maintain normal ionized calcium levels. Moreover, reduced albumin levels could alter the activity of ion channels involved in the QTc interval, and hypoalbuminemia is often an indicator of underlying inflammation or malnutrition, which can also have effects on cardiac electrophysiology.

Even hypoalbuminemia was not found to have significant association with prolonged QTc on multivariate analysis.

Many patients in our study were receiving QTc prolonging drugs. Prior research on nonselective emergency medical patients has indicated that the prescription rate of QTc-prolonging medications is notably high in this group [29,43]. A study by Tisdale et al. in a cardiac care unit showed that 26% of patients with already prolonged QTc intervals were administered one or more QT-prolonging drugs, and 18% of these patients suffered from cardiac events [31]. The QTIP study also revealed a high prevalence of prolonged QT interval, with a significant proportion of patients being administered one or more QT-prolonging drugs [19]. This is a crucial modifiable risk factor. Studies have shown that changing or adjusting medications can normalize the QT interval and potentially reduce the risk of life-threatening cardiac arrhythmias [53]. In our study drugs like amiodarone, levosalbutamol, furosemide, haloperidol, nor epinephrine and epinephrine were significantly associated with LQTS. QT prolongation is known to occur with all of these medications [4,39,40,41]. Among the drugs not known to cause QT prolongation, we found significant association with spironolactone. However, on multivariate analysis only amiodarone and haloperidol were significantly linked with QTc prolongation.

When different ECG patterns were examined and contrasted between the two groups, no discernible differences were found (table – 29). While there is evidence suggesting a relationship between LVH and prolonged QT intervals, some studies show that this association may not be statistically significant or clinically relevant in all cases [54].

QT interval prolongation is prevalent among surgical patients, particularly after major noncardiac procedures. This prolongation is often influenced by perioperative medications and electrolyte disturbances [55]. Direct studies specifically addressing QT prolongation in trauma patients may be limited but existing literature suggests that trauma-related factors such as electrolyte imbalances, medications, and systemic responses can contribute to prolonged QT intervals [55]. In

our study too, most of the surgical and trauma patients had prolonged QTc intervals but the results were statistically non-significant.

In patients with prolonged QTc, the median length of stay in the intensive care unit was significantly longer [median of 6.5 days (IQR 4-10) vs 5 days (IQR 2.25-7), p = 0.001] (table – 31, figure – 22), however their mortality rates did not differ significantly [27/37 (73%) vs 10/37 (27%), (p = 0.732)], although numerically there were more deaths in the LQTS group (table – 32, figure – 23). But ICU mortality co-related with APACHE II score (table – 33, figure – 24). Mean APACHE II score in the patients who died was 22.73 ± 7.88 vs 14.96 ± 6.84 in the patients who survived (p = 0.001). And the mean APACHE II score was significantly more in patients with prolonged QTc (17.43 ± 7.32 vs 13.01 ± 7.13, p = 0.001) (table – 34, figure – 25). So, indirectly mortality was associated with prolonged QTc. Results from earlier research on these patients have been inconsistent. The Oregeon sudden unexpected death study [6] and Rotterdam study [56] showed linear relationship between degree of QT prolongation & all-cause mortality, however, a retrospective study by Seftchick MW et al. [28] and a cross-sectional study at Swiss teaching hospital [29] did not find an association between prolonged QT interval and mortality. In an Indian study, patients with a prolonged QT interval had a worse prognosis, with an odds ratio of 3 for adverse ICU outcomes [43]. In our study, patients with prolonged QTc had significantly greater risk of ventricular tachycardia. This observation is supported by study done in Japanese population [26] and by Rotterdam study [56].

Our study had various limitations. Firstly, it was a single center study from different ICUs, so the findings of this study cannot be generalized to patients from a different clinical set up. Secondly, ECG monitoring was not done continuously and therefore some new cases of prolonged QTc may have been missed and vice versa. Thirdly, A more distinct pattern of QTc variation in connection to the factors under analysis would have been discovered with a longer follow-up time following ICU release. Fourthly, A significant portion of our subjects had one or more

cardiac co-morbidities, which could have contributed to the elevated LQTS prevalence.

SUMMARY

This prospective observational study was conducted on 245 patients admitted in medical, surgical and cardiac ICUs with variety of illnesses and other factors affecting the QT interval to find out the prevalence of LQTS and its prognostic implications.

- Prevalence of prolonged QTc interval was high (70.6 %) in these ICU patients consistent with and even higher than the results from western studies undertaken in similar set up.
- Prevalence of markedly prolonged QTc was 27.3%.
- There was no age or gender predilection.
- QTc interval was significantly prolonged in patients of heart failure, shock, and LV dysfunction.
- Patients with prolonged QTc had significantly lower mean hemoglobin levels.
- Biochemical abnormalities significantly associated with LQTS were hypokalemia, hypocalcemia, hyponatremia, and hypoalbuminemia.
- Drugs like amiodarone, levosalbutamol, furosemide, spironolactone, norepinephrine, dopamine, and haloperidol were significantly associated with LQTS.
- The median length of stay in ICU was much longer in the patients with prolonged QTc, however there was no significant difference in ICU mortality between two groups, although proportionally there were more deaths in the LQTS group.
- Ventricular tachycardia was considerably more common in the group with the longer QTc interval.
- Multivariate analysis revealed that the risk of QTc prolongation was significantly associated only with heart failure and the use medications like haloperidol, amiodarone and levosalbutamol. None of the electrolyte abnormality was significantly associated with LQTS.

CONCLUSION

As shown in our study, the prevalence of LQTS is high in Indian ICU patients. The length of stay in the intensive care unit is considerably longer for individuals with longer QTc, however there is no significant difference in ICU mortality. A variety of factors including certain co-morbidities, dyselectrolemia, deranged liver functions and specific drugs are linked with QTc prolongation. Considering the results of our study, it would be prudent to closely monitor for QTc prolongation particularly in patients with certain co-morbidities, avoid drugs associated with QTc prolongation if possible, and aggressively correct dyselectrolemia.

BIBLIOGRAPHY

1. Khan IA. Long QT syndrome: Diagnosis and management. *Am Heart J.* 2002;143:7–14.
2. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. *J Clin Invest.* 2005;115:2025–32.
3. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: A comprehensive review. *ScientificWorldJournal.* 2012;2012:212178.
4. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: Recent advances. *Curr Opin Cardiol.* 2007;22:39–43.
5. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. *Heart.* 2003;89:1363–72.
6. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: The Oregon sudden unexpected death study. *Circulation.* 2009;119:663–70.
7. Fukui S, Katoh H, Tsuzuki N, Ishihara S, Otani N, Ooigawa H, et al. Multivariate analysis of risk factors for QT prolongation following subarachnoid hemorrhage. *Crit Care.* 2003;7:R7–12.
8. Cichoż-Lach H, Tomaszewski M, Kowalik A, Lis E, Tomaszewski A, Lach T, et al. QT interval prolongation and QRS voltage reduction in patients with liver cirrhosis. *Adv Clin Exp Med.* 2015;24:615–22.
9. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. *Lancet.* 1993;341:1423–8.
10. Voiculescu M, Ionescu C, Ismail G. Frequency and prognostic significance of QT prolongation in chronic renal failure patients. *Rom J Intern Med.* 2006;44:407–17
11. Kolo PM, Opadijo OG, Omotoso AB, Katibi IA, Balogun MO, Araoye MA. Prognostic significance of QT interval prolongation in adult

Nigerian with congestive heart failure. *Niger J Clin Pract.* 2008;11:336–40.

12. Purushothaman S, Salmani D, Prarthana KG, Bandelkar SM, Varghese S. Study of ECG changes and its relation to mortality in cases of cerebrovascular accidents. *J Nat Sci Biol Med.* 2014;5:434–6.
13. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Drew BJ. How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. *J. Electrocardiol*. 2010;43:572–6.
14. Ng TM, Olsen KM, McCartan MA, Speidel KM, Miller MA, Levit AV. Pharmacologic predictors of qtc prolongation and proarrhythmia in the adult medical Intensive Care Unit. *Crit Care Med*. 2004;32:A40.
15. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. *Drug Saf*. 2012;35:459–70.
16. Ng TM, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, et al. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study. *Ann Pharmacother*. 2008;42:475–82.
17. Ng TM, Olsen KM, McCartan MA, Puumala SE, Speidel KM, Miller MA, et al. Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors. *J Pharm Pract*. 2010;23:19–24.
18. Hoogstraaten E, Rijkenberg S, van der Voort PH. Corrected QT-interval prolongation and variability in intensive care patients. *J Crit Care Med*. 2014;29:835–9.
19. Moss AJ. Long QT syndrome. JAMA. 2003;289: 2041-44.
20. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17–26.

21. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 1966;59:263-72.
22. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart rhythm. 2006;3:1003-7.
23. Cowan JC, Yusoff K, Moore M, Amos PA, Gold AE, Bourke JP, et al. Importance of lead selection in QT interval measurement. The American journal of cardiology. 1988;61:83-7.
24. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:35–70.
25. Mirvis DM, Goldberger AL. Electrocardiography. Braunwald's Heart Disease.11th ed.Philadelphia, PA: Elsevier Saunders. 2019.
26. Ishikawa J, Ishikawa S, Kario K, JMS Cohort Study Investigator Group. Relationships between the QTc interval and cardiovascular, stroke, or sudden cardiac mortality in the general Japanese population. Journal of Cardiology. 2015;65:237-42.
27. Rezus C, Moga VD, Ouatu A, Floria M. QT interval variation and mortality risk: Is there any relationship? Anatol J Cardiol 2015;15: 255-8.
28. Seftchick MW, Adler PH, Hsieh M, Wolfson AB, Chan ST, Webster BW, et al. The prevalence and factors associated with QTc prolongation among emergency department patients. Annals of emergency medicine. 2009;54:763-8.
29. Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J. 2012;42:933-40.
30. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study*.Crit Care Med. 2012;40:394-9
31. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective,

observational study in a large urban academic medical center in the US. Drug Saf. 2012;35:459-70

32. Rabkin SW. Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics. Can J Psychiatry 2015; 60:206-14.
33. Makkar RR, Fromm BS, Steinman RT. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590–7.
34. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407–11.
35. Soliman EZ, Shah AJ, Boerkereier A. Interrelationship between Electrocardiographic Left Ventricular Hypertrophy and QT prolongation as predictor of Increase Risk of mortality in General Population. Circ Arrhythm Electrophysiol. 2014;7:400-6.
36. Hung CS, Tseng PH, Tu CH. Non Alcoholic Fatty Liver Disease Is Associated with QT Prolongation in General Population. J Am Heart Assoc. 2015;4:e001820.
37. Sani MU, Okeahialam BN. QTc Interval Prolongation in patients with HIV and AIDS. J Natt Med Assoc. 2005;97:1657-61.
38. Taooka Y, Takerawa G, Ohe M. Multiple logistic regression analysis of risk factors in elderly pneumonia patients: QT Interval prolongation as prognostic factor. Multidisciplinary Respiratory Medicine 2014; 9:59.
39. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088–93
40. Yal YG, Camm AJ. Drug induced QT prolongation and Torsades de Pointes. Heart 2003;89:1363-72.
41. Zareba W. Drug induced QT prolongation. Cardiology journal 2007;14:523-33.
42. Freeman BD, Dixon DJ, Coopersmith CM, Zehnbauer BA, Buchman TG. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf. 2008;17:971-81.

43. George TK, Chase D, Peter JV, Satyendra S, Kavitha R, George LR, et al. Association between a prolonged corrected QT interval and outcomes in patients in a medical Intensive Care Unit. Indian J Crit Care Med. 2015;19:326-32.
44. Golzari H, Dawson NV, Speroff T, Thomas C. Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities. Conn Med. 2007;71:389-97.
45. Tan HH, Hoppe J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med. 2009;27:607-16.
46. Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997;96:2149–54.
47. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7:381-90.
48. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation. 2004;110:2721-46.
49. Ninkovic VM, Ninkovic SM, Miloradovic V, Stanojevic D, Babic M, Giga V, et al. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol. 2016;53:737-44.
50. Kosaraju A, Pendela VS, Hai O. Cardiogenic Shock. [Updated 2023 Apr 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482255/

51. Stanojovic M, Stankov S. Electrocardiographic changes in patients with chronic anemia. Srp Arh Celok Lek. 1998;126:461-6.
52. Wu CC, Lu YC, Yu TH, Wang CP, Hung WC, Tang WH, et al. Serum albumin level and abnormal corrected QT interval in patients with coronary artery disease and chronic kidney disease. Intern Med J. 2018;48:1242-51.
53. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047-60.
54. Panikkath R, Panikkath D. Influence of left ventricular type on QT interval in hypertensive patients. Anatol J Cardiol. 2015;15:40-1.
55. Nagele P, Pal S, Brown F, Blood J, Miller JP, Johnston J. Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia. Anesthesiology. 2012;117:321-8.
56. Niemeijer MN, van den Berg ME, Deckers JW, Franco OH, Hofman A, Kors JA, et al. Consistency of heart rate-QTc prolongation consistency and sudden cardiac death: The Rotterdam Study. Heart Rhythm. 2015;12:2078-85.

S No	MRD	NAME	AGE	AGE GROUP	SEX	OCCUPATION	RELIGION	SBP	DBP	PR	MARITAL STATUS	CONSANGUINITY	TEMPERATURE	APACHE II SCORE	HYPERTENSION	ENDOCRINE	ENDOCRINE_HYPOTHYROID	ENDOCRINE_HYPERTHYROID	ENDOCRINE_DM1
1	152110	JJ	67	3	M	RTD	H	110	60	72	M	-	98	7	Y	Y	-	-	-
2	1521147	CR	64	3	F	HOUSEWIFE	H	140	80	61	M	-	98	10	Y	Y	-	-	-
3	1689927	S.K.	49	2	F	HOUSEWIFE	H	110	70	110	M	-	98	19	-	Y	-	-	-
4	1648247	R.B.	60	3	F	HOUSEWIFE	H	130	70	74	M	-	98	12	Y	Y	-	-	-
5	1701634	D.P.S.	77	4	M	RETIRED	S	100	60	112	M	-	98	15	Y	Y	-	-	-
6	1671423	A.K.	62	3	M	BUSINESS OWNER	H	110	60	120	M	-	98	11	-	-	-	-	-
7	1605734	D.K.	70	3	F	RETIRED	S	90	60	74	M	-	99	21	Y	Y	Y	-	-
8	1207210	S.R.	62	3	F	HOMEMAKER	H	80	50	90	M	-	101	18	Y	Y	-	-	-
9	1689634	B.S.	71	4	M	RETIRED	S	110	70	90	M	-	98	14	Y	Y	-	-	-
10	1703912	B.S.	82	4	M	RETIRED	S	120	70	70	M	-	98	11	Y	Y	Y	-	-
11	1400391	K.P.J.	79	4	M	RETIRED	H	140	70	70	M	-	98	8	Y	-	-	-	-
12	1647316	A.K.J.	81	4	M	RETIRED	H	110	70	92	M	-	98	9	-	-	-	-	-
13	1680441	Z.S.	84	4	M	RETIRED	S	110	70	80	M	-	98	12	Y	-	-	-	-
14	687926	B.S.	65	3	M	BUSINESS OWNER	S	120	70	80	M	-	98	15	-	-	-	-	-
15	1681845	R.K.	75	4	M	RETIRED	S	130	70	140	M	-	98	17	Y	Y	-	-	-
16	1704069	S.B.	70	3	M	RETIRED	H	120	70	101	M	-	98	15	Y	Y	-	-	-
17	185597	M.J.N.	58	3	F	HOUSEWIFE	H	130	80	62	M	-	98	9	Y	-	-	-	-
18	729759	R.K.	64	3	M	BUSINESSMAN	H	130	80	82	M	-	98	13	Y	Y	-	-	-
19	623543	A.S.S.	76	4	M	RETIRED	S	130	80	94	M	-	98	4	-	-	-	-	-
20	1711734	D.S.	71	4	M	RETIRED	S	130	70	84	M	-	98	8	-	-	-	-	-
21	1712984	G.S.	71	4	M	FARMER	S	100	70	78	M	-	98	11	-	-	-	-	-
22	1713637	S.J.	59	3	M	BUSINESSMAN	H	130	60	30	M	-	98	14	Y	Y	-	-	-
23	1715678	A.S.	78	4	M	FARMER	S	120	70	74	M	-	98	8	-	-	-	-	-
24	1714332	A.P.S	70	3	M	RETIRED	S	110	70	114	M	-	98	13	Y	-	-	-	-
25	442888	H.K.	77	4	F	HOUSEWIFE	S	110	70	162	M	-	98	16	Y	Y	Y	-	-
26	1715680	R.C.	62	3	M	RETIRED	H	130	70	80	M	-	98	9	-	-	-	-	-
27	508536	B.R.	64	3	M	RETIRED	H	160	90	98	M	-	98	13	-	Y	-	-	-
28	1651633	S.P.	46	2	M	BUSINESS MAN	H	90	50	66	M	-	98	10	-	-	-	-	-
29	1714175	J.R.	76	4	M	RETIRED	H	140	70	34	M	-	98	17	-	Y	-	-	-
30	148539	S.S.K.	79	4	M	RETIRED	S	110	70	76	M	-	98	2	-	-	-	-	-
31	1717592	H.K.	52	3	M	BUSINESS OWNER	H	140	80	86	M	-	98	9	-	-	-	-	-
32	1718337	C.K.	76	4	F	HOUSEWIFE	H	110	70	70	M	-	98	5	-	-	-	-	-
33	1714328	A.K.A.	75	4	M	RETIRED	H	140	70	72	M	-	98	12	Y	-	-	-	-
34	1446710	R.S.	63	3	M	RETIRED	S	130	90	127	M	-	98	14	Y	Y	-	-	-
35	1714839	B.K.	64	3	M	RETIRED	S	130	70	90	M	-	98	11	Y	Y	-	-	-
36	1577383	G.D.	35	2	F	HOUSEWIFE	H	90	50	185	M	-	98	10	-	-	-	-	-
37	1713662	R.K.	63	3	M	BUSINESS OWNER	H	140	70	91	W	-	98	15	Y	Y	-	-	-
38	1711622	T.R.	64	3	M	RETIRED	H	110	70	72	M	-	98	6	-	Y	-	-	-
39	1521165	VK	46	2	M	FARMER	H	120	70	107	M	-	98	4	Y	Y	-	-	-
40	1514866	VA	73	4	M	DEPENDENT	H	110	70	90	M	-	98	9	-	Y	-	-	-
41	1521263	TK	79	4	F	DEPENDENT	S	100	60	135	M	-	97.8	15	-	-	-	-	-
42	1522478	R	57	3	F	HOUSEWIFE	H	120	80	111	M	-	97.6	11	Y	-	-	-	-
43	1521982	VK	70	3	M	DEPENDENT	H	110	70	87	M	-	98.2	9	-	-	-	-	-
44	1416151	KS	57	3	M	DEPENDENT	S	130	50	149	M	-	98.6	6	-	-	-	-	-
45	1532448	JS	70	3	M	DEPENDENT	S	140	80	91	M	-	100.6	31	Y	Y	-	-	-
46	1536516	KK	46	2	F	HOUSEWIFE	S	100	60	71	M	-	97	7	-	Y	Y	-	-
47	1022684	DG	27	1	F	HOUSEWIFE	H	90	60	160	M	-	98	11	-	-	-	-	-
48	1537805	RS	50	2	M	BUSNIESS	S	106	62	126	M	-	98.4	24	-	-	-	-	-
49	1570614	K	40	2	M	SELF	S	200	90	90	M	-	98	9	Y	-	-	-	-
50	1571397	NS	84	4	F	DEPENDENT	H	200	90	63	M	-	97.6	17	Y	Y	-	-	-
51	1554272	YS	60	3	M	RTD	S	110	70	74	M	-	98.2	4	Y	Y	-	-	-
52	1571917	SS	75	4	M	DEPENDENT	S	120	70	76	M	-	97.5	12	-	-	-	-	-
53	1572188	SK	60	3	M	DEPENDENT	H	110	60	77	M	-	100.2	8	Y	-	-	-	-
54	1572282	RL	58	3	M	GOVT SERVICE	H	140	90	105	M	-	97	13	-	Y	-	-	-
55	1572885	GR	55	3	F	HOUSEWIFE	H	100	60	73	M	-	98.4	0	Y	Y	-	-	-
56	1572998	VK	65	3	M	BUSNIESS	H	110	80	114	M	-	97.3	6	-	-	-	-	-
57	1573825	VW	75	4	F	DOCTOR	H	120	80	69	M	-	97.6	26	Y	-	-	-	-
58	168296	RN	83	4	M	DEPENDENT	H	100	70	97	M	-	98.4	31	Y	Y	-	-	-
59	1574419	AK	42	2	F	HOUSEWIFE	H	180	90	122	M	-	98.2	13	Y	Y	Y	-	-
60	1574513	AR	43	2	F	HOUSEWIFE	H	90	50	62	M	-	97.2	24	-	-	-	-	-
61	1468392	VG	65	3	M	DEPENDENT	H	110	60	47	M	-	97.6	21	Y	Y	-	-	-
62	74034	MS	69	3	M	DEPENDENT	S	110	70	101	M	-	98.6	28	Y	Y	-	-	-
63	1243060	AK	50	2	M	BUSNIESS	H	130	80	63	M	-	97.2	6	-	Y	-	-	-
64	1580185	AA	26	1	M	SERVICE	H	70	50	103	S	-	98.6	18	-	-	-	-	-

S No	MRD	NAME	ENDOCRINE_DM2	ENDOCRINE_OTHERS	NEUROLOGIC	NEUROLOGIC_HEMORRHAGIC CVA	NEUROLOGIC_ISCHAEMIC CVA	NEUROLOGIC_SEIZURE	NEUROLOGIC_SPINAL CORD INVOLVEMENT	NEUROLOGIC_OTHERS	PULMONARY	PULMONARY_PNEUMONIA	PULMONARY_COPD
1	152110	JJ	Y	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	Y	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	Y	-	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	Y	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	Y	-	-	-	-	-	-	-	Y	Y	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	Y	-	-	-	-	-	-	-	Y	Y	-
8	1207210	S.R.	Y	-	-	-	-	-	-	-	Y	Y	-
9	1689634	B.S.	Y	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	Y	-	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	Y	Y	Y
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	Y	Y	Y
15	1681845	R.K.	Y	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	Y	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	Y	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	Y	-	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	Y	Y	Y
25	442888	H.K.	-	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	Y	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	Y	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	Y	-	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	Y	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	Y	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	Y	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	Y	-	-	-	-	-	-	-	Y	-	-
40	1514866	VA	Y	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	Y	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	Y	-	Y	-	Y	-	-	-	Y	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	Y	Y	-
47	1022684	DG	-	-	-	-	-	-	-	-	Y	-	-
48	1537805	RS	-	-	-	-	-	-	-	-	Y	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	Y	-	Y	-	-	Y	-	1	Y	-	Y
51	1554272	YS	Y	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	Y	-	Y
54	1572282	RL	Y	-	-	-	-	-	-	-	Y	-	-
55	1572885	GR	Y	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	Y	-	-	Y	-	-	Y	-	-
58	168296	RN	Y	-	Y	-	-	-	-	2	Y	-	Y
59	1574419	AK	Y	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	Y	-	-	-	-	-	-	-	Y	Y	Y
62	74034	MS	Y	-	Y	-	Y	-	-	-	Y	Y	-
63	1243060	AK	Y	-	Y	-	-	-	-	2	-	-	-
64	1580185	AA	-	-	-	-	-	-	-	-	Y	Y	-

S No	MRD	NAME	PULMONARY_PLEURAL EFFUSION	PULMONARY_PNEUMOTHORAX	PULMONARY_OTHER	CARDIAC	CARDIAC_STEMI	CARDIAC_NSTEMI	CARDIAC_UNSTABLE ANGINA	CARDIAC_STABLE ANGINA	CARDIAC_CAD	CARDIAC_CONGENITAL HEART DISEASE	CARDIAC_CHF
1	152110	JJ	-	-	-	Y	Y	-	-	-	-	-	-
2	1521147	CR	-	-	-	Y	-	Y	-	-	-	-	Y
3	1689927	S.K.	-	-	-	Y	-	-	-	-	Y	-	-
4	1648247	R.B.	-	-	-	Y	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	Y	-	Y	-	-	-	-	Y
6	1671423	A.K.	-	-	-	Y	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	-	Y	-	-	-	-	Y	-	-
8	1207210	S.R.	-	-	-	Y	-	-	-	-	Y	-	-
9	1689634	B.S.	-	-	-	N	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	Y	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	Y	-	-	-	-	Y	-	-
12	1647316	A.K.J.	-	Y	-	N	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	Y	-	-	-	-	Y	-	-
14	687926	B.S.	-	-	1	Y	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	Y	-	-	-	-	-	-	Y
16	1704069	S.B.	-	-	-	Y	-	-	-	-	Y	-	-
17	185597	M.J.N.	-	-	-	Y	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	Y	-	-	-	-	Y	-	-
19	623543	A.S.S.	-	-	-	N	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	Y	-	-	-	-	Y	-	-
21	1712984	G.S.	-	-	-	Y	-	-	-	Y	Y	-	-
22	1713637	S.J.	-	-	-	Y	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	Y	-	-	Y	-	-	-	-
24	1714332	A.P.S	-	-	-	Y	-	-	-	-	-	-	Y
25	442888	H.K.	-	-	-	Y	-	-	-	-	-	-	Y
26	1715680	R.C.	-	-	-	Y	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	Y	Y	-	-	-	Y	-	-
28	1651633	S.P.	-	-	-	Y	-	-	-	-	Y	-	-
29	1714175	J.R.	-	-	-	Y	-	-	-	-	Y	-	-
30	148539	S.S.K.	-	-	-	Y	-	-	-	-	Y	-	-
31	1717592	H.K.	-	-	-	Y	-	Y	-	-	-	-	-
32	1718337	C.K.	-	-	-	Y	-	Y	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	Y	-	-	-	-	-	-	Y
34	1446710	R.S.	-	-	-	Y	-	-	-	-	Y	-	-
35	1714839	B.K.	-	-	-	Y	-	Y	-	-	Y	-	Y
36	1577383	G.D.	-	-	-	Y	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	Y	-	Y	-	-	Y	-	Y
38	1711622	T.R.	-	-	-	N	-	-	-	-	-	-	-
39	1521165	VK	-	-	2	N	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	Y	Y	-	-	-	-	-	-
41	1521263	TK	-	-	-	Y	Y	-	-	-	-	-	-
42	1522478	R	-	-	2	Y	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	Y	-	Y	-	-	-	-	-
44	1416151	KS	-	-	-	Y	-	-	Y	-	-	-	-
45	1532448	JS	Y	-	-	Y	-	Y	-	-	-	-	-
46	1536516	KK	-	-	-	Y	-	Y	-	-	-	-	-
47	1022684	DG	-	-	2	N	-	-	-	-	-	-	-
48	1537805	RS	Y	-	-	N	-	-	-	-	-	-	-
49	1570614	K	-	-	-	Y	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	N	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	Y	-	-	Y	-	Y	-	-
52	1571917	SS	-	-	-	Y	Y	-	-	-	-	-	-
53	1572188	SK	-	-	-	Y	-	Y	-	-	-	-	-
54	1572282	RL	-	-	3	Y	Y	-	-	-	-	-	-
55	1572885	GR	-	-	-	Y	Y	-	-	-	-	-	-
56	1572998	VK	-	-	-	Y	-	Y	-	-	-	-	-
57	1573825	VW	Y	-	2	Y	-	-	-	-	Y	-	-
58	168296	RN	-	-	3	N	-	-	-	-	-	-	-
59	1574419	AK	-	-	-	Y	-	-	-	-	-	-	Y
60	1574513	AR	-	-	-	Y	-	-	-	-	-	-	Y
61	1468392	VG	-	-	-	Y	-	-	-	-	Y	-	Y
62	74034	MS	-	-	3	Y	-	-	-	-	Y	-	-
63	1243060	AK	-	-	-	Y	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	Y	-	-	-	-	-	-	Y

S No	MRD	NAME	CARDIAC_ARRYTHMIA_AT	AF	AFL	PSVT	NSVT	VT	TDP	APC	VPC	OTHER	CMP_DCMP	RCMP	ICMP	HCMP	VALVULAR HEART DISEASE	VALVULAR HEART DISEASE_AS	AR	MS	MR	PERICARDIAL DISEASE_CCP	TAMPONADE	EFFUSION	OTHERS	GASTRO-INTESTINAL
1	152110	JJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	Y	Y	Y	-	-	-	4	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-	Y
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-
7	1605734	D.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	5	-
15	1681845	R.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	Y	Y	Y	-	-	-	-	Y
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	4	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	6	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	Y	Y	Y	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	7	-
27	508536	B.R.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
36	1577383	G.D.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	4	Y
37	1713662	R.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	Y	-	-	-	-	Y
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	1	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	5	Y
50	1571397	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
55	1572885	GR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	2	-
60	1574513	AR	-	-	-	-	-	Y	Y	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	Y
61	1468392	VG	-	-	-	-	-	Y	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	-
62	74034	MS	-	Y	-	-	-	Y	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	Y
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	Y
64	1580185	AA	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	3	-

S No	MRD	NAME	GASTRO-INTESTINAL_CLD	GASTRO-INTESTINAL_HEPATITIS	GASTRO-INTESTINAL_ALF	GASTRO-INTESTINAL_PANCREATITIS	GASTRO-INTESTINAL_SAIO	GASTRO-INTESTINAL_CHOLECYSTITIS	GASTRO-INTESTINAL_OTHER	NEPHRO	NEPHRO_AKI
1	152110	JJ	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	-	Y	-	Y	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	-	Y	Y	Y
6	1671423	A.K.	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	-	-	-	-	-	Y	-
8	1207210	S.R.	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	1	-	-
13	1680441	Z.S.	-	-	-	-	-	-	-	Y	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	Y	-	-	-	-	-	-	-	-
16	1704069	S.B.	Y	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	2	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	-	-	Y	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	Y	-
28	1651633	S.P.	-	-	-	-	-	-	-	Y	-
29	1714175	J.R.	-	-	-	-	-	-	-	Y	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	Y	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	Y	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	2	-	-
37	1713662	R.K.	-	-	-	-	-	-	3	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	Y	-
39	1521165	VK	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	Y	Y
41	1521263	TK	-	-	-	-	-	-	-	Y	Y
42	1522478	R	-	-	-	-	-	-	-	Y	Y
43	1521982	VK	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	Y	Y
46	1536516	KK	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	-	-
48	1537805	RS	Y	-	-	-	-	-	-	Y	Y
49	1570614	K	-	-	-	Y	-	-	-	-	-
50	1571397	NS	-	-	-	-	-	-	-	Y	-
51	1554272	YS	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	Y	-	-	-	-	-	Y	Y
55	1572885	GR	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	4	-	-
58	168296	RN	-	-	-	-	-	-	-	Y	Y
59	1574419	AK	-	-	-	-	-	-	-	-	-
60	1574513	AR	Y	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	-	-	-	Y	Y
62	74034	MS	-	-	Y	-	-	-	-	Y	Y
63	1243060	AK	Y	-	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	-	-	-	-	Y	Y

S No	MRD	NAME	NEPHRO_CKD	NEPHRO_NEPHROTIC	NEPHRO_NEPHRITIC	NEPHRO_OBSTRUCTIVE UROPATHY	NEPHRO_UTI	NEPHRO_USE OF RRT	NEPHRO_OTHER	SEPSIS	INFECTIONS	INFECTIONS_TB	HIV	DENGUE	ENTERIC	MALARIA	LEPTOSPIRA	SCRUB TYPHUS	COVID	H1N1
1	152110	JJ	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	Y	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	Y
9	1689634	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	Y	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
27	508536	B.R.	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	Y	-	-	-	-	N	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	Y	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
42	1522478	R	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
58	168296	RN	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
61	1468392	VG	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
62	74034	MS	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
63	1243060	AK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHER	MALIGNANCY	SURGICAL ILLNESS	SURGICAL ILLNESS_GI	ORTHOPEDIC	NEURO	URO	OBG	ENT	PLASTIC	TRAUMA	CTVS	SHOCK	PSYCHIATRIC	PSYCHIATRIC_DEPRESSION	ANXIETY	PSYCHOSIS	DELIRIUM	HALLUCINATION	PTSD	SCHIZOPHRENIA
1	152110	JJ	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
2	1521147	CR	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	Y	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	Y	-	-	-
9	1689634	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	Y	-	-	-	Y	-	-	-	-	-	-	N	-	-	-	-	-	-	-
14	687926	B.S.	-	-	Y	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	Y	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-
18	729759	R.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-
23	1715678	A.S.	-	-	Y	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
25	442888	H.K.	-	-	Y	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
27	508536	B.R.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
39	1521165	VK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
40	1514866	VA	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
41	1521263	TK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
42	1522478	R	-	-	Y	Y	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-
43	1521982	VK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
44	1416151	KS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
45	1532448	JS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
46	1536516	KK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
47	1022684	DG	-	-	Y	-	-	-	-	Y	-	-	-	-	Y	N	-	-	-	-	-	-	-
48	1537805	RS	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
49	1570614	K	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
50	1571397	NS	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-
51	1554272	YS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
52	1571917	SS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
53	1572188	SK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
54	1572282	RL	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
55	1572885	GR	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
56	1572998	VK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
57	1573825	VW	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
58	168296	RN	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
59	1574419	AK	-	-	Y	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-
60	1574513	AR	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
61	1468392	VG	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
62	74034	MS	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	Y	-	-	-
63	1243060	AK	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	Y	-	Y	-	-	-	-
64	1580185	AA	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-

S No	MRD	NAME	CATATONIA	WITHDRAWAL	OTHER	OTHER	HISTORY SUGGESTING LQTS	HISTORY SUGGESTING LQTS VT	SYNCOPE	SEIZURE	CARDIAC ARREST	UNEXPLAINED MOTOR ACCIDENT	UNEXPLAINED DROWNING	HEARING LOSS	PERIODIC PARALYSIS	SKELETAL DYSMORPHISM	COGNITIVE ISSUES	IMMUNE DYSFUNCTION
1	152110	JJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	-	-	PREECLAMPSIA	-	-	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
62	74034	MS	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
63	1243060	AK	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	AUTISM	FAMILY HISTORY	FAMILY HISTORY_PREMATURE SUDDEN DEATH <40 YRS	SYNCOPE	CONSANGUINITY	DROWNING	DEATH WHILE DRIVING	SEIZURES	CONGENITAL DEAFNESS	KNOWN LQT MUTATION	RELATION WITH AFFECTED PERSON	DRUGS WITH RISK OF QTC PROLONGATION	ANTIARRYTHMICS	ANTIARRYTHMICS_AMIODARONE	1A
1	152110	JJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
25	442888	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
45	1532448	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
54	1572282	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
62	74034	MS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-

S No	MRD	NAME	OTHERS	ANTIMICROBIALS	ANTIMICROBIALS_MACROLIDES	FLUOROQUINOLONES	TRIMETH-SULPHAMETHO	CLINDAMYCIN	ATT	METRONIDAZOLE	ANTIMALARIAL	ANTIFUNGAL	ANTIVIRAL	OTHERS	ANTIPSYCHOTICS
1	152110	JJ	-	-	-	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	Y - IB	Y	-	-	-	-	-	Y	-	-	-	-	Y
4	1648247	R.B.	-	Y	-	Y	-	-	-	-	-	-	-	LEVOFLOX	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	Y	-	-	-	-	-	-	-	Y	-	-	-
8	1207210	S.R.	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	Y
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	Y	-	Y	-	-	-	-	-	-	-	LEVOFLOX	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	Y
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	Y	-	-	-	-	-	-	-	Y	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	Y	-	-	-	-	-	-	-	Y	-	-	-
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	Y	-	-	-	-	-	Y	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	Y	-	-	-	-	-	Y	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	Y	-	-	-	-	-	Y	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	Y	-	Y	-	-	-	-	-	-	-	OFLOX	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-
47	1022684	DG	-	Y	-	-	-	-	-	Y	-	-	-	-	-
48	1537805	RS	-	Y	-	-	-	-	-	Y	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	Y
51	1554272	YS	-	-	-	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	Y	-	-	-	Y	-	-	-	-	-	-	-
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	Y	-	-	-	-	-	Y	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	-	-	-	-	-	-	-	-	-
62	74034	MS	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	-	-	Y
64	1580185	AA	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-

S No	MRD	NAME	ANTIPSYCHOTICS_HALOPERIDOL	OLANZAPINE	QUETIAPINE	RISPERIDONE	OTHERS	ANTIDEPRESSANTS	ANTIDEPRESSANTS_ESCITALOPRAM	FLUOXETINE	SERTRALINE	MIRTAZAPINE	IMIPRAMINE	AMITRYPTILINE	NORTRYPTILINE	OTHERS
1	152110	JJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	-	-	-	-	-	-	-	-
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
62	74034	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
63	1243060	AK	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	ANTIHISTAMINES	ANTIHISTAMINES_ DIPHENHYDRAMINE	HYDROXYZINE	OTHER	ANALGESICS, ANESTHETICS, SEDATIVES	ANALGESICS, ANESTHETICS, SEDATIVES OPIOIDS	PROPOFOL	BENZODIAZEPINES	OTHERS	ANTINEOPLASTICS	BRONCHODILATORS	BRONCHODILATORS_TERBUTALINE
1	152110	JJ	-	-	-	-	Y	-	-	Y	C	-	-	-
2	1521147	CR	-	-	-	-	Y	-	-	Y	C	-	-	-
3	1689927	S.K.	-	-	-	-	Y	F	-	Y	M	-	Y	-
4	1648247	R.B.	-	-	-	-	Y	-	-	Y	M	-	-	-
5	1701634	D.P.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
6	1671423	A.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
7	1605734	D.K.	-	-	-	-	Y	-	-	Y	-	-	Y	-
8	1207210	S.R.	-	-	-	-	Y	-	-	Y	C	-	-	-
9	1689634	B.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
10	1703912	B.S.	-	-	-	-	Y	-	-	Y	-	-	Y	-
11	1400391	K.P.J.	-	-	-	-	Y	-	-	Y	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	Y	-	-	Y	M	-	-	-
14	687926	B.S.	-	-	-	-	Y	-	-	Y	-	-	Y	-
15	1681845	R.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
16	1704069	S.B.	-	-	-	-	Y	-	-	Y	-	-	-	-
17	185597	M.J.N.	-	-	-	-	Y	-	-	Y	-	-	-	-
18	729759	R.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
21	1712984	G.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
22	1713637	S.J.	-	-	-	-	Y	-	-	Y	-	-	-	-
23	1715678	A.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
24	1714332	A.P.S	-	-	-	-	Y	-	-	Y	-	-	-	-
25	442888	H.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	Y	-	-	Y	-	-	-	-
28	1651633	S.P.	-	-	-	-	Y	-	-	Y	-	-	-	-
29	1714175	J.R.	-	-	-	-	Y	-	-	Y	-	-	-	-
30	148539	S.S.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
31	1717592	H.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
32	1718337	C.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	Y	-	-	Y	-	-	-	-
34	1446710	R.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
35	1714839	B.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
36	1577383	G.D.	-	-	-	-	Y	-	-	Y	-	-	-	-
37	1713662	R.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
38	1711622	T.R.	-	-	-	-	Y	-	-	Y	-	-	-	-
39	1521165	VK	-	-	-	-	Y	-	-	Y	C	-	-	-
40	1514866	VA	-	-	-	-	Y	-	-	Y	C	-	-	-
41	1521263	TK	-	-	-	-	Y	-	-	Y	C	-	-	-
42	1522478	R	-	-	-	-	Y	-	-	Y	C	-	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	Y	-	-	Y	D	-	-	-
45	1532448	JS	-	-	-	-	Y	F	-	-	-	-	Y	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	Y	-	-	Y	C	-	-	-
48	1537805	RS	-	-	-	-	Y	F	-	Y	M	-	-	-
49	1570614	K	-	-	-	-	Y	-	-	Y	D	-	-	-
50	1571397	NS	-	-	-	-	-	-	-	-	-	-	Y	-
51	1554272	YS	-	-	-	-	Y	-	-	Y	D	-	-	-
52	1571917	SS	-	-	-	-	Y	-	-	Y	D	-	-	-
53	1572188	SK	-	-	-	-	Y	-	-	Y	C	-	-	-
54	1572282	RL	-	-	-	-	Y	F	-	Y	D	-	Y	-
55	1572885	GR	-	-	-	-	Y	-	-	Y	C	-	-	-
56	1572998	VK	-	-	-	-	Y	M	-	Y	C	-	Y	-
57	1573825	VW	-	-	-	-	Y	F	-	Y	M	-	-	-
58	168296	RN	-	-	-	-	Y	F	-	Y	M	-	Y	-
59	1574419	AK	-	-	-	-	Y	-	-	Y	C	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	-	-	-	-	-	-	Y	-
62	74034	MS	-	-	-	-	Y	F	-	Y	M	-	Y	-
63	1243060	AK	-	-	-	-	Y	-	-	Y	L	-	-	-
64	1580185	AA	-	-	-	-	Y	-	-	Y	C	-	-	-

S No	MRD	NAME	FORMETROL	INDACATEROL	SALMETROL	SALBUTAMOL	LEVOSALBUTAMOL	OTHERS	DIURETICS	DIURETICS_FUROSEMIDE	TORSEMIDE	METOLAZONE	SPIRONOLACTONE	HYDROCHLORTHIAZIDE	CTD	GIDRUGS	GI DRUGS_LOPERAMIDE
1	152110	JJ	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
2	1521147	CR	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
3	1689927	S.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
4	1648247	R.B.	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
5	1701634	D.P.S.	-	-	-	-	-	-	Y	Y	-	Y	Y	-	-	Y	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
7	1605734	D.K.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
8	1207210	S.R.	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
10	1703912	B.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
11	1400391	K.P.J.	-	-	-	-	-	-	Y	-	-	-	-	-	Y	Y	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
13	1680441	Z.S.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
14	687926	B.S.	-	-	-	Y	-	-	Y	-	Y	-	Y	-	-	Y	-
15	1681845	R.K.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
18	729759	R.K.	-	-	-	-	-	-	Y	-	Y	-	-	-	-	Y	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
20	1711734	D.S.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
24	1714332	A.P.S	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
25	442888	H.K.	-	-	-	-	-	-	Y	Y	Y	-	Y	-	-	Y	-
26	1715680	R.C.	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
28	1651633	S.P.	-	-	-	-	-	-	Y	-	Y	-	-	-	-	Y	-
29	1714175	J.R.	-	-	-	-	-	-	Y	Y	Y	-	-	-	-	Y	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
33	1714328	A.K.A.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
35	1714839	B.K.	-	-	-	-	-	-	Y	Y	Y	Y	Y	-	-	Y	-
36	1577383	G.D.	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
37	1713662	R.K.	-	-	-	-	-	-	Y	Y	Y	-	Y	-	-	Y	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
40	1514866	VA	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
41	1521263	TK	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
44	1416151	KS	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
45	1532448	JS	-	-	Y	-	-	-	Y	Y	-	-	-	-	-	Y	-
46	1536516	KK	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
48	1537805	RS	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
50	1571397	NS	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
51	1554272	YS	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
52	1571917	SS	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
53	1572188	SK	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
54	1572282	RL	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
55	1572885	GR	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
56	1572998	VK	-	-	-	-	Y	-	Y	-	Y	-	Y	-	-	Y	-
57	1573825	VW	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
58	168296	RN	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
59	1574419	AK	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
60	1574513	AR	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
61	1468392	VG	-	-	-	-	Y	-	Y	Y	-	Y	-	-	-	Y	-
62	74034	MS	-	-	-	-	Y	-	Y	Y	-	Y	-	-	-	Y	-
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
64	1580185	AA	-	-	-	-	-	-	Y	Y	-	Y	Y	-	-	Y	-

S No	MRD	NAME	ONDANSETRON	GRANISETRON	PALONOSETRON	DOMPERIDONE	METOCLOPRAMIDE	PANTOPRAZOLE	ESOMEPRAZOLE	OMEPRAZOLE	OTHERS	DRUGS FOR BPH	DRUGS FOR BPH TAMSULOSIN	ALFUZOSIN	SILODOSIN	CHOLINERGIC ANTAGONIST	CITRATE MASSIVE BT	COCAINE
1	152110	JJ	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	Y	-	-	-	Y	-	Y	-	-	Y	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-	-	-
14	687926	B.S.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	Y	-	-	Y	-	-	Y	Y	-	-	-	-	-
28	1651633	S.P.	Y	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	LEVOSULPRIDE	-	-	-	-	-	-	-
43	1521982	VK	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
49	1570614	K	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
58	168296	RN	Y	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
59	1574419	AK	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
61	1468392	VG	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
62	74034	MS	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
63	1243060	AK	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
64	1580185	AA	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	RANOLAZINE	INOTROPES	INOTROPES_NOREPINEPHRINE	EPINEPHRINE	DOPAMINE	DOBUTAMINE	VASOPRESSIN	OTHERS	ANTIEPILEPTICS_	ANTIEPILEPTICS_LEVETIRACITAM	ANTIEPILEPTICS_OTHERS	OTHERS
1	152110	JJ	-	Y	Y	-	Y	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	Y	Y	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-
25	442888	H.K.	-	-	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	Y	Y	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	Y	Y	Y	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	Y	Y	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	Y	Y	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	Y	Y	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	Y	Y	-	Y	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	-	-	-	Y	Y	-	-
46	1536516	KK	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	Y	Y	Y	Y	-	-	-	-	-	-	-
48	1537805	RS	-	Y	Y	-	Y	-	-	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	-	-	-	-	-	-	-	Y	-	V	-
51	1554272	YS	-	-	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	Y	Y	Y	Y	-	-	-	-	-	-	-
55	1572885	GR	-	Y	Y	-	Y	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	Y	Y	-	-	-	-	-	Y	Y	-	-
58	168296	RN	-	Y	Y	-	Y	-	Y	-	-	-	-	-
59	1574419	AK	-	-	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	Y	Y	-	Y	Y	-	-	-	-	-	-
61	1468392	VG	-	Y	Y	-	-	-	-	-	-	-	-	-
62	74034	MS	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	-	-
64	1580185	AA	-	Y	Y	Y	Y	-	Y	-	-	-	-	-

S No	MRD	NAME	OTHER CONDITIONS PREDISPOSING TO PROLONGED QTC	ELECTROLYTE ABNORMALITIES	ELECTROLYTE ABNORMALITIES HYPOKALEMIA	HYPOMAGNESEMIA	HYPOCALCEMIA	OTHERS	CARDIAC CONDITIONS	CARDIAC CONDITIONS ISCHEMIA	MYOCARDITIS	BRADYCARDIA	STRESS CMP	OTHERS	ENDOCRINE DISORDERS
1	152110	JJ	Y	Y	Y	-	-	-	Y	Y	-	-	-	-	-
2	1521147	CR	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
3	1689927	S.K.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	N	-	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	Y	Y	Y	Y	Y	-	-	-	-	-	-	-	Y
8	1207210	S.R.	-	Y	-	-	Y	-	-	-	-	-	-	-	-
9	1689634	B.S.	Y	Y	-	-	-	1	Y	-	-	Y	-	-	-
10	1703912	B.S.	Y	N	-	-	-	-	Y	-	-	Y	-	-	Y
11	1400391	K.P.J.	-	N	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	N	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	Y	Y	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	N	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	N	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	Y	N	-	-	-	-	Y	-	-	Y	-	-	-
23	1715678	A.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
25	442888	H.K.	Y	Y	Y	-	-	-	-	-	-	-	-	-	Y
26	1715680	R.C.	-	N	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
28	1651633	S.P.	-	N	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	Y	Y	-	-	-	1	Y	-	-	Y	-	-	-
30	148539	S.S.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
32	1718337	C.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
33	1714328	A.K.A.	Y	N	-	-	-	-	Y	-	-	-	Y	-	-
34	1446710	R.S.	-	Y	-	-	Y	-	-	-	-	-	-	-	-
35	1714839	B.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
36	1577383	G.D.	-	N	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
38	1711622	T.R.	-	N	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	Y	-	-	Y	-	-	-	-	-	-	-	-
40	1514866	VA	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
41	1521263	TK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
42	1522478	R	-	N	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
44	1416151	KS	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
45	1532448	JS	Y	Y	-	Y	Y	-	Y	Y	-	-	Y	-	-
46	1536516	KK	Y	Y	-	Y	-	-	Y	Y	-	-	-	-	Y
47	1022684	DG	-	N	-	-	-	-	-	-	-	-	-	-	-
48	1537805	RS	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
49	1570614	K	Y	N	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	Y	-	-	Y	-	-	-	-	-	-	-	-
51	1554272	YS	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
52	1571917	SS	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
53	1572188	SK	Y	Y	Y	Y	Y	-	Y	Y	-	-	-	-	-
54	1572282	RL	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
55	1572885	GR	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
56	1572998	VK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
57	1573825	VW	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
58	168296	RN	Y	N	-	-	-	-	Y	-	-	-	Y	-	-
59	1574419	AK	Y	N	-	-	-	-	-	-	-	-	-	-	Y
60	1574513	AR	Y	Y	-	-	Y	-	Y	-	-	Y	-	-	-
61	1468392	VG	Y	N	-	-	-	-	Y	-	-	Y	-	-	-
62	74034	MS	-	Y	-	-	Y	-	-	-	-	-	-	-	-
63	1243060	AK	Y	N	-	-	-	-	-	-	-	-	-	-	-
64	1580185	AA	Y	N	-	-	-	-	Y	-	Y	-	-	-	-

S No	MRD	NAME	ENDOCRINE DISORDERS HYPOTHYROIDISM	HYPER PTH	PHAEOCHROMOCYTOMA	HYPERALDOSTERONISM	OTHERS	INTRACRANIAL DISORDERS	INTRACRANIAL DISORDERS SAH	THALAMIC HEMATOMA	CVA	ENCEPHALITIS	HEAD INJURY	OTHERS	NUTRITIONAL DISORDERS	NUTRITIONAL DISORDERS ANOREXIA NERVOSA
1	152110	JJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	687926	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	442888	H.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	508536	B.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	1651633	S.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	1577383	G.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	1532448	JS	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
46	1536516	KK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	1537805	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
50	1571397	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
52	1571917	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
54	1572282	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	-	-	-	-	-	-	-	-	-	-	-	-	-
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-	-
59	1574419	AK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
61	1468392	VG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
62	74034	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
64	1580185	AA	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	STARVATION	LIQUID PROTEIN DIET	H/O GI SURGERY	CELIAC DISEASE	OTHERS	HYPOTHERMIA	OTHERS	ECG RATE	RHYTHM_SINUS	AT	AF	AFL	APC	VPC	NSVT	VT	PSVT	OTHER	QRS DURATION	QTC INTERVAL	QTC INTERVAL GROUP	QTC INTERVAL GP
1	152110	JJ	-	-	-	-	-	-	-	72	Y	-	-	-	-	-	-	-	-	-	94	438	0	0
2	1521147	CR	-	-	-	-	-	-	-	61	Y	-	-	-	-	-	-	-	-	-	76	444	0	0
3	1689927	S.K.	-	-	-	-	-	-	-	109	Y	-	-	-	-	-	-	-	-	-	98	417	0	0
4	1648247	R.B.	-	-	-	-	-	-	-	74	Y	-	-	-	-	-	-	-	-	-	98	395	0	0
5	1701634	D.P.S.	-	-	-	-	-	-	-	112	Y	-	-	-	-	-	-	-	-	-	98	398	0	0
6	1671423	A.K.	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	82	426	0	0
7	1605734	D.K.	-	-	-	-	-	-	-	106	Y	-	-	-	-	-	-	-	-	-	118	390	0	0
8	1207210	S.R.	-	-	-	-	-	-	-	102	Y	-	-	-	-	-	-	-	-	-	70	474	1	0
9	1689634	B.S.	-	-	-	-	-	-	-	38	Y	-	-	-	-	-	-	-	-	Y - JUNCTIONAL BRADYCARDIA	78	357	0	0
10	1703912	B.S.	-	-	-	-	-	-	-	62	Y	-	-	-	-	-	-	-	-	JUNCTIONAL BRADYCARDIA	106	444	0	0
11	1400391	K.P.J.	-	-	-	-	-	-	-	89	Y	-	-	-	-	-	-	-	-	-	96	443	0	0
12	1647316	A.K.J.	-	-	-	-	-	-	-	92	Y	-	-	-	-	-	-	-	-	-	92	450	1	0
13	1680441	Z.S.	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	120	546	1	1
14	687926	B.S.	-	-	-	-	-	-	-	64	Y	-	-	-	-	Y	-	-	-	-	68	420	0	0
15	1681845	R.K.	-	-	-	-	-	-	-	132	Y	-	Y	-	-	-	-	-	-	-	88	480	1	0
16	1704069	S.B.	-	-	-	-	-	-	-	89	Y	-	-	-	-	-	-	-	-	-	117	496	1	0
17	185597	M.J.N.	-	-	-	-	-	-	-	62	Y	-	-	-	-	-	-	-	-	-	109	402	0	0
18	729759	R.K.	-	-	-	-	-	-	-	68	Y	-	-	-	-	-	-	-	-	-	84	413	0	0
19	623543	A.S.S.	-	-	-	-	-	-	-	70	Y	-	-	-	-	-	-	-	-	-	88	449	0	0
20	1711734	D.S.	-	-	-	-	-	-	-	93	Y	-	-	-	-	-	-	-	-	-	78	497	1	0
21	1712984	G.S.	-	-	-	-	-	-	-	74	Y	-	-	-	-	-	-	-	-	-	94	418	0	0
22	1713637	S.J.	-	-	-	-	-	-	-	30	Y	-	-	-	-	-	-	-	-	-	116	377	0	0
23	1715678	A.S.	-	-	-	-	-	-	-	73	Y	-	-	-	-	-	-	-	-	-	94	435	0	0
24	1714332	A.P.S	-	-	-	-	-	-	-	114	Y	-	-	-	-	-	Y	-	-	-	120	452	1	0
25	442888	H.K.	-	-	-	-	-	-	-	162	Y	-	Y	-	-	-	-	-	-	-	120	443	0	0
26	1715680	R.C.	-	-	-	-	-	-	-	97	Y	-	-	-	-	-	-	-	-	-	102	462	1	0
27	508536	B.R.	-	-	-	-	-	-	-	78	Y	-	-	-	-	-	-	Y	-	-	92	442	0	0
28	1651633	S.P.	-	-	-	-	-	-	-	66	Y	-	-	-	-	-	-	-	-	-	92	422	0	0
29	1714175	J.R.	-	-	-	-	-	-	-	34	Y	-	-	-	-	-	-	-	-	-	118	463	1	0
30	148539	S.S.K.	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	86	384	0	0
31	1717592	H.K.	-	-	-	-	-	-	-	86	Y	-	-	-	-	-	-	-	-	-	72	456	1	0
32	1718337	C.K.	-	-	-	-	-	-	-	94	Y	-	-	-	-	-	-	-	-	-	68	415	0	0
33	1714328	A.K.A.	-	-	-	-	-	-	-	76	Y	-	-	-	-	Y	-	-	-	BIGEMINY	76	441	0	0
34	1446710	R.S.	-	-	-	-	-	-	-	127	Y	-	-	-	-	-	-	-	-	-	76	441	0	0
35	1714839	B.K.	-	-	-	-	-	-	-	98	Y	-	-	-	-	-	-	-	-	-	118	493	1	0
36	1577383	G.D.	-	-	-	-	-	-	-	185	Y	-	Y	-	-	-	-	-	-	-	84	421	0	0
37	1713662	R.K.	-	-	-	-	-	-	-	91	Y	-	-	Y	-	-	-	-	-	-	120	492	1	0
38	1711622	T.R.	-	-	-	-	-	-	-	72	Y	-	-	-	-	-	-	-	-	-	98	432	0	0
39	1521165	VK	-	-	-	-	-	-	-	107	Y	-	-	-	-	-	-	-	-	-	82	427	0	0
40	1514866	VA	-	-	-	-	-	-	-	90	Y	-	-	-	-	-	-	-	-	-	120	441	0	0
41	1521263	TK	-	-	-	-	-	-	-	135	Y	-	-	-	-	-	-	-	-	-	82	540	1	1
42	1522478	R	-	-	-	-	-	-	-	111	Y	-	-	-	-	-	-	-	-	-	84	490	1	0
43	1521982	VK	-	-	-	-	-	-	-	87	Y	-	-	-	-	-	-	-	-	-	120	433	0	0
44	1416151	KS	-	-	-	-	-	-	-	149	Y	-	-	-	-	-	-	Y	-	-	106	548	1	1
45	1532448	JS	-	-	-	-	-	-	-	91	Y	-	-	-	-	-	-	-	-	-	120	590	1	1
46	1536516	KK	-	-	-	-	-	-	-	71	Y	-	-	-	-	-	-	-	-	-	76	439	0	0
47	1022684	DG	-	-	-	-	-	-	-	160	Y	-	-	-	-	-	-	-	-	-	92	464	1	0
48	1537805	RS	-	-	-	-	-	-	-	126	Y	-	-	-	-	-	-	-	-	-	84	469	1	0
49	1570614	K	Y	-	-	-	-	-	-	90	Y	-	-	-	-	-	-	-	-	-	94	432	0	0
50	1571397	NS	-	-	-	-	-	-	-	63	Y	-	-	-	-	-	-	-	-	-	76	390	0	0
51	1554272	YS	-	-	-	-	-	-	-	74	Y	-	-	-	-	-	Y	-	-	-	114	455	1	0
52	1571917	SS	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	88	407	0	0
53	1572188	SK	-	-	-	-	-	-	-	77	Y	-	Y	-	-	-	-	-	-	-	106	500	1	1
54	1572282	RL	-	-	-	-	-	-	-	105	Y	-	-	-	-	-	-	-	-	-	72	415	0	0
55	1572885	GR	-	-	-	-	-	-	-	73	Y	-	-	-	-	-	-	-	-	-	96	460	1	0
56	1572998	VK	-	-	-	-	-	-	-	114	Y	-	-	-	-	-	-	-	-	-	70	452	1	0
57	1573825	VW	-	-	-	-	-	-	-	69	Y	-	-	-	-	-	-	-	-	-	78	413	0	0
58	168296	RN	-	-	-	-	-	-	-	97	Y	-	-	-	-	-	-	-	-	-	80	396	0	0
59	1574419	AK	-	-	-	-	-	-	-	122	Y	-	-	-	-	-	-	-	-	-	66	478	1	0
60	1574513	AR	-	-	-	Y	-	-	-	62	Y	-	-	-	-	-	-	-	-	-	70	738	1	1
61	1468392	VG	-	-	-	-	-	-	-	47	Y	-	-	-	-	-	-	Y	-	-	120	562	1	1
62	74034	MS	-	-	-	-	-	-	-	101	Y	-	-	-	-	-	-	Y	-	-	120	503	1	1
63	1243060	AK	Y	-	-	-	-	-	-	63	Y	-	-	-	-	-	-	-	-	-	94	577	1	1
64	1580185	AA	-	-	-	-	-	-	-	103	Y	-	-	-	-	-	Y	-	-	-	76	505	1	1

S No	MRD	NAME	BROAD BASE T WAVE	NOTCHED T WAVE	LONG ISOELEC SEG & NARROW BASE T WAVE	T ALTERNANS	U WAVE	AV BLOCK	ST ELEVATION	ST DEPRESSION	TORSADES	LVH	RVH	POOR R PROGRESSION	BRUGADA	EPSILON WAVE	EARLY REPOLARISATION	OTHERS	RBS
1	152110	JJ	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	186
2	1521147	CR	-	-	-	N	-	-	-	Y	-	Y	-	-	-	-	-	-	500
3	1689927	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145
4	1648247	R.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	156
5	1701634	D.P.S.	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	373
6	1671423	A.K.	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	103
7	1605734	D.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	115
8	1207210	S.R.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	500
9	1689634	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	501
10	1703912	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-	88
11	1400391	K.P.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	108
12	1647316	A.K.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	90
13	1680441	Z.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85
14	687926	B.S.	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-	130
15	1681845	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94
16	1704069	S.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	130
17	185597	M.J.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145
18	729759	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	156
19	623543	A.S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	133
20	1711734	D.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	174
21	1712984	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84
22	1713637	S.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	233
23	1715678	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140
24	1714332	A.P.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	188
25	442888	H.K.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	163
26	1715680	R.C.	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	132
27	508536	B.R.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	212
28	1651633	S.P.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	140
29	1714175	J.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	144
30	148539	S.S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	102
31	1717592	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84
32	1718337	C.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92
33	1714328	A.K.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88
34	1446710	R.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	164
35	1714839	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	198
36	1577383	G.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	104
37	1713662	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	170
38	1711622	T.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	149
39	1521165	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	310
40	1514866	VA	-	-	-	-	-	Y/1 °	Y	Y	-	-	-	-	-	-	-	-	148
41	1521263	TK	INVERTED	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	142
42	1522478	R	INVERTED	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	135
43	1521982	VK	INVERTED	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	180
44	1416151	KS	UPRIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	132
45	1532448	JS	INVERTED	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	475
46	1536516	KK	-	-	-	-	-	Y/MOBITZ TYPE -1	-	-	-	-	-	-	-	-	-	-	108
47	1022684	DG	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	128
48	1537805	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	160
49	1570614	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72
50	1571397	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122
51	1554272	YS	INVERTED	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	160
52	1571917	SS	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	124
53	1572188	SK	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	-	112
54	1572282	RL	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	168
55	1572885	GR	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	148
56	1572998	VK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	192
57	1573825	VW	INVERTED	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	106
58	168296	RN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	73
59	1574419	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112
60	1574513	AR	Y	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	142
61	1468392	VG	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	120
62	74034	MS	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	136
63	1243060	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	102
64	1580185	AA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100

S No	MRD	NAME	HB	TLC	PLATELET	PH	PCO2	PO2	HCO3	SO2	LACTATE	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB	PH	HCO3	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB
1	152110	JJ	14.5	21.6	259	7.42	36	231	23.4	100	2.2	3.4	9.7	2.1	2.4	139	28	0.8	0.5	136	57	87	6.7	3.9	2	2	1	2	2	1	2	2	2	2	3	3	2	2	2
2	1521147	CR	10.1	8.8	160	7.44	30	99	20.4	100	1.1	4.1	8	2	4	141	39	0.6	0.6	79	150	136	5.8	3.5	2	1	2	1	2	2	2	2	1	2	3	3	3	1	2
3	1689927	S.K.	9	18.7	460	7.3	25	187	12.3	100	0.8	2.4	8.7	2	2	140	26	1	0.9	42	81	783	7.2	3.15	1	1	1	2	2	1	2	2	2	2	3	3	3	2	1
4	1648247	R.B.	11.2	7.8	110	7.47	37	277	26.9	100	1.3	4.2	9	2.6	4	141	42	1.3	0.67	28	16	70	7.9	3.68	3	3	2	2	2	2	2	2	3	2	2	2	2	2	2
5	1701634	D.P.S.	13.9	32.3	328	7.36	25	70	14.1	93	5	5	8.9	2.5	3.6	132	39	1.8	1.61	120	42	112	7.2	4.1	2	1	3	2	2	2	1	2	3	3	3	3	2	2	2
6	1671423	A.K.	14	11.1	250	7.35	37	106	22.3	96	1	4.3	9.5	2.6	4	136	19	0.8	0.67	29	40	108	6.9	3.73	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
7	1605734	D.K.	10.7	4.9	172	7.44	33	102	22.4	98	1.9	2.7	7.5	1	4.68	136	308	5.1	0.58	20	12	65	5.7	3	2	2	1	1	1	3	2	3	3	2	2	2	1	1	1
8	1207210	S.R.	9.2	8.2	320	7.35	42	44	23.2	77	1.1	5	7.9	1.7	3.1	137	65	1.4	0.2	40	20	152	6.7	3.1	2	2	3	1	2	2	2	3	3	2	3	2	3	2	1
9	1689634	B.S.	12.8	12.2	238	7.4	29	72	18	94	2.4	6.3	8.8	2.4	4.4	128	63	1.8	0.7	29	14	103	6.7	3.54	2	1	3	2	2	2	1	3	3	2	2	2	2	2	2
10	1703912	B.S.	12.4	8.7	405	7.39	35	88	20	90	0.7	4.8	9	2.5	3.9	129	29	0.9	0.5	45	40	125	7.7	3.7	2	1	2	2	2	2	1	2	2	2	3	2	2	2	2
11	1400391	K.P.J.	13.5	10.5	264	7.37	39	107	24	100	1.6	4.8	8.2	3	4	134	35	1.4	0.9	39	59	78	8	4.2	2	2	2	1	3	2	1	2	3	2	2	3	2	2	2
12	1647316	A.K.J.	6.3	11.7	402	7.51	32	111	25.5	99	0.7	3.7	9.4	2.9	2.9	132	43	0.7	0.27	19	15	161	5.5	2	3	2	2	2	3	2	1	2	2	2	2	2	3	1	1
13	1680441	Z.S.	9.4	5.8	150	7.44	42	87	28.5	97	1.5	3.3	10	2.6	3.4	138	19	1.4	0.68	56	23	145	7.9	4	2	3	1	2	2	2	2	2	3	2	3	2	3	2	2
14	687926	B.S.	8.2	17.5	674	7.45	43	85	21.5	96	1	4	9.5	2.7	1.5	126	32	0.4	0.44	17	21	98	5.3	2.1	3	1	2	2	2	1	1	2	1	2	2	2	2	1	1
15	1681845	R.K.	13.4	6.4	150	7.43	36	88	21.7	93	0.8	4.1	8.7	2.9	3.3	139	42	1.1	1.17	28	16	103	7.4	3.71	2	1	2	2	3	2	2	2	2	2	2	2	2	2	2
16	1704069	S.B.	8.1	9	305	7.43	39	89	24	92	0.9	4.5	8.8	2.4	3.6	137	72	0.9	0.8	40	20	156	7	3.5	2	2	2	2	2	2	2	3	2	2	3	2	3	2	2
17	185597	M.J.N.	11.3	9.5	234	7.46	40	156	22	100	1.3	4.2	9.2	3	2.9	139	19	0.5	0.37	25	23	115	6.8	3.49	3	2	2	2	3	2	2	2	1	2	2	2	2	2	1
18	729759	R.K.	15	8.8	224	7.4	42	127	23	100	0.5	4.8	9.3	2.8	4.6	138	36	0.82	0.8	45	24	89	6.7	4	2	2	2	2	3	3	2	2	2	2	3	2	2	2	2
19	623543	A.S.S.	12.5	9.5	140	7.37	45	103	22.9	98	0.9	3.8	9.6	2.4	1.9	132	22	0.8	0.45	29	21	73	7.6	4.3	2	2	2	2	2	1	1	2	2	2	2	2	2	2	2
20	1711734	D.S.	13.3	10.3	288	7.43	43	97	20	88	1.4	3.9	9.5	2.9	3.7	121	17	0.9	1.8	45	54	124	7.3	4	2	1	2	2	3	2	1	2	2	3	3	3	2	2	2
21	1712984	G.S.	9.1	7.6	210	7.42	39	92	21.4	94	1.2	4.8	9	2.8	3.9	136	35	1	1.2	18	16	98	6.9	3.9	2	1	2	2	3	2	2	2	2	3	2	2	2	2	2
22	1713637	S.J.	12.6	8.1	247	7.24	34	98	18.9	95	2.1	5.1	8.8	2.6	4	136	44	3.3	0.16	16	13	170	6.3	3	1	1	3	2	2	2	2	2	3	2	2	2	3	1	1
23	1715678	A.S.	10.5	14.6	178	7.36	38	90	21	96	1	4.49	8.7	2.5	2.3	134	40	1.41	1	25	16	156	7	3.6	2	1	2	2	2	1	1	2	3	2	2	2	3	2	2
24	1714332	A.P.S	15	18.5	340	7.38	35	101	20.7	98	3.6	4.8	8.3	2.2	3	132	29	1.2	0.8	59	71	117	6.9	4	2	1	2	1	2	2	1	2	3	2	3	3	2	2	2
25	442888	H.K.	11.4	8.5	206	7.45	45	104	23	100	0.2	3.1	9.5	2.8	3	130	40	0.8	0.64	22	9	91	6.8	3.6	3	2	1	2	3	2	1	2	2	2	2	2	2	2	2
26	1715680	R.C.	14.9	14.2	373	7.47	47	116	22.4	100	0.9	4.5	9.2	3	3.5	134	40	1	1	33	15	67	7	4.3	3	2	2	2	3	2	1	2	2	2	2	2	2	2	2
27	508536	B.R.	11	8.8	130	7.2	35	98	14.9	98	4	4.5	8	2.1	3.2	136	49	3.2	0.9	48	58	88	7.2	4.1	1	1	2	1	2	2	2	2	3	2	3	2	3	2	2
28	1651633	S.P.	12.5	7.5	233	7.43	26	87	21	96	1.5	4	9	2.9	4	141	27	1.1	0.33	17	25	77	7	4	2	1	2	2	3	2	2	2	2	2	2	2	2	2	2
29	1714175	J.R.	13.5	6.8	184	7.25	40	94	19	97	2.3	6	9.4	2.3	5.3	136	91	2.2	0.67	25	42	102	6.9	3.7	1	1	3	2	2	3	2	3	3	2	2	3	2	2	2
30	148539	S.S.K.	10.7	9.2	171	7.38	29	132	24.1	100	0.5	4.4	9	2.7	2.4	137	32	0.9	0.5	19	25	96	6.7	3.5	2	2	2	2	2	1	2	2	2	2	2	2	2	2	2
31	1717592	H.K.	13.1	7.4	177	7.4	38	94	22.3	99	0.9	4.4	8.9	3	2.9	146	34	1.3	0.8	27	21	93	7	4	2	2	2	2	3	2	3	2	3	2	2	2	2	2	2
32	1718337	C.K.	12.6	6.7	240	7.43	37	102	22	96	0.6	4.4	9.6	2.4	1.7	141	23	0.6	0.3	17	9	79	7.6	4.1	2	2	2	2	2	1	2	2	1	2	2	2	2	2	2
33	1714328	A.K.A.	13.5	11	223	7.45	44	89	21.8	98	0.7	4.4	10	2.5	3	136	20	1.8	0.3	20	14	98	7.5	3.7	3	1	2	2	2	2	2	2	3	2	2	2	2	2	2
34	1446710	R.S.	12.8	1.9	86	7.41	43	96	20.9	99	1.4	4.1	7.7	1.9	2.1	132	66	1.8	0.5	28	23	49	4.9	2.4	2	1	2	1	2	1	1	3	3	2	2	2	2	1	1
35	1714839	B.K.	15.2	18.4	285	7.45	39	98	20.5	95	0.9	6.3	9	2.8	2.6	137	24	1.2	0.65	308	71	77	6.7	3.4	3	1	3	2	3	1	2	2	3	2	3	3	2	2	1
36	1577383	G.D.	12.1	8.9	150	7.39	46	99	22	96	0.3	4.2	8.6	1.7	3.5	137	17	0.9	1	130	129	76	6.7	4.3	2	2	2	2	2	2	2	2	2	2	3	3	2	2	2
37	1713662	R.K.	12.5	9.5	243	7.38	38	85	23	92	1	5.7	9.4	1.77	3.2	136	36	0.8	0.45	30	17	64	7.5	4.42	2	2	3	2	2	2	2	2	2	2	2	2	2	2	2
38	1711622	T.R.	12.9	5.5	120	7.36	36	84	21.5	90	1.2	3.8	9	2.5	1.9	143	31	0.9	0.26	21	25	107	7	4.16	2	1	2	2	2	1	2	2	2	2	2	2	2	2	2
39	1521165	VK	12.3	5.7	140	7.47	30	115	21.8	99	1.8	4.4	8.1	2.4	3.7	138	59	0.7	0.7	23	41	142	5.8	3.2	3	1	2	1	2	2	2	3	2	2	2	3	3	1	1
40	1514866	VA	11.5	10.6	194	7.43	38	131	25.2	99	0.8	4.6	9.4	1.9	4.1	136	43	1.5	0.7	28	27	35	6.4	4	2	2	2	2	2	2	2	3	2	2	2	1	1	2
41	1521263	TK	10.4	23.1	183	7.4	30	101	18.6	98	2.1	4.6	9.2	1.8	3	141	99	1	0.5	299	236	84	6.4	3.5	2	1	2	2	2	2	3	2	2	3	3	2	1	2
42	1522478	R	8.9	5.6	274	7.39	35	98	21	96	1.4	3.73	8.9	2.4	3.7	132	36	1.59	0.9	45	25	88	7.3	2.8	2	1	2	2	2	2	1	2	3	2	3	2	2	2	1
43	1521982	VK	11.5	7.5	87	7.35	34	102	18.8	98	2.2	4.1	9	2.3	4.5	141	31	1	0.3	23	12	111	6.9	4.1	2	1	2	2	2	3	2	2	2	2	2	2	2	2	2
44	1416151	KS	10.1	6.3	416	7.46	30	82	21.2	97	1.2	3.6	8.5	2.3	3.2	136	23	0.9	0.5	34	32	170	5.5	2.8	3	1	2	1	2	2	2	2	2	2	2	2	3	1	1
45	1532448	JS	11.3	14.7	412	7.33	28	325	14.8	100	2.8	4.5	7.7	1.6	3.1	136	43	1.2	0.5	89	85	131	5.1	2.3	1	1	2	1	1	2	2	2	3	2	3	3	3	1	1
46	1536516	KK	14.1	13	240	7.51	37	189	29.5	100	1.1	3.6	9.4	1.6	4.4	143	280	0.8	0.8	74	56	98	7.4	3.8	3	3	2	2	1	2	2	3	2	2	3	3	2	2	2
47	1022684	DG	11.3	17.8	121	7.47	29	134	21.1	99	1.5	3.8	10	3	1.7	141	77	0.6	0.2	38	22	399	6.9	3.2	3	1	2	2	3	1	2	3	1	2	2	2	3	2	1
48	1537805	RS	9.6	43	259	7.06	42	130	11.9	97	11.3	6.2	7.6	2	5.8	132	129	2.2	6.1	85	28	126	7.5	2.2	1	1	3	1	2	3	1	3	3	3	3	2	2	2	1
49	1570614	K	9.1	15	267	7.4	36	75	22.3	95	2	4.6	11	2.1	1.6	140	35	0.9	0.4	32	20	141	7	4.1	2	2	2	3	2	1	2	2	2	2	2	3	2	2	2
50	1571397	NS	11.9	11.1	229	7.4	52	148	32.2	99	0.9	4.4	8.1	1.9	4.6	137	33	0.6	0.2	27	19	44	5.6	3.1	2	3	2	1	2	3	2	2	1	2	2	2	2	1	1
51	1554272	YS	14.4	6.3	152	7.42	35	86	22.7	97	0.8	4.3	9.4	2.2	2.6	134	24	0.9	0.5	40	80	89	7.1	4.4	2	2	2	2	2	1	1	2	2	2	3	3	2	2	2
52	1571917	SS	12.8	12.8	215	7.31	41	120	20.6	98	1.7	4.1	9.5	2.7	3.4	139	37	1.4	0.4	31	24	80	7.8	4	1	1	2	2	2	2	2	2	3	2	2	2	2	2	2
53	1572188	SK	11.1	11.5	150	7.46	33	103	23.5	98	1.5	3	6.2	1.4	2.4	143	19	0.7	0.2	16	13	56	4.7	2.7	3	2	1	1	1	1	2	2	2	2	2	2	2	1	1
54	1572282	RL	13.3	15.1	140	7.44	26	83	17.7	97	2.1	4.9	7.8	2.2	5.1	140	45	1.3	0.7	1196	654	97	6.7	4.3	2	1	2	1	2	3	2	2	3	2	3	3	2	2	2
55	1572885	GR	11.8	23.3	323	7.43	28	125	21	100	1.2	5	9.2	2.8	4	135	22	0.8	0.2	148	85	118	7	4.4	2	1	3	2	3	2	2	2	2	2	3	3	2	2	2
56	1572998	VK	14.4	8.9	203	7.35	36	98	22.8	98	1.6	4.5	9.8	1.9	3.4	138	24	0.8	0.6	21	21	116	7	4.5	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
57	1573825	VW	11.1	7.9	360	7.39	51	80	24	92	0.8	3	8.9	2.04	3.6	129	13	0.8	0.5	45	32	92	6.4	3.7	2	2	1	2	2	2	1	2	2	2	3	2	2	1	2
58	168296	RN	11.6	4.9	86	7.21	16	320	6.4	100	9.6	4.6	9.2	2.9	2.5	141	105	3.5	1.2	70	40	83	5.1	3.1	1	1	2	2	3	1	2	3	3	3	3	2	2	1	1
59	1574419	AK	12.3	15	206	7.45	39	78	27.1	96	0.8	4.9	9	2.8	3.6	135	14	0.5	0.4	26	28	141	5.6	2.8	3	3	2	2	3	2	2	2	1	2	2	2	3	1	1
60	1574513	AR	13.2	37	144	7.34	23	127	12.4	99	6.4	4.8	8.2	3.5	4.1	135	28	0.7	25.2	136	28	187	7.1	3.1	1	1	2	1	3	2	2	2	2	3	2	3	2	3	2	1
61	1468392	VG	13.1	8.9	152	7.45	36	98	19	98	3	4.7	9.2	2.1	4.2	134	142	3.7	0.8	10	9	140	7.3	4	3	1	2	2	2	2	1	3	3	2	2	2	3	2	2
62	74034	MS	9.3	18.4	233	7.43	41	90	25	98	1.5	5	8.1	2.1	3.4	124	98	1.9	1.6	123	99	92	6.1	3.6	2	2	3	1	2	2	1	3	3	3	3	3	2	1	2
63	1243060	AK	16.5	8.4	185	7.53	21	105	17.5	99	2.6	4.7	9.5	1.9	4.2	139	51	0.9	2.1	51	37	161	7.4	3.7	3	1	2	2	2	2	2	3	2	3	3	2	3	2	2
64	1580185	AA	13.6	8.9	162	7.45	44	98	21	96	1.8	5.3	8.6	2.2	3.8	132	76	1.9	1.3	102	136	30	5.6	3.1	3	1	3	2	2	2	1	3	3	3	3	3	3	1	1

S No	MRD	NAME	BLOOD CULTURE	LVEF	SPECIFIC TREATEMENT GIVEN FOR PROLONGED QTC T/T OF REVERSIBLE CAUSE	BETA BLOCKER	IV MGSO4	ISOPROTERENOL	IV XYLOCAINE	MEXILETINE	SYMPATHETIC DENERVATION	OVERDRIVE PACING	AICD	OTHERS	OUTCOMES OF TREATMENT SPECIFIC TO PROLONGED QTC BENEFIT ACHIEVED
1	152110	JJ	-	20	-	-	-	-	-	-	-	-	-	-	-
2	1521147	CR	-	18	-	-	-	-	-	-	-	-	-	-	-
3	1689927	S.K.	-	18	-	-	-	-	-	-	-	-	-	-	-
4	1648247	R.B.	-	54	-	-	-	-	-	-	-	-	-	-	-
5	1701634	D.P.S.	-	26	-	-	-	-	-	-	-	-	-	-	-
6	1671423	A.K.	-	34	-	-	-	-	-	-	-	-	-	-	-
7	1605734	D.K.	-	40	-	-	-	-	-	-	-	-	-	-	-
8	1207210	S.R.	-	30	-	-	-	-	-	-	-	-	-	-	Y
9	1689634	B.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
10	1703912	B.S.	-	54	-	-	-	-	-	-	-	-	-	-	-
11	1400391	K.P.J.	-	35	-	Y	-	-	-	-	-	-	-	-	-
12	1647316	A.K.J.	-	60	-	-	-	-	-	-	-	-	-	-	-
13	1680441	Z.S.	-	42	Y	-	Y	-	-	-	-	-	-	-	Y
14	687926	B.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
15	1681845	R.K.	-	38	Y	-	Y	-	-	-	-	-	-	-	Y
16	1704069	S.B.	-	50	Y	Y	Y	-	-	-	-	-	-	-	Y
17	185597	M.J.N.	-	60	-	-	-	-	-	-	-	-	-	-	-
18	729759	R.K.	-	60	-	-	-	-	-	-	-	-	-	-	-
19	623543	A.S.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
20	1711734	D.S.	-	25	Y	Y	-	-	-	-	-	-	-	-	Y
21	1712984	G.S.	-	45	-	-	-	-	-	-	-	-	-	-	-
22	1713637	S.J.	-	60	Y	-	-	-	-	-	-	Y	-	-	Y
23	1715678	A.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
24	1714332	A.P.S	-	60	Y	Y	Y	-	Y	-	-	-	-	-	Y
25	442888	H.K.	-	60	Y	Y	Y	-	-	-	-	-	-	-	-
26	1715680	R.C.	-	60	Y	Y	-	-	-	-	-	-	-	-	Y
27	508536	B.R.	-	46	Y	Y	-	-	-	-	-	-	-	-	Y
28	1651633	S.P.	-	30	Y	-	-	-	-	-	-	-	-	-	-
29	1714175	J.R.	-	40	Y	Y	-	-	-	-	-	-	-	-	Y
30	148539	S.S.K.	-	52	-	-	-	-	-	-	-	-	-	-	-
31	1717592	H.K.	-	60	Y	Y	Y	-	Y	-	-	-	-	-	Y
32	1718337	C.K.	-	50	-	-	-	-	-	-	-	-	-	-	-
33	1714328	A.K.A.	-	42	Y	Y	Y	-	-	-	-	-	-	-	Y
34	1446710	R.S.	-	50	Y	-	Y	-	-	-	-	-	-	-	Y
35	1714839	B.K.	-	24	Y	Y	Y	-	-	-	-	-	-	-	Y
36	1577383	G.D.	-	50	-	-	-	-	-	-	-	-	-	-	-
37	1713662	R.K.	-	24	-	-	-	-	-	-	-	-	-	-	-
38	1711622	T.R.	-	60	-	-	-	-	-	-	-	-	-	-	-
39	1521165	VK	-	60	-	-	-	-	-	-	-	-	-	-	-
40	1514866	VA	-	27	-	-	-	-	-	-	-	-	-	-	-
41	1521263	TK	-	12	-	-	-	-	-	-	-	-	-	-	-
42	1522478	R	-	60	-	-	-	-	-	-	-	-	-	-	-
43	1521982	VK	-	30	-	-	-	-	-	-	-	-	-	-	-
44	1416151	KS	-	30	-	Y	Y	-	Y	Y	-	-	-	-	Y
45	1532448	JS	-	16	Y	-	Y	-	-	-	-	-	-	-	Y
46	1536516	KK	-	42	-	-	-	-	-	-	-	-	-	-	-
47	1022684	DG	Y	60	-	-	-	-	-	-	-	-	-	-	-
48	1537805	RS	Y	-	-	-	-	-	-	-	-	-	-	-	-
49	1570614	K	-	60	-	-	-	-	-	-	-	-	-	-	-
50	1571397	NS	-	60	-	-	-	-	-	-	-	-	-	-	-
51	1554272	YS	-	46	Y	Y	Y	-	-	Y	-	-	-	-	Y
52	1571917	SS	-	32	-	-	-	-	-	-	-	-	-	-	-
53	1572188	SK	-	30	Y	-	-	-	-	-	-	-	-	-	Y
54	1572282	RL	-	42	-	-	-	-	-	-	-	-	-	-	-
55	1572885	GR	-	25	-	-	-	-	-	-	-	-	-	-	-
56	1572998	VK	-	30	-	-	-	-	-	-	-	-	-	-	-
57	1573825	VW	-	35	-	-	-	-	-	-	-	-	-	-	-
58	168296	RN	Y	30	-	-	-	-	-	-	-	-	-	-	-
59	1574419	AK	-	42	-	-	-	-	-	-	-	-	-	-	-
60	1574513	AR	Y	35	Y	-	Y	-	Y	Y	-	-	-	-	Y
61	1468392	VG	-	18	Y	-	Y	-	Y	Y	-	-	-	-	Y
62	74034	MS	Y	20	Y	-	Y	-	Y	Y	-	-	-	-	Y
63	1243060	AK	-	27	Y	-	-	-	-	-	-	-	-	-	Y
64	1580185	AA	-	20	Y	-	Y	-	Y	Y	-	-	-	-	Y

S No	MRD	NAME	QTC SHORTENED	SYNCOPE CONTROLLED	SEIZURE CONTROLLED	ARRYTHMIA CONTROLLED	DURATION OF ICU STAY	NO OF VT EPISODES	QTC UNCHANGED	QTC SHORTENED BY	QTC PROLONGED BY	-	-	-	DISCHARGED	DEATH	TREATMENT COMPLICATION
1	152110	JJ	-	-	-	-	5	-	Y	-	-	438	438	0	Y	N	-
2	1521147	CR	-	-	-	-	4	-	Y	-	-	444	444	0	Y	N	-
3	1689927	S.K.	-	-	-	-	11	-	N	-	-	417	417	0	Y	N	-
4	1648247	R.B.	-	-	-	-	6	-	N	-	-	395	395	0	Y	N	-
5	1701634	D.P.S.	-	-	-	-	5	-	N	-	-	398	398	0	Y	N	-
6	1671423	A.K.	-	-	-	-	3	-	N	-	-	426	426	0	Y	N	-
7	1605734	D.K.	-	-	-	-	9	-	N	-	-	390	390	0	Y	N	-
8	1207210	S.R.	Y	-	-	-	3	-	N	34	-	440	440	0	N	Y	-
9	1689634	B.S.	-	-	-	-	2	-	N	-	-	357	357	0	Y	N	-
10	1703912	B.S.	-	-	-	-	2	-	N	-	-	444	444	0	Y	N	-
11	1400391	K.P.J.	-	-	-	-	1	-	N	4	-	439	439	0	Y	N	-
12	1647316	A.K.J.	-	-	-	-	4	-	N	-	-	450	450	1	Y	N	-
13	1680441	Z.S.	-	-	-	-	3	-	N	56	-	490	490	1	Y	N	-
14	687926	B.S.	-	-	-	-	3	-	N	-	-	420	420	0	Y	N	-
15	1681845	R.K.	Y	-	-	-	2	-	N	49	-	431	431	0	Y	N	-
16	1704069	S.B.	Y	-	-	-	1	-	N	26	-	470	470	1	Y	N	-
17	185597	M.J.N.	-	-	-	-	1	-	N	-	-	402	402	0	Y	N	-
18	729759	R.K.	-	-	-	-	2	-	N	-	-	413	413	0	Y	N	-
19	623543	A.S.S.	-	-	-	-	1	-	N	-	-	449	449	0	Y	N	-
20	1711734	D.S.	Y	-	-	-	3	-	N	14	-	483	483	1	Y	N	-
21	1712984	G.S.	-	-	-	-	1	-	N	-	-	418	418	0	Y	N	-
22	1713637	S.J.	-	-	-	-	4	-	N	-	-	377	377	0	N	N	-
23	1715678	A.S.	-	-	-	-	2	-	N	-	-	435	435	0	Y	N	-
24	1714332	A.P.S	-	-	-	Y	4	-	N	-	65	452	517	1	Y	N	-
25	442888	H.K.	-	-	-	Y	3	-	N	-	45	443	488	1	Y	N	-
26	1715680	R.C.	-	-	-	-	3	-	N	2	-	460	460	1	Y	N	-
27	508536	B.R.	Y	-	-	-	2	1	N	9	-	433	433	0	Y	N	-
28	1651633	S.P.	-	-	-	-	1	-	N	-	-	422	422	0	Y	N	-
29	1714175	J.R.	-	-	-	-	3	-	N	26	-	437	437	0	Y	N	-
30	148539	S.S.K.	-	-	-	-	2	-	N	-	-	384	384	0	Y	N	-
31	1717592	H.K.	Y	-	-	Y	3	2	N	17	-	439	439	0	Y	N	-
32	1718337	C.K.	-	-	-	-	2	-	N	-	-	415	415	0	Y	N	-
33	1714328	A.K.A.	-	-	-	-	2	-	N	6	-	435	435	0	Y	N	-
34	1446710	R.S.	Y	-	-	-	4	-	N	12	-	429	429	0	Y	N	-
35	1714839	B.K.	-	-	-	-	5	-	N	33	-	460	460	1	Y	N	-
36	1577383	G.D.	-	-	-	-	2	-	N	-	-	421	421	0	Y	N	-
37	1713662	R.K.	-	-	-	-	5	-	N	-	-	492	492	1	Y	N	-
38	1711622	T.R.	-	-	-	-	1	-	N	-	-	432	432	0	Y	N	-
39	1521165	VK	-	-	-	-	4	-	Y	-	-	427	427	0	Y	N	-
40	1514866	VA	-	-	-	-	6	-	Y	-	-	441	441	0	Y	N	-
41	1521263	TK	-	-	-	-	7	-	N	35	-	505	505	1	Y	N	-
42	1522478	R	-	-	-	-	3	-	N	72	-	418	418	0	Y	N	-
43	1521982	VK	-	-	-	-	10	-	N	-	87	433	520	1	N	N	-
44	1416151	KS	Y	-	-	Y	3	6	N	86	-	462	462	1	Y	N	-
45	1532448	JS	Y	-	-	-	10	-	N	135	-	455	455	1	N	Y	-
46	1536516	KK	-	-	-	-	5	-	N	-	-	439	439	0	Y	N	-
47	1022684	DG	-	-	-	-	10	-	Y	-	-	464	464	1	Y	N	-
48	1537805	RS	-	-	-	-	10	-	N	-	25	469	494	1	N	Y	-
49	1570614	K	-	-	-	-	7	-	Y	-	-	432	432	0	Y	N	-
50	1571397	NS	-	-	-	-	10	-	N	-	68	390	458	1	N	Y	-
51	1554272	YS	Y	-	-	Y	6	1	N	21	-	434	434	0	Y	N	-
52	1571917	SS	-	-	-	-	3	-	N	-	-	407	407	0	Y	N	-
53	1572188	SK	-	-	-	-	4	-	Y	-	-	500	500	1	Y	N	-
54	1572282	RL	-	-	-	-	2	-	N	-	52	415	467	1	N	Y	-
55	1572885	GR	-	-	-	-	4	-	Y	-	-	460	460	1	Y	N	-
56	1572998	VK	-	-	-	-	6	-	N	437	-	15	15	0	Y	N	-
57	1573825	VW	-	-	-	-	20	-	N	-	17	413	430	0	Y	N	-
58	168296	RN	-	-	-	-	1	-	N	-	22	396	418	0	N	Y	-
59	1574419	AK	-	-	-	-	6	-	N	24	-	454	454	1	Y	N	-
60	1574513	AR	Y	-	-	Y	20	6	N	188	-	550	550	1	Y	N	-
61	1468392	VG	Y	-	-	Y	8	1	N	84	-	478	478	1	Y	N	-
62	74034	MS	Y	-	-	Y	16	4	N	19	-	484	484	1	N	Y	-
63	1243060	AK	Y	-	-	-	3	-	N	52	-	525	525	1	Y	N	-
64	1580185	AA	Y	-	-	Y	5	3	N	36	-	469	469	1	N	Y	-

S No	MRD	NAME	AGE	AGE GROUP	SEX	OCCUPATION	RELIGION	SBP	DBP	PR	MARITAL STATUS	CONSANGUINITY	TEMPERATURE	APACHE II SCORE	HYPERTENSION	ENDOCRINE	ENDOCRINE_HYPOTHYROID	ENDOCRINE_HYPERTHYROID	ENDOCRINE_DM1
65	1588011	NS	65	3	M	DEPENDENT	S	100	60	174	M	-	97.8	10	-	-	-	-	-
66	1589396	PS	72	4	M	DEPENDENT	H	-	-	63	M	-	100	22	Y	Y	-	-	-
67	146195	RC	74	4	M	DEPENDENT	H	90	60	150	M	-	97.6	6	-	-	-	-	-
68	1593613	PK	33	2	F	HOUSEWIFE	S	110	70	90	M	-	98	8	-	-	-	-	-
69	14594147	SK	33	2	M	BUSNIESS	H	100	80	70	M	-	100	6	-	-	-	-	-
70	1592868	HK	68	3	F	HOUSEWIFE	S	120	60	76	M	-	97.6	9	Y	-	-	-	-
71	1597803	RK	52	3	F	DEPENDENT	S	100	60	114	M	-	98.4	10	Y	Y	Y	-	-
72	1412995	M	52	3	F	HOUSEWIFE	H	100	70	98	M	-	102	28	-	Y	-	-	-
73	1633241	NSG	82	4	M	DEPENDENT	H	-	-	80	M	-	92	30	Y	Y	-	-	-
74	1633143	SR	80	4	F	DEPENDENT	H	80	60	140	M	-	99.8	24	Y	-	-	-	-
75	1633719	GS	39	2	M	SERVICE	H	110	60	175	M	-	97.6	0	Y	-	-	-	-
76	1632590	KS	63	3	M	RTD	S	160	90	125	M	-	97.2	8	Y	-	-	-	-
77	1598500	AJ	64	3	M	BUSINESS	H	150	70	106	M	-	97.6	3	Y	Y	-	-	-
78	266158	AK	72	4	F	DEPENDENT	S	120	70	137	M	-	101.2	16	Y	Y	-	-	-
79	1221379	RK	62	3	M	FARMER	H	120	60	75	M	-	94	22	Y	Y	-	-	-
80	1623921	NK	65	3	F	HOUSEWIFE	H	120	60	86	M	-	98.7	6	Y	-	-	-	-
81	1634549	RM	54	3	M	SERVICE	M	120	80	96	M	Y	98.6	6	-	Y	-	-	-
82	1634655	MS	60	3	M	DEPENDENT	S	140	80	121	M	-	98.6	9	Y	Y	-	-	-
83	1632765	RK	81	4	F	HOUSEWIFE	S	150	60	73	M	-	96	14	Y	-	-	-	-
84	694895	NC	56	3	M	BUSINESS	H	120	80	113	M	-	98.6	6	-	Y	-	-	-
85	1634698	MK	37	2	F	HOUSEWIFE	S	100	70	97	M	-	99.8	18	-	Y	Y	-	-
86	1632033	SK	62	3	F	HOUSEWIFE	S	140	80	123	M	-	101	21	Y	-	-	-	-
87	297402	R	66	3	F	HOUSEWIFE	H	160	90	98	M	-	98.6	6	Y	Y	Y	-	-
88	1635798	BG	76	4	F	DEPENDENT	H	160	80	90	M	-	98.6	3	Y	-	-	-	-
89	269628	RLP	89	4	M	DEPENDENT	H	-	-	141	M	-	96	31	-	-	-	-	-
90	1636098	JS	42	2	M	SERVICE	S	110	70	76	M	-	98.2	12	-	Y	-	-	-
91	1636504	JS	42	2	M	FARMER	S	-	-	138	M	-	97.6	36	-	-	-	-	-
92	1636474	AS	26	1	M	STUDENT	S	130	80	114	S	-	100.4	3	-	-	-	-	-
93	794933	DV	65	3	M	DEPENDENT	H	100	60	118	M	-	97.2	3	Y	Y	-	-	-
94	1031223	N	59	3	F	DEPENDENT	S	110	70	60	S	-	98	12	Y	Y	Y	-	Y
95	1636360	TS	69	3	M	DEPENDENT	S	90	60	95	M	-	98.7	23	-	-	-	-	-
96	1637086	GK	70	3	F	DEPENDENT	S	120	70	88	M	-	99.6	18	Y	Y	-	-	-
97	1354326	SD	66	3	M	DEPENDENT	H	130	80	119	M	-	99	11	Y	Y	-	-	-
98	1637220	KD	80	4	F	DEPENDENT	H	150	90	101	M	-	97.6	11	Y	Y	-	-	-
99	1621286	SS	72	4	M	DEPENDENT	S	-	-	120	M	-	100.9	14	Y	-	-	-	-
100	1637116	D	80	4	M	DEPENDENT	H	150	100	82	M	-	101.4	9	Y	Y	-	-	-
101	1637226	VP	72	4	M	DEPENDENT	H	130	70	116	M	-	97.4	4	Y	-	-	-	-
102	1637726	RR	63	3	F	HOUSEWIFE	H	110	70	106	M	-	98.6	4	Y	Y	-	-	-
103	1637746	AS	60	3	M	DEPENDENT	S	-	-	106	M	-	96.3	32	Y	Y	-	-	-
104	1637086	GK	70	3	F	DEPENDENT	S	120	70	88	M	-	101.2	29	Y	Y	-	-	-
105	1637865	KD	52	3	F	HOUSEWIFE	H	70	50	136	M	-	98	38	-	-	-	-	-
106	1637103	DL	80	4	M	DEPENDENT	H	110	60	100	M	-	98.2	6	Y	Y	-	-	-
107	1645458	MR	48	2	F	BUSINESS	H	130	70	120	M	-	102	12	-	-	-	-	-
108	1521863	SA	67	3	M	DEPENDENT	M	130	80	120	M	Y	101.6	28	Y	-	-	-	-
109	1608961	RKB	57	3	M	BUSINESS	H	120	70	79	M	-	97.6	4	-	-	-	-	-
110	618241	BK	65	3	F	DEPENDENT	S	100	70	79	M	-	98.2	3	Y	-	-	-	-
111	1563586	SK	78	4	F	DEPENDENT	S	140	50	119	M	-	100.4	18	Y	-	-	-	-
112	1510911	GS	65	3	M	RETIRED	S	80	50	126	M	-	102	17	-	-	-	-	-
113	878118	RG	56	3	M	BUSINESS	H	110	70	93	M	-	100.6	11	Y	Y	Y	-	-
114	1646391	PV	65	3	M	BUSINESS	H	120	60	81	M	-	101.3	15	Y	Y	Y	-	-
115	1647777	RS	61	3	M	DEPENDENT	H	140	80	143	M	-	101.6	15	-	-	-	-	-
116	1648371	KG	80	4	F	DEPENDENT	H	160	80	75	M	-	97.2	6	Y	-	-	-	-
117	453937	MB	68	3	F	DEPENDENT	H	50	30	133	M	-	98.4	24	Y	Y	Y	-	-
118	476441	PC	87	4	M	DEPENDENT	H	90	60	61	M	-	101	16	Y	Y	-	-	-
119	1646754	DK	68	3	F	DEPENDENT	S	130	70	86	M	-	100	18	Y	Y	-	-	-
120	1648289	PK	53	3	M	BUSINESS	H	150	80	119	M	-	99	6	-	Y	-	-	-
121	1648810	RL	73	4	M	DEPENDENT	H	100	60	60	M	-	96	17	-	-	-	-	-
122	200550	SK	62	3	F	HOUSEWIFE	S	110	60	89	M	-	97.8	9	Y	Y	Y	-	-
123	1647890	PN	67	3	M	B USINESS	H	110	70	101	M	-	99.1	12	-	-	-	-	-
124	1366283	RK	62	3	M	BUSINESS	H	150	80	105	M	-	97	12	Y	-	-	-	-
125	164953	JS	75	4	M	DEPENDENT	S	110	70	79	M	-	98.2	6	Y	-	-	-	-
126	1649550	PK	54	3	F	HOUSEWIFE	S	150	90	120	M	-	98.2	13	Y	Y	-	-	-
127	1649747	SR	75	4	F	DEPENDENT	H	160	80	94	M	-	100.3	18	Y	Y	-	-	-
128	1650194	D	80	4	F	DEPENDENT	H	140	80	82	M	-	99	11	-	-	-	-	-

S No	MRD	NAME	ENDOCRINE_DM2	ENDOCRINE_OTHERS	NEUROLOGIC	NEUROLOGIC_HEMORRHAGIC CVA	NEUROLOGIC_ISCHAEMIC CVA	NEUROLOGIC_SEIZURE	NEUROLOGIC_SPINAL CORD INVOLVEMENT	NEUROLOGIC_OTHERS	PULMONARY	PULMONARY_PNEUMONIA	PULMONARY_COPD
65	1588011	NS	-	-	-	-	-	-	-	-	-	-	-
66	1589396	PS	Y	-	Y	-	-	Y	-	-	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	Y	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	-	-	-	-	-	-	-	-
72	1412995	M	Y	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	Y	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	Y	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	Y	-	-	-	-	-	-	-	-	-	-
78	266158	AK	Y	-	Y	-	Y	-	-	-	Y	Y	-
79	1221379	RK	Y	-	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	Y	-	Y	-	-	Y	-	-	-	-	-
82	1634655	MS	Y	-	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	-	Y	-	Y	-	-	-	-	-	-
84	694895	NC	Y	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	Y	Y	-
86	1632033	SK	-	-	-	-	-	-	-	-	Y	Y	-
87	297402	R	-	-	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	Y	-	-	Y	-	-	-	-	-
90	1636098	JS	Y	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	Y	-	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	Y	Y	-
96	1637086	GK	Y	-	-	-	-	-	-	-	-	-	-
97	1354326	SD	Y	-	-	-	-	-	-	-	Y	-	Y
98	1637220	KD	Y	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	Y	-	-
100	1637116	D	Y	-	Y	-	-	-	-	2	-	-	-
101	1637226	VP	-	-	Y	-	-	-	-	2	-	-	-
102	1637726	RR	Y	-	-	-	-	-	-	-	Y	-	Y
103	1637746	AS	Y	-	-	-	-	-	-	-	Y	Y	-
104	1637086	GK	Y	-	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-
106	1637103	DL	Y	-	Y	-	-	-	-	2	-	-	-
107	1645458	MR	-	-	-	-	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	Y	Y	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	Y	-	Y
111	1563586	SK	-	-	-	-	-	-	-	-	Y	Y	-
112	1510911	GS	-	-	-	-	-	-	-	-	Y	-	Y
113	878118	RG	-	-	-	-	-	-	-	-	Y	Y	Y
114	1646391	PV	-	-	-	-	-	-	-	-	Y	Y	-
115	1647777	RS	-	-	-	-	-	-	-	-	Y	Y	-
116	1648371	KG	-	-	Y	-	Y	Y	-	-	-	-	-
117	453937	MB	Y	-	-	-	-	-	-	-	Y	Y	-
118	476441	PC	Y	-	-	-	-	-	-	-	-	-	-
119	1646754	DK	Y	-	-	-	-	-	-	-	Y	Y	Y
120	1648289	PK	Y	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	Y	-	Y	-	-	-	-	-	-
122	200550	SK	Y	-	-	-	-	-	-	-	Y	Y	-
123	1647890	PN	-	-	-	-	-	-	-	-	Y	Y	-
124	1366283	RK	-	-	Y	-	Y	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	Y	-	-	-	-	-	-	-	Y	Y	-
127	1649747	SR	Y	-	-	-	-	-	-	-	Y	Y	-
128	1650194	D	-	-	-	-	-	-	-	-	Y	Y	Y

S No	MRD	NAME	PULMONARY_PLEURAL EFFUSION	PULMONARY_PNEUMOTHORAX	PULMONARY_OTHER	CARDIAC	CARDIAC_STEMI	CARDIAC_NSTEMI	CARDIAC_UNSTABLE ANGINA	CARDIAC_STABLE ANGINA	CARDIAC_CAD	CARDIAC_CONGENITAL HEART DISEASE	CARDIAC_CHF
65	1588011	NS	-	-	-	Y	-	-	-	-	Y	-	-
66	1589396	PS	-	-	-	Y	-	-	-	-	Y	-	Y
67	146195	RC	-	-	-	Y	-	-	-	-	Y	-	-
68	1593613	PK	-	-	3	N	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	N	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	Y	Y	-	-	-	Y	-	-
71	1597803	RK	-	-	-	Y	-	-	-	-	-	-	Y
72	1412995	M	-	-	-	N	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	Y	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	N	-	-	-	-	-	-	-
75	1633719	GS	-	-	4	Y	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	Y	Y	-	-	-	-	-	Y
77	1598500	AJ	-	-	-	Y	-	-	-	-	Y	-	-
78	266158	AK	-	-	-	Y	-	-	-	-	Y	-	-
79	1221379	RK	-	-	-	Y	-	-	-	-	Y	-	Y
80	1623921	NK	-	-	-	Y	-	-	-	-	Y	-	-
81	1634549	RM	-	-	-	Y	-	-	-	-	Y	-	Y
82	1634655	MS	-	-	-	Y	-	-	-	-	Y	-	-
83	1632765	RK	-	-	-	Y	-	-	-	-	Y	-	Y
84	694895	NC	-	-	-	N	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	Y	-	-	-	-	-	Y	-
86	1632033	SK	-	-	-	Y	-	-	-	-	-	-	Y
87	297402	R	-	-	-	Y	-	-	-	-	Y	-	-
88	1635798	BG	-	-	-	Y	-	Y	-	-	-	-	-
89	269628	RLP	-	-	-	Y	-	-	-	-	Y	-	-
90	1636098	JS	-	-	-	N	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	N	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	Y	-	-	-	-	-	-	-
93	794933	DV	-	-	-	Y	-	-	-	-	Y	-	-
94	1031223	N	-	-	-	Y	-	Y	-	-	Y	-	-
95	1636360	TS	-	-	-	N	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	Y	-	Y	-	-	Y	-	Y
97	1354326	SD	-	-	-	Y	-	-	-	-	Y	-	-
98	1637220	KD	-	-	-	Y	-	-	-	-	-	-	Y
99	1621286	SS	-	-	2,4	N	-	-	-	-	-	-	-
100	1637116	D	-	-	-	N	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	Y	-	Y	-	-	Y	-	-
102	1637726	RR	-	-	-	Y	Y	-	-	-	-	-	-
103	1637746	AS	-	-	-	Y	-	-	-	-	-	-	Y
104	1637086	GK	-	-	-	Y	-	Y	-	-	Y	-	Y
105	1637865	KD	-	-	-	N	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	Y	-	-	-	-	-	-	-
107	1645458	MR	-	-	-	N	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	Y	-	-	-	-	Y	-	Y
109	1608961	RKB	-	-	-	Y	Y	-	-	-	-	-	-
110	618241	BK	-	-	-	N	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	Y	-	-	-	-	Y	-	-
112	1510911	GS	-	Y	-	Y	-	-	-	-	-	-	Y
113	878118	RG	-	-	-	Y	-	-	-	-	Y	-	-
114	1646391	PV	-	-	-	Y	-	-	-	-	-	-	-
115	1647777	RS	Y	-	-	Y	-	-	-	-	Y	-	Y
116	1648371	KG	-	-	-	Y	-	-	-	-	-	-	-
117	453937	MB	-	-	-	Y	-	-	-	-	-	-	Y
118	476441	PC	-	-	-	N	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	N	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	Y	Y	-	-	-	-	-	Y
121	1648810	RL	-	-	-	Y	-	-	-	-	Y	-	-
122	200550	SK	-	-	-	Y	-	-	-	-	Y	-	-
123	1647890	PN	-	-	-	Y	-	-	-	-	-	-	-
124	1366283	RK	-	-	-	Y	-	Y	-	-	-	-	Y
125	164953	JS	-	-	-	Y	Y	-	-	-	-	-	-
126	1649550	PK	-	-	-	Y	Y	-	-	-	-	-	Y
127	1649747	SR	-	-	-	Y	-	Y	-	-	-	-	-
128	1650194	D	-	-	-	Y	-	-	-	-	-	-	-

S No	MRD	NAME	CARDIAC_ARRYTHMIA_AT	AF	AFL	PSVT	NSVT	VT	TDP	APC	VPC	OTHER	CMP_DCMP	RCMP	ICMP	HCMP	VALVULAR HEART DISEASE	VALVULAR HEART DISEASE_AS	AR	MS	MR	PERICARDIAL DISEASE_CCP	TAMPONADE	EFFUSION	OTHERS	GASTRO-INTESTINAL
65	1588011	NS	-	-	-	-	-	Y	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	-	Y	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	Y	-	-	Y	-	-	-	Y	1,4	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
73	1633241	NSG	-	Y	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	Y
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
78	266158	AK	-	Y	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
79	1221379	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
85	1634698	MK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
87	297402	R	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
92	1636474	AS	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	Y
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	4	-
104	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	5	-
107	1645458	MR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
108	1521863	SA	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
112	1510911	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-
113	878118	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	Y
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
118	476441	PC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-
123	1647890	PN	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	4	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
128	1650194	D	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-

S No	MRD	NAME	GASTRO-INTESTINAL_CLD	GASTRO-INTESTINAL_HEPATITIS	GASTRO-INTESTINAL_ALF	GASTRO-INTESTINAL_PANCREATITIS	GASTRO-INTESTINAL_SAIO	GASTRO-INTESTINAL_CHOLECYSTITIS	GASTRO-INTESTINAL_OTHER	NEPHRO	NEPHRO_AKI
65	1588011	NS	-	-	-	-	-	-	-	Y	-
66	1589396	PS	-	-	-	-	-	-	-	Y	Y
67	146195	RC	-	-	-	-	-	-	-	Y	Y
68	1593613	PK	-	-	-	-	-	-	-	Y	-
69	14594147	SK	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	-	-	-	-	-	-
72	1412995	M	-	-	Y	-	-	-	-	Y	Y
73	1633241	NSG	Y	-	Y	-	-	-	-	Y	Y
74	1633143	SR	-	-	-	-	-	-	-	Y	Y
75	1633719	GS	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	-	-	-	Y	Y
79	1221379	RK	-	-	-	-	-	-	-	Y	Y
80	1623921	NK	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	Y	-	-	-
83	1632765	RK	-	-	-	-	-	-	-	Y	Y
84	694895	NC	-	-	-	-	-	Y	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-
87	297402	R	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	-	-	-	Y	Y
90	1636098	JS	-	Y	-	-	-	-	-	-	-
91	1636504	JS	-	Y	Y	-	-	-	-	Y	Y
92	1636474	AS	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	Y	-
94	1031223	N	-	-	-	-	-	-	-	Y	-
95	1636360	TS	-	-	-	-	-	-	-	Y	Y
96	1637086	GK	-	-	-	-	-	-	-	Y	-
97	1354326	SD	Y	-	-	-	-	-	-	Y	Y
98	1637220	KD	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	Y	-
100	1637116	D	-	-	-	-	-	-	-	Y	-
101	1637226	VP	-	-	-	-	-	-	-	Y	-
102	1637726	RR	-	-	-	-	-	-	-	Y	-
103	1637746	AS	-	-	-	-	-	-	-	Y	Y
104	1637086	GK	-	-	-	-	-	-	-	Y	-
105	1637865	KD	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	-	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	Y	Y
109	1608961	RKB	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	-	Y	Y
112	1510911	GS	-	-	-	-	-	-	-	Y	Y
113	878118	RG	-	-	-	-	-	-	-	-	-
114	1646391	PV	Y	-	-	-	-	-	-	Y	Y
115	1647777	RS	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	-	-	Y	Y
117	453937	MB	-	-	-	-	-	-	-	Y	Y
118	476441	PC	-	-	-	-	-	-	-	Y	Y
119	1646754	DK	-	-	-	-	-	-	-	Y	Y
120	1648289	PK	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	Y	Y
122	200550	SK	-	-	-	-	-	-	-	Y	Y
123	1647890	PN	-	-	-	-	-	-	-	Y	Y
124	1366283	RK	-	-	-	-	-	-	-	Y	Y
125	164953	JS	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	-	-	Y	Y
127	1649747	SR	-	-	-	-	-	-	-	Y	-
128	1650194	D	-	-	-	-	-	-	-	Y	Y

S No	MRD	NAME	NEPHRO_CKD	NEPHRO_NEPHROTIC	NEPHRO_NEPHRITIC	NEPHRO_OBSTRUCTIVE UROPATHY	NEPHRO_UTI	NEPHRO_USE OF RRT	NEPHRO_OTHER	SEPSIS	INFECTIONS	INFECTIONS_TB	HIV	DENGUE	ENTERIC	MALARIA	LEPTOSPIRA	SCRUB TYPHUS	COVID	H1N1
65	1588011	NS	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
72	1412995	M	-	-	-	-	-	Y	-	Y	Y	-	-	Y	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
79	1221379	RK	Y	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y
87	297402	R	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	Y	-	Y	Y	-	-	Y	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
94	1031223	N	Y	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
96	1637086	GK	Y	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
104	1637086	GK	Y	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
108	1521863	SA	Y	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	-	-	-	Y
109	1608961	RKB	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	Y
112	1510911	GS	-	-	-	-	-	Y	-	Y	N	-	-	-	-	-	-	-	-	-
113	878118	RG	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y
114	1646391	PV	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y
115	1647777	RS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-	-	-	-	Y
120	1648289	PK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-	-	-	-	Y
123	1647890	PN	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y
124	1366283	RK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
127	1649747	SR	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHER	MALIGNANCY	SURGICAL ILLNESS	SURGICAL ILLNESS_GI	ORTHOPEDIC	NEURO	URO	OBG	ENT	PLASTIC	TRAUMA	CTVS	SHOCK	PSYCHIATRIC	PSYCHIATRIC_DEPRESSION	ANXIETY	PSYCHOSIS	DELIRIUM	HALLUCINATION	PTSD	SCHIZOPHRENIA
65	1588011	NS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
66	1589396	PS	HSV	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
67	146195	RC	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
68	1593613	PK	-	-	Y	-	-	-	Y	Y	-	-	-	-	-	N	-	-	-	-	-	-	-
69	14594147	SK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
70	1592868	HK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
71	1597803	RK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
72	1412995	M	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	Y	-	-	-
73	1633241	NSG	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
74	1633143	SR	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	Y	-	-	-
75	1633719	GS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
76	1632590	KS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
77	1598500	AJ	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
78	266158	AK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
79	1221379	RK	-	1	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
80	1623921	NK	-	-	Y	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
81	1634549	RM	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
82	1634655	MS	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
83	1632765	RK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
84	694895	NC	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
85	1634698	MK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
86	1632033	SK	-	2	Y	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-
87	297402	R	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
88	1635798	BG	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
89	269628	RLP	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
90	1636098	JS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
91	1636504	JS	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
92	1636474	AS	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-
93	794933	DV	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
94	1031223	N	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
95	1636360	TS	-	-	Y	-	-	-	Y	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
96	1637086	GK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
97	1354326	SD	-	3	Y	-	-	-	Y	-	-	-	-	-	-	N	-	-	-	-	-	-	-
98	1637220	KD	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
99	1621286	SS	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
100	1637116	D	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-
101	1637226	VP	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
102	1637726	RR	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
103	1637746	AS	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
104	1637086	GK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
105	1637865	KD	-	-	Y	Y	-	-	Y	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
106	1637103	DL	-	-	Y	-	-	-	Y	-	-	-	-	-	-	N	-	-	-	-	-	-	-
107	1645458	MR	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
108	1521863	SA	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
109	1608961	RKB	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
110	618241	BK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
111	1563586	SK	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	Y	-	-	-	-	-	-
112	1510911	GS	-	-	Y	-	-	-	-	-	-	-	Y	-	Y	Y	-	-	Y	-	-	-	-
113	878118	RG	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
114	1646391	PV	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
115	1647777	RS	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
116	1648371	KG	-	-	Y	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
117	453937	MB	-	-	Y	-	-	-	-	-	-	-	-	Y	Y	N	-	-	-	-	-	-	-
118	476441	PC	-	-	Y	-	-	-	Y	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
119	1646754	DK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
120	1648289	PK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
121	1648810	RL	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
122	200550	SK	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-
123	1647890	PN	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-
124	1366283	RK	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
125	164953	JS	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
126	1649550	PK	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	Y
127	1649747	SR	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
128	1650194	D	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-

S No	MRD	NAME	CATATONIA	WITHDRAWAL	OTHER	OTHER	HISTORY SUGGESTING LQTS	HISTORY SUGGESTING LQTS_VT	SYNCOPE	SEIZURE	CARDIAC ARREST	UNEXPLAINED MOTOR ACCIDENT	UNEXPLAINED DROWNING	HEARING LOSS	PERIODIC PARALYSIS	SKELETAL DYSMORPHISM	COGNITIVE ISSUES	IMMUNE DYSFUNCTION
65	1588011	NS	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	-	-	-	Y	Y	-	Y	Y	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	Y	Y	Y	-	-	-	-	Y	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
79	1221379	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
87	297402	R	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	Y	-	-	Y	Y	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
112	1510911	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
113	878118	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	Y	-	Y	-	Y	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	Y	-	-	-	-	-	-	Y	-	-	-	-
123	1647890	PN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	AUTISM	FAMILY HISTORY	FAMILY HISTORY_PREMATURE SUDDEN DEATH <40 YRS	SYNCOPE	CONSANGUINITY	DROWNING	DEATH WHILE DRIVING	SEIZURES	CONGENITAL DEAFNESS	KNOWN LQT MUTATION	RELATION WITH AFFECTED PERSON	DRUGS WITH RISK OF QTC PROLONGATION	ANTIARRYTHMICS	ANTIARRYTHMICS_AMIODARONE	1A
65	1588011	NS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
66	1589396	PS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
71	1597803	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
79	1221379	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	Y	-	Y	-	-	-	-	-	-	-	-	Y	Y	-
81	1634549	RM	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
87	297402	R	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
89	269628	RLP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
112	1510911	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
113	878118	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	Y	Y	-	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
123	1647890	PN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHERS	ANTIMICROBIALS	ANTIMICROBIALS_MACROLIDES	FLUOROQUINOLONES	TRIMETH-SULPHAMETHO	CLINDAMYCIN	ATT	METRONIDAZOLE	ANTIMALARIAL	ANTIFUNGAL	ANTIVIRAL	OTHERS	ANTIPSYCHOTICS
65	1588011	NS	-	-	-	-	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	Y	-	-	-	-	-	-	-	-	Y	ACYCLOVIR	-
67	146195	RC	-	-	-	-	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	Y	-	-	-	-	Y	-	-	-	-	-	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	Y	-	Y	-	-	-	-	-	-	-	LEVOFLOX	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-	-
78	266158	AK	-	Y	Y	-	-	-	-	Y	-	-	-	AZITHRO	-
79	1221379	RK	-	Y	-	-	-	Y	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	Y	-	-	-	-	-	Y	-	-	-	-	-
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-	-
84	694895	NC	-	Y	-	-	-	-	-	Y	-	-	-	-	-
85	1634698	MK	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-
86	1632033	SK	-	Y	Y	-	-	-	-	-	-	Y	Y	VORICONAZOLE, OSELTAMIVIR	-
87	297402	R	-	-	-	-	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	Y	-	-	-	-	-	Y	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	Y	-	-	-	-	-	-	-	Y	-	ITRACONAZOLE	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	Y	-	-	-	-	-	Y	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	Y	-	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
108	1521863	SA	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	Y	-	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
112	1510911	GS	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	Y
113	878118	RG	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
114	1646391	PV	-	Y	-	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
115	1647777	RS	-	Y	Y	-	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
120	1648289	PK	-	-	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
123	1647890	PN	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	Y
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	ANTIPSYCHOTICS_HALOPERIDOL	OLANZAPINE	QUETIAPINE	RISPERIDONE	OTHERS	ANTIDEPRESSANTS	ANTIDEPRESSANTS_ESCITALOPRAM	FLUOXETINE	SERTRALINE	MIRTAZAPINE	IMIPRAMINE	AMITRYPTILINE	NORTRYPTILINE	OTHERS
65	1588011	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
79	1221379	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
87	297402	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	-	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	-	-	-	-	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	Y	-	-	-	-	-	-	Y	-
107	1645458	MR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	-	-	-	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
112	1510911	GS	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
113	878118	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	-	-	-	-	-	-	-	-	-	-	-	-	-
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	-	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
123	1647890	PN	-	-	-	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	Y	Y	-	Y	-	-	Y	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	ANTIHISTAMINES	ANTIHISTAMINES_ DIPHENHYDRAMINE	HYDROXYZINE	OTHER	ANALGESICS, ANESTHETICS, SEDATIVES	ANALGESICS, ANESTHETICS, SEDATIVES OPIOIDS	PROPOFOL	BENZODIAZEPINES	OTHERS	ANTINEOPLASTICS	BRONCHODILATORS	BRONCHODILATORS_TERBUTALINE
65	1588011	NS	-	-	-	-	Y	-	-	Y	C	-	-	-
66	1589396	PS	-	-	-	-	Y	F	-	Y	M	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	Y	F	-	Y	M	-	-	-
69	14594147	SK	-	-	-	-	Y	-	-	Y	M	-	-	-
70	1592868	HK	-	-	-	-	Y	-	-	Y	C	-	-	-
71	1597803	RK	-	-	-	-	Y	-	-	Y	C	-	-	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	Y	-	-	Y	C	-	-	-
77	1598500	AJ	-	-	-	-	Y	-	-	Y	C	-	-	-
78	266158	AK	-	-	-	-	Y	F	-	Y	M	-	Y	-
79	1221379	RK	-	-	-	-	-	-	-	-	-	Y/IMATINIB	Y	-
80	1623921	NK	-	-	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	Y	-	-	Y	L	-	-	-
82	1634655	MS	-	-	-	-	Y	T	-	-	-	-	-	-
83	1632765	RK	-	-	-	-	Y	F	-	Y	M	-	Y	-
84	694895	NC	-	-	-	-	Y	-	-	Y	C	-	-	-
85	1634698	MK	-	-	-	-	Y	-	-	Y	C	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	Y	-
87	297402	R	-	-	-	-	Y	T	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	Y	-	-	Y	C	-	-	-
89	269628	RLP	-	-	-	-	Y	F	-	Y	M	-	Y	-
90	1636098	JS	-	-	-	-	Y	-	-	Y	C	-	-	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	Y	-
96	1637086	GK	-	-	-	-	Y	F	-	Y	M	-	-	-
97	1354326	SD	-	-	-	-	Y	-	-	Y	C	-	Y	-
98	1637220	KD	-	-	-	-	Y	-	-	Y	C	-	-	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	Y	F	-	Y	M	-	-	-
101	1637226	VP	-	-	-	-	Y	-	-	Y	L	-	-	-
102	1637726	RR	-	-	-	-	Y	-	-	Y	C	-	Y	-
103	1637746	AS	-	-	-	-	Y	F	-	Y	M	-	-	-
104	1637086	GK	-	-	-	-	Y	F	-	Y	M	-	-	-
105	1637865	KD	-	-	-	-	Y	F	-	Y	M	-	-	-
106	1637103	DL	-	-	-	-	Y	T	-	-	-	-	-	-
107	1645458	MR	-	-	-	-	Y	F	-	Y	M	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	Y	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	Y	F	-	Y	M	-	Y	-
112	1510911	GS	-	-	-	-	-	-	-	-	-	-	Y	-
113	878118	RG	-	-	-	-	Y	-	-	Y	C	-	Y	-
114	1646391	PV	-	-	-	-	Y	-	-	Y	C	-	Y	-
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	Y	-
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	Y	F	-	Y	M	-	Y	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	Y	-
120	1648289	PK	-	-	-	-	Y	-	-	Y	C	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	-	-	-	-	-	-	Y	-
123	1647890	PN	-	-	-	-	Y	-	-	Y	C	-	Y	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	Y	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	Y	-
126	1649550	PK	-	-	-	-	-	-	-	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	FORMETROL	INDACATEROL	SALMETROL	SALBUTAMOL	LEVOSALBUTAMOL	OTHERS	DIURETICS	DIURETICS_FUROSEMIDE	TORSEMIDE	METOLAZONE	SPIRONOLACTONE	HYDROCHLORTHIAZIDE	CTD	GIDRUGS	GI DRUGS_LOPERAMIDE
65	1588011	NS	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
66	1589396	PS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
70	1592868	HK	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
71	1597803	RK	-	-	-	-	-	-	Y	-	Y	-	Y	-	-	Y	-
72	1412995	M	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
73	1633241	NSG	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
76	1632590	KS	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
78	266158	AK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
79	1221379	RK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
80	1623921	NK	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
81	1634549	RM	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
82	1634655	MS	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
83	1632765	RK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
85	1634698	MK	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
86	1632033	SK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
87	297402	R	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
88	1635798	BG	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
89	269628	RLP	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
94	1031223	N	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
95	1636360	TS	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
96	1637086	GK	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
97	1354326	SD	-	-	-	-	Y	-	Y	Y	-	-	Y	-	-	Y	-
98	1637220	KD	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
99	1621286	SS	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
102	1637726	RR	-	-	-	-	Y	-	Y	-	-	-	Y	-	-	Y	-
103	1637746	AS	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
104	1637086	GK	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
107	1645458	MR	-	-	-	-	-	-	Y	-	Y	-	Y	-	-	Y	-
108	1521863	SA	-	-	-	-	Y	-	Y	Y	-	Y	-	-	-	Y	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
112	1510911	GS	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
113	878118	RG	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
114	1646391	PV	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
115	1647777	RS	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
117	453937	MB	-	-	-	-	-	-	Y	Y	-	Y	-	-	-	Y	-
118	476441	PC	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
119	1646754	DK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
120	1648289	PK	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
122	200550	SK	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
123	1647890	PN	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
124	1366283	RK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
125	164953	JS	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
126	1649550	PK	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
127	1649747	SR	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-

S No	MRD	NAME	ONDANSETRON	GRANISETRON	PALONOSETRON	DOMPERIDONE	METOCLOPRAMIDE	PANTOPRAZOLE	ESOMEPRAZOLE	OMEPRAZOLE	OTHERS	DRUGS FOR BPH	DRUGS FOR BPH TAMSULOSIN	ALFUZOSIN	SILODOSIN	CHOLINERGIC ANTAGONIST	CITRATE MASSIVE BT	COCAINE
65	1588011	NS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-
68	1593613	PK	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	Y	-
69	14594147	SK	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	LEVOSULPRIDE	-	-	-	-	-	-	-
71	1597803	RK	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
72	1412995	M	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
73	1633241	NSG	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
79	1221379	RK	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
84	694895	NC	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
87	297402	R	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
104	1637086	GK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
105	1637865	KD	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
106	1637103	DL	Y	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	-	-
107	1645458	MR	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
108	1521863	SA	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
112	1510911	GS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
113	878118	RG	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	-	-	-	-	-	-	-	LEVOSULPRIDE	Y	Y	-	-	-	-	-
115	1647777	RS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
117	453937	MB	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
123	1647890	PN	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
124	1366283	RK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	RANOLAZINE	INOTROPES	INOTROPES_NOREPINEPHRINE	EPINEPHRINE	DOPAMINE	DOBUTAMINE	VASOPRESSIN	OTHERS	ANTIEPILEPTICS_	ANTIEPILEPTICS_LEVETIRACITAM	ANTIEPILEPTICS_OTHERS	OTHERS
65	1588011	NS	-	Y	Y	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	Y	Y	Y	Y	-	Y	-	Y	Y	-	-
67	146195	RC	-	Y	Y	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	Y	Y	-	-	-	-	-	-	-	-	-
71	1597803	RK	-	Y	Y	-	Y	-	-	-	-	-	-	-
72	1412995	M	-	Y	Y	-	Y	-	Y	-	-	-	-	-
73	1633241	NSG	-	Y	Y	-	Y	-	-	-	-	-	-	-
74	1633143	SR	-	Y	Y	-	Y	-	-	-	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	Y	Y	-	Y	-	Y	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-
78	266158	AK	-	Y	Y	-	-	-	-	-	-	-	-	-
79	1221379	RK	-	Y	Y	-	Y	-	-	-	-	-	-	-
80	1623921	NK	-	-	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	Y	Y	-	-
82	1634655	MS	-	Y	Y	-	-	-	Y	-	-	-	-	-
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	-	-	-	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-
87	297402	R	-	-	-	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	Y	Y	-	Y	-	Y	-	Y	Y	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	Y	Y	-	-	-	Y	-	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	Y	Y	-	Y	-	-	-	-	-	-	-
96	1637086	GK	-	Y	Y	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	Y	Y	-	-	-	-	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	Y	Y	-	Y	-	-	-	-	-	-	-
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	Y	Y	-	Y	-	Y	-	-	-	-	-
104	1637086	GK	-	Y	Y	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	Y	Y	-	Y	-	-	-	-	-	-	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	-	-	-	-	-	-	-	Y	Y	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	-	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	Y	Y	-	Y	-	-	-	-	-	-	-
112	1510911	GS	-	Y	Y	Y	-	-	Y	-	-	-	-	-
113	878118	RG	-	-	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	-	-	-	-	-	-	-	-	-	-	-
115	1647777	RS	-	Y	Y	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	-	-	-	Y	Y	-	-
117	453937	MB	-	Y	Y	-	Y	-	-	-	-	-	-	-
118	476441	PC	-	Y	Y	-	Y	-	Y	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	-	-	-	-	-	-	-	-	-	-	-
123	1647890	PN	-	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	-	-
125	164953	JS	-	Y	Y	-	Y	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	-	-	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHER CONDITIONS PREDISPOSING TO PROLONGED QTC	ELECTROLYTE ABNORMALITIES	ELECTROLYTE ABNORMALITIES HYPOKALEMIA	HYPOMAGNESEMIA	HYPOCALCEMIA	OTHERS	CARDIAC CONDITIONS	CARDIAC CONDITIONS ISCHEMIA	MYOCARDITIS	BRADYCARDIA	STRESS CMP	OTHERS	ENDOCRINE DISORDERS
65	1588011	NS	-	N	-	-	-	-	-	-	-	-	-	-	-
66	1589396	PS	Y	Y	Y	Y	Y	-	Y	-	-	Y	-	-	-
67	146195	RC	-	N	-	-	-	-	-	-	-	-	-	-	-
68	1593613	PK	Y	Y	Y	-	Y	-	-	-	-	-	-	-	-
69	14594147	SK	-	N	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
71	1597803	RK	Y	Y	Y	Y	-	-	-	-	-	-	-	-	Y
72	1412995	M	Y	N	-	-	-	-	-	-	-	-	-	-	-
73	1633241	NSG	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
74	1633143	SR	Y	Y	-	-	Y	-	Y	-	-	-	Y	-	-
75	1633719	GS	-	N	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
77	1598500	AJ	-	N	-	-	-	-	-	-	-	-	-	-	-
78	266158	AK	Y	Y	Y	-	Y	-	-	-	-	-	-	-	-
79	1221379	RK	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
80	1623921	NK	-	N	-	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	N	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	Y	N	-	-	-	-	-	-	-	-	-	-	-
83	1632765	RK	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
84	694895	NC	Y	N	-	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	Y	N	-	-	-	-	-	-	-	-	-	-	Y
86	1632033	SK	Y	N	-	-	-	-	Y	-	-	-	Y	-	-
87	297402	R	Y	N	-	-	-	-	-	-	-	-	-	-	Y
88	1635798	BG	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
89	269628	RLP	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
90	1636098	JS	Y	Y	Y	-	-	-	Y	-	Y	-	-	-	-
91	1636504	JS	Y	N	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	N	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	-	N	-	-	-	-	-	-	-	-	-	-	-
94	1031223	N	Y	Y	-	Y	Y	-	Y	Y	-	-	-	-	Y
95	1636360	TS	-	N	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
97	1354326	SD	-	N	-	-	-	-	-	-	-	-	-	-	-
98	1637220	KD	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	Y	N	-	-	-	-	-	-	-	-	-	-	-
100	1637116	D	Y	N	-	-	-	-	-	-	-	-	-	-	-
101	1637226	VP	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
102	1637726	RR	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
103	1637746	AS	-	N	-	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
105	1637865	KD	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
106	1637103	DL	-	N	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	Y	Y	Y	-	-	-	-	-	-	-	-	-	Y
108	1521863	SA	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
109	1608961	RKB	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
110	618241	BK	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	N	-	-	-	-	-	-	-	-	-	-	-
112	1510911	GS	Y	Y	-	Y	-	-	Y	-	Y	-	-	-	-
113	878118	RG	Y	N	-	-	-	-	-	-	-	-	-	-	Y
114	1646391	PV	Y	N	-	-	-	-	-	-	-	-	-	-	Y
115	1647777	RS	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
116	1648371	KG	-	N	-	-	-	-	-	-	-	-	-	-	-
117	453937	MB	Y	N	-	-	-	-	-	-	-	-	-	-	Y
118	476441	PC	-	N	-	-	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	N	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
121	1648810	RL	Y	N	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	Y	N	-	-	-	-	-	-	-	-	-	-	Y
123	1647890	PN	-	N	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
125	164953	JS	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
126	1649550	PK	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
127	1649747	SR	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
128	1650194	D	-	N	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	ENDOCRINE DISORDERS HYPOTHYROIDISM	HYPER PTH	PHAEOCHROMOCYTOMA	HYPERALDOSTERONISM	OTHERS	INTRACRANIAL DISORDERS	INTRACRANIAL DISORDERS SAH	THALAMIC HEMATOMA	CVA	ENCEPHALITIS	HEAD INJURY	OTHERS	NUTRITIONAL DISORDERS	NUTRITIONAL DISORDERS ANOREXIA NERVOSA
65	1588011	NS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
66	1589396	PS	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
67	146195	RC	-	-	-	-	-	-	-	-	-	-	-	-	-	-
68	1593613	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
71	1597803	RK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
72	1412995	M	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
73	1633241	NSG	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
74	1633143	SR	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-
78	266158	AK	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
79	1221379	RK	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
80	1623921	NK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
81	1634549	RM	-	-	-	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
83	1632765	RK	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
85	1634698	MK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
87	297402	R	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	-	-	-	-	-	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
91	1636504	JS	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
93	794933	DV	-	-	-	-	-	-	-	-	-	-	-	-	-	-
94	1031223	N	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
97	1354326	SD	-	-	-	-	-	-	-	-	-	-	-	-	-	-
98	1637220	KD	-	-	-	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
100	1637116	D	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
101	1637226	VP	-	-	-	-	-	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
105	1637865	KD	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	Y	-	-	-	-	Y	-	-	-	Y	-	-	-	-
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	-	-	-	-
109	1608961	RKB	-	-	-	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
111	1563586	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
112	1510911	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
113	878118	RG	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
117	453937	MB	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	-	-	-	-	-	-	-	-	-	-	-	-	-
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
122	200550	SK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
123	1647890	PN	-	-	-	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
125	164953	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
126	1649550	PK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	STARVATION	LIQUID PROTEIN DIET	H/O GI SURGERY	CELIAC DISEASE	OTHERS	HYPOTHERMIA	OTHERS	ECG RATE	RHYTHM_SINUS	AT	AF	AFL	APC	VPC	NSVT	VT	PSVT	OTHER	QRS DURATION	QTC INTERVAL	QTC INTERVAL GROUP	QTC INTERVAL GP
65	1588011	NS	-	-	-	-	-	-	-	174	Y	-	-	-	-	-	-	Y	-	-	120	509	1	1
66	1589396	PS	-	-	-	-	-	-	-	50	Y	-	-	-	-	-	-	Y	-	-	116	560	1	1
67	146195	RC	-	-	-	-	-	-	-	152	Y	-	-	-	-	-	-	Y	-	-	120	470	1	0
68	1593613	PK	-	-	-	-	-	-	-	106	Y	-	-	-	-	-	-	-	-	-	86	496	1	0
69	14594147	SK	-	-	-	-	-	-	-	68	Y	-	-	-	-	-	-	-	-	-	70	391	0	0
70	1592868	HK	-	-	-	-	-	-	-	76	Y	-	Y	-	-	-	-	-	-	-	70	411	0	0
71	1597803	RK	-	-	-	-	-	-	-	114	Y	-	-	-	-	Y	-	-	-	-	76	661	1	1
72	1412995	M	-	-	-	-	-	-	-	98	Y	-	-	-	-	-	-	-	-	-	74	487	1	0
73	1633241	NSG	-	-	-	-	-	Y	-	80	Y	-	-	-	-	-	-	-	-	-	120	542	1	1
74	1633143	SR	-	-	-	-	-	-	-	118	Y	-	-	-	-	-	-	-	-	-	56	473	1	0
75	1633719	GS	-	-	-	-	-	-	-	175	Y	-	Y	-	-	-	-	-	-	-	80	459	1	0
76	1632590	KS	-	-	-	-	-	-	-	125	Y	-	-	-	-	-	-	-	-	-	100	441	0	0
77	1598500	AJ	-	-	-	-	-	-	-	100	Y	-	-	-	-	-	-	-	-	-	90	472	1	0
78	266158	AK	-	-	-	-	-	-	-	137	Y	-	-	-	-	-	-	-	-	-	82	495	1	0
79	1221379	RK	Y	-	-	-	-	Y	-	75	Y	-	-	-	-	-	-	-	-	-	100	509	1	1
80	1623921	NK	-	-	-	-	-	-	-	86	Y	-	-	-	-	Y	-	-	-	-	90	496	1	0
81	1634549	RM	-	-	-	-	-	-	-	96	Y	-	-	-	-	Y	-	-	-	-	96	452	1	0
82	1634655	MS	Y	-	-	-	-	-	-	121	Y	-	-	-	-	-	-	-	-	-	74	440	0	0
83	1632765	RK	-	-	-	-	-	Y	-	73	Y	-	-	-	-	-	-	-	-	-	106	502	1	1
84	694895	NC	-	-	Y	-	-	-	-	113	Y	-	-	-	-	-	-	-	-	-	98	433	0	0
85	1634698	MK	-	-	-	-	-	-	-	97	Y	-	-	-	-	-	-	-	-	-	90	478	1	0
86	1632033	SK	-	-	-	-	-	-	-	123	Y	-	-	-	-	-	-	-	-	-	74	497	1	0
87	297402	R	-	-	-	-	-	-	-	98	Y	-	-	-	-	-	-	-	-	-	72	476	1	0
88	1635798	BG	-	-	-	-	-	-	-	90	Y	-	-	-	-	Y	-	-	-	-	64	440	0	0
89	269628	RLP	-	-	-	-	-	Y	-	191	Y	-	-	-	-	Y	-	-	-	-	88	401	0	0
90	1636098	JS	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	88	482	1	0
91	1636504	JS	-	-	-	-	-	-	-	138	Y	-	-	-	-	-	-	-	-	-	80	433	0	0
92	1636474	AS	-	-	-	-	-	-	-	114	Y	-	-	-	-	Y	-	-	-	-	70	496	1	0
93	794933	DV	-	-	-	-	-	-	-	118	Y	-	-	-	-	-	-	-	-	-	108	498	1	0
94	1031223	N	-	-	-	-	-	-	-	60	Y	-	-	-	-	-	-	-	-	-	78	424	0	0
95	1636360	TS	-	-	-	-	-	-	-	95	Y	-	-	-	-	-	-	-	-	-	76	417	0	0
96	1637086	GK	-	-	-	-	-	-	-	88	Y	-	-	-	-	-	-	-	-	-	120	474	1	0
97	1354326	SD	-	-	-	-	-	-	-	119	Y	-	-	-	-	-	-	-	-	-	84	438	0	0
98	1637220	KD	-	-	-	-	-	-	-	101	Y	-	-	-	-	-	-	-	-	-	118	484	1	0
99	1621286	SS	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	94	500	1	1
100	1637116	D	-	-	-	-	-	-	-	82	Y	-	-	-	-	-	-	-	-	-	78	448	0	0
101	1637226	VP	-	-	-	-	-	-	-	116	Y	-	-	-	-	-	-	-	-	-	84	461	1	0
102	1637726	RR	-	-	-	-	-	-	-	106	Y	-	-	-	-	-	-	-	-	-	82	419	0	0
103	1637746	AS	-	-	-	-	-	-	-	106	Y	-	Y	-	-	-	-	-	-	-	76	497	1	0
104	1637086	GK	-	-	-	-	-	-	-	88	Y	-	-	-	-	-	-	-	-	-	92	474	1	0
105	1637865	KD	-	-	Y	-	-	-	-	136	Y	-	-	-	-	-	-	-	-	-	72	484	1	0
106	1637103	DL	-	-	-	-	-	-	-	100	Y	-	-	-	-	-	-	-	-	-	68	428	0	0
107	1645458	MR	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	68	455	0	0
108	1521863	SA	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	100	419	0	0
109	1608961	RKB	-	-	-	-	-	-	-	79	Y	-	-	-	Y	-	-	-	-	-	76	440	0	0
110	618241	BK	-	-	-	-	-	-	-	79	Y	-	-	-	-	-	-	-	-	-	86	483	1	0
111	1563586	SK	-	-	-	-	-	-	-	119	Y	-	-	-	-	-	-	-	-	-	74	447	0	0
112	1510911	GS	-	-	-	-	-	-	-	126	Y	-	-	-	-	-	-	-	-	-	80	616	1	1
113	878118	RG	-	-	-	-	-	-	-	93	Y	-	-	-	-	-	-	-	-	-	96	425	0	0
114	1646391	PV	-	-	-	-	-	-	-	81	Y	-	-	-	-	-	-	-	-	-	92	478	1	0
115	1647777	RS	-	-	-	-	-	-	-	143	Y	-	-	-	-	-	-	-	-	-	88	533	1	1
116	1648371	KG	-	-	-	-	-	-	-	75	Y	-	-	-	-	-	-	-	-	-	72	415	0	0
117	453937	MB	-	-	-	-	-	-	-	133	Y	-	-	-	-	-	-	-	-	-	118	488	1	0
118	476441	PC	-	-	-	-	-	Y	-	61	Y	-	-	-	-	-	-	-	-	-	116	495	1	0
119	1646754	DK	-	-	-	-	-	-	-	86	Y	-	-	-	-	-	-	-	-	-	74	435	0	0
120	1648289	PK	-	-	-	-	-	-	-	119	Y	-	-	-	-	-	-	-	-	-	118	461	1	0
121	1648810	RL	-	-	-	-	-	-	-	60	Y	-	-	-	-	-	-	-	-	-	84	434	0	0
122	200550	SK	-	-	-	-	-	-	-	89	Y	-	-	-	-	-	-	-	-	-	75	411	0	0
123	1647890	PN	-	-	-	-	-	-	-	101	Y	-	-	-	-	-	-	-	-	-	70	446	0	0
124	1366283	RK	-	-	-	-	-	-	-	105	Y	-	-	-	-	-	-	-	-	-	102	520	1	1
125	164953	JS	-	-	-	-	-	-	-	79	Y	-	-	-	-	-	-	-	-	-	110	465	1	0
126	1649550	PK	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	116	517	1	1
127	1649747	SR	-	-	-	-	-	-	-	94	Y	-	-	-	-	-	-	-	-	-	76	457	0	0
128	1650194	D	-	-	-	-	-	-	-	82	Y	-	-	-	-	-	-	-	-	-	90	493	1	0

S No	MRD	NAME	BROAD BASE T WAVE	NOTCHED T WAVE	LONG ISOELEC SEG & NARROW BASE T WAVE	T ALTERNANS	U WAVE	AV BLOCK	ST ELEVATION	ST DEPRESSION	TORSADES	LVH	RVH	POOR R PROGRESSION	BRUGADA	EPSILON WAVE	EARLY REPOLARISATION	OTHERS	RBS
65	1588011	NS	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	110
66	1589396	PS	Y	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	184
67	146195	RC	INVERTED	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	100
68	1593613	PK	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	154
69	14594147	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98
70	1592868	HK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	104
71	1597803	RK	Y/NVERTED	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96
72	1412995	M	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	166
73	1633241	NSG	INVERTED	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	-	-	113
74	1633143	SR	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	120
75	1633719	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	130
76	1632590	KS	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	146
77	1598500	AJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	270
78	266158	AK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	225
79	1221379	RK	-	-	Y	-	-	-	-	-	-	-	-	Y	-	-	-	-	103
80	1623921	NK	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	120
81	1634549	RM	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	88
82	1634655	MS	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	199
83	1632765	RK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	194
84	694895	NC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	250
85	1634698	MK	T-WAVE MORPHOLOGY/ INVERTED/V1-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122
86	1632033	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120
87	297402	R	T-WAVE MORPHOLOGY/ INVERTED/V4-6	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	116
88	1635798	BG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80
89	269628	RLP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	148
90	1636098	JS	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	289
91	1636504	JS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	121
92	1636474	AS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180
93	794933	DV	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	300
94	1031223	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	156
95	1636360	TS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	130
96	1637086	GK	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	206
97	1354326	SD	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	282
98	1637220	KD	T-WAVE MORPHOLOGY/INVERTED/V4-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	433
99	1621286	SS	T-WAVE MORPHOLOGY/INVERTED/V1-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	141
100	1637116	D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98
101	1637226	VP	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	228
102	1637726	RR	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	146
103	1637746	AS	T-WAVE MORPHOLOGY/INVERTED/V1-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	258
104	1637086	GK	T-WAVE MORPHOLOGY/INVERTED/V1-6	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	200
105	1637865	KD	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	22
106	1637103	DL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	143
107	1645458	MR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147
108	1521863	SA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112
109	1608961	RKB	-	Y/V1-3	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	102
110	618241	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100
111	1563586	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	129
112	1510911	GS	-	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	100
113	878118	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96
114	1646391	PV	T-WAVE MORPHOLOGY/INVERTED/V3-6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	108
115	1647777	RS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	110
116	1648371	KG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94
117	453937	MB	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	162
118	476441	PC	T-WAVE MORPHOLOGY/INVERTED/V1-4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	116
119	1646754	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168
120	1648289	PK	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	250
121	1648810	RL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	121
122	200550	SK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300
123	1647890	PN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	138
124	1366283	RK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98
125	164953	JS	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	135
126	1649550	PK	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	139
127	1649747	SR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	253
128	1650194	D	Y	-	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	120

S No	MRD	NAME	HB	TLC	PLATELET	PH	PCO2	PO2	HCO3	SO2	LACTATE	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB	PH	HCO3	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB
65	1588011	NS	11.6	11.7	216	7.3	26	308	12.8	100	1.3	5.3	9.2	2.5	1.9	138	73	1.6	0.6	73	36	460	6.7	4.1	1	1	3	2	2	1	2	3	3	2	3	2	3	2	2
66	1589396	PS	11.2	16	280	7.23	32	125	22	96	3.8	3	7.8	1.5	1.5	120	78	4.5	0.6	50	29	70	3.9	2.3	1	2	1	1	1	1	3	3	2	3	2	2	1	1
67	146195	RC	11.9	6.3	66	7.43	38	106	21.3	97	0.8	5	8.6	2	4	144	57	1.3	0.8	15	12	107	6.8	3.9	2	1	3	2	2	2	2	3	3	2	2	2	2	2	2
68	1593613	PK	10.9	9.4	309	7.46	44	84	21	92	0.5	3.4	7	1.9	3.3	138	15	0.4	1.4	284	397	128	7	3	3	1	1	1	2	2	2	2	1	3	3	3	2	2	1
69	14594147	SK	15.4	2.7	10	7.48	29	101	26	98	1.9	3.8	9	2.8	1.8	138	17	0.8	0.6	9	68	119	6.3	3.5	3	3	2	2	3	1	2	2	2	2	3	2	1	2
70	1592868	HK	10.7	14.3	275	7.45	33	135	22.9	99	0.8	4.8	9.4	2.4	2.5	133	41	1.1	0.9	87	83	233	6.7	3.2	3	2	2	2	2	1	1	2	2	2	3	3	3	2	1
71	1597803	RK	13	22.7	499	7.57	27	353	24.7	100	1.7	3.4	9.5	1.4	5.7	130	38	0.9	1.9	49	43	124	6.6	3.1	3	2	1	2	1	3	1	2	2	3	3	3	2	2	1
72	1412995	M	14.2	16.1	16	6.82	12	119	3	96	15	6	9	2.8	6	140	58	2.6	1.6	13165	3025	349	5.2	2.8	1	1	3	2	3	3	2	3	3	3	3	3	3	1	1
73	1633241	NSG	5.7	14	215	7.37	36	90	24	100	1.9	4.9	8.1	2.1	8.3	136	90	2.2	4.4	64	44	165	4.3	2.9	2	2	2	1	2	3	2	3	3	3	3	3	3	1	1
74	1633143	SR	12	43	505	7.43	28	124	17.4	98	3.9	3.9	8.2	2.5	6.4	132	63	3.6	1.8	32	28	109	7.2	3	2	1	2	1	2	3	1	3	3	3	2	2	2	2	1
75	1633719	GS	11.9	8	337	7.4	36	98	21	93	1.4	4.1	9.5	1.9	2.6	142	18	0.7	0.6	35	43	98	7.2	3.5	2	1	2	2	2	1	2	2	2	2	3	2	2	2	2
76	1632590	KS	16.9	13.7	264	7.43	42	104	22.3	96	0.4	4.2	9.3	2.8	3	135	27	0.7	0.37	25	20	129	7.4	4.5	2	2	2	2	3	2	2	2	2	2	3	2	2	2	2
77	1598500	AJ	12.4	9.8	223	7.42	37	88	21	94	1.4	4.2	9	2.7	1.7	136	42	1.1	1.1	27	43	71	6.7	3.8	2	1	2	2	2	1	2	2	2	2	3	2	2	2	2
78	266158	AK	11	12.6	319	7.33	34	150	17.9	99	1.7	3.4	7.7	1.9	1.5	148	61	1.1	0.5	60	45	122	6.8	3.2	1	1	1	1	2	1	3	3	2	2	3	3	2	2	1
79	1221379	RK	8.8	8.9	280	7.21	37	70	14.8	90	0.5	4.6	8.1	1.7	8	152	285	7	0.3	42	22	159	6.5	2.7	1	1	2	1	2	3	3	3	2	3	2	3	2	1	1
80	1623921	NK	11.1	7.1	317	7.25	35	75	20	85	0.9	4.1	8.9	2.8	2	137	27	0.7	0.4	20	51	90	7.4	4.7	1	1	2	2	3	1	2	2	2	2	3	2	2	2	2
81	1634549	RM	10.1	8.2	150	7.42	40	93	21	92	1.2	5.2	9.5	2.9	3.4	140	46	1.2	1.2	75	56	122	7.5	4	2	1	3	2	3	2	2	2	3	3	3	3	2	2	2
82	1634655	MS	9.1	24.7	340	7.39	29	105	17.6	98	2	5.3	9.2	2.5	4	131	41	1.1	6.8	40	26	200	6.4	3.4	2	1	3	2	2	2	1	2	2	3	3	2	3	1	1
83	1632765	RK	11.8	13.9	117	7.39	32	98	19.4	98	0.9	4	8.3	1.9	5	138	91	1.5	1.1	46	21	69	6.9	3.1	2	1	2	1	2	3	2	3	3	2	3	2	2	2	1
84	694895	NC	11.2	19.2	410	7.21	16	108	6.4	97	0.6	6.2	8.9	2.7	3	135	44	1.1	0.8	45	54	102	7.2	3.3	1	1	3	2	2	2	2	2	2	2	3	3	2	2	1
85	1634698	MK	8.3	6.5	60	7.4	35	60	24.9	80	1	4.4	9.4	2.5	4	137	30	1	0.9	16	16	80	6.1	3	2	2	2	2	2	2	2	2	2	2	2	2	1	1
86	1632033	SK	7.4	2.2	46	7.6	33	45	32.4	89	1.3	3.6	9	3	2.9	129	48	0.6	0.6	135	71	120	4.9	2.9	3	3	2	2	3	2	1	2	1	2	3	3	2	1	1
87	297402	R	9.3	7.3	473	7.43	29	82	19.2	96	2	5.6	9.1	1.8	4.3	127	33	1.2	0.3	16	7	150	7	3.2	2	1	3	2	2	2	1	2	3	2	2	2	3	2	1
88	1635798	BG	12.7	9.1	364	7.41	34	44	21	95	0.9	4	9	1.7	3.3	140	36	0.7	0.5	17	8	61	6.3	3.6	2	1	2	2	2	2	2	2	2	2	2	2	1	2
89	269628	RLP	10.6	9.5	242	7.4	41	352	25.4	100	5.5	5.4	8	2.4	4.2	128	62	1.2	0.7	49	38	131	6.8	3.3	2	2	3	1	2	2	1	3	3	2	3	2	3	2	1
90	1636098	JS	12.5	4.2	56	7.39	23	112	13.9	98	0.5	2.8	9.4	1.8	2.9	137	28	0.9	0.3	357	48	83	5.2	2.8	2	1	1	2	2	2	2	2	2	2	3	3	2	1	1
91	1636504	JS	13.5	46	110	7.15	48	71	16.7	88	11.3	5.4	8.8	2	4.4	131	63	2.3	3.2	13938	8160	491	5.4	3.1	1	1	3	2	2	2	1	3	3	3	3	3	3	1	1
92	1636474	AS	15.2	22.7	220	7.41	34	128	21.6	99	1.3	4.8	9.6	2.9	2.7	139	28	0.8	1	50	34	120	7.5	3.8	2	1	2	2	3	2	2	2	2	2	3	2	2	2	2
93	794933	DV	9.4	11	346	7.42	36	95	22	98	1	4.5	9	2.1	3.8	134	60	1.1	0.7	46	23	104	5.9	3	2	2	2	2	2	2	1	3	2	2	3	2	2	1	1
94	1031223	N	5.9	11.1	120	7.31	32	75	16.1	93	0.4	5.9	7.8	1.5	4.5	134	168	7.7	0.4	26	16	103	5.4	2.8	1	1	3	1	1	3	1	3	3	2	2	2	2	1	1
95	1636360	TS	13	20	88	7.36	34	89	21.9	96	1.2	6.5	9	1.9	4.5	139	110	4	1.2	404	303	95	6.2	3.4	2	1	3	2	2	3	2	3	3	3	3	3	2	1	1
96	1637086	GK	9	15.1	264	7.37	28	233	16.2	100	1.8	5.2	8.7	2.4	6.1	140	162	5	0.3	654	348	191	6.7	3.3	2	1	3	2	2	3	2	3	3	2	3	3	3	2	1
97	1354326	SD	18.4	8	150	7.26	63	156	28.3	99	0.7	4.2	9.1	2.5	3	139	58	1.2	0.6	40	37	83	6.8	3.7	1	3	2	2	2	2	3	3	2	3	2	2	2	2
98	1637220	KD	12.6	11.3	210	7.34	48	235	25.9	100	1.8	3.4	8.7	2.1	4.5	134	41	0.1	0.4	15	11	59	7.3	3.9	1	2	1	2	2	3	1	2	1	2	2	2	2	2	2
99	1621286	SS	10.6	17.9	354	7.41	24	72	15.2	94	2.6	3.9	9.2	2.5	4.4	137	40	1.1	1.4	45	49	179	5.8	2.4	2	1	2	2	2	2	2	2	2	3	3	3	3	1	1
100	1637116	D	11.6	10.8	188	7.45	36	454	25	100	0.8	3.9	9	2.8	3.9	138	47	0.8	0.6	46	26	118	6	2.7	3	2	2	2	3	2	2	2	2	2	3	2	2	1	1
101	1637226	VP	14.3	12	237	7.42	43	95	22	100	1.2	5.1	9.5	1.8	2.2	138	42	0.9	0.2	29	25	150	7.1	4.4	2	2	3	2	2	1	2	2	2	2	2	2	3	2	2
102	1637726	RR	12.5	17.7	294	7.45	35	116	25.5	99	0.8	3.8	9	2.9	2.5	124	17	0.5	0.3	269	53	98	7	4	3	2	2	2	3	1	1	2	1	2	3	3	2	2	2
103	1637746	AS	11.2	25.8	346	7.04	61	59	16.5	75	7.3	3.9	8.8	1.9	4.5	136	42	1.9	1	34	18	124	7.3	4.2	1	1	2	2	2	3	2	2	3	2	2	2	2	2	2
104	1637086	GK	9	15.1	264	7.37	28	233	16.2	100	1.8	5.2	8.7	2.4	6.1	140	162	5	0.3	654	348	191	6.7	3.3	2	1	3	2	2	3	2	3	3	2	3	3	3	2	1
105	1637865	KD	8.2	31.8	638	7.25	38	148	16.7	99	4.2	3.4	9.3	2.9	2.8	136	49	0.9	1	1843	471	99	5.6	2.3	1	1	1	2	3	2	2	2	2	2	3	3	2	1	1
106	1637103	DL	14.3	7.7	120	7.29	36	74	21	92	0.4	4.1	9.6	2.5	4	141	36	1.3	0.6	24	18	48	7.4	4.4	1	1	2	2	2	2	2	2	3	2	2	2	2	2	2
107	1645458	MR	7	10.6	12	7.5	41	274	32	100	1.1	3.4	8.8	1.9	2.2	137	38	1.2	1.7	65	35	114	7.1	4	3	3	1	2	2	1	2	2	3	3	3	2	2	2	2
108	1521863	SA	12.1	8.5	222	7	27	60	3.3	88	10	6.3	7.7	1.8	6.6	139	235	6.7	0.4	318	206	97	5	2.5	1	1	3	1	2	3	2	3	3	2	3	3	2	1	1
109	1608961	RKB	15.3	6.8	244	7.42	35	98	21	98	0.8	4.1	9.2	2.4	4.1	139	26	0.6	0.8	38	74	102	6.6	4	2	1	2	2	2	2	2	2	1	2	2	3	2	2	2
110	618241	BK	11.4	4.8	234	7.45	43	122	24	100	0.9	3.3	9.5	2.3	3.5	124	33	0.6	1	25	15	75	7	4.3	3	2	1	2	2	2	1	2	1	2	2	2	2	2	2
111	1563586	SK	13.5	35.5	381	7.33	53	50	27.9	82	1.8	4.1	8.6	2.1	4.6	141	87	1.1	0.5	36	20	96	5.5	2.8	1	3	2	2	2	3	2	3	2	2	2	2	2	1	1
112	1510911	GS	11.4	18.7	469	7.46	31	155	22	99	1.7	3.6	9.2	1.4	3.6	139	18	1.4	0.9	123	44	99	6	2.1	3	2	2	2	1	2	2	2	3	2	3	3	2	1	1
113	878118	RG	12.4	5.1	212	7.43	38	106	23	98	1.2	3.5	9.5	2.9	3	137	40	1.2	0.5	35	24	41	6.5	3.9	2	2	2	2	3	2	2	2	3	2	2	2	2	1	2
114	1646391	PV	9.6	7.7	140	7.49	29	58	22.6	92	0.7	4	9.7	2.8	4.5	134	36	1.4	0.4	56	24	28	7	2.9	3	2	2	2	3	3	1	2	3	2	3	2	1	2	1
115	1647777	RS	11.1	19.9	306	7.47	32	176	23.3	98	2.3	4.4	7.7	1.9	3.9	132	40	0.9	1.3	139	130	216	5.7	2.6	3	2	2	1	2	2	1	2	2	3	3	3	3	1	1
116	1648371	KG	10.6	9.2	224	7.4	34	99	22.4	98	1.8	4.5	10	2.5	2.9	139	55	1.2	1.1	54	36	120	6.4	3.3	2	2	2	2	2	2	3	3	2	3	2	2	1	1
117	453937	MB	9.8	17.7	406	7.45	31	94	21.5	98	3	4.3	9.5	2.8	4	139	54	1.1	0.4	59	57	126	6.6	4	3	1	2	2	3	2	2	3	2	2	3	3	2	2	2
118	476441	PC	6.4	11.7	413	7.14	51	377	17.4	100	2.1	6.3	9.2	2.2	7.4	128	177	3.3	0.1	200	141	186	5.7	3.3	1	1	3	2	2	3	1	3	3	2	3	3	3	1	1
119	1646754	DK	12.4	9.4	214	7.2	83	39	32.4	60	0.6	5.3	8.8	1.7	3.5	132	61	1.5	0.3	21	20	63	6.6	3.7	1	3	3	2	2	2	1	3	3	2	2	2	2	2	2
120	1648289	PK	14.6	17.2	297	7.44	42	156	23	100	0.8	5.1	9.5	2.7	2.9	138	28	0.7	0.3	251	62	120	7.4	4	2	2	3	2	2	2	2	2	2	2	3	3	2	2	2
121	1648810	RL	12.3	10.2	349	7.43	45	87	20	98	1.4	5	9	2.6	4	135	68	1.2	0.6	22	19	88	7.5	3.5	2	1	3	2	2	2	2	3	3	2	2	2	2	2	2
122	200550	SK	12	5.9	132	7.38	40	73	23.7	94	1.2	4.6	8.9	2.9	3	136	56	1.2	0.2	50	38	72	7.3	3.7	2	2	2	2	3	2	2	3	3	2	3	2	2	2	2
123	1647890	PN	14	5	360	7.41	37	98	21	95	1.3	3.8	9.1	2.7	3.5	135	96	1.2	0.8	31	20	114	7.6	3.8	2	1	2	2	2	2	2	3	3	2	2	2	2	2	2
124	1366283	RK	17.8	19	277	7.4	32	49	19.8	84	1	4.2	10	2.5	2	145	38	1.6	0.4	25	56	141	7.2	4.4	2	1	2	2	2	1	3	2	3	2	2	3	3	2	2
125	164953	JS	15.9	7.5	221	7.38	32	317	18.9	100	1.5	3.7	9.5	2.4	3.1	139	24	1	0.8	61	51	70	6.7	4	2	1	2	2	2	2	2	2	2	2	3	3	2	2	2
126	1649550	PK	10.5	22.7	346	7.35	39	83	21.5	96	0.9	4.8	9.2	2	6.1	140	68	2	0.1	27	23	72	6.7	3.9	2	1	2	2	2	3	2	3	3	2	2	2	2	2	2
127	1649747	SR	8.6	10.2	259	7.44	44	75	29.9	95	2.6	3.7	8.7	1.9	5.1	145	101	2	0.2	16	13	90	6.2	3.3	2	3	2	2	2	3	3	3	3	2	2	2	2	1	1
128	1650194	D	11	9.5	269	7.48	29	86	21.6	97	0.9	4.2	9.5	2.5	3.6	135	80	1.4	0.7	19	25	55	5.1	3	3	1	2	2	2	2	2	3	3	2	2	2	2	1	1

S No	MRD	NAME	BLOOD CULTURE	LVEF	SPECIFIC TREATEMENT GIVEN FOR PROLONGED QTC T/T OF REVERSIBLE CAUSE	BETA BLOCKER	IV MGSO4	ISOPROTERENOL	IV XYLOCAINE	MEXILETINE	SYMPATHETIC DENERVATION	OVERDRIVE PACING	AICD	OTHERS	OUTCOMES OF TREATMENT SPECIFIC TO PROLONGED QTC BENEFIT ACHIEVED
65	1588011	NS	-	15	Y	-	Y	-	Y	-	-	-	-	-	Y
66	1589396	PS	Y	30	Y	-	Y	-	Y	-	-	Y	-	-	Y
67	146195	RC	-	15	Y	Y	-	-	Y	-	-	-	Y	-	Y
68	1593613	PK	-	60	Y	-	Y	-	-	-	-	-	-	-	Y
69	14594147	SK	-	46	-	-	-	-	-	-	-	-	-	-	-
70	1592868	HK	-	34	-	-	-	-	-	-	-	-	-	-	-
71	1597803	RK	Y	40	Y	-	Y	-	Y	-	-	-	-	-	Y
72	1412995	M	Y	60	Y	-	-	-	-	-	-	-	-	-	Y
73	1633241	NSG	Y	30	-	-	-	-	-	-	-	-	-	-	-
74	1633143	SR	Y	20	-	-	-	-	-	-	-	-	-	-	-
75	1633719	GS	-	60	-	-	-	-	-	-	-	-	-	-	-
76	1632590	KS	-	30	-	-	-	-	-	-	-	-	-	-	-
77	1598500	AJ	-	30	Y	Y	-	-	-	-	-	-	-	-	Y
78	266158	AK	Y	26	Y	-	-	-	-	-	-	-	-	-	Y
79	1221379	RK	Y	35	-	-	-	-	-	-	-	-	-	-	-
80	1623921	NK	-	35	Y	Y	Y	-	Y	-	-	-	-	-	Y
81	1634549	RM	-	25	-	-	-	-	-	-	-	-	-	-	-
82	1634655	MS	Y	60	-	-	-	-	-	-	-	-	-	-	-
83	1632765	RK	-	35	-	-	-	-	-	-	-	-	-	-	Y
84	694895	NC	Y	60	-	-	-	-	-	-	-	-	-	-	-
85	1634698	MK	Y	60	-	-	-	-	-	-	-	-	-	-	-
86	1632033	SK	Y	25	Y	-	Y	-	-	-	-	-	-	-	Y
87	297402	R	-	25	-	-	-	-	-	-	-	-	-	-	Y
88	1635798	BG	-	32	-	-	-	-	-	-	-	-	-	-	-
89	269628	RLP	Y	60	-	-	-	-	-	-	-	-	-	-	-
90	1636098	JS	-	60	Y	-	Y	-	-	-	-	-	-	-	Y
91	1636504	JS	Y	60	-	-	-	-	-	-	-	-	-	-	-
92	1636474	AS	-	60	Y	-	-	Y	-	-	-	-	-	-	Y
93	794933	DV	-	20	Y	Y	-	-	-	-	-	-	-	-	Y
94	1031223	N	-	60	-	-	-	-	-	-	-	-	-	-	-
95	1636360	TS	Y	60	-	-	-	-	-	-	-	-	-	-	-
96	1637086	GK	Y	15	Y	-	-	-	-	-	-	-	-	-	Y
97	1354326	SD	-	26	-	-	-	-	-	-	-	-	-	-	-
98	1637220	KD	-	25	-	-	-	-	-	-	-	-	-	-	-
99	1621286	SS	-	60	Y	-	-	-	-	-	-	-	-	-	-
100	1637116	D	Y	60	-	-	-	-	-	-	-	-	-	-	Y
101	1637226	VP	-	45	Y	Y	-	-	-	-	-	-	-	-	-
102	1637726	RR	-	50	-	-	-	-	-	-	-	-	-	-	-
103	1637746	AS	Y	40	Y	-	-	-	-	-	-	-	-	-	-
104	1637086	GK	Y	15	Y	-	-	-	-	-	-	-	-	-	Y
105	1637865	KD	Y	60	Y	-	-	-	-	-	-	-	-	-	Y
106	1637103	DL	-	60	-	-	-	-	-	-	-	-	-	-	-
107	1645458	MR	-	60	-	-	-	-	-	-	-	-	-	-	Y
108	1521863	SA	Y	38	-	-	-	-	-	-	-	-	-	-	Y
109	1608961	RKB	-	35	-	-	-	-	-	-	-	-	-	-	-
110	618241	BK	-	60	Y	-	-	-	-	-	-	-	-	-	Y
111	1563586	SK	Y	60	-	-	-	-	-	-	-	-	-	-	-
112	1510911	GS	Y	60	Y	-	Y	-	-	-	-	-	-	-	Y
113	878118	RG	-	60	-	-	-	-	-	-	-	-	-	-	-
114	1646391	PV	-	60	-	-	-	-	-	-	-	-	-	-	-
115	1647777	RS	Y	26	Y	-	-	-	-	-	-	-	-	-	Y
116	1648371	KG	-	60	-	-	-	-	-	-	-	-	-	-	-
117	453937	MB	Y	20	-	-	-	-	-	-	-	-	-	-	-
118	476441	PC	-	60	-	-	-	-	-	-	-	-	-	-	Y
119	1646754	DK	-	60	-	-	-	-	-	-	-	-	-	-	-
120	1648289	PK	-	25	-	-	-	-	-	-	-	-	-	-	-
121	1648810	RL	-	35	-	-	-	-	-	-	-	-	-	-	-
122	200550	SK	-	35	-	-	-	-	-	-	-	-	-	-	-
123	1647890	PN	-	60	-	-	-	-	-	-	-	-	-	-	-
124	1366283	RK	-	22	Y	Y	Y	-	-	-	-	-	-	-	Y
125	164953	JS	-	45	Y	-	-	-	-	-	-	-	-	-	Y
126	1649550	PK	-	25	Y	Y	Y	-	-	-	-	-	-	-	Y
127	1649747	SR	-	60	Y	-	-	-	-	-	-	-	-	-	-
128	1650194	D	-	60	-	-	-	-	-	-	-	-	-	-	Y

S No	MRD	NAME	QTC SHORTENED	SYNCOPE CONTROLLED	SEIZURE CONTROLLED	ARRYTHMIA CONTROLLED	DURATION OF ICU STAY	NO OF VT EPISODES	QTC UNCHANGED	QTC SHORTENED BY	QTC PROLONGED BY	-	-	-	DISCHARGED	DEATH	TREATMENT COMPLICATION
65	1588011	NS	-	-	-	Y	5	1	Y	-	-	509	509	1	Y	N	-
66	1589396	PS	Y	-	Y	Y	5	8	N	140	-	420	420	0	N	Y	PERICARDIAL EFFUSION
67	146195	RC	-	-	-	Y	3	1	Y	-	-	470	470	1	N	Y	-
68	1593613	PK	Y	-	-	-	3	0	N	22	-	474	474	1	Y	N	-
69	14594147	SK	-	-	-	-	3	-	Y	-	-	391	391	0	Y	N	-
70	1592868	HK	-	-	-	-	7	-	N	-	30	411	441	0	Y	N	-
71	1597803	RK	Y	-	-	Y	7	-	N	166	-	495	495	1	Y	N	-
72	1412995	M	Y	-	-	-	5	-	N	28	-	459	459	1	N	Y	-
73	1633241	NSG	-	-	-	-	2	-	Y	-	-	542	542	1	N	Y	-
74	1633143	SR	-	-	-	-	10	-	N	-	21	473	494	1	N	Y	-
75	1633719	GS	-	-	-	-	1	-	Y	-	-	459	459	1	Y	N	-
76	1632590	KS	-	-	-	-	10	-	N	-	69	441	510	1	Y	N	-
77	1598500	AJ	Y	Y	-	Y	4	-	N	20	-	452	452	1	Y	N	-
78	266158	AK	Y	-	-	-	5	-	N	36	-	459	459	1	N	Y	-
79	1221379	RK	-	-	-	-	13	-	N	-	10	509	519	1	Y	N	-
80	1623921	NK	Y	Y	-	Y	4	-	N	42	-	454	454	1	Y	N	-
81	1634549	RM	-	-	-	-	2	-	Y	-	-	452	452	1	Y	N	-
82	1634655	MS	-	-	-	-	11	-	Y	-	-	440	440	0	Y	N	-
83	1632765	RK	Y	-	-	-	6	-	N	31	-	471	471	1	N	Y	-
84	694895	NC	-	-	-	-	5	-	Y	-	-	433	433	0	N	Y	-
85	1634698	MK	-	-	-	-	7	-	Y	-	-	478	478	1	Y	N	-
86	1632033	SK	Y	-	-	-	16	-	N	90	-	407	407	0	Y	N	-
87	297402	R	Y	Y	-	-	6	-	N	21	-	455	455	1	Y	N	-
88	1635798	BG	-	Y	-	Y	5	-	Y	-	-	440	440	0	Y	N	-
89	269628	RLP	-	-	-	-	12	-	Y	-	-	401	401	0	Y	N	-
90	1636098	JS	Y	-	-	-	7	-	N	26	-	456	456	1	Y	N	-
91	1636504	JS	-	-	-	-	4	-	Y	-	-	433	433	0	N	Y	-
92	1636474	AS	Y	Y	-	Y	4	1	N	54	-	442	442	0	Y	N	-
93	794933	DV	Y	Y	-	-	4	-	N	29	-	469	469	1	Y	N	-
94	1031223	N	-	-	-	-	7	-	Y	-	-	424	424	0	Y	N	-
95	1636360	TS	-	-	-	-	9	-	Y	-	-	417	417	0	Y	N	-
96	1637086	GK	Y	-	-	-	8	-	N	18	-	456	456	1	Y	N	-
97	1354326	SD	-	-	-	-	7	-	Y	-	-	438	438	0	Y	N	-
98	1637220	KD	Y	-	-	-	4	-	N	23	-	461	461	1	Y	N	-
99	1621286	SS	-	-	-	-	11	-	N	-	27	500	527	1	Y	N	-
100	1637116	D	Y	-	-	-	8	-	N	15	-	433	433	0	Y	N	-
101	1637226	VP	-	-	-	-	5	-	Y	-	-	461	461	1	Y	N	-
102	1637726	RR	-	-	-	-	3	-	N	-	29	419	448	0	Y	N	-
103	1637746	AS	-	-	-	-	6	-	N	-	15	497	512	1	N	Y	-
104	1637086	GK	Y	-	-	-	6	-	N	33	-	441	441	0	Y	N	-
105	1637865	KD	-	-	-	-	13	-	N	22	-	462	462	1	N	Y	-
106	1637103	DL	-	-	-	-	3	-	Y	-	-	428	428	0	Y	N	-
107	1645458	MR	Y	-	-	-	16	-	N	56	-	399	399	0	Y	N	-
108	1521863	SA	Y	-	-	-	21	-	N	20	-	399	399	0	N	Y	-
109	1608961	RKB	-	-	-	-	5	-	Y	-	-	440	440	0	Y	N	-
110	618241	BK	Y	Y	-	-	3	-	N	33	-	450	450	1	Y	N	-
111	1563586	SK	-	-	-	-	4	-	N	-	26	447	473	1	N	Y	-
112	1510911	GS	Y	-	-	-	2	-	N	102	-	514	514	1	N	Y	-
113	878118	RG	-	-	-	-	6	-	Y	-	-	425	425	0	Y	N	-
114	1646391	PV	-	-	-	-	10	-	Y	-	-	478	478	1	Y	N	-
115	1647777	RS	Y	-	-	-	11	-	N	59	-	474	474	1	Y	N	-
116	1648371	KG	-	-	-	-	3	-	Y	-	-	415	415	0	Y	N	-
117	453937	MB	-	-	-	-	4	-	Y	-	-	488	488	1	N	Y	-
118	476441	PC	Y	-	-	-	4	-	N	65	-	430	430	0	N	Y	-
119	1646754	DK	-	-	-	-	7	-	Y	-	-	435	435	0	Y	N	-
120	1648289	PK	-	-	-	-	5	-	Y	-	-	461	461	1	Y	N	-
121	1648810	RL	-	-	-	-	6	-	Y	-	-	434	434	0	N	Y	-
122	200550	SK	-	-	-	-	7	-	N	39	-	372	372	0	Y	N	-
123	1647890	PN	-	-	-	-	7	-	N	20	-	426	426	0	Y	N	-
124	1366283	RK	Y	Y	-	-	8	-	N	73	-	447	447	0	Y	N	-
125	164953	JS	Y	-	-	-	5	-	N	26	-	439	439	0	Y	N	-
126	1649550	PK	Y	-	-	-	8	-	N	41	-	476	476	1	Y	N	-
127	1649747	SR	-	-	-	-	8	-	N	10	-	447	447	0	Y	N	-
128	1650194	D	Y	-	-	-	4	-	N	36	-	457	457	1	Y	N	-

S No	MRD	NAME	AGE	AGE GROUP	SEX	OCCUPATION	RELIGION	SBP	DBP	PR	MARITAL STATUS	CONSANGUINITY	TEMPERATURE	APACHE II SCORE	HYPERTENSION	ENDOCRINE	ENDOCRINE_HYPOTHYROID	ENDOCRINE_HYPERTHYROID	ENDOCRINE_DM1
129	1618943	SM	56	3	F	HOUSEWIFE	H	150	80	108	M	-	101.2	21	-	-	-	-	-
130	757363	RG	69	3	M	BUSINESS	H	120	70	77	M	-	99.4	10	Y	Y	-	-	-
131	1649733	GS	75	4	M	DEPENDENT	S	110	70	130	M	-	97.2	13	-	Y	-	-	-
132	1650520	BK	50	2	F	HOUSEWIFE	S	110	60	72	M	-	99.8	31	-	Y	Y	-	-
133	1649755	PL	70	3	M	DEPENDENT	H	150	80	88	M	-	100.1	18	-	Y	-	-	-
134	1649234	SJ	68	3	M	DEPENDENT	H	110	70	76	M	-	99.1	16	Y	Y	Y	-	-
135	1649723	DK	36	2	M	BUSINESS	H	150	80	122	S	-	100	10	Y	Y	-	-	-
136	1649031	GS	78	4	M	DEPENDENT	S	110	60	105	M	-	101	16	Y	-	-	-	-
137	1654431	K	50	2	F	DEPENDENT	H	50	30	174	M	-	99	18	-	-	-	-	-
138	1387853	VK	66	3	M	DEPENDENT	H	110	50	120	M	-	98.2	10	-	-	-	-	-
139	1565910	K.S.	60	3	M	RETIRED	S	160	80	128	M	-	98	9	Y	-	-	-	-
140	331301	S.K.	75	4	F	HOMEMAKER	S	160	80	105	M	-	97.4	14	Y	-	-	-	-
141	305463	K.K.	82	4	F	HOMEMAKER	S	110	70	114	M	-	98	23	Y	Y	Y	-	-
142	1610751	S.K.	70	3	F	HOMEMAKER	S	160	110	80	M	-	98	19	Y	-	-	-	-
143	1600117	B.K.	45	2	M	UNEMPLOYED	H	-	-	124	M	-	99	30	-	-	-	-	-
144	398208	C.K.B.	85	4	F	HOMEMAKER	H	100	80	112	M	-	98.4	20	Y	Y	-	-	-
145	1594276	B.S.	65	3	M	RETIRED	S	150	70	86	M	-	97.4	12	-	-	-	-	-
146	735876	M.L.	73	4	M	RETIRED	H	140	80	114	M	-	98	12	-	-	-	-	-
147	1600929	G.S.G	73	4	M	RETIRED	S	130	80	49	M	-	98	10	-	Y	-	-	-
148	1591266	S.S.	65	3	F	HOMEMAKER	H	120	80	160	M	-	98	18	-	Y	-	-	-
149	146315	A.J.	64	3	M	BUSINESSMAN	H	150	70	108	M	-	100	17	Y	Y	-	-	-
150	1468392	V.G.	65	3	M	HOMEMAKER	H	90	60	86	M	-	99	18	Y	Y	-	-	-
151	1415553	S.D.	85	4	F	HOMEMAKER	H	130	80	85	M	-	98.4	18	Y	-	-	-	-
152	1599952	S.S.	61	3	M	HOMEMAKER	S	160	90	49	M	-	98.4	11	Y	Y	-	-	-
153	1464575	H.K.	74	4	F	HOMEMAKER	S	150	90	69	M	-	98.4	16	Y	Y	-	-	-
154	1596394	M.K.	50	2	F	HOMEMAKER	S	130	100	119	M	-	98.4	29	-	-	-	-	-
155	1589369	P.S.	72	4	M	BUSINESSMAN	H	100	60	137	M	-	98.4	29	Y	Y	-	-	-
156	1599285	N.	60	3	F	HOMEMAKER	H	100	60	101	M	-	98	11	-	Y	-	-	-
157	974264	P	72	4	F	HOMEMAKER	H	90	60	83	M	-	99	12	Y	Y	-	-	-
158	1612997	G.J.	51	3	M	BUSINESSMAN	H	130	70	72	M	-	98.4	10	-	-	-	-	-
159	254232	S.K.	86	4	F	HOMEMAKER	S	110	50	115	M	-	98.2	16	Y	Y	Y	-	-
160	1613629	D.K.G.	70	3	M	RETIRED	H	170	90	112	M	-	98	13	-	Y	-	-	-
161	1613098	B.S.	65	3	M	DEPENDENT	S	70	40	74	M	-	99	18	Y	-	-	-	-
162	1614887	L.C.	67	3	M	RETIRED	H	100	70	143	M	-	98.4	17	Y	Y	-	-	-
163	1615312	V.S.	38	2	M	BUSINESSMAN	H	150	80	95	M	-	98.4	9	Y	Y	-	-	-
164	1485288	M.L.	74	4	M	BUSINESS OWNER	H	130	70	102	M	-	98.4	22	Y	Y	-	-	-
165	1613664	G.S.	80	4	M	HOSPITAL EMPLOYEE	S	90	60	103	M	-	98.4	26	Y	Y	-	-	-
166	1616073	A.K.	60	3	M	RETIRED	H	90	60	102	M	-	98.4	23	Y	Y	-	-	-
167	1615339	K.	47	2	F	HOMEMAKER	H	140	90	72	M	-	98.4	17	Y	Y	-	-	-
168	195141	N.K.	63	3	F	HOMEMAKER	H	150	90	70	M	-	98.4	21	-	-	-	-	-
169	1612837	K.K.	63	3	M	FARMER	H	160	80	161	M	-	100	24	-	-	-	-	-
170	1614824	H.K.	75	4	F	HOMEMAKER	S	140	80	109	M	-	98.4	22	-	-	-	-	-
171	157175	M.S.	75	4	M	RETIRED	S	-	-	85	M	-	99.4	25	Y	-	-	-	-
172	1616176	S.S.	26	1	M	FARMER	S	100	60	110	S	-	98.4	27	-	-	-	-	-
173	1614830	R.K.	40	2	F	HOMEMAKER	S	180	90	127	M	-	100.4	23	-	-	-	-	-
174	1615380	K.S.	62	3	M	RETIRED	S	180	100	139	M	-	98.4	16	Y	Y	-	-	-
175	1505967	B.S.	78	4	M	RETIRED	S	90	60	120	M	-	101	29	-	Y	-	-	-
176	1615320	K.R.	58	3	F	HOMEMAKER	H	100	60	110	M	-	98.4	17	-	Y	-	-	-
177	1614918	B.	55	3	F	HOMEMAKER	H	130	90	171	M	-	98.4	22	-	Y	-	-	-
178	1615457	K.S.	65	3	M	RETIRED	S	140	90	76	M	-	98.4	14	-	Y	-	-	-
179	1606389	J.K.	68	3	F	HOMEMAKER	S	100	70	76	M	-	98.4	19	Y	Y	Y	-	-
180	1606942	O.P.K	99	4	M	RETIRED	H	80	50	116	M	-	100	16	-	-	-	-	-
181	1608577	A.S.	35	2	M	BUSINESS OWNER	S	130	70	144	M	-	101	21	-	Y	-	-	-
182	1596363	T.C.	65	3	M	BUSINESSMAN	H	90	60	108	M	-	102	28	Y	Y	-	-	-
183	1614799	G.K.	34	2	F	HOMEMAKER	S	60	40	154	M	-	101	26	-	-	-	-	-
184	1526638	B.S.	63	3	M	RETIRED	S	180	90	104	M	-	101	23	Y	Y	-	-	-
185	1616148	S.A.	38	2	M	BUSINESS MAN	H	100	60	94	M	-	98.4	9	-	-	-	-	-
186	1615380	K.S.	62	3	M	RETIRED	S	180	100	139	M	-	98.4	17	Y	Y	-	-	-
187	654262	R.K.G.	61	3	M	PVT SECTOR EMPLOYEE	H	120	80	91	M	-	100	18	-	Y	-	-	-
188	1616724	V.D.M	77	4	M	BUSINESS OWNER	H	100	60	88	M	-	98.4	25	-	-	-	-	-
189	1608602	A.S.	77	4	M	RETIRED	S	130	90	66	M	-	98.4	20	Y	Y	-	-	-
190	1610418	K.S.	40	2	F	HOMEMAKER	S	120	70	122	M	-	98.4	24	-	-	-	-	-
191	1615464	V.R.	70	3	F	RETIRED	H	90	60	115	M	-	101	30	Y	Y	-	-	-
192	1615424	K.C.	74	4	M	PHYSICIAN	H	90	60	122	M	-	100	25	Y	-	-	-	-

S No	MRD	NAME	ENDOCRINE_DM2	ENDOCRINE_OTHERS	NEUROLOGIC	NEUROLOGIC_HEMORRHAGIC CVA	NEUROLOGIC_ISCHAEMIC CVA	NEUROLOGIC_SEIZURE	NEUROLOGIC_SPINAL CORD INVOLVEMENT	NEUROLOGIC_OTHERS	PULMONARY	PULMONARY_PNEUMONIA	PULMONARY_COPD
129	1618943	SM	-	-	-	-	-	-	-	-	-	-	-
130	757363	RG	Y	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	Y	-	-	-	-	-	-	-	-	-	-
132	1650520	BK	Y	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	Y	-	-	-	-	-	-	-	Y	Y	-
134	1649234	SJ	Y	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	Y	-	-	-	-	-	-	-	Y	Y	-
136	1649031	GS	-	-	-	-	-	-	-	-	Y	Y	-
137	1654431	K	-	-	-	-	-	-	-	-	Y	-	-
138	1387853	VK	-	-	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	Y	-	-	-	-	-	-	-	Y	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	Y	-	Y	-	Y	Y	-	-	Y	-	Y
145	1594276	B.S.	-	-	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	Y	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	Y	-	-	-	-	-	-	-	-	-	-
149	146315	A.J.	Y	-	-	-	-	-	-	-	-	-	-
150	1468392	V.G.	Y	-	-	-	-	-	-	-	Y	Y	Y
151	1415553	S.D.	-	-	Y	-	Y	-	-	-	Y	-	Y
152	1599952	S.S.	Y	-	Y	-	-	-	-	2	-	-	-
153	1464575	H.K.	Y	-	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	-	Y	Y	-	-	-	-	-	-	-
155	1589369	P.S.	Y	-	Y	-	-	Y	-	-	Y	Y	-
156	1599285	N.	Y	-	-	-	-	-	-	-	-	-	-
157	974264	P	Y	-	-	-	-	-	-	-	Y	Y	Y
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	Y	-	Y
160	1613629	D.K.G.	Y	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	-	-	-	-	-	-
162	1614887	L.C.	Y	-	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	Y	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	Y	-	-	-	-	-	-	-	Y	Y	-
165	1613664	G.S.	Y	-	-	-	-	-	-	-	Y	Y	-
166	1616073	A.K.	Y	-	Y	-	Y	-	-	-	-	-	-
167	1615339	K.	Y	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	-	-	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	Y	Y	Y
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	-	Y	-	Y
172	1616176	S.S.	-	-	Y	-	-	-	-	3	Y	Y	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	Y	Y	-
174	1615380	K.S.	Y	-	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	Y	-	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	Y	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	Y	-	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	Y	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	Y	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	Y	-	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	Y	-	-	-	-	-	-	-	-	-	-
183	1614799	G.K.	-	-	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	Y	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	Y	-	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	Y	-	Y	-	-	Y	-	-	Y	Y	-
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	Y	-	Y	Y	-	-	-	-	Y	-	-
190	1610418	K.S.	-	-	Y	Y	-	-	-	-	-	-	-
191	1615464	V.R.	Y	-	-	-	-	-	-	-	Y	Y	-
192	1615424	K.C.	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	PULMONARY_PLEURAL EFFUSION	PULMONARY_PNEUMOTHORAX	PULMONARY_OTHER	CARDIAC	CARDIAC_STEMI	CARDIAC_NSTEMI	CARDIAC_UNSTABLE ANGINA	CARDIAC_STABLE ANGINA	CARDIAC_CAD	CARDIAC_CONGENITAL HEART DISEASE	CARDIAC_CHF
129	1618943	SM	-	-	-	Y	-	-	-	-	-	-	-
130	757363	RG	-	-	-	Y	-	-	-	-	Y	-	-
131	1649733	GS	-	-	-	Y	-	-	-	-	Y	-	-
132	1650520	BK	-	-	-	Y	-	-	-	-	Y	-	-
133	1649755	PL	-	-	-	Y	-	Y	-	-	-	-	-
134	1649234	SJ	-	-	-	Y	-	Y	-	-	-	-	Y
135	1649723	DK	-	-	-	Y	-	-	-	-	-	-	Y
136	1649031	GS	-	-	-	Y	-	-	-	-	Y	-	-
137	1654431	K	Y	-	-	Y	Y	-	-	-	-	-	Y
138	1387853	VK	-	-	-	Y	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	Y	-	-	-	-	Y	-	Y
140	331301	S.K.	-	-	-	Y	-	-	-	-	Y	-	Y
141	305463	K.K.	Y	-	-	Y	-	-	-	-	-	-	Y
142	1610751	S.K.	-	-	-	Y	Y	-	-	-	Y	-	-
143	1600117	B.K.	-	-	-	Y	-	-	-	-	-	-	-
144	398208	C.K.B.	Y	-	-	Y	-	-	-	-	-	-	Y
145	1594276	B.S.	-	-	-	N	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	Y	-	-	-	-	Y	-	-
147	1600929	G.S.G	-	-	-	Y	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	N	-	-	-	-	-	-	-
149	146315	A.J.	-	-	-	Y	-	-	-	-	Y	-	-
150	1468392	V.G.	-	-	-	Y	-	-	-	-	Y	-	Y
151	1415553	S.D.	-	-	-	Y	-	-	-	-	Y	-	-
152	1599952	S.S.	-	-	-	N	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	Y	-	-	-	-	Y	-	-
154	1596394	M.K.	-	-	-	Y	-	-	-	-	-	-	-
155	1589369	P.S.	-	-	-	N	-	-	-	-	-	-	-
156	1599285	N.	-	-	-	N	-	-	-	-	-	-	-
157	974264	P	-	-	-	Y	-	-	-	-	Y	-	-
158	1612997	G.J.	-	-	-	Y	Y	-	-	-	-	-	-
159	254232	S.K.	-	-	-	Y	-	-	-	-	Y	-	Y
160	1613629	D.K.G.	-	-	-	Y	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	Y	Y	-	-	-	-	-	-
162	1614887	L.C.	-	-	-	Y	Y	-	-	-	Y	-	-
163	1615312	V.S.	-	-	-	Y	-	-	-	-	-	Y	-
164	1485288	M.L.	-	-	-	Y	-	-	-	-	Y	-	-
165	1613664	G.S.	Y	-	-	Y	-	-	-	-	-	-	-
166	1616073	A.K.	-	-	-	Y	Y	-	-	-	Y	-	Y
167	1615339	K.	-	-	-	Y	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	Y	-	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	Y	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	Y	Y	-	-	-	-	-	-
171	157175	M.S.	-	-	-	Y	-	-	-	-	-	-	-
172	1616176	S.S.	-	-	-	N	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	Y	-	-	-	-	-	-	Y
174	1615380	K.S.	-	-	-	Y	Y	-	-	-	-	-	Y
175	1505967	B.S.	-	-	-	Y	-	-	-	-	Y	-	Y
176	1615320	K.R.	-	-	-	Y	-	Y	-	-	-	-	Y
177	1614918	B.	-	-	-	Y	Y	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	N	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	Y	Y	-	-	-	Y	-	-
180	1606942	O.P.K	-	-	-	Y	-	-	-	-	Y	-	-
181	1608577	A.S.	-	-	-	N	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	-	Y	Y	-	-	-	Y	-	Y
183	1614799	G.K.	-	-	-	N	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	Y	-	-	-	-	Y	-	Y
185	1616148	S.A.	-	-	-	Y	Y	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	Y	Y	-	-	-	-	-	Y
187	654262	R.K.G.	-	-	-	Y	-	-	-	-	Y	-	-
188	1616724	V.D.M	-	-	-	Y	Y	-	-	-	-	-	-
189	1608602	A.S.	-	-	2	Y	-	Y	-	-	-	-	-
190	1610418	K.S.	-	-	-	Y	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	N	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	Y	-	-	-	-	-	-	-

S No	MRD	NAME	CARDIAC_ARRYTHMIA_AT	AF	AFL	PSVT	NSVT	VT	TDP	APC	VPC	OTHER	CMP_DCMP	RCMP	ICMP	HCMP	VALVULAR HEART DISEASE	VALVULAR HEART DISEASE_AS	AR	MS	MR	PERICARDIAL DISEASE_CCP	TAMPONADE	EFFUSION	OTHERS	GASTRO-INTESTINAL
129	1618943	SM	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
132	1650520	BK	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
133	1649755	PL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
134	1649234	SJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
136	1649031	GS	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
137	1654431	K	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
138	1387853	VK	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	Y	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	Y	-	-	-	-	-
142	1610751	S.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	Y
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	-	Y	-	-	-	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-	-	-	Y
145	1594276	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
149	146315	A.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-
150	1468392	V.G.	-	Y	-	-	-	Y	-	-	-	CHB	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
151	1415553	S.D.	-	-	-	-	-	-	-	-	-	CHB	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-
155	1589369	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
156	1599285	N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	Y	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	Y
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
162	1614887	L.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
165	1613664	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-
166	1616073	A.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	Y	-	-	-	-	-
168	195141	N.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	4	-
169	1612837	K.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
172	1616176	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	Y	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
181	1608577	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
183	1614799	G.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	-	Y
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	1	-
191	1615464	V.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	GASTRO-INTESTINAL_CLD	GASTRO-INTESTINAL_HEPATITIS	GASTRO-INTESTINAL_ALF	GASTRO-INTESTINAL_PANCREATITIS	GASTRO-INTESTINAL_SAIO	GASTRO-INTESTINAL_CHOLECYSTITIS	GASTRO-INTESTINAL_OTHER	NEPHRO	NEPHRO_AKI
129	1618943	SM	-	-	-	-	-	-	-	Y	Y
130	757363	RG	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	-	-	-	-	-	-	Y	Y
132	1650520	BK	-	Y	-	-	-	-	-	Y	-
133	1649755	PL	-	-	-	-	-	-	-	Y	Y
134	1649234	SJ	-	-	-	-	-	-	-	Y	Y
135	1649723	DK	-	-	-	-	-	-	-	Y	Y
136	1649031	GS	-	-	-	-	-	-	-	Y	Y
137	1654431	K	-	-	-	-	-	-	-	Y	Y
138	1387853	VK	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	-	-	Y	Y
142	1610751	S.K.	-	-	-	-	-	-	Y	-	-
143	1600117	B.K.	-	-	-	-	-	-	-	Y	Y
144	398208	C.K.B.	-	Y	-	-	-	-	-	Y	Y
145	1594276	B.S.	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	Y	Y
147	1600929	G.S.G	-	-	-	-	-	-	-	Y	Y
148	1591266	S.S.	-	-	-	-	-	Y	-	Y	-
149	146315	A.J.	-	-	-	-	-	-	-	-	-
150	1468392	V.G.	-	-	-	-	-	-	-	Y	-
151	1415553	S.D.	-	-	-	-	-	-	-	Y	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	-	-	Y	-
154	1596394	M.K.	-	-	-	-	-	-	-	Y	Y
155	1589369	P.S.	-	-	-	-	-	-	-	Y	Y
156	1599285	N.	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	-	-	-	Y	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	Y	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	-	-	Y	Y
162	1614887	L.C.	-	-	-	-	-	-	-	Y	Y
163	1615312	V.S.	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	-	-	Y	-
165	1613664	G.S.	-	-	-	-	-	-	-	Y	Y
166	1616073	A.K.	-	-	-	-	-	-	-	Y	-
167	1615339	K.	-	-	-	-	-	-	-	Y	Y
168	195141	N.K.	-	-	-	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	5	Y	Y
172	1616176	S.S.	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	Y	Y
174	1615380	K.S.	-	-	-	-	-	-	-	Y	Y
175	1505967	B.S.	-	-	-	-	-	-	-	Y	Y
176	1615320	K.R.	-	-	-	-	-	-	-	Y	Y
177	1614918	B.	-	-	-	-	-	-	-	Y	Y
178	1615457	K.S.	-	-	-	-	-	-	-	Y	-
179	1606389	J.K.	-	-	-	-	-	-	-	Y	-
180	1606942	O.P.K	-	-	-	-	-	-	2	Y	-
181	1608577	A.S.	-	-	-	-	-	-	-	Y	Y
182	1596363	T.C.	-	-	-	Y	-	-	2	Y	Y
183	1614799	G.K.	-	-	-	-	-	-	-	Y	-
184	1526638	B.S.	Y	-	-	-	-	-	-	Y	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	Y	Y
187	654262	R.K.G.	-	-	-	-	-	-	-	Y	-
188	1616724	V.D.M	-	-	-	-	-	-	-	Y	-
189	1608602	A.S.	-	-	-	-	-	-	-	Y	Y
190	1610418	K.S.	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	-	-	-	-	Y	Y
192	1615424	K.C.	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	NEPHRO_CKD	NEPHRO_NEPHROTIC	NEPHRO_NEPHRITIC	NEPHRO_OBSTRUCTIVE UROPATHY	NEPHRO_UTI	NEPHRO_USE OF RRT	NEPHRO_OTHER	SEPSIS	INFECTIONS	INFECTIONS_TB	HIV	DENGUE	ENTERIC	MALARIA	LEPTOSPIRA	SCRUB TYPHUS	COVID	H1N1
129	1618943	SM	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
132	1650520	BK	Y	-	-	-	-	Y	-	Y	N	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
134	1649234	SJ	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	Y
136	1649031	GS	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	Y
137	1654431	K	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
138	1387853	VK	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
141	305463	K.K.	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	Y	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
145	1594276	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
149	146315	A.J.	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-
150	1468392	V.G.	Y	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
151	1415553	S.D.	Y	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
155	1589369	P.S.	-	-	-	-	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-	-
156	1599285	N.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	Y	-	-	-	Y	-	-	Y	-	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
162	1614887	L.C.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	Y	-	-	-	-	N	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	-	-	Y	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
172	1616176	S.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	Y	-	-	-	Y	Y	-	Y	N	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	Y	-	-	-	-	Y	-	Y	Y	-	-	Y	-	-	-	-	-	-
179	1606389	J.K.	Y	-	-	-	Y	Y	-	Y	N	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	-	-	Y	Y	-	Y	N	-	-	-	-	-	-	-	-	-
183	1614799	G.K.	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	Y	-	-	-	Y	Y	-	Y	N	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
188	1616724	V.D.M	Y	-	-	-	-	Y	-	Y	N	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHER	MALIGNANCY	SURGICAL ILLNESS	SURGICAL ILLNESS_GI	ORTHOPEDIC	NEURO	URO	OBG	ENT	PLASTIC	TRAUMA	CTVS	SHOCK	PSYCHIATRIC	PSYCHIATRIC_DEPRESSION	ANXIETY	PSYCHOSIS	DELIRIUM	HALLUCINATION	PTSD	SCHIZOPHRENIA
129	1618943	SM	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
130	757363	RG	-	-	Y	-	-	Y	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-
131	1649733	GS	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
132	1650520	BK	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
133	1649755	PL	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-
134	1649234	SJ	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	Y	-	-	-	-	-
135	1649723	DK	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-
136	1649031	GS	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-
137	1654431	K	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
138	1387853	VK	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-
139	1565910	K.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
140	331301	S.K.	-	-	Y	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
141	305463	K.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-
144	398208	C.K.B.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	Y	-	-	-	-	-	-
145	1594276	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
146	735876	M.L.	-	-	Y	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
149	146315	A.J.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
150	1468392	V.G.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
151	1415553	S.D.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	Y	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-
154	1596394	M.K.	-	-	Y	-	-	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
155	1589369	P.S.	HSV	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
156	1599285	N.	-	-	Y	-	-	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-
157	974264	P	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
158	1612997	G.J.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
159	254232	S.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-
162	1614887	L.C.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
164	1485288	M.L.	-	4	N	-	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-
165	1613664	G.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
166	1616073	A.K.	-	5	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
167	1615339	K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
168	195141	N.K.	-	-	Y	Y	-	-	-	Y	-	-	-	-	-	Y	Y	-	-	-	-	-	-
169	1612837	K.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
171	157175	M.S.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
172	1616176	S.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
174	1615380	K.S.	-	6	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
175	1505967	B.S.	-	-	Y	-	-	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	Y	-	Y	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
177	1614918	B.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
181	1608577	A.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
183	1614799	G.K.	-	-	Y	-	-	-	-	Y	-	-	-	-	Y	Y	Y	-	-	-	-	-	-
184	1526638	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
187	654262	R.K.G.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
188	1616724	V.D.M	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	Y	-	-	Y	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	Y	-	Y	Y	-	-	-	-	Y	-	Y	N	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-

S No	MRD	NAME	CATATONIA	WITHDRAWAL	OTHER	OTHER	HISTORY SUGGESTING LQTS	HISTORY SUGGESTING LQTS_VT	SYNCOPE	SEIZURE	CARDIAC ARREST	UNEXPLAINED MOTOR ACCIDENT	UNEXPLAINED DROWNING	HEARING LOSS	PERIODIC PARALYSIS	SKELETAL DYSMORPHISM	COGNITIVE ISSUES	IMMUNE DYSFUNCTION
129	1618943	SM	-	-	-	-	Y	Y	-	-	Y	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
131	1649733	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
132	1650520	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
134	1649234	SJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
137	1654431	K	-	-	-	-	Y	Y	Y	-	Y	-	-	-	-	-	-	-
138	1387853	VK	-	-	-	-	Y	Y	Y	-	Y	-	-	Y	-	-	-	-
139	1565910	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	-	-	-	-	Y	-	-	-	-	-	-	Y	-	-	-	-
145	1594276	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
149	146315	A.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
150	1468392	V.G.	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
151	1415553	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
155	1589369	P.S.	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
156	1599285	N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
162	1614887	L.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
172	1616176	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
183	1614799	G.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	AUTISM	FAMILY HISTORY	FAMILY HISTORY_PREMATURE SUDDEN DEATH <40 YRS	SYNCOPE	CONSANGUINITY	DROWNING	DEATH WHILE DRIVING	SEIZURES	CONGENITAL DEAFNESS	KNOWN LQT MUTATION	RELATION WITH AFFECTED PERSON	DRUGS WITH RISK OF QTC PROLONGATION	ANTIARRYTHMICS	ANTIARRYTHMICS_AMIODARONE	1A
129	1618943	SM	-	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
132	1650520	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
134	1649234	SJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
137	1654431	K	-	Y	Y	-	-	-	-	-	-	-	-	-	Y	Y	-
138	1387853	VK	-	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-
139	1565910	K.S.	-	Y	Y	-	-	-	-	Y	-	-	UNCLE	-	Y	Y	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
144	398208	C.K.B.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
145	1594276	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
149	146315	A.J.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-
150	1468392	V.G.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
151	1415553	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
154	1596394	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
155	1589369	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
156	1599285	N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-
162	1614887	L.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
172	1616176	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
183	1614799	G.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	Y	Y	-	-	-	-	-	-	-	COUSIN	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHERS	ANTIMICROBIALS	ANTIMICROBIALS_MACROLIDES	FLUOROQUINOLONES	TRIMETH-SULPHAMETHO	CLINDAMYCIN	ATT	METRONIDAZOLE	ANTIMALARIAL	ANTIFUNGAL	ANTIVIRAL	OTHERS	ANTIPSYCHOTICS
129	1618943	SM	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-
132	1650520	BK	-	-	-	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	Y	Y	-	-	-	-	-	-	-	-	AZITHRO	-
134	1649234	SJ	-	-	-	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	-
136	1649031	GS	-	Y	Y	-	-	-	-	-	-	-	Y	OSELTAMIVIR	Y
137	1654431	K	-	-	-	-	-	-	-	-	-	-	-	-	-
138	1387853	VK	-	-	-	-	-	-	-	-	-	-	-	-	Y
139	1565910	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	-	-	-	-	-	-	-	-	-	-	-	-	-
145	1594276	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
149	146315	A.J.	Y - IB	Y	Y	-	-	-	Y	-	-	-	-	-	-
150	1468392	V.G.	Y - IB	-	-	-	-	-	-	-	-	-	-	-	-
151	1415553	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	Y
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	Y	Y	-	-	-	-	-	-	-	-	-	Y
155	1589369	P.S.	-	Y	Y	Y	-	Y	-	-	-	Y	Y	-	-
156	1599285	N.	-	-	-	-	-	-	-	-	-	-	-	-	-
157	974264	P	-	Y	-	-	-	-	-	-	-	Y	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	Y - IB	-	-	-	-	-	-	-	-	-	-	-	Y
162	1614887	L.C.	-	-	-	-	-	-	-	-	-	-	-	-	Y
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	Y	Y	-	-	-	-	-	-	-	-	-	Y
165	1613664	G.S.	-	Y	-	-	-	-	-	-	-	Y	-	-	-
166	1616073	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y
169	1612837	K.K.	-	Y	Y	-	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
172	1616176	S.S.	-	Y	Y	-	-	-	-	Y	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	-	Y	-	-	-	Y	-	-	-	-	-	-	Y
176	1615320	K.R.	-	-	-	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	Y - IB	-	-	-	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	-	Y	-	-	-	Y	-	-	-	-	-	-	Y
182	1596363	T.C.	-	Y	-	-	-	Y	-	-	-	-	-	-	Y
183	1614799	G.K.	-	Y	-	-	-	-	-	Y	-	-	-	-	Y
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	-	Y	Y	-	-	-	-	-	-	-	-	-	Y
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	-	Y	Y	-	-	-	-	Y	-	-	-	-	Y
192	1615424	K.C.	-	Y	-	-	-	-	-	Y	-	-	-	-	-

S No	MRD	NAME	ANTIPSYCHOTICS_HALOPERIDOL	OLANZAPINE	QUETIAPINE	RISPERIDONE	OTHERS	ANTIDEPRESSANTS	ANTIDEPRESSANTS_ESCITALOPRAM	FLUOXETINE	SERTRALINE	MIRTAZAPINE	IMIPRAMINE	AMITRYPTILINE	NORTRYPTILINE	OTHERS
129	1618943	SM	-	-	-	-	-	-	-	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
132	1650520	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	-	-	-	-	-	-	-	-	-	-	-	-	-
134	1649234	SJ	-	-	-	-	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
137	1654431	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
138	1387853	VK	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	-	-	-	-	-	Y	-	-	-	-	-	Y	-	-
145	1594276	B.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
149	146315	A.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
150	1468392	V.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
151	1415553	S.D.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
155	1589369	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
156	1599285	N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
162	1614887	L.C.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	Y	-	-	-	-	Y	-	Y	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
172	1616176	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
183	1614799	G.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	ANTIHISTAMINES	ANTIHISTAMINES_ DIPHENHYDRAMINE	HYDROXYZINE	OTHER	ANALGESICS, ANESTHETICS, SEDATIVES	ANALGESICS, ANESTHETICS, SEDATIVES OPIOIDS	PROPOFOL	BENZODIAZEPINES	OTHERS	ANTINEOPLASTICS	BRONCHODILATORS	BRONCHODILATORS_TERBUTALINE
129	1618943	SM	-	-	-	-	-	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	-	-	-	-	-	-	-	-	-	Y	-
132	1650520	BK	-	-	-	-	Y	F	-	Y	M	-	-	-
133	1649755	PL	-	-	-	-	Y	M	-	-	-	-	Y	-
134	1649234	SJ	-	-	-	-	Y	M	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	Y	-
136	1649031	GS	-	-	-	-	-	-	-	-	-	-	Y	-
137	1654431	K	-	-	-	-	-	-	-	-	-	-	-	-
138	1387853	VK	-	-	-	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	-	Y	-	-	Y	C	-	-	-
140	331301	S.K.	-	-	-	-	Y	-	-	Y	C	-	-	-
141	305463	K.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
142	1610751	S.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
143	1600117	B.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
144	398208	C.K.B.	-	-	-	-	Y	-	-	Y	C	-	Y	-
145	1594276	B.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
146	735876	M.L.	-	-	-	-	Y	-	-	Y	C	-	Y	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
149	146315	A.J.	-	-	-	-	Y	-	-	Y	C	-	Y	-
150	1468392	V.G.	-	-	-	-	Y	T	-	-	-	-	Y	-
151	1415553	S.D.	-	-	-	-	Y	-	-	Y	C	-	Y	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	Y	-
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	Y	-
154	1596394	M.K.	-	-	-	-	Y	T	-	-	-	-	Y	-
155	1589369	P.S.	-	-	-	-	Y	F	-	Y	M	-	Y	-
156	1599285	N.	-	-	-	-	Y	-	-	Y	C	-	Y	-
157	974264	P	-	-	-	-	Y	-	-	Y	C	-	Y	-
158	1612997	G.J.	-	-	-	-	Y	-	-	Y	C	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	Y	-
160	1613629	D.K.G.	-	-	-	-	Y	-	-	Y	C	-	-	-
161	1613098	B.S.	-	-	-	-	Y	F	-	Y	M	-	-	-
162	1614887	L.C.	-	-	-	-	Y	-	-	Y	C	-	Y	-
163	1615312	V.S.	-	-	-	-	Y	-	-	Y	C	-	-	-
164	1485288	M.L.	-	-	-	-	Y	F	-	Y	M	-	Y	-
165	1613664	G.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
166	1616073	A.K.	-	-	-	-	Y	F	-	Y	M	-	-	-
167	1615339	K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
168	195141	N.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	-	-	Y	-
170	1614824	H.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
171	157175	M.S.	-	-	-	-	Y	F	-	Y	M	-	Y	-
172	1616176	S.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
173	1614830	R.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
174	1615380	K.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
175	1505967	B.S.	-	-	-	-	Y	F	-	Y	M	-	-	-
176	1615320	K.R.	-	-	-	-	Y	F	-	Y	M	-	Y	-
177	1614918	B.	-	-	-	-	Y	F	-	Y	M	-	Y	-
178	1615457	K.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
179	1606389	J.K.	-	-	-	-	Y	-	-	Y	C	-	Y	-
180	1606942	O.P.K	-	-	-	-	Y	-	-	Y	C	-	-	-
181	1608577	A.S.	-	-	-	-	Y	F	-	Y	M	-	Y	-
182	1596363	T.C.	-	-	-	-	Y	F	-	Y	M	-	Y	-
183	1614799	G.K.	-	-	-	-	Y	F	-	Y	M	-	Y	-
184	1526638	B.S.	-	-	-	-	Y	F	-	Y	M	-	Y	-
185	1616148	S.A.	-	-	-	-	Y	-	-	Y	C	-	-	-
186	1615380	K.S.	-	-	-	-	Y	-	-	Y	C	-	Y	-
187	654262	R.K.G.	-	-	-	-	Y	-	-	Y	C	-	Y	-
188	1616724	V.D.M	-	-	-	-	Y	-	-	Y	C	-	Y	-
189	1608602	A.S.	-	-	-	-	Y	F	-	Y	M	-	Y	-
190	1610418	K.S.	-	-	-	-	Y	F	-	Y	-	-	-	-
191	1615464	V.R.	-	-	-	-	Y	F	-	Y	-	-	-	-
192	1615424	K.C.	-	-	-	-	Y	F	-	Y	M	-	Y	-

S No	MRD	NAME	FORMETROL	INDACATEROL	SALMETROL	SALBUTAMOL	LEVOSALBUTAMOL	OTHERS	DIURETICS	DIURETICS_FUROSEMIDE	TORSEMIDE	METOLAZONE	SPIRONOLACTONE	HYDROCHLORTHIAZIDE	CTD	GIDRUGS	GI DRUGS_LOPERAMIDE
129	1618943	SM	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
131	1649733	GS	-	-	-	-	Y	-	Y	Y	-	-	Y	-	-	Y	-
132	1650520	BK	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
133	1649755	PL	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
134	1649234	SJ	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
135	1649723	DK	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
136	1649031	GS	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	Y	-
137	1654431	K	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
138	1387853	VK	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
139	1565910	K.S.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
140	331301	S.K.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
141	305463	K.K.	-	-	-	Y	-	-	Y	Y	Y	Y	Y	-	-	Y	-
142	1610751	S.K.	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
143	1600117	B.K.	-	-	-	Y	-	-	Y	Y	-	-	-	-	-	Y	-
144	398208	C.K.B.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
145	1594276	B.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
146	735876	M.L.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
148	1591266	S.S.	-	-	-	Y	-	-	Y	-	Y	-	-	-	-	Y	-
149	146315	A.J.	-	-	-	Y	-	-	Y	Y	Y	-	Y	-	-	Y	-
150	1468392	V.G.	-	-	-	Y	-	-	Y	Y	-	Y	-	-	-	Y	-
151	1415553	S.D.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
152	1599952	S.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
153	1464575	H.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
154	1596394	M.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
155	1589369	P.S.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
156	1599285	N.	-	-	-	Y	-	-	Y	Y	-	-	-	-	-	Y	-
157	974264	P	Y	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
159	254232	S.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
160	1613629	D.K.G.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
161	1613098	B.S.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
162	1614887	L.C.	-	-	-	Y	-	-	Y	Y	-	-	-	-	-	Y	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
164	1485288	M.L.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
165	1613664	G.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
166	1616073	A.K.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
167	1615339	K.	-	-	-	Y	-	-	Y	Y	-	-	-	-	-	Y	-
168	195141	N.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
169	1612837	K.K.	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
170	1614824	H.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
171	157175	M.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
172	1616176	S.S.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
173	1614830	R.K.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
174	1615380	K.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
175	1505967	B.S.	-	-	-	-	-	-	Y	Y	-	Y	-	-	-	Y	-
176	1615320	K.R.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
177	1614918	B.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
178	1615457	K.S.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
179	1606389	J.K.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
180	1606942	O.P.K	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
181	1608577	A.S.	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
182	1596363	T.C.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
183	1614799	G.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
184	1526638	B.S.	-	-	-	Y	-	-	Y	-	Y	Y	-	-	-	Y	-
185	1616148	S.A.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
186	1615380	K.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
187	654262	R.K.G.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
188	1616724	V.D.M	-	-	-	Y	-	-	Y	Y	-	-	-	-	-	Y	-
189	1608602	A.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
191	1615464	V.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
192	1615424	K.C.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-

S No	MRD	NAME	ONDANSETRON	GRANISETRON	PALONOSETRON	DOMPERIDONE	METOCLOPRAMIDE	PANTOPRAZOLE	ESOMEPRAZOLE	OMEPRAZOLE	OTHERS	DRUGS FOR BPH	DRUGS FOR BPH TAMSULOSIN	ALFUZOSIN	SILODOSIN	CHOLINERGIC ANTAGONIST	CITRATE MASSIVE BT	COCAINE
129	1618943	SM	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
132	1650520	BK	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
134	1649234	SJ	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
137	1654431	K	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
138	1387853	VK	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
145	1594276	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	-	-
149	146315	A.J.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
150	1468392	V.G.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
151	1415553	S.D.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
155	1589369	P.S.	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
156	1599285	N.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
157	974264	P	Y	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
162	1614887	L.C.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
165	1613664	G.S.	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-	-	-
166	1616073	A.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
169	1612837	K.K.	-	-	-	Y	-	Y	-	-	-	Y	Y	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	-	-
172	1616176	S.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
175	1505967	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
183	1614799	G.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	Y	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
187	654262	R.K.G.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
188	1616724	V.D.M	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	RANOLAZINE	INOTROPES	INOTROPES_NOREPINEPHRINE	EPINEPHRINE	DOPAMINE	DOBUTAMINE	VASOPRESSIN	OTHERS	ANTIEPILEPTICS_	ANTIEPILEPTICS_LEVETIRACITAM	ANTIEPILEPTICS_OTHERS	OTHERS
129	1618943	SM	-	Y	Y	-	Y	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	Y	Y	Y	-	-	-	-	-	-	-	-	-
132	1650520	BK	-	Y	Y	-	Y	-	Y	-	-	-	-	-
133	1649755	PL	Y	-	-	-	-	-	-	-	-	-	-	-
134	1649234	SJ	Y	Y	Y	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	-	-	-	-	-	-	-	-	-	-	-	-
137	1654431	K	-	Y	Y	-	Y	-	-	-	-	-	-	-
138	1387853	VK	-	Y	Y	-	Y	-	-	-	Y	-	P	-
139	1565910	K.S.	-	-	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
144	398208	C.K.B.	-	Y	Y	-	-	-	-	-	-	-	-	-
145	1594276	B.S.	-	Y	Y	-	Y	-	-	-	-	-	-	-
146	735876	M.L.	-	Y	Y	-	Y	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	Y	Y	-	Y	-	-	-	-	-	-	-
149	146315	A.J.	-	Y	Y	-	Y	-	-	-	-	-	-	-
150	1468392	V.G.	-	Y	Y	-	Y	-	-	-	-	-	-	-
151	1415553	S.D.	-	-	-	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
154	1596394	M.K.	-	Y	Y	-	Y	-	-	-	Y	Y	-	-
155	1589369	P.S.	-	Y	Y	Y	Y	-	Y	-	Y	Y	-	-
156	1599285	N.	-	Y	Y	-	Y	-	-	-	-	-	-	-
157	974264	P	-	Y	Y	-	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	Y	Y	-	Y	-	-	-	-	-	-	-
159	254232	S.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	Y	Y	-	Y	-	-	-	-	-	-	-
161	1613098	B.S.	-	Y	Y	Y	Y	-	-	-	-	-	-	-
162	1614887	L.C.	-	Y	Y	-	Y	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	Y	Y	-	Y	-	-	-	-	-	-	-
166	1616073	A.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
167	1615339	K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
168	195141	N.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
169	1612837	K.K.	-	Y	Y	Y	Y	-	Y	-	Y	Y	-	-
170	1614824	H.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
172	1616176	S.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
173	1614830	R.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
174	1615380	K.S.	-	Y	Y	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
176	1615320	K.R.	-	Y	Y	-	Y	-	-	-	-	-	-	-
177	1614918	B.	-	Y	Y	-	Y	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
180	1606942	O.P.K	-	Y	Y	-	Y	-	-	-	-	-	-	-
181	1608577	A.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
182	1596363	T.C.	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
183	1614799	G.K.	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	Y	Y	-	Y	-	-	-	-	-	-	-
187	654262	R.K.G.	-	-	-	-	-	-	-	-	Y	Y	P	-
188	1616724	V.D.M	-	Y	Y	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	Y	Y	Y	Y	-	-	-	Y	Y	-	-
190	1610418	K.S.	-	Y	Y	-	Y	-	-	-	Y	Y	P	-
191	1615464	V.R.	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
192	1615424	K.C.	-	Y	Y	-	-	-	Y	-	-	-	-	-

S No	MRD	NAME	OTHER CONDITIONS PREDISPOSING TO PROLONGED QTC	ELECTROLYTE ABNORMALITIES	ELECTROLYTE ABNORMALITIES HYPOKALEMIA	HYPOMAGNESEMIA	HYPOCALCEMIA	OTHERS	CARDIAC CONDITIONS	CARDIAC CONDITIONS ISCHEMIA	MYOCARDITIS	BRADYCARDIA	STRESS CMP	OTHERS	ENDOCRINE DISORDERS
129	1618943	SM	-	N	-	-	-	-	-	-	-	-	-	-	-
130	757363	RG	Y	N	-	-	-	-	-	-	-	-	-	-	-
131	1649733	GS	Y	Y	Y	-	Y	-	-	-	-	-	-	-	-
132	1650520	BK	Y	Y	-	-	Y	-	-	-	-	-	-	-	Y
133	1649755	PL	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
134	1649234	SJ	Y	Y	-	Y	-	-	Y	Y	-	-	-	-	Y
135	1649723	DK	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-
136	1649031	GS	-	N	-	-	-	-	-	-	-	-	-	-	-
137	1654431	K	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
138	1387853	VK	Y	Y	Y	Y	Y	-	-	-	-	-	-	-	-
139	1565910	K.S.	Y	N	-	-	-	-	-	-	-	-	-	-	Y
140	331301	S.K.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	Y	Y	-	-	-	1	-	-	-	-	-	-	Y
142	1610751	S.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
143	1600117	B.K.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
144	398208	C.K.B.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
145	1594276	B.S.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
146	735876	M.L.	-	N	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	Y	Y	-	Y	-	1	-	-	-	-	-	-	-
148	1591266	S.S.	Y	N	-	-	-	-	-	-	-	-	-	-	-
149	146315	A.J.	Y	Y	Y	-	Y	-	-	-	-	-	-	-	-
150	1468392	V.G.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
151	1415553	S.D.	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-
152	1599952	S.S.	Y	Y	-	-	Y	1	-	-	-	-	-	-	-
153	1464575	H.K.	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-
154	1596394	M.K.	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-
155	1589369	P.S.	Y	Y	Y	-	Y	2	-	-	-	-	-	-	-
156	1599285	N.	-	N	-	-	-	-	-	-	-	-	-	-	-
157	974264	P	Y	Y	Y	-	Y	2	-	-	-	-	-	-	-
158	1612997	G.J.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
159	254232	S.K.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	Y	Y	Y	-	Y	-	Y	Y	-	-	-	-	-
162	1614887	L.C.	Y	Y	-	Y	-	1	Y	Y	-	-	-	-	-
163	1615312	V.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	N	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	Y	Y	-	-	-	2	Y	Y	-	-	-	-	-
167	1615339	K.	Y	Y	-	-	-	2	-	-	-	-	-	-	-
168	195141	N.K.	Y	Y	-	Y	Y	2	-	-	-	-	-	-	-
169	1612837	K.K.	-	Y	-	-	Y	-	-	-	-	-	-	-	-
170	1614824	H.K.	Y	Y	-	-	-	2	Y	Y	-	-	-	-	-
171	157175	M.S.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
172	1616176	S.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
174	1615380	K.S.	Y	Y	-	Y	Y	1	Y	Y	-	-	-	-	-
175	1505967	B.S.	Y	N	-	-	-	-	-	-	-	-	-	-	-
176	1615320	K.R.	Y	Y	-	-	-	1	Y	Y	-	-	-	-	-
177	1614918	B.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
178	1615457	K.S.	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-
179	1606389	J.K.	Y	Y	-	-	Y	3	Y	Y	-	-	-	-	Y
180	1606942	O.P.K	-	Y	-	Y	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	Y	Y	-	Y	Y	-	Y	Y	-	-	-	-	-
183	1614799	G.K.	Y	Y	Y	-	Y	-	Y	-	Y	-	-	-	-
184	1526638	B.S.	Y	Y	-	-	Y	3	-	-	-	-	-	-	-
185	1616148	S.A.	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
186	1615380	K.S.	Y	Y	-	Y	Y	1	Y	Y	-	-	-	-	-
187	654262	R.K.G.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
188	1616724	V.D.M	Y	Y	-	-	Y	1	Y	Y	-	-	-	-	-
189	1608602	A.S.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	Y	N	-	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	Y	Y	Y	Y	Y	-	-	-	-	-	-	-	-
192	1615424	K.C.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-

S No	MRD	NAME	ENDOCRINE DISORDERS HYPOTHYROIDISM	HYPER PTH	PHAEOCHROMOCYTOMA	HYPERALDOSTERONISM	OTHERS	INTRACRANIAL DISORDERS	INTRACRANIAL DISORDERS SAH	THALAMIC HEMATOMA	CVA	ENCEPHALITIS	HEAD INJURY	OTHERS	NUTRITIONAL DISORDERS	NUTRITIONAL DISORDERS ANOREXIA NERVOSA
129	1618943	SM	-	-	-	-	-	-	-	-	-	-	-	-	-	-
130	757363	RG	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-
131	1649733	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
132	1650520	BK	Y	-	-	-	-	Y	-	-	-	Y	-	-	-	-
133	1649755	PL	-	-	-	-	-	-	-	-	-	-	-	-	-	-
134	1649234	SJ	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	-	-	-	-	-	-	-	-	-	-	-	-	-	-
137	1654431	K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
138	1387853	VK	-	-	-	-	-	-	-	-	-	-	-	-	-	-
139	1565910	K.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
140	331301	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
141	305463	K.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
144	398208	C.K.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
145	1594276	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
146	735876	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
149	146315	A.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
150	1468392	V.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
151	1415553	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
152	1599952	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
154	1596394	M.K.	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
155	1589369	P.S.	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
156	1599285	N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
157	974264	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
162	1614887	L.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
163	1615312	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
168	195141	N.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
169	1612837	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
170	1614824	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
171	157175	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
172	1616176	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
174	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
175	1505967	B.S.	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
176	1615320	K.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
177	1614918	B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
181	1608577	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
183	1614799	G.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
185	1616148	S.A.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
186	1615380	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
187	654262	R.K.G.	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
188	1616724	V.D.M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
189	1608602	A.S.	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
190	1610418	K.S.	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
191	1615464	V.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
192	1615424	K.C.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-

S No	MRD	NAME	STARVATION	LIQUID PROTEIN DIET	H/O GI SURGERY	CELIAC DISEASE	OTHERS	HYPOTHERMIA	OTHERS	ECG RATE	RHYTHM_SINUS	AT	AF	AFL	APC	VPC	NSVT	VT	PSVT	OTHER	QRS DURATION	QTC INTERVAL	QTC INTERVAL GROUP	QTC INTERVAL GP
129	1618943	SM	-	-	-	-	-	-	-	108	Y	-	-	-	-	-	-	-	-	-	118	487	1	0
130	757363	RG	-	-	-	-	-	-	-	77	Y	-	-	-	-	-	-	-	-	-	84	597	1	1
131	1649733	GS	-	-	-	-	-	-	-	130	Y	-	-	-	-	-	-	-	-	-	116	491	1	0
132	1650520	BK	-	-	-	-	-	-	-	72	Y	-	-	-	-	-	-	-	-	-	116	394	0	0
133	1649755	PL	-	-	-	-	-	-	-	88	Y	-	-	-	-	-	-	-	-	-	72	411	0	0
134	1649234	SJ	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	86	416	0	0
135	1649723	DK	-	-	-	-	-	-	-	122	Y	-	-	-	-	-	-	-	-	-	90	444	0	0
136	1649031	GS	-	-	-	-	-	-	-	105	Y	-	-	-	-	-	-	-	-	-	112	539	1	1
137	1654431	K	-	-	-	-	-	-	-	112	Y	-	-	-	-	-	-	-	-	-	70	510	1	1
138	1387853	VK	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	118	815	1	1
139	1565910	K.S.	-	-	-	-	-	-	-	106	Y	-	-	Y	-	-	-	-	-	-	120	512	1	1
140	331301	S.K.	-	-	-	-	-	-	-	105	Y	-	-	-	-	-	-	-	-	-	114	518	1	1
141	305463	K.K.	-	-	-	-	-	-	-	114	Y	-	-	-	-	-	-	-	-	-	118	532	1	1
142	1610751	S.K.	-	-	-	-	-	-	-	118	Y	-	Y	-	-	-	-	-	-	-	92	520	1	1
143	1600117	B.K.	-	-	-	-	-	-	-	124	Y	-	-	-	-	-	Y	-	-	-	88	482	1	0
144	398208	C.K.B.	-	-	-	-	-	-	-	112	Y	-	Y	-	-	-	-	-	-	-	116	576	1	1
145	1594276	B.S.	-	-	-	-	-	-	-	98	Y	-	-	-	-	-	-	-	-	-	82	469	1	0
146	735876	M.L.	-	-	-	-	-	-	-	58	Y	-	-	-	-	-	-	-	-	-	64	484	1	0
147	1600929	G.S.G	-	-	-	-	-	-	-	49	Y	-	-	Y	-	-	-	-	-	-	112	461	1	0
148	1591266	S.S.	-	-	Y	-	-	-	-	160	Y	-	Y	-	-	-	-	-	-	-	118	518	1	1
149	146315	A.J.	-	-	-	-	-	-	-	108	Y	-	-	-	-	-	-	-	-	-	80	460	1	0
150	1468392	V.G.	-	-	-	-	-	-	-	86	Y	-	Y	-	-	-	-	-	-	-	108	631	1	1
151	1415553	S.D.	-	-	-	-	-	-	-	85	Y	-	-	-	-	-	-	-	-	-	116	533	1	1
152	1599952	S.S.	-	-	-	-	-	-	-	49	Y	-	-	-	-	-	-	-	-	-	120	460	1	0
153	1464575	H.K.	-	-	-	-	-	-	-	69	Y	-	-	-	-	-	-	-	-	-	92	503	1	1
154	1596394	M.K.	-	-	-	-	-	-	-	119	Y	-	Y	-	-	-	-	-	-	-	94	467	1	0
155	1589369	P.S.	-	-	-	-	-	-	-	121	Y	-	-	-	-	-	-	-	-	-	120	482	1	0
156	1599285	N.	-	-	-	-	-	-	-	103	Y	-	-	-	-	-	-	-	-	-	92	479	1	0
157	974264	P	-	-	-	-	-	-	-	83	Y	-	-	-	-	-	-	-	-	-	118	521	1	1
158	1612997	G.J.	-	-	-	-	-	-	-	72	Y	-	-	-	-	-	-	-	-	-	78	464	1	0
159	254232	S.K.	-	-	-	-	-	-	-	115	Y	-	Y	-	-	-	-	-	-	-	106	525	1	1
160	1613629	D.K.G.	-	-	-	-	-	-	-	115	Y	-	-	-	-	-	-	-	-	-	92	485	1	0
161	1613098	B.S.	-	-	-	-	-	-	-	74	Y	-	-	-	-	-	-	-	-	-	92	450	1	0
162	1614887	L.C.	-	-	-	-	-	-	-	143	Y	-	-	-	-	-	-	-	-	-	118	601	1	1
163	1615312	V.S.	-	-	-	-	-	-	-	95	Y	-	-	-	-	-	-	-	-	-	116	517	1	1
164	1485288	M.L.	-	-	-	-	-	-	-	102	Y	-	-	-	-	-	-	-	-	-	92	495	1	0
165	1613664	G.S.	-	-	-	-	-	-	-	103	Y	-	-	-	-	-	-	-	-	-	100	495	1	0
166	1616073	A.K.	-	-	-	-	-	-	-	85	Y	-	Y	-	-	-	-	-	-	-	80	456	1	0
167	1615339	K.	-	-	-	-	-	-	-	72	Y	-	-	-	-	-	-	-	-	-	120	479	1	0
168	195141	N.K.	-	-	Y	-	-	-	-	70	Y	-	Y	-	-	-	-	-	-	-	90	505	1	1
169	1612837	K.K.	-	-	-	-	-	-	-	129	Y	-	Y	-	-	-	-	-	-	-	120	492	1	0
170	1614824	H.K.	-	-	-	-	-	-	-	109	Y	-	-	-	-	-	-	-	-	-	104	500	1	1
171	157175	M.S.	-	-	Y	-	-	-	-	85	Y	-	-	-	-	Y	-	-	-	-	116	487	1	0
172	1616176	S.S.	-	-	-	-	-	-	-	110	Y	-	-	-	-	-	-	-	-	-	68	500	1	1
173	1614830	R.K.	-	-	-	-	-	-	-	127	Y	-	-	-	-	-	-	-	-	-	92	470	1	0
174	1615380	K.S.	-	-	-	-	-	-	-	139	Y	-	-	-	-	-	-	-	-	-	112	459	1	0
175	1505967	B.S.	-	-	-	-	-	-	-	120	Y	-	-	-	-	-	-	-	-	-	114	689	1	1
176	1615320	K.R.	-	-	-	-	-	-	-	110	Y	-	-	-	-	-	-	-	-	-	94	492	1	0
177	1614918	B.	-	-	-	-	-	-	-	171	Y	-	-	-	-	-	-	-	-	-	66	465	1	0
178	1615457	K.S.	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	118	535	1	1
179	1606389	J.K.	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	84	474	1	0
180	1606942	O.P.K	-	-	-	-	-	-	-	116	Y	-	-	-	-	-	-	-	-	-	72	447	0	0
181	1608577	A.S.	-	-	-	-	-	-	-	144	Y	-	-	-	-	-	-	-	-	-	94	510	1	1
182	1596363	T.C.	-	-	Y	-	-	-	-	108	Y	-	-	-	-	-	-	-	-	-	94	477	1	0
183	1614799	G.K.	-	-	-	-	-	-	-	154	Y	-	-	-	-	-	-	-	-	-	58	506	1	1
184	1526638	B.S.	-	-	-	-	-	-	-	104	Y	-	-	-	-	-	-	-	-	-	90	486	1	0
185	1616148	S.A.	-	-	-	-	-	-	-	94	Y	-	-	-	-	-	-	-	-	-	80	447	0	0
186	1615380	K.S.	-	-	-	-	-	-	-	139	Y	-	-	-	-	-	-	-	-	-	112	459	1	0
187	654262	R.K.G.	-	-	-	-	-	-	-	91	Y	-	-	-	-	-	-	-	-	-	86	472	1	0
188	1616724	V.D.M	-	-	-	-	-	-	-	88	Y	-	-	-	-	-	-	-	-	-	120	469	1	0
189	1608602	A.S.	-	-	-	-	-	-	-	70	Y	-	-	-	-	-	-	-	-	-	120	678	1	1
190	1610418	K.S.	-	-	-	-	-	-	-	132	Y	-	-	-	-	-	-	-	-	-	56	480	1	0
191	1615464	V.R.	-	-	-	-	-	-	-	115	Y	-	-	-	-	-	-	-	-	-	70	484	1	0
192	1615424	K.C.	-	Y	Y	-	-	-	-	122	Y	-	-	-	-	-	-	-	-	-	78	464	1	0

S No	MRD	NAME	BROAD BASE T WAVE	NOTCHED T WAVE	LONG ISOELEC SEG & NARROW BASE T WAVE	T ALTERNANS	U WAVE	AV BLOCK	ST ELEVATION	ST DEPRESSION	TORSADES	LVH	RVH	POOR R PROGRESSION	BRUGADA	EPSILON WAVE	EARLY REPOLARISATION	OTHERS	RBS
129	1618943	SM	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	500
130	757363	RG	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-	-	186
131	1649733	GS	Y	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	192
132	1650520	BK	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	60
133	1649755	PL	T-WAVE MORPHOLOGY/INVERTED V1-5	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	266
134	1649234	SJ	T-WAVE MORPHOLOGY/INVERTED V1-3	-	Y	-	-	-	-	Y	-	-	-	Y	-	-	-	-	94
135	1649723	DK	T-WAVE MORPHOLOGY/INVERTED V4-6/AVL	Y/2-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136
136	1649031	GS	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	112
137	1654431	K	Y	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	118
138	1387853	VK	T-WAVE MORPHOLOGY /INVERTED	-	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	108
139	1565910	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	188
140	331301	S.K.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	266
141	305463	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	175
142	1610751	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113
143	1600117	B.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	220
144	398208	C.K.B.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	188
145	1594276	B.S.	Y	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	127
146	735876	M.L.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	122
147	1600929	G.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	272
148	1591266	S.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	89
149	146315	A.J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200
150	1468392	V.G.	Y	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	127
151	1415553	S.D.	Y	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	105
152	1599952	S.S.	-	-	-	-	-	CHB	-	-	-	-	-	-	-	-	-	-	336
153	1464575	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	252
154	1596394	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120
155	1589369	P.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	184
156	1599285	N.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	501
157	974264	P	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	298
158	1612997	G.J.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	112
159	254232	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	103
160	1613629	D.K.G.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	154
161	1613098	B.S.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	162
162	1614887	L.C.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	487
163	1615312	V.S.	-	-	-	-	-	BIFASCICULAR BLOCK	-	-	-	-	-	-	-	-	-	-	180
164	1485288	M.L.	-	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	168
165	1613664	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	190
166	1616073	A.K.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	98
167	1615339	K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136
168	195141	N.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100
169	1612837	K.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	147
170	1614824	H.K.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	148
171	157175	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79
172	1616176	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122
173	1614830	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180
174	1615380	K.S.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	248
175	1505967	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180
176	1615320	K.R.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	486
177	1614918	B.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	501
178	1615457	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	216
179	1606389	J.K.	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-	145
180	1606942	O.P.K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120
181	1608577	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	501
182	1596363	T.C.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	155
183	1614799	G.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	210
184	1526638	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113
185	1616148	S.A.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	118
186	1615380	K.S.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	501
187	654262	R.K.G.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	90
188	1616724	V.D.M	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	70
189	1608602	A.S.	-	-	-	-	-	Y - 1ST DEGREE	-	-	-	-	-	-	-	-	-	-	231
190	1610418	K.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	146
191	1615464	V.R.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98
192	1615424	K.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	151

S No	MRD	NAME	HB	TLC	PLATELET	PH	PCO2	PO2	HCO3	SO2	LACTATE	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB	PH	HCO3	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB
129	1618943	SM	9.4	19.1	120	7.51	22	81	17.6	97	2.5	4.6	8.6	1.9	4.1	122	147	2.8	0.8	18	20	180	6.7	2.8	3	1	2	2	2	2	1	3	3	2	2	2	3	2	1
130	757363	RG	12.2	9.9	199	7.47	36	91	26.2	98	1.8	4.1	9	2.5	3	138	24	1.2	0.4	40	45	72	6.5	3.5	3	3	2	2	2	2	2	2	3	2	3	3	2	1	2
131	1649733	GS	13.7	17.2	209	7.55	34	61	29.7	94	1.9	2.7	8.2	2.4	2.7	147	92	1.3	2.1	414	1130	94	6.5	2.9	3	3	1	1	2	2	3	3	3	3	3	3	2	1	1
132	1650520	BK	9.5	18	90	7.41	31	56	19.6	89	4.5	4.3	8	1.9	6.1	141	121	3	13.8	329	35	154	6.9	2.8	2	1	2	1	2	3	2	3	3	3	3	2	3	2	1
133	1649755	PL	9.9	20.7	120	7.4	36	98	21	93	1.2	3.9	7.9	1.9	1.4	135	53	1.6	0.8	34	27	97	6.7	3.7	2	1	2	1	2	1	2	3	3	2	2	2	2	2	2
134	1649234	SJ	9.9	12.2	228	7.42	44	126	23	100	0.5	4.6	9	1.6	3.8	140	49	1.1	0.1	21	35	26	6.7	3.6	2	2	2	2	1	2	2	2	2	2	2	2	1	2	2
135	1649723	DK	12.3	11.7	236	7.49	33	118	25.1	99	1.8	4.3	8.3	1.6	4.4	140	30	1.2	0.4	70	36	131	5.8	2.7	3	2	2	1	1	2	2	2	3	2	3	2	3	1	1
136	1649031	GS	15.2	6.5	94	7.42	32	48	20.8	84	1.9	3.6	9.1	2.5	3	129	121	1.9	0.7	182	101	91	6.7	3.2	2	1	2	2	2	2	1	3	3	2	3	3	2	2	1
137	1654431	K	11.4	20	502	7.48	30	183	22.3	100	1.5	3.6	8.1	3.2	5.7	137	5.8	1.1	0.7	21	30	139	7.4	3.6	3	2	2	1	3	3	2	1	2	2	2	2	3	2	2
138	1387853	VK	11.5	7.7	86	7.53	27	94	22.6	98	4.7	2.8	7.4	1.3	2.4	139	15	0.8	3	245	85	178	6.3	3.2	3	2	1	1	1	1	2	2	2	3	3	3	3	1	1
139	1565910	K.S.	11.8	7.1	270	7.49	29	125	21.3	100	1.5	3.5	9.5	1.8	3	140	31	1	1.1	31	26	89	7.4	4.1	3	1	2	2	2	2	2	2	2	2	2	2	2	2	2
140	331301	S.K.	9	3	195	7.26	44	161	19.7	99	3.6	3.6	8.7	2.1	5.7	132	38	0.9	0.3	24	15	100	7.1	4	1	1	2	2	2	3	1	2	2	2	2	2	2	2	2
141	305463	K.K.	8.5	9.9	128	7.36	26	85	14.7	96	1	6	8.8	3.3	4.3	125	248	4.7	0.9	21	17	210	5.6	3.2	2	1	3	2	3	2	1	3	3	2	2	2	3	1	1
142	1610751	S.K.	11.7	10.4	230	7.39	44	165	22.6	97	1.2	4.1	8.9	1.8	5.7	133	26	0.9	0.54	20	12	77	6.7	3.64	2	2	2	2	2	3	1	2	2	2	2	2	2	2	2
143	1600117	B.K.	13.9	35.6	154	7.01	23	265	5.8	100	14.8	5	8.6	3.8	5.8	141	85	2.3	2.1	2504	1576	82	6.1	4	1	1	3	2	3	3	2	3	3	3	3	3	2	1	2
144	398208	C.K.B.	11.7	16	169	7.48	37	76	27.6	96	3.2	3.8	9.7	2.2	4.3	141	133	1.5	1.5	2470	2045	58	6.4	3.8	3	3	2	2	2	2	2	3	3	3	3	3	2	1	2
145	1594276	B.S.	12	11.3	352	7.35	46	85	22	97	0.2	4.7	8.3	2.6	3.9	130	52	1	1.1	35	61	72	6.3	3.1	2	2	2	1	2	2	1	3	2	2	2	3	2	1	1
146	735876	M.L.	17.3	13.4	222	7.45	42	90	24	98	1	4.1	9	2.8	3.6	139	36	1.4	0.7	186	33	123	7.6	4.3	3	2	2	2	3	2	2	2	3	2	3	2	2	2	2
147	1600929	G.S.G	14.5	8.4	182	7.36	39	154	21.7	100	1.5	5.3	9.7	1.9	3.1	132	41	1.5	0.6	45	33	77	7	4.25	2	1	3	2	2	2	1	2	3	2	3	2	2	2	2
148	1591266	S.S.	9.6	6.9	237	7.47	34	106	24.7	98	0.8	4	9.5	2.6	3.5	144	36	1.1	0.6	45	75	80	7.5	3.8	3	2	2	2	2	2	2	2	2	2	3	3	2	2	2
149	146315	A.J.	10.2	10.2	383	7.47	27	88	19.7	97	1.1	3.4	8.2	1.9	3.4	136	54	1.5	0.9	61	72	132	6.4	3.3	3	1	1	1	2	2	2	3	3	2	3	3	3	1	1
150	1468392	V.G.	11	13.4	150	7.59	34	61	32.6	95	1.2	2.2	9.2	2.7	3	141	319	2.8	1.1	15	9	132	7.8	3.7	3	3	1	2	2	2	2	3	3	2	2	2	3	2	2
151	1415553	S.D.	11.5	7.4	301	7.45	42	87	22	94	1	4.6	7.8	1.6	3.9	137	124	1	0.5	48	70	92	6.8	3.3	3	2	2	1	2	2	3	2	2	3	3	2	2	2	1
152	1599952	S.S.	8.9	12.7	170	7.38	37	153	21.9	99	1.6	5.4	8.4	2.2	3.8	138	89	1.7	0.6	1027	516	190	6.7	3.6	2	1	3	1	2	2	2	3	3	2	3	3	3	2	2
153	1464575	H.K.	9.4	19.6	303	7.38	42	64	24.8	92	1.6	4.3	8.2	1.2	2.3	134	63	2.5	0.6	27	51	84	5.7	3.1	2	2	2	1	1	1	1	3	3	2	2	3	2	1	1
154	1596394	M.K.	9.4	18.8	267	7.37	33	275	19.1	100	3.8	3.8	7.9	1.5	2.9	136	56	1.1	1.4	5134	1863	393	5.5	2.4	2	1	2	1	1	2	2	3	2	3	3	3	3	1	1
155	1589369	P.S.	11.2	16	280	7.47	24	200	17.5	100	1.3	3.4	8.4	1.9	3.9	120	3	0.8	2.3	44	50	95	7	4.6	3	1	1	1	2	2	1	1	2	3	3	3	2	2	2
156	1599285	N.	11.2	8.2	267	7.43	41	144	20.9	100	0.8	3.9	8.9	2.6	3.2	137	33	0.8	1.4	54	32	106	6.9	3.4	2	1	2	2	2	2	2	2	2	3	3	2	2	2	1
157	974264	P	12.5	2.8	150	7.35	27	98	16	92	5	4	8.5	2.4	3	128	46	1.2	0.3	41	28	78	6.7	3.5	2	1	2	1	2	2	1	2	3	2	3	2	2	2	2
158	1612997	G.J.	14.7	8.6	283	7.39	44	85	21.4	96	1.2	4.6	8.8	2.8	4	140	14	0.9	0.6	84	85	141	6.6	4.1	2	1	2	2	3	2	2	2	2	2	3	3	3	2	2
159	254232	S.K.	10.9	14.8	399	7.38	39	129	22	98	1.3	3.7	9.1	2.1	6.9	133	24	0.8	1.4	1737	1641	126	6	3.6	2	2	2	2	2	3	1	2	2	3	3	3	2	1	2
160	1613629	D.K.G.	15	13.3	335	7.43	32	249	21.2	100	2	4.3	8.9	2.5	2.9	136	25	0.8	0.5	89	22	83	7.8	4.4	2	1	2	2	2	2	2	2	2	3	3	2	2	2	2
161	1613098	B.S.	9.5	14.8	201	7.37	29	82	16.8	96	0.9	4.2	7.9	2.5	1.6	131	87	2.4	1.7	236	36	154	6.5	3.4	2	1	2	1	2	1	1	3	3	3	3	2	3	1	1
162	1614887	L.C.	7.2	21.5	203	7.17	57	82	20.8	92	5.6	5.6	9.2	1.2	6.3	138	77	1.8	1	325	353	130	7	3.5	1	1	3	2	1	3	2	3	3	2	3	3	3	2	2
163	1615312	V.S.	12.8	10.3	160	7.36	34	86	21	95	1.2	3.9	8.9	2.6	2.9	137	31	0.9	0.7	39	49	119	7.6	3.8	2	1	2	2	2	2	2	2	2	2	3	2	2	2	2
164	1485288	M.L.	9.8	7.2	150	7.49	27	113	20.6	99	1.9	5.3	8.8	2.1	3.7	133	67	1.5	1.6	98	85	75	6.9	4.3	3	1	3	2	2	2	1	3	3	3	3	3	2	2	2
165	1613664	G.S.	10.9	10.7	295	7.38	24	155	14.2	99	1.7	4	9.2	2.8	3.5	128	49	1.5	1.1	35	24	148	6.5	3.3	2	1	2	2	3	2	1	2	3	2	2	2	3	1	1
166	1616073	A.K.	10.4	13.4	200	7.41	42	154	21.5	100	1.4	5	9	2.6	3.2	120	35	0.7	1.2	49	70	188	5.3	3	2	1	3	2	2	2	1	2	2	3	3	3	3	1	1
167	1615339	K.	9.5	11.1	358	7.44	31	102	21.1	98	0.5	4	8.6	2.2	5.3	120	93	2.5	0.1	10	11	90	4.5	2.4	2	1	2	2	2	3	1	3	3	2	2	2	2	1	1
168	195141	N.K.	12.2	6.1	120	7.54	26	86	22.2	98	4.4	3.8	7.7	1.5	1.3	128	35	0.9	0.7	32	23	167	6.1	3.1	3	2	2	1	1	1	1	2	2	2	2	2	3	1	1
169	1612837	K.K.	12.5	8.3	160	7.49	37	75	28.2	96	1.3	3.6	7.5	2.2	1.2	138	53	0.7	1.8	54	62	58	6	3.5	3	2	1	2	1	2	3	2	3	3	3	2	1	2
170	1614824	H.K.	11.4	11.2	325	7.45	34	255	23.6	100	1.4	4.8	9.3	2.6	1	126	43	0.8	0.4	40	68	172	7.2	3.9	3	2	2	2	1	1	2	2	2	3	3	3	3	2	2
171	157175	M.S.	14.1	43.6	435	7.41	32	96	20.3	98	1.8	3.4	8.7	2.5	3	132	44	1.4	0.6	18	14	129	6.1	3	2	1	1	2	2	2	1	2	3	2	2	2	3	1	1
172	1616176	S.S.	14.2	18	329	7.47	36	334	26.2	100	1.5	4.08	9.62	2.3	3.1	144	40	0.67	0.86	38	30	105	7.5	4	3	3	2	2	2	2	2	2	1	2	2	2	2	2	2
173	1614830	R.K.	10.3	110.6	128	7.02	30	65	7.7	79	15	5.4	8.3	2.5	6.3	140	98	2.2	1.7	884	347	122	6.6	3.3	1	1	3	1	2	3	2	3	3	3	3	3	2	2	1
174	1615380	K.S.	12.3	11.5	150	7.18	37	87	13.8	94	6.3	6.2	8.4	1.3	2.6	135	53	1.2	0.5	36	33	86	7.7	4.6	1	1	3	1	1	1	2	3	3	2	2	2	2	2	2
175	1505967	B.S.	11.6	12.7	144	7.43	45	49	29.9	85	1.3	4	8.6	2.04	3.83	146	308	6	0.6	161	39	83	6.9	2.1	2	3	2	2	2	2	3	3	3	2	3	2	2	2	1
176	1615320	K.R.	9.4	15.4	260	7.42	44	85	23	89	1.2	6.5	8.9	2.7	3.6	134	42	1.3	0.6	82	45	99	7.1	3.5	2	2	3	2	2	2	1	2	3	2	3	3	2	2	2
177	1614918	B.	13.5	9.7	232	7.25	42	99	18.4	96	4.5	4.8	9	2.3	3.7	135	55	1.1	0.6	26	20	131	7.3	4.6	1	1	2	2	2	2	2	3	2	2	2	2	3	2	2
178	1615457	K.S.	11.4	18.3	168	7.46	38	180	27	100	1.2	3.9	7.7	1.5	8.5	137	246	6.9	9.8	193	207	219	6	2.6	3	3	2	1	1	3	2	3	3	3	3	3	3	1	1
179	1606389	J.K.	9.2	11.1	617	7.38	34	78	20.1	95	0.8	3.8	8.1	2.4	8.8	137	133	7.5	0.2	33	27	104	5.5	2.6	2	1	2	1	2	3	2	3	3	2	2	2	2	1	1
180	1606942	O.P.K	11.5	3.8	150	7.5	30	85	23.4	97	2	3.8	8.8	1.6	1.3	139	52	2.2	3.2	551	168	393	5.1	2.7	3	2	2	2	1	1	2	3	3	3	3	3	3	1	1
181	1608577	A.S.	14.6	47.2	611	7	45	433	11	100	2.6	3.3	8.8	2.3	3.2	146	59	1.7	0.1	22	11	195	7.8	4.4	1	1	1	2	2	2	3	3	3	2	2	2	3	2	2
182	1596363	T.C.	7.4	14.4	150	7.43	27	103	18	98	1.6	4.7	7.7	1.5	7.9	137	231	5.7	0.3	32	34	512	6.5	3.2	2	1	2	1	1	3	2	3	3	2	2	2	3	1	1
183	1614799	G.K.	10.2	40	181	7.46	33	248	23.5	100	2.7	3.2	7.5	1.9	1.8	141	50	0.7	4.5	89	57	60	5.3	3	3	3	2	1	1	2	1	2	3	2	3	3	3	2	1	1
184	1526638	B.S.	6.4	3.6	70	7.3	39	124	19	96	4	4.7	8.5	2.8	4.1	137	112	7.2	0.6	100	19	80	6	3.7	1	1	2	1	3	2	2	3	3	2	3	2	2	1	2
185	1616148	S.A.	15.2	14.7	261	7.45	36	94	22.2	100	1.8	4.4	8.1	2.5	7.9	135	21	0.8	1.8	181	45	100	8	5.3	3	2	2	1	2	3	2	2	2	3	3	3	2	2	3
186	1615380	K.S.	12.3	11.5	150	7.18	37	87	14	94	6.3	6.2	8.4	1.3	2.6	135	53	1.2	0.5	36	33	72	7.7	4.6	1	1	3	1	1	1	2	3	3	2	2	2	2	2	2
187	654262	R.K.G.	11.9	7.6	153	7.39	32	186	19.4	100	1.4	4.7	8.5	2.7	3	126	74	1.4	0.4	85	28	104	6.5	3.8	2	1	2	1	2	2	1	3	3	2	3	2	2	1	2
188	1616724	V.D.M	6.3	13.5	104	7.33	23	285	12.1	100	0.9	5.5	8.3	2.3	4.9	133	281	12.1	1	62	46	80	7	3.7	1	1	3	1	2	3	1	3	3	2	3	3	2	2	2
189	1608602	A.S.	11.6	11.8	155	7.42	38	66	24.6	93	1.1	4.61	9.2	2.2	3.6	134	36	1.64	0.79	21	20	75	7.2	4.13	2	2	2	2	2	2	1	2	3	2	2	2	2	2	2
190	1610418	K.S.	8.2	9.4	50	7.46	31	80	22	96	1.1	3.9	8.8	2.6	3.8	151	54	0.91	0.67	82	48	78	6.5	3.27	3	2	2	2	2	2	3	3	2	2	3	3	2	1	1
191	1615464	V.R.	10.1	6.2	280	7.58	45	213	42.2	100	2.8	2.8	6.1	1.3	4	145	76	1.4	1.6	247	88	147	5.2	1.7	3	3	1	1	1	2	3	3	3	3	3	3	3	1	1
192	1615424	K.C.	15.1	3.69	124	7.17	41	73	15	89	5.1	3.6	8.3	2.5	3.6	140	23	1.2	1.2	36	18	56	6	3.6	1	1	2	1	2	2	2	2	3	3	2	2	2	1	2

S No	MRD	NAME	BLOOD CULTURE	LVEF	SPECIFIC TREATEMENT GIVEN FOR PROLONGED QTC T/T OF REVERSIBLE CAUSE	BETA BLOCKER	IV MGSO4	ISOPROTERENOL	IV XYLOCAINE	MEXILETINE	SYMPATHETIC DENERVATION	OVERDRIVE PACING	AICD	OTHERS	OUTCOMES OF TREATMENT SPECIFIC TO PROLONGED QTC BENEFIT ACHIEVED
129	1618943	SM	Y	30	Y	Y	-	-	-	-	-	-	-	-	Y
130	757363	RG	-	40	Y	-	Y	-	-	-	-	-	-	-	Y
131	1649733	GS	-	15	Y	-	Y	-	-	-	-	-	-	-	Y
132	1650520	BK	Y	8	-	-	-	-	-	-	-	-	-	-	-
133	1649755	PL	-	44	-	-	-	-	-	-	-	-	-	-	-
134	1649234	SJ	Y	18	-	-	-	-	-	-	-	-	-	-	-
135	1649723	DK	-	24	-	-	-	-	-	-	-	-	-	-	-
136	1649031	GS	Y	38	-	-	Y	-	-	Y	-	-	-	-	Y
137	1654431	K	-	28	Y	-	Y	-	Y	Y	-	-	-	-	Y
138	1387853	VK	-	34	Y	-	Y	-	Y	Y	-	Y	Y	-	Y
139	1565910	K.S.	-	20	-	Y	Y	-	-	-	-	-	-	-	Y
140	331301	S.K.	-	20	-	-	Y	-	-	-	-	-	-	-	-
141	305463	K.K.	NO GROWTH	14	-	-	Y	-	-	-	-	-	-	-	Y
142	1610751	S.K.	-	40	Y	Y	Y	-	-	-	-	-	-	-	Y
143	1600117	B.K.	-	20	-	-	Y	-	Y	-	-	-	-	-	Y
144	398208	C.K.B.	KLEBSIELLA	10	-	Y	-	-	-	-	-	-	-	-	Y
145	1594276	B.S.	-	26	-	Y	Y	-	Y	-	-	-	-	-	-
146	735876	M.L.	-	35	-	-	Y	-	-	-	-	-	-	-	Y
147	1600929	G.S.G	-	60	-	-	-	-	-	-	-	-	-	-	Y
148	1591266	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y
149	146315	A.J.	-	42	-	-	Y	-	-	-	-	-	-	-	-
150	1468392	V.G.	-	14	-	-	Y	-	-	-	-	-	-	-	Y
151	1415553	S.D.	-	20	-	-	-	-	-	-	-	-	-	-	Y
152	1599952	S.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
153	1464575	H.K.	-	28	-	-	Y	-	-	-	-	-	-	-	Y
154	1596394	M.K.	STAPHYLOCOCCUS HEMOLYTICUS	60	Y	-	Y	-	-	-	-	-	-	-	-
155	1589369	P.S.	ACINETOBACTER	30	Y	-	Y	-	-	Y	-	-	-	-	-
156	1599285	N.	-	14	-	-	-	-	-	-	-	-	-	-	Y
157	974264	P	-	25	Y	-	Y	-	-	-	-	-	-	-	-
158	1612997	G.J.	-	48	-	-	-	-	-	-	-	-	-	-	-
159	254232	S.K.	-	16	-	-	Y	-	-	-	-	-	-	-	-
160	1613629	D.K.G.	-	26	-	-	-	-	-	-	-	-	-	-	-
161	1613098	B.S.	-	26	Y	-	Y	-	Y	-	-	-	-	-	-
162	1614887	L.C.	-	35	-	-	Y	-	-	-	-	-	-	-	Y
163	1615312	V.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
164	1485288	M.L.	-	18	-	-	-	-	-	-	-	-	-	-	-
165	1613664	G.S.	-	60	-	-	-	-	-	-	-	-	-	-	-
166	1616073	A.K.	-	40	Y	-	-	-	-	-	-	-	-	-	-
167	1615339	K.	-	12	-	-	-	-	-	-	-	-	-	-	Y
168	195141	N.K.	-	60	Y	-	Y	-	-	-	-	-	-	-	Y
169	1612837	K.K.	-	60	Y	-	Y	-	-	-	-	-	-	-	Y
170	1614824	H.K.	-	18	Y	-	-	-	-	-	-	-	-	-	Y
171	157175	M.S.	-	60	Y	-	Y	-	-	-	-	-	-	-	Y
172	1616176	S.S.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
173	1614830	R.K.	-	60	Y	-	Y	-	-	-	-	-	-	-	Y
174	1615380	K.S.	-	24	Y	-	-	-	-	-	-	-	-	-	Y
175	1505967	B.S.	-	25	Y	-	Y	-	-	-	-	-	-	-	-
176	1615320	K.R.	-	25	Y	-	Y	-	-	-	-	-	-	-	Y
177	1614918	B.	-	32	Y	-	Y	-	Y	-	-	-	-	-	-
178	1615457	K.S.	-	45	-	-	-	-	-	-	-	-	-	-	-
179	1606389	J.K.	-	22	Y	-	-	-	-	-	-	-	-	-	-
180	1606942	O.P.K	-	48	Y	-	Y	-	-	-	-	-	-	-	Y
181	1608577	A.S.	-	60	Y	-	Y	-	-	-	-	-	-	-	-
182	1596363	T.C.	-	25	Y	Y	Y	-	-	-	-	-	-	-	Y
183	1614799	G.K.	-	38	Y	-	Y	-	-	-	-	-	-	-	Y
184	1526638	B.S.	-	24	Y	-	-	-	-	-	-	-	-	-	Y
185	1616148	S.A.	-	30	Y	-	-	-	-	-	-	-	-	-	Y
186	1615380	K.S.	-	24	Y	-	Y	-	-	-	-	-	-	-	-
187	654262	R.K.G.	-	50	Y	-	-	-	-	-	-	-	-	-	Y
188	1616724	V.D.M	-	25	Y	-	-	-	-	-	-	-	-	-	Y
189	1608602	A.S.	KLEBSIELLA AND ACINETOBACTER	60	Y	-	-	-	-	-	-	-	-	-	-
190	1610418	K.S.	-	60	Y	-	-	-	-	-	-	-	-	-	-
191	1615464	V.R.	E. COLI, CANDIDA	60	Y	-	Y	-	-	-	-	-	-	-	Y
192	1615424	K.C.	-	55	Y	-	-	-	-	-	-	-	-	-	Y

S No	MRD	NAME	QTC SHORTENED	SYNCOPE CONTROLLED	SEIZURE CONTROLLED	ARRYTHMIA CONTROLLED	DURATION OF ICU STAY	NO OF VT EPISODES	QTC UNCHANGED	QTC SHORTENED BY	QTC PROLONGED BY	-	-	-	DISCHARGED	DEATH	TREATMENT COMPLICATION
129	1618943	SM	-	Y	-	Y	3	-	Y	-	-	487	487	1	N	Y	-
130	757363	RG	Y	-	-	-	12	-	N	81	-	516	516	1	Y	N	-
131	1649733	GS	Y	-	-	-	13	-	N	39	-	452	452	1	Y	N	-
132	1650520	BK	-	-	-	-	4	-	N	-	56	394	450	1	N	Y	-
133	1649755	PL	-	-	-	-	16	-	N	-	61	411	472	1	Y	N	-
134	1649234	SJ	-	-	-	-	7	-	N	-	53	416	469	1	N	Y	-
135	1649723	DK	-	-	-	-	7	-	N	-	23	444	467	1	Y	N	-
136	1649031	GS	Y	-	-	-	8	-	N	40	-	499	499	1	N	Y	-
137	1654431	K	Y	Y	Y	Y	15	7	N	51	-	459	459	1	Y	N	-
138	1387853	VK	Y	Y	Y	Y	10	6	N	195	-	620	620	1	Y	N	-
139	1565910	K.S.	Y	-	-	-	8	-	N	42	-	470	470	1	N	N	-
140	331301	S.K.	-	-	-	-	6	-	N	-	-	518	518	1	N	N	-
141	305463	K.K.	Y	-	-	-	3	-	N	24	-	508	508	1	N	N	-
142	1610751	S.K.	Y	-	-	-	4	-	N	92	-	428	428	0	Y	N	-
143	1600117	B.K.	Y	-	-	Y	10	-	N	10	-	472	472	1	N	Y	-
144	398208	C.K.B.	Y	-	-	-	9	-	N	32	-	544	544	1	Y	N	-
145	1594276	B.S.	-	-	-	Y	11	1	N	-	34	469	503	1	Y	N	-
146	735876	M.L.	Y	-	-	-	6	-	N	40	-	444	444	0	Y	N	-
147	1600929	G.S.G	-	-	-	Y	8	-	N	48	-	413	413	0	Y	N	-
148	1591266	S.S.	Y	-	-	Y	7	2	N	61	-	457	457	1	Y	N	-
149	146315	A.J.	-	-	-	-	6	-	N	-	62	460	522	1	Y	N	-
150	1468392	V.G.	Y	-	-	-	9	-	N	48	-	583	583	1	Y	N	-
151	1415553	S.D.	Y	-	-	-	4	-	N	-	22	533	555	1	Y	N	-
152	1599952	S.S.	-	-	-	-	7	-	N	-	47	460	507	1	Y	N	-
153	1464575	H.K.	Y	-	-	-	9	-	N	100	-	403	403	0	Y	N	-
154	1596394	M.K.	-	-	-	-	-	-	N	-	56	467	523	1	N	Y	-
155	1589369	P.S.	-	-	-	-	22	7	N	-	24	482	506	1	Y	N	-
156	1599285	N.	Y	-	-	-	3	-	N	42	-	437	437	0	Y	N	-
157	974264	P	-	-	-	-	7	-	N	-	52	521	573	1	Y	N	-
158	1612997	G.J.	-	-	-	-	5	-	N	-	14	464	478	1	Y	N	-
159	254232	S.K.	-	-	-	-	6	-	Y	-	-	525	525	1	Y	N	-
160	1613629	D.K.G.	-	-	-	-	5	-	N	-	34	485	519	1	Y	N	-
161	1613098	B.S.	-	-	-	-	10	3	N	-	25	450	475	1	Y	N	-
162	1614887	L.C.	Y	-	-	-	8	-	N	182	-	419	419	0	Y	N	-
163	1615312	V.S.	Y	-	-	-	2	-	N	35	-	482	482	1	Y	N	-
164	1485288	M.L.	Y	-	-	-	4	-	N	9	-	486	486	1	Y	N	-
165	1613664	G.S.	Y	-	-	-	5	-	N	17	-	478	478	1	Y	N	-
166	1616073	A.K.	-	-	-	Y	8	-	N	-	19	456	475	1	Y	N	-
167	1615339	K.	Y	-	-	-	5	-	N	5	-	474	474	1	Y	N	-
168	195141	N.K.	Y	-	-	-	11	-	N	65	-	440	440	0	Y	N	-
169	1612837	K.K.	Y	-	-	-	14	-	N	93	-	399	399	0	Y	N	-
170	1614824	H.K.	Y	-	-	-	9	-	N	36	-	464	464	1	Y	N	-
171	157175	M.S.	Y	-	-	-	12	-	N	53	-	434	434	0	Y	N	-
172	1616176	S.S.	Y	-	-	-	16	-	N	59	-	441	441	0	Y	N	-
173	1614830	R.K.	Y	-	-	-	10	-	N	6	-	464	464	1	Y	N	-
174	1615380	K.S.	Y	-	-	-	6	-	Y	-	-	459	459	1	Y	N	-
175	1505967	B.S.	-	-	-	-	11	-	N	-	-	689	689	1	N	Y	-
176	1615320	K.R.	Y	-	-	-	9	-	N	35	-	457	457	1	Y	N	-
177	1614918	B.	-	-	-	-	12	-	N	-	54	465	519	1	Y	N	-
178	1615457	K.S.	-	-	-	-	8	-	Y	-	-	535	535	1	Y	N	-
179	1606389	J.K.	-	-	-	-	26	-	N	-	10	474	484	1	Y	N	-
180	1606942	O.P.K	Y	-	-	-	11	-	N	8	-	439	439	0	Y	N	-
181	1608577	A.S.	Y	-	-	-	27	-	N	71	-	439	439	0	Y	N	-
182	1596363	T.C.	Y	-	-	-	12	-	N	7	-	470	470	1	Y	N	-
183	1614799	G.K.	Y	-	-	-	19	-	N	104	-	402	402	0	Y	N	-
184	1526638	B.S.	Y	-	-	-	9	-	N	30	-	456	456	1	Y	N	-
185	1616148	S.A.	Y	-	-	-	5	-	N	13	-	434	434	0	Y	N	-
186	1615380	K.S.	-	-	-	-	6	-	Y	-	-	459	459	1	Y	N	-
187	654262	R.K.G.	Y	-	-	-	9	-	N	8	-	464	464	1	Y	N	-
188	1616724	V.D.M	Y	-	-	-	11	-	N	14	-	455	455	1	Y	N	-
189	1608602	A.S.	-	Y	Y	-	12	-	N	157	-	521	521	1	Y	N	-
190	1610418	K.S.	-	-	-	-	23	-	N	23	-	457	457	1	Y	N	-
191	1615464	V.R.	Y	-	-	-	16	-	N	74	-	410	410	0	Y	N	-
192	1615424	K.C.	Y	-	-	-	10	-	N	12	-	452	452	1	Y	N	-

S No	MRD	NAME	AGE	AGE GROUP	SEX	OCCUPATION	RELIGION	SBP	DBP	PR	MARITAL STATUS	CONSANGUINITY	TEMPERATURE	APACHE II SCORE	HYPERTENSION	ENDOCRINE	ENDOCRINE_HYPOTHYROID	ENDOCRINE_HYPERTHYROID	ENDOCRINE_DM1
193	1614889	M.K.	28	1	F	HOMEMAKER	S	80	60	160	M	-	97	27	-	-	-	-	-
194	1609942	V.S.	35	2	M	DAILY WAGE WORKER	S	70	40	150	M	-	97.4	30	-	-	-	-	-
195	1582678	S.D.	63	3	F	FARMER	H	130	80	130	M	-	100	24	-	-	-	-	-
196	1614320	J.S.	47	2	M	FARMER	S	60	40	70	M	-	101	29	-	-	-	-	-
197	1598436	S.	29	1	M	PVT SECTOR EMPLOYEE	M	110	70	90	M	Y	96	28	-	-	-	-	-
198	257508	M.K.	71	4	F	HOMEMAKER	S	140	80	97	M	-	100	24	-	Y	-	-	-
199	1616775	S.S.A	76	4	M	RETIRED	S	140	80	96	M	-	102	28	Y	Y	-	-	-
200	1616730	P.G.	19	1	M	STUDENT	S	90	50	101	S	-	100	23	-	-	-	-	-
201	27962	A.S.	58	3	M	RETIRED	S	100	60	101	M	-	101	20	-	-	-	-	-
202	1451743	H.S.M.	55	3	M	BUSINESS OWNER	S	130	80	100	M	-	98.4	19	Y	Y	-	-	-
203	1611853	S.S	55	3	M	RETIRED	S	110	80	110	M	-	98.4	24	-	-	-	-	-
204	1438856	U.K.	52	3	M	PVT SECTOR EMPLOYEE	H	110	70	108	M	-	98.4	21	-	-	-	-	-
205	1616014	P.C.	64	3	M	RETIRED	H	140	70	96	M	-	98.4	16	Y	Y	-	-	-
206	1612025	J.S.	65	3	M	RETIRED	S	120	80	70	M	-	98.4	11	-	-	-	-	-
207	1612075	R.D.	52	3	F	HOMEMAKER	H	130	70	99	M	-	98.4	13	Y	-	-	-	-
208	735295	N.D.	56	3	M	GOVT SECTOR EMPLOYEE	H	220	110	150	M	-	100	19	Y	-	-	-	-
209	1336159	B.S.	73	4	M	RETIRED	S	120	70	84	M	-	98.4	15	-	-	-	-	-
210	1612065	H.S.	27	1	M	DEPENDENT	S	130	70	50	M	-	98.4	26	-	-	-	-	-
211	180340	J.K.	69	3	F	HOMEMAKER	S	100	60	127	M	-	100	20	Y	Y	-	-	-
212	1388578	A.P.	44	2	M	BUSINESSMAN	S	120	60	104	M	-	98.4	13	-	-	-	-	-
213	869393	P.S.	56	3	M	RETIRED	S	110	70	121	M	-	100	19	-	-	-	-	-
214	58356	S.R.J	70	3	F	HOMEMAKER	H	150	80	92	M	-	98.4	22	Y	Y	-	-	-
215	1616771	J.	80	4	F	RETIRED	M	100	60	119	M	Y	98.4	19	Y	Y	-	-	-
216	1604066	A.K.	52	3	F	HOMEMAKER	S	90	60	65	M	-	98.4	20	Y	Y	-	-	-
217	1284195	K.K.G.	82	4	M	RETIRED	H	140	80	98	M	-	98.4	25	Y	-	-	-	-
218	1516533	R.K.	52	3	M	SELF-EMPLOYED	H	100	70	85	M	-	98.4	16	Y	-	-	-	-
219	1507895	H.K.	57	3	F	HOMEMAKER	S	160	90	109	M	-	98.4	18	-	Y	-	-	-
220	160969	B.S.	73	4	M	RETIRED	S	110	70	72	M	-	98.4	14	Y	Y	-	-	-
221	1615282	M.S.	74	4	M	RETIRED	S	160	90	100	M	-	98.4	17	Y	Y	-	-	-
222	1614287	S.L.	64	3	M	RETIRED	H	60	40	155	M	-	99	26	Y	Y	-	-	-
223	1604415	M.L.J	75	4	M	RETIRED	H	110	70	146	M	-	98.4	23	-	-	-	-	-
224	161199	A.L.K.	73	4	M	RETIRED	H	110	70	80	M	-	98.4	19	Y	Y	-	-	-
225	1612797	V.B.	54	3	F	HOMEMAKER	H	180	100	72	M	-	99.4	16	Y	-	-	-	-
226	1611113	P.S.	40	2	M	BUSINESSMAN	S	-	-	89	M	-	98.4	14	-	-	-	-	-
227	1607769	S.S.	35	2	M	BUSINESSMAN	S	130	70	97	M	-	100	21	-	-	-	-	-
228	1612850	V.K.	32	2	M	PVT SECTOR EMPLOYEE	H	130	70	116	M	-	98.4	15	-	-	-	-	-
229	145532	J.N.S	74	4	M	RETIRED	H	130	80	80	M	-	98.4	23	Y	Y	-	-	-
230	1489344	O.P.	59	3	M	GOVT SECTOR EMPLOYEE	H	90	70	104	M	-	98.4	19	-	Y	-	-	-
231	1610942	P.L.	58	3	M	SELF-EMPLOYED	H	120	70	42	M	-	98.4	18	-	Y	-	-	-
232	16009973	A.K.V	60	3	M	SELF-EMPLOYED	H	160	80	108	M	-	98.4	22	Y	-	-	-	-
233	1468451	M.K.	65	3	F	HOMEMAKER	S	120	80	80	M	-	101	16	Y	Y	Y	-	-
234	1547415	B.S.G	66	3	M	RETIRED	S	110	70	62	M	-	98.6	19	Y	-	-	-	-
235	476777	G.S.	60	3	M	SELF-EMPLOYED	S	110	60	84	M	-	98.2	20	Y	Y	-	-	-
236	1610801	B.S.	60	3	M	FARMER	S	110	70	76	M	-	100	26	Y	Y	Y	-	-
237	1570112	J.S.	74	4	M	RETIRED	S	130	90	88	M	-	98.4	15	Y	Y	-	-	-
238	1613544	S.S.	74	4	M	RETIRED	S	140	80	94	M	-	98.4	18	Y	-	-	-	-
239	450989	C.L.	68	3	M	DAILY WAGE WORKER	H	110	80	159	M	-	98.4	17	-	-	-	-	-
240	1677376	R.K.N.	94	4	F	RETIRED	S	70	40	121	M	-	98.4	14	Y	Y	-	-	-
241	1698067	S.K.	50	2	M	BUSINESSMAN	H	150	90	103	M	-	98.4	12	Y	-	-	-	-
242	1696132	V.S.	84	4	F	HOMEMAKER	H	100	50	41	M	-	98.4	19	Y	Y	-	-	-
242	1648739	J.K.	62	3	F	HOMEMAKER	S	140	80	97	M	-	98.4	24	Y	Y	-	-	-
243	1632765	R.K.	81	4	F	HOMEMAKER	S	120	60	64	M	-	98.4	27	Y	-	-	-	-
244	1698359	B.D.	70	3	F	HOMEMAKER	H	120	70	61	M	-	98.4	22	-	Y	Y	-	-

S No	MRD	NAME	ENDOCRINE_DM2	ENDOCRINE_OTHERS	NEUROLOGIC	NEUROLOGIC_HEMORRHAGIC CVA	NEUROLOGIC_ISCHAEMIC CVA	NEUROLOGIC_SEIZURE	NEUROLOGIC_SPINAL CORD INVOLVEMENT	NEUROLOGIC_OTHERS	PULMONARY	PULMONARY_PNEUMONIA	PULMONARY_COPD
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	-	-	-	-	-	-	Y	-	-
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	Y	-	-
197	1598436	S.	-	-	Y	-	-	Y	-	-	Y	-	-
198	257508	M.K.	Y	-	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	Y	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	Y	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	-	-	-	-	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	Y	-	Y	-	Y	-	-	-	Y	Y	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	Y	-	Y	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-
210	1612065	H.S.	-	-	-	-	-	-	-	-	Y	-	-
211	180340	J.K.	Y	-	-	-	-	-	-	-	Y	Y	-
212	1388578	A.P.	-	-	Y	-	-	Y	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	Y	Y	-
214	58356	S.R.J	Y	-	-	-	-	-	-	-	-	-	-
215	1616771	J.	Y	-	-	-	-	-	-	-	Y	-	Y
216	1604066	A.K.	Y	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	Y	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	Y	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	Y	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	Y	-	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	-	-	Y	-	Y	-	-	-	Y	Y	Y
224	161199	A.L.K.	Y	-	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	-	-	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	Y	-	-
229	145532	J.N.S	Y	-	Y	-	Y	-	-	-	-	-	-
230	1489344	O.P.	Y	-	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	Y	-	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	Y	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	Y	-	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	Y	-	-	-	-	-	-	-	-	-	-
237	1570112	J.S.	Y	-	-	-	-	-	-	-	Y	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	Y	-	-	-	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	Y	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	Y	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	Y	-	Y	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	PULMONARY_PLEURAL EFFUSION	PULMONARY_PNEUMOTHORAX	PULMONARY_OTHER	CARDIAC	CARDIAC_STEMI	CARDIAC_NSTEMI	CARDIAC_UNSTABLE ANGINA	CARDIAC_STABLE ANGINA	CARDIAC_CAD	CARDIAC_CONGENITAL HEART DISEASE	CARDIAC_CHF
193	1614889	M.K.	-	-	-	N	-	-	-	-	-	-	-
194	1609942	V.S.	Y	-	-	N	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	-	N	-	-	-	-	-	-	-
196	1614320	J.S.	-	Y	-	N	-	-	-	-	-	-	-
197	1598436	S.	Y	-	-	N	-	-	-	-	-	-	-
198	257508	M.K.	-	-	-	Y	-	-	-	-	Y	-	-
199	1616775	S.S.A	-	-	-	N	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	Y	-	-	-	-	-	-	Y
201	27962	A.S.	-	-	-	N	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	-	-	N	-	-	-	-	-	-	-
203	1611853	S.S	-	-	-	N	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	N	-	-	-	-	-	-	-
205	1616014	P.C.	-	-	-	Y	-	Y	-	-	Y	-	-
206	1612025	J.S.	-	-	-	Y	-	Y	-	-	Y	-	-
207	1612075	R.D.	-	-	-	Y	-	Y	-	-	-	-	-
208	735295	N.D.	-	-	-	Y	-	-	-	-	-	-	Y
209	1336159	B.S.	-	-	-	Y	Y	-	-	-	Y	-	-
210	1612065	H.S.	-	-	2	N	-	-	-	-	-	-	-
211	180340	J.K.	-	-	-	Y	-	-	-	-	Y	-	-
212	1388578	A.P.	-	-	-	Y	Y	-	-	-	-	-	-
213	869393	P.S.	-	-	-	N	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	Y	-	-	-	-	Y	-	Y
215	1616771	J.	-	-	-	Y	-	Y	-	-	-	-	Y
216	1604066	A.K.	-	-	-	Y	-	-	-	-	Y	-	Y
217	1284195	K.K.G.	-	-	-	Y	-	-	-	-	-	-	Y
218	1516533	R.K.	-	-	-	Y	Y	-	-	Y	Y	-	-
219	1507895	H.K.	-	-	-	Y	Y	-	Y	-	Y	-	Y
220	160969	B.S.	-	-	-	Y	Y	-	-	-	Y	-	-
221	1615282	M.S.	-	-	-	Y	-	-	-	-	Y	-	-
222	1614287	S.L.	-	-	-	Y	Y	-	-	-	Y	-	-
223	1604415	M.L.J	-	-	-	Y	Y	-	-	-	Y	-	-
224	161199	A.L.K.	-	-	-	Y	-	Y	-	-	Y	-	-
225	1612797	V.B.	-	-	-	N	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	Y	Y	-	-	-	Y	-	Y
227	1607769	S.S.	-	-	-	N	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	2	Y	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	-	Y	Y	-	-	-	Y	-	-
230	1489344	O.P.	-	-	-	Y	-	Y	Y	-	Y	-	-
231	1610942	P.L.	-	-	-	Y	Y	-	-	-	Y	-	-
232	16009973	A.K.V	-	-	-	Y	Y	-	-	-	Y	-	-
233	1468451	M.K.	-	-	-	N	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	Y	-	-	-	-	Y	-	-
235	476777	G.S.	-	-	-	Y	Y	-	-	-	Y	-	Y
236	1610801	B.S.	-	-	-	Y	Y	-	-	-	Y	-	-
237	1570112	J.S.	Y	-	-	Y	-	Y	-	-	Y	-	-
238	1613544	S.S.	-	-	-	Y	Y	-	-	-	Y	-	-
239	450989	C.L.	-	-	-	Y	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	Y	Y	-	-	-	Y	-	Y
241	1698067	S.K.	-	-	-	Y	-	Y	-	-	-	-	-
242	1696132	V.S.	-	-	-	Y	Y	-	-	-	Y	-	Y
242	1648739	J.K.	-	-	-	Y	-	Y	-	-	Y	-	-
243	1632765	R.K.	-	-	-	Y	-	-	-	-	Y	-	-
244	1698359	B.D.	-	-	-	Y	-	-	-	-	-	-	-

S No	MRD	NAME	CARDIAC_ARRYTHMIA_AT	AF	AFL	PSVT	NSVT	VT	TDP	APC	VPC	OTHER	CMP_DCMP	RCMP	ICMP	HCMP	VALVULAR HEART DISEASE	VALVULAR HEART DISEASE_AS	AR	MS	MR	PERICARDIAL DISEASE_CCP	TAMPONADE	EFFUSION	OTHERS	GASTRO-INTESTINAL
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
202	1451743	H.S.M.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
203	1611853	S.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
205	1616014	P.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
210	1612065	H.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
211	180340	J.K.	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	Y	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	Y
215	1616771	J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
217	1284195	K.K.G.	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
224	161199	A.L.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y
227	1607769	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	1	-
229	145532	J.N.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
230	1489344	O.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	Y	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
236	1610801	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
239	450989	C.L.	-	-	-	-	Y	-	-	-	-	-	Y	-	-	-	Y	-	-	-	Y	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	Y

S No	MRD	NAME	GASTRO-INTESTINAL_CLD	GASTRO-INTESTINAL_HEPATITIS	GASTRO-INTESTINAL_ALF	GASTRO-INTESTINAL_PANCREATITIS	GASTRO-INTESTINAL_SAIO	GASTRO-INTESTINAL_CHOLECYSTITIS	GASTRO-INTESTINAL_OTHER	NEPHRO	NEPHRO_AKI
193	1614889	M.K.	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	-	Y	-	-	-	Y	Y
195	1582678	S.D.	-	-	-	Y	-	Y	-	Y	Y
196	1614320	J.S.	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	Y	-	-	-	Y	Y
198	257508	M.K.	-	-	-	-	-	Y	-	Y	Y
199	1616775	S.S.A	-	-	-	-	-	-	-	Y	Y
200	1616730	P.G.	-	-	-	-	-	-	-	-	-
201	27962	A.S.	Y	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	Y	-	-	Y	-	-	6	Y	-
203	1611853	S.S	Y	-	-	-	-	-	6	Y	Y
204	1438856	U.K.	Y	-	-	-	-	-	6	Y	Y
205	1616014	P.C.	Y	-	-	-	-	-	-	Y	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	Y	Y
209	1336159	B.S.	-	-	-	-	-	-	7	Y	Y
210	1612065	H.S.	-	-	-	-	-	-	-	-	-
211	180340	J.K.	-	-	-	-	-	-	-	Y	Y
212	1388578	A.P.	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	Y	-	Y	-
215	1616771	J.	-	-	-	-	-	-	-	Y	Y
216	1604066	A.K.	-	-	-	-	-	-	-	Y	Y
217	1284195	K.K.G.	-	-	-	-	-	-	-	Y	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	-	-	-	-	-	-	-	Y	-
223	1604415	M.L.J	-	-	-	-	-	-	-	Y	Y
224	161199	A.L.K.	-	-	-	-	-	-	-	Y	-
225	1612797	V.B.	-	-	-	-	-	-	-	Y	Y
226	1611113	P.S.	-	Y	-	-	-	-	-	Y	Y
227	1607769	S.S.	-	-	-	-	-	-	-	Y	Y
228	1612850	V.K.	-	-	-	-	-	-	-	Y	Y
229	145532	J.N.S	-	-	-	-	-	-	-	Y	-
230	1489344	O.P.	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	Y	Y
234	1547415	B.S.G	-	-	-	-	-	-	-	Y	-
235	476777	G.S.	-	-	-	-	-	-	-	Y	Y
236	1610801	B.S.	-	-	-	-	-	-	-	Y	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	-	-	-	Y	Y
241	1698067	S.K.	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	Y	Y
242	1648739	J.K.	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	Y	-	-	-

S No	MRD	NAME	NEPHRO_CKD	NEPHRO_NEPHROTIC	NEPHRO_NEPHRITIC	NEPHRO_OBSTRUCTIVE UROPATHY	NEPHRO_UTI	NEPHRO_USE OF RRT	NEPHRO_OTHER	SEPSIS	INFECTIONS	INFECTIONS_TB	HIV	DENGUE	ENTERIC	MALARIA	LEPTOSPIRA	SCRUB TYPHUS	COVID	H1N1
193	1614889	M.K.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	-	Y	Y	-	-	N	-	-	-	-	-	-	-	-	-
198	257508	M.K.	-	-	-	-	Y	-	-	Y	N	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	Y	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
203	1611853	S.S	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	Y	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
210	1612065	H.S.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
211	180340	J.K.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	Y	-	-	-	-	Y	-	Y	Y	Y	-	-	-	-	-	-	Y	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	Y	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	-	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	Y	-
224	161199	A.L.K.	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	-	Y	Y	-	-	-	Y	-	-	-	-	-	-	-	Y	-
230	1489344	O.P.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-	-
234	1547415	B.S.G	Y	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	-	-	-	Y	-	-	-	N	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	Y	-	-	-	Y	Y	-	-	N	-	-	-	-	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	Y	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	-	Y	-	-	N	-	-	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHER	MALIGNANCY	SURGICAL ILLNESS	SURGICAL ILLNESS_GI	ORTHOPEDIC	NEURO	URO	OBG	ENT	PLASTIC	TRAUMA	CTVS	SHOCK	PSYCHIATRIC	PSYCHIATRIC_DEPRESSION	ANXIETY	PSYCHOSIS	DELIRIUM	HALLUCINATION	PTSD	SCHIZOPHRENIA
193	1614889	M.K.	-	-	Y	Y	Y	Y	-	-	-	Y	Y	-	Y	N	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	Y	-	Y	-	-	-	-	-	Y	-	Y	N	-	-	-	-	-	-	-
197	1598436	S.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
198	257508	M.K.	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	Y	-	-	-	Y	-	-	-
199	1616775	S.S.A	-	-	Y	-	-	-	-	-	-	-	-	Y	-	N	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
201	27962	A.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
203	1611853	S.S	-	-	Y	Y	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
205	1616014	P.C.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
206	1612025	J.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
208	735295	N.D.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
210	1612065	H.S.	-	-	Y	-	Y	-	-	-	-	-	Y	-	Y	N	-	-	-	-	-	-	-
211	180340	J.K.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
212	1388578	A.P.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
213	869393	P.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	Y	-	-	-	-	-
215	1616771	J.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
220	160969	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
222	1614287	S.L.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
223	1604415	M.L.J	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-
224	161199	A.L.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	Y	-	-	-	-	-	-
226	1611113	P.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
227	1607769	S.S.	-	-	Y	-	Y	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-
228	1612850	V.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	Y	-	-	-	Y	-	-	-	-	-	-	N	-	-	-	-	-	-	-
230	1489344	O.P.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-
231	1610942	P.L.	-	-	Y	-	Y	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	Y	-	Y	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
233	1468451	M.K.	-	-	Y	-	Y	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
235	476777	G.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
236	1610801	B.S.	-	-	N	-	-	-	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	-	-
237	1570112	J.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
239	450989	C.L.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	N	-	-	-	-	-	-	-	-	-	Y	N	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	N	-	-	-	-	-	-	-	-	-	-	Y	-	-	Y	-	-	-	-
244	1698359	B.D.	-	-	Y	Y	-	-	-	-	-	-	-	-	-	N	-	-	-	-	-	-	-

S No	MRD	NAME	CATATONIA	WITHDRAWAL	OTHER	OTHER	HISTORY SUGGESTING LQTS	HISTORY SUGGESTING LQTS VT	SYNCOPE	SEIZURE	CARDIAC ARREST	UNEXPLAINED MOTOR ACCIDENT	UNEXPLAINED DROWNING	HEARING LOSS	PERIODIC PARALYSIS	SKELETAL DYSMORPHISM	COGNITIVE ISSUES	IMMUNE DYSFUNCTION
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	Y - THALASSEMIA MAJOR	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	-	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	Y	-	Y	-	-	-	-	-	-	-	-	-
210	1612065	H.S.	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	-	-
211	180340	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	Y	-	Y	Y	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	Y	Y	Y	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
224	161199	A.L.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
230	1489344	O.P.	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	Y	Y	-	-	Y	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	AUTISM	FAMILY HISTORY	FAMILY HISTORY_PREMATURE SUDDEN DEATH <40 YRS	SYNCOPE	CONSANGUINITY	DROWNING	DEATH WHILE DRIVING	SEIZURES	CONGENITAL DEAFNESS	KNOWN LQT MUTATION	RELATION WITH AFFECTED PERSON	DRUGS WITH RISK OF QTC PROLONGATION	ANTIARRYTHMICS	ANTIARRYTHMICS_AMIODARONE	1A
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
210	1612065	H.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
211	180340	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
223	1604415	M.L.J	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
224	161199	A.L.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
230	1489344	O.P.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
236	1610801	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-	-
240	1677376	R.K.N.	-	-	-	-	-	-	-	-	-	-	-	-	Y	Y	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHERS	ANTIMICROBIALS	ANTIMICROBIALS_MACROLIDES	FLUOROQUINOLONES	TRIMETH-SULPHAMETHO	CLINDAMYCIN	ATT	METRONIDAZOLE	ANTIMALARIAL	ANTIFUNGAL	ANTIVIRAL	OTHERS	ANTIPSYCHOTICS
193	1614889	M.K.	-	Y	-	-	-	-	-	Y	-	-	-	-	-
194	1609942	V.S.	-	Y	-	-	-	-	-	Y	-	Y	-	-	-
195	1582678	S.D.	-	Y	Y	-	-	-	-	Y	-	-	-	-	-
196	1614320	J.S.	-	Y	-	-	-	-	-	Y	-	Y	-	-	-
197	1598436	S.	-	Y	-	-	-	Y	-	Y	-	Y	-	-	-
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	Y	-	-	-	Y	-	-	-	-	-	-	Y
202	1451743	H.S.M.	-	Y	-	-	-	-	-	Y	-	-	-	-	Y
203	1611853	S.S	-	Y	-	-	-	-	-	Y	-	-	-	-	Y
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	-	Y	-	-	-	-	-	Y	-	-	-	-	Y
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	-	-	-	-	Y
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-	-	Y
209	1336159	B.S.	-	Y	-	-	-	-	-	-	-	Y	-	-	-
210	1612065	H.S.	-	Y	-	-	-	Y	-	Y	-	-	-	-	-
211	180340	J.K.	-	Y	Y	-	-	-	-	-	-	-	-	-	Y
212	1388578	A.P.	-	-	-	-	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	Y	Y	-	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	Y	Y	-	-	-	Y	Y	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y
222	1614287	S.L.	Y - IB	Y	-	-	-	-	-	Y	-	-	-	-	Y
223	1604415	M.L.J	-	Y	Y	-	-	-	-	-	-	-	-	-	Y
224	161199	A.L.K.	-	Y	-	Y	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	Y	Y	-	-	-	-	-	-	Y	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	-	Y	-	-	-	Y	-	-	-	-	-	-	Y
228	1612850	V.K.	-	Y	Y	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	Y	-	Y	-	-	-	-	-	-	-	-	Y
230	1489344	O.P.	Y - IB	-	-	-	-	-	-	-	-	-	-	-	Y
231	1610942	P.L.	-	Y	-	-	-	-	-	Y	-	-	-	-	-
232	16009973	A.K.V	-	Y	-	-	-	-	-	Y	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	Y	-	Y	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	-	Y	-	Y	-	-	-	-	-	-	-	-	Y
237	1570112	J.S.	-	Y	-	-	-	-	Y	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
239	450989	C.L.	Y - IB	-	-	-	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	Y - IB	-	-	-	-	-	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-	-	Y

S No	MRD	NAME	ANTIPSYCHOTICS_HALOPERIDOL	OLANZAPINE	QUETIAPINE	RISPERIDONE	OTHERS	ANTIDEPRESSANTS	ANTIDEPRESSANTS_ESCITALOPRAM	FLUOXETINE	SERTRALINE	MIRTAZAPINE	IMIPRAMINE	AMITRYPTILINE	NORTRYPTILINE	OTHERS
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
194	1609942	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
208	735295	N.D.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
210	1612065	H.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
211	180340	J.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
224	161199	A.L.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
230	1489344	O.P.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	ANTIHISTAMINES	ANTIHISTAMINES_ DIPHENHYDRAMINE	HYDROXYZINE	OTHER	ANALGESICS, ANESTHETICS, SEDATIVES	ANALGESICS, ANESTHETICS, SEDATIVES_OPIOIDS	PROPOFOL	BENZODIAZEPINES	OTHERS	ANTINEOPLASTICS	BRONCHODILATORS	BRONCHODILATORS_TERBUTALINE
193	1614889	M.K.	-	-	-	-	Y	F	-	Y	M	-	Y	-
194	1609942	V.S.	-	-	-	-	Y	F	-	Y	M	-	-	-
195	1582678	S.D.	-	-	-	-	Y	F	-	Y	M	-	-	-
196	1614320	J.S.	-	-	-	-	Y	F	-	Y	M	-	-	-
197	1598436	S.	-	-	-	-	Y	F	-	Y	M	-	-	-
198	257508	M.K.	-	-	-	-	Y	F	-	Y	M	-	-	-
199	1616775	S.S.A	-	-	-	-	Y	F	-	Y	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	-	-	-	Y	T	-	-	-	-	-	-
202	1451743	H.S.M.	-	-	-	-	Y	T	-	-	-	-	-	-
203	1611853	S.S	-	-	-	-	Y	T	-	-	-	-	-	-
204	1438856	U.K.	-	-	-	-	Y	M	-	-	-	-	-	-
205	1616014	P.C.	-	-	-	-	Y	F	-	Y	-	-	Y	-
206	1612025	J.S.	-	-	-	-	Y	-	-	Y	-	-	Y	-
207	1612075	R.D.	-	-	-	-	Y	-	-	Y	-	-	-	-
208	735295	N.D.	-	-	-	-	Y	-	-	Y	-	-	Y	-
209	1336159	B.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
210	1612065	H.S.	-	-	-	-	Y	F	-	Y	-	-	Y	-
211	180340	J.K.	-	-	-	-	Y	F	-	Y	-	-	Y	-
212	1388578	A.P.	-	-	-	-	Y	M	-	-	-	-	-	-
213	869393	P.S.	Y	-	-	Y	Y	-	-	Y	-	-	-	-
214	58356	S.R.J	-	-	-	-	Y	-	-	Y	-	-	Y	-
215	1616771	J.	-	-	-	-	Y	-	-	Y	-	-	Y	-
216	1604066	A.K.	-	-	-	-	Y	-	-	Y	-	-	Y	-
217	1284195	K.K.G.	-	-	-	-	Y	-	-	Y	-	-	Y	-
218	1516533	R.K.	-	-	-	-	Y	-	-	Y	-	-	Y	-
219	1507895	H.K.	-	-	-	-	Y	-	-	Y	-	-	Y	-
220	160969	B.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
221	1615282	M.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
222	1614287	S.L.	-	-	-	-	Y	F	-	Y	-	-	Y	-
223	1604415	M.L.J	-	-	-	-	Y	F	-	Y	-	-	Y	-
224	161199	A.L.K.	-	-	-	-	Y	-	-	Y	-	-	Y	-
225	1612797	V.B.	-	-	-	-	Y	-	-	Y	-	-	-	-
226	1611113	P.S.	-	-	-	-	Y	F	-	Y	-	-	Y	-
227	1607769	S.S.	-	-	-	-	Y	F	-	Y	-	-	-	-
228	1612850	V.K.	-	-	-	-	Y	-	-	Y	-	-	Y	-
229	145532	J.N.S	-	-	-	-	Y	F	-	Y	-	-	-	-
230	1489344	O.P.	-	-	-	-	Y	-	-	Y	-	-	Y	-
231	1610942	P.L.	-	-	-	-	Y	F	-	Y	M	-	Y	-
232	16009973	A.K.V	-	-	-	-	Y	F	-	Y	-	-	Y	-
233	1468451	M.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
234	1547415	B.S.G	-	-	-	-	Y	-	-	Y	-	-	-	-
235	476777	G.S.	-	-	-	-	Y	-	-	Y	-	-	Y	-
236	1610801	B.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
237	1570112	J.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
238	1613544	S.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
239	450989	C.L.	-	-	-	-	Y	-	-	Y	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	Y	-	-	Y	-	-	Y	-
241	1698067	S.K.	-	-	-	-	Y	-	-	Y	-	-	-	-
242	1696132	V.S.	-	-	-	-	Y	-	-	Y	-	-	-	-
242	1648739	J.K.	-	-	-	-	Y	F	-	Y	-	-	Y	-
243	1632765	R.K.	-	-	-	-	Y	F	-	Y	-	-	Y	-
244	1698359	B.D.	-	-	-	-	Y	-	-	Y	-	-	-	-

S No	MRD	NAME	FORMETROL	INDACATEROL	SALMETROL	SALBUTAMOL	LEVOSALBUTAMOL	OTHERS	DIURETICS	DIURETICS_FUROSEMIDE	TORSEMIDE	METOLAZONE	SPIRONOLACTONE	HYDROCHLORTHIAZIDE	CTD	GIDRUGS	GI DRUGS_LOPERAMIDE
193	1614889	M.K.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
194	1609942	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
201	27962	A.S.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
202	1451743	H.S.M.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
203	1611853	S.S	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
205	1616014	P.C.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
206	1612025	J.S.	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
207	1612075	R.D.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
208	735295	N.D.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
210	1612065	H.S.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
211	180340	J.K.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
213	869393	P.S.	-	-	-	-	-	-	Y	-	-	-	-	-	Y	Y	-
214	58356	S.R.J	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
215	1616771	J.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
216	1604066	A.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
217	1284195	K.K.G.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
218	1516533	R.K.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
219	1507895	H.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
222	1614287	S.L.	-	-	-	Y	-	-	Y	Y	-	Y	Y	-	-	Y	-
223	1604415	M.L.J	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
224	161199	A.L.K.	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
225	1612797	V.B.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
226	1611113	P.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
227	1607769	S.S.	-	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-
228	1612850	V.K.	-	-	-	Y	-	-	-	-	-	-	-	-	-	Y	-
229	145532	J.N.S	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
230	1489344	O.P.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
231	1610942	P.L.	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
232	16009973	A.K.V	-	-	-	Y	-	-	Y	-	-	-	Y	-	-	Y	-
233	1468451	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
234	1547415	B.S.G	-	-	-	-	-	-	Y	-	-	Y	-	-	-	Y	-
235	476777	G.S.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
236	1610801	B.S.	-	-	-	-	-	-	Y	-	-	Y	Y	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
238	1613544	S.S.	-	-	-	-	-	-	Y	Y	-	-	Y	-	-	Y	-
239	450989	C.L.	-	-	-	-	-	-	Y	Y	-	-	-	-	-	Y	-
240	1677376	R.K.N.	-	-	-	Y	-	Y	Y	Y	-	Y	Y	-	-	Y	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
242	1648739	J.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
243	1632765	R.K.	-	-	-	Y	-	-	Y	Y	-	-	Y	-	-	Y	-
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	Y	-

S No	MRD	NAME	ONDANSETRON	GRANISETRON	PALONOSETRON	DOMPERIDONE	METOCLOPRAMIDE	PANTOPRAZOLE	ESOMEPRAZOLE	OMEPRAZOLE	OTHERS	DRUGS FOR BPH	DRUGS FOR BPH TAMSULOSIN	ALFUZOSIN	SILODOSIN	CHOLINERGIC ANTAGONIST	CITRATE MASSIVE BT	COCAINE
193	1614889	M.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
194	1609942	V.S.	-	-	-	Y	-	-	Y	-	-	-	-	-	-	-	-	-
195	1582678	S.D.	-	-	-	Y	-	-	Y	-	-	-	-	-	-	-	-	-
196	1614320	J.S.	-	-	-	Y	-	-	Y	-	-	-	-	-	-	-	Y	-
197	1598436	S.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
198	257508	M.K.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
204	1438856	U.K.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	Y	-
210	1612065	H.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
211	180340	J.K.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
224	161199	A.L.K.	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
226	1611113	P.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
230	1489344	O.P.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	Y	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
232	16009973	A.K.V	Y	-	-	-	-	Y	-	-	-	Y	-	-	Y	-	-	-
233	1468451	M.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	Y	-	-	-	Y	Y	-	-	-	-	-
235	476777	G.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	-	-	-	-	-	-	-	-	-	Y	Y	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	Y	-	-	-	Y	-	-	Y	-	-	-
239	450989	C.L.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	Y	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	RANOLAZINE	INOTROPES	INOTROPES_NOREPINEPHRINE	EPINEPHRINE	DOPAMINE	DOBUTAMINE	VASOPRESSIN	OTHERS	ANTIEPILEPTICS_	ANTIEPILEPTICS_LEVETIRACITAM	ANTIEPILEPTICS_OTHERS	OTHERS
193	1614889	M.K.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
194	1609942	V.S.	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
195	1582678	S.D.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
196	1614320	J.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
197	1598436	S.	-	Y	Y	-	Y	-	Y	-	Y	Y	-	-
198	257508	M.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	Y	Y	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
203	1611853	S.S	-	Y	Y	-	Y	-	Y	-	-	-	-	-
204	1438856	U.K.	-	Y	Y	-	-	-	Y	-	-	-	-	-
205	1616014	P.C.	-	Y	Y	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	-	Y	Y	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	-	-	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-	-
210	1612065	H.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
211	180340	J.K.	-	Y	Y	Y	Y	-	Y	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	Y	Y	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	Y	Y	-	Y	-	-	-	-	-	-	-
215	1616771	J.	-	Y	Y	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	Y	Y	-	Y	-	-	-	-	-	-	-
218	1516533	R.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	-	Y	Y	Y	Y	-	Y	-	Y	Y	-	-
223	1604415	M.L.J	-	Y	Y	-	-	-	-	-	-	-	-	-
224	161199	A.L.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	-	-	-	Y	Y	-	-
226	1611113	P.S.	-	Y	Y	-	Y	-	-	-	-	-	-	-
227	1607769	S.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
228	1612850	V.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	Y	Y	-	-	-	-	-	Y	Y	-	-
230	1489344	O.P.	-	Y	Y	-	Y	-	-	-	-	-	-	-
231	1610942	P.L.	-	Y	Y	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	Y	Y	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	-	Y	Y	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	Y	Y	-	Y	-	-	-	-	-	-	-
235	476777	G.S.	-	-	-	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	-	Y	Y	-	Y	-	Y	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	Y	Y	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	Y	Y	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	Y	Y	-	Y	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	Y	Y	-	Y	-	-	-	-	-	-	-
242	1648739	J.K.	-	Y	Y	-	Y	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	-	-	-	-	-	-	-
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-	-

S No	MRD	NAME	OTHER CONDITIONS PREDISPOSING TO PROLONGED QTC	ELECTROLYTE ABNORMALITIES	ELECTROLYTE ABNORMALITIES HYPOKALEMIA	HYPOMAGNESEMIA	HYPOCALCEMIA	OTHERS	CARDIAC CONDITIONS	CARDIAC CONDITIONS ISCHEMIA	MYOCARDITIS	BRADYCARDIA	STRESS CMP	OTHERS	ENDOCRINE DISORDERS
193	1614889	M.K.	Y	Y	Y	-	Y	-	-	-	-	-	-	-	-
194	1609942	V.S.	Y	Y	Y	-	-	-	-	-	-	-	-	-	-
195	1582678	S.D.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
196	1614320	J.S.	Y	Y	-	-	-	1	-	-	-	-	-	-	-
197	1598436	S.	Y	Y	-	-	Y	1	-	-	-	-	-	-	-
198	257508	M.K.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
199	1616775	S.S.A	Y	Y	Y	-	Y	4	-	-	-	-	-	-	-
200	1616730	P.G.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
201	27962	A.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	N	-	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	Y	N	-	-	-	-	-	-	-	-	-	-	-
204	1438856	U.K.	Y	Y	-	-	Y	-	-	-	-	-	-	-	-
205	1616014	P.C.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
206	1612025	J.S.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
207	1612075	R.D.	Y	Y	Y	-	Y	2	Y	Y	-	-	-	-	-
208	735295	N.D.	-	Y	-	-	Y	-	-	-	-	-	-	-	-
209	1336159	B.S.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
210	1612065	H.S.	Y	Y	Y	-	-	-	Y	-	-	Y	-	-	-
211	180340	J.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
212	1388578	A.P.	Y	Y	-	-	-	-	Y	Y	-	-	-	-	-
213	869393	P.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	Y	Y	-	-	-	2	-	-	-	-	-	-	-
215	1616771	J.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
216	1604066	A.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	Y	Y	-	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
219	1507895	H.K.	Y	Y	-	Y	-	-	Y	Y	-	-	-	-	-
220	160969	B.S.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
221	1615282	M.S.	-	N	-	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	Y	Y	-	-	-	1	Y	Y	-	-	-	-	-
223	1604415	M.L.J	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
224	161199	A.L.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
225	1612797	V.B.	Y	Y	Y	-	-	2	-	-	-	-	-	-	-
226	1611113	P.S.	Y	Y	Y	-	-	-	Y	Y	-	-	-	-	-
227	1607769	S.S.	Y	Y	Y	-	Y	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	N	-	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
230	1489344	O.P.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
231	1610942	P.L.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
232	16009973	A.K.V	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
233	1468451	M.K.	Y	N	-	-	-	-	-	-	-	-	-	-	Y
234	1547415	B.S.G	-	N	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	-
236	1610801	B.S.	Y	Y	-	-	Y	-	Y	Y	-	-	-	-	Y
237	1570112	J.S.	Y	Y	Y	-	-	-	Y	Y	-	-	-	-	-
238	1613544	S.S.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
239	450989	C.L.	Y	Y	-	-	Y	-	Y	-	-	-	-	Y	-
240	1677376	R.K.N.	Y	Y	-	-	-	1	Y	Y	-	-	-	-	-
241	1698067	S.K.	Y	N	-	-	-	-	Y	Y	-	-	-	-	-
242	1696132	V.S.	Y	Y	-	Y	-	-	Y	Y	-	-	-	-	-
242	1648739	J.K.	Y	Y	-	Y	-	-	Y	Y	-	-	-	-	-
243	1632765	R.K.	Y	Y	-	Y	Y	-	-	-	-	-	-	-	-
244	1698359	B.D.	Y	Y	-	Y	-	-	-	-	-	-	-	-	Y

S No	MRD	NAME	ENDOCRINE DISORDERS HYPOTHYROIDISM	HYPER PTH	PHAEOCHROMOCYTOMA	HYPERALDOSTERONISM	OTHERS	INTRACRANIAL DISORDERS	INTRACRANIAL DISORDERS SAH	THALAMIC HEMATOMA	CVA	ENCEPHALITIS	HEAD INJURY	OTHERS	NUTRITIONAL DISORDERS	NUTRITIONAL DISORDERS ANOREXIA NERVOSA
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
194	1609942	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	-
200	1616730	P.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
201	27962	A.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
203	1611853	S.S	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
204	1438856	U.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
205	1616014	P.C.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
206	1612025	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
207	1612075	R.D.	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	Y	-
210	1612065	H.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
211	180340	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
212	1388578	A.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
213	869393	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-
215	1616771	J.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
216	1604066	A.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
217	1284195	K.K.G.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
218	1516533	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
222	1614287	S.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
223	1604415	M.L.J	-	-	-	-	-	Y	-	-	Y	-	-	-	-	-
224	161199	A.L.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
225	1612797	V.B.	-	-	-	-	-	Y	-	-	-	Y	-	-	-	-
226	1611113	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
227	1607769	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
228	1612850	V.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
229	145532	J.N.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-
230	1489344	O.P.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
231	1610942	P.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
232	16009973	A.K.V	-	-	-	-	-	-	-	-	-	-	-	-	-	-
233	1468451	M.K.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-
235	476777	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
236	1610801	B.S.	Y	-	-	-	-	-	-	-	-	-	-	-	-	-
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
239	450989	C.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
240	1677376	R.K.N.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
241	1698067	S.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
243	1632765	R.K.	-	-	-	-	-	Y	-	-	Y	-	-	-	Y	-
244	1698359	B.D.	Y	-	-	-	-	-	-	-	-	-	-	-	Y	-

S No	MRD	NAME	STARVATION	LIQUID PROTEIN DIET	H/O GI SURGERY	CELIAC DISEASE	OTHERS	HYPOTHERMIA	OTHERS	ECG RATE	RHYTHM_SINUS	AT	AF	AFL	APC	VPC	NSVT	VT	PSVT	OTHER	QRS DURATION	QTC INTERVAL	QTC INTERVAL GROUP	QTC INTERVAL GP
193	1614889	M.K.	-	Y	Y	-	-	-	-	132	Y	-	-	-	-	-	-	-	-	-	60	465	1	0
194	1609942	V.S.	-	Y	Y	-	-	-	-	140	Y	-	-	-	-	-	-	-	-	-	72	537	1	1
195	1582678	S.D.	-	Y	Y	-	-	-	-	107	Y	-	-	-	-	-	-	-	-	-	98	461	1	0
196	1614320	J.S.	-	-	-	-	-	-	-	85	Y	-	-	-	-	-	-	-	-	-	86	478	1	0
197	1598436	S.	-	Y	Y	-	-	Y	-	142	Y	-	-	-	-	-	-	-	-	-	74	556	1	1
198	257508	M.K.	-	-	Y	-	-	-	-	97	Y	-	-	-	-	-	-	-	-	-	80	467	1	0
199	1616775	S.S.A	-	-	-	-	-	-	-	96	Y	-	-	-	-	-	-	-	-	-	94	497	1	0
200	1616730	P.G.	-	-	-	-	-	-	-	101	Y	-	-	-	-	-	-	-	-	-	86	518	1	1
201	27962	A.S.	-	-	-	-	-	-	-	101	Y	-	-	-	-	-	-	-	-	-	102	450	1	0
202	1451743	H.S.M.	-	-	-	-	-	-	-	93	Y	-	-	-	-	-	-	-	-	-	84	462	1	0
203	1611853	S.S	-	-	Y	-	-	-	-	130	Y	-	-	-	-	-	-	-	-	-	96	506	1	1
204	1438856	U.K.	-	-	-	-	-	-	-	86	Y	-	-	-	-	-	-	-	-	-	92	504	1	1
205	1616014	P.C.	-	-	-	-	-	-	-	96	Y	-	-	-	-	-	-	-	-	-	120	507	1	1
206	1612025	J.S.	-	-	-	-	-	-	-	104	Y	-	-	-	-	Y	-	-	-	-	100	474	1	0
207	1612075	R.D.	-	-	-	-	-	-	-	99	Y	-	-	-	-	-	-	-	-	-	76	462	1	0
208	735295	N.D.	-	-	-	-	-	-	-	153	Y	-	-	-	-	-	-	-	-	-	116	520	1	1
209	1336159	B.S.	-	-	Y	-	-	-	-	88	Y	-	-	-	-	-	-	-	-	-	78	446	0	0
210	1612065	H.S.	-	-	-	-	-	-	-	57	Y	-	-	-	-	-	-	-	-	Y - JUNCTIONAL BRADYCARDIA	104	468	1	0
211	180340	J.K.	-	-	-	-	-	-	-	127	Y	-	-	-	-	-	-	-	-	-	118	459	0	0
212	1388578	A.P.	-	-	-	-	-	-	-	104	Y	-	-	-	-	-	-	-	-	-	90	449	0	0
213	869393	P.S.	-	-	-	-	-	-	-	94	Y	-	-	-	-	-	-	-	-	-	116	518	1	1
214	58356	S.R.J	-	-	-	-	-	-	-	88	Y	-	-	-	-	-	-	-	-	-	88	464	1	0
215	1616771	J.	-	-	-	-	-	-	-	119	Y	-	-	-	-	-	-	-	-	-	98	489	1	0
216	1604066	A.K.	-	-	-	-	-	-	-	66	Y	-	-	-	-	-	-	-	-	-	114	547	1	1
217	1284195	K.K.G.	-	-	-	-	-	-	-	68	Y	-	-	-	-	-	-	-	-	-	100	495	1	0
218	1516533	R.K.	-	-	-	-	-	-	-	85	Y	-	Y	-	-	-	-	-	-	-	84	454	1	0
219	1507895	H.K.	-	-	-	-	-	-	-	109	Y	-	-	-	-	-	-	-	-	-	98	487	1	0
220	160969	B.S.	-	-	-	-	-	-	-	72	Y	-	-	-	-	-	-	-	-	-	94	442	0	0
221	1615282	M.S.	-	-	-	-	-	-	-	100	Y	-	-	-	-	-	-	-	-	-	90	451	1	0
222	1614287	S.L.	-	-	-	-	-	-	-	155	Y	-	-	-	-	-	-	-	-	-	62	514	1	1
223	1604415	M.L.J	-	-	-	-	-	-	-	77	Y	-	Y	-	-	-	-	-	-	-	84	495	1	0
224	161199	A.L.K.	-	-	-	-	-	-	-	80	Y	-	-	-	-	-	-	-	-	-	120	487	1	0
225	1612797	V.B.	-	-	-	-	-	-	-	102	Y	-	-	-	-	-	-	-	-	-	94	471	1	0
226	1611113	P.S.	-	-	-	-	-	-	-	107	Y	-	-	-	-	-	-	-	-	-	120	457	1	0
227	1607769	S.S.	-	-	-	-	-	-	-	90	Y	-	-	-	-	-	-	-	-	-	96	563	1	1
228	1612850	V.K.	-	-	-	-	-	-	-	115	Y	-	-	-	-	-	-	-	-	-	84	475	1	0
229	145532	J.N.S	-	-	-	-	-	-	-	80	Y	-	-	-	-	-	-	-	-	-	108	519	1	1
230	1489344	O.P.	-	-	-	-	-	-	-	102	Y	-	-	-	-	-	-	-	-	-	78	516	1	1
231	1610942	P.L.	-	-	-	-	-	-	-	85	Y	-	-	-	-	-	-	-	-	-	112	476	1	0
232	16009973	A.K.V	-	-	-	-	-	-	-	106	Y	-	-	-	-	-	-	-	-	-	72	464	1	0
233	1468451	M.K.	-	-	-	-	-	-	-	85	Y	-	-	-	-	-	-	-	-	-	82	525	1	1
234	1547415	B.S.G	-	-	-	-	-	-	-	110	Y	-	-	-	-	-	-	-	-	-	120	523	1	1
235	476777	G.S.	-	-	-	-	-	-	-	133	Y	-	Y	-	-	-	-	-	-	-	120	502	1	1
236	1610801	B.S.	-	-	-	-	-	-	-	76	Y	-	-	-	-	-	-	-	-	-	91	480	1	0
237	1570112	J.S.	-	-	-	-	-	-	-	83	Y	-	-	-	-	-	-	-	-	-	80	547	1	1
238	1613544	S.S.	-	-	-	-	-	-	-	94	Y	-	-	-	-	-	-	-	-	-	102	485	1	0
239	450989	C.L.	-	-	-	-	-	-	-	108	Y	-	-	-	-	-	-	-	-	-	120	525	1	1
240	1677376	R.K.N.	-	-	-	-	-	-	-	121	Y	-	-	-	-	-	-	-	-	-	84	497	1	0
241	1698067	S.K.	-	-	-	-	-	-	-	103	Y	-	-	-	-	-	-	-	-	-	118	463	1	0
242	1696132	V.S.	-	-	-	-	-	-	-	41	Y	-	-	-	-	-	-	-	-	-	116	551	1	1
242	1648739	J.K.	-	-	-	-	-	-	-	97	Y	-	-	-	-	-	-	-	-	-	110	535	1	1
243	1632765	R.K.	-	Y	-	-	-	-	-	64	Y	-	-	-	-	Y	-	-	-	-	120	544	1	1
244	1698359	B.D.	-	-	Y	-	-	-	-	61	Y	-	-	-	-	-	-	-	-	Y - JUNCTIONAL BRADYCARDIA	78	384	0	0

S No	MRD	NAME	BROAD BASE T WAVE	NOTCHED T WAVE	LONG ISOELEC SEG & NARROW BASE T WAVE	T ALTERNANS	U WAVE	AV BLOCK	ST ELEVATION	ST DEPRESSION	TORSADES	LVH	RVH	POOR R PROGRESSION	BRUGADA	EPSILON WAVE	EARLY REPOLARISATION	OTHERS	RBS
193	1614889	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	174
194	1609942	V.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78
195	1582678	S.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	183
196	1614320	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	75
197	1598436	S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71
198	257508	M.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	126
199	1616775	S.S.A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	154
200	1616730	P.G.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	162
201	27962	A.S.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	103
202	1451743	H.S.M.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	90
203	1611853	S.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	190
204	1438856	U.K.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	161
205	1616014	P.C.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	172
206	1612025	J.S.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	79
207	1612075	R.D.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	164
208	735295	N.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	245
209	1336159	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	170
210	1612065	H.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84
211	180340	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	230
212	1388578	A.P.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	172
213	869393	P.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	126
214	58356	S.R.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	274
215	1616771	J.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	332
216	1604066	A.K.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	167
217	1284195	K.K.G.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	102
218	1516533	R.K.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	97
219	1507895	H.K.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	200
220	160969	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	204
221	1615282	M.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168
222	1614287	S.L.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	154
223	1604415	M.L.J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145
224	161199	A.L.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	174
225	1612797	V.B.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180
226	1611113	P.S.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	157
227	1607769	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50
228	1612850	V.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	195
229	145532	J.N.S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98
230	1489344	O.P.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	116
231	1610942	P.L.	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	298
232	16009973	A.K.V	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	-	97
233	1468451	M.K.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	27
234	1547415	B.S.G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124
235	476777	G.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	131
236	1610801	B.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	160
237	1570112	J.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122
238	1613544	S.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150
239	450989	C.L.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	123
240	1677376	R.K.N.	-	-	-	-	-	-	Y	-	-	-	-	Y	-	-	-	-	140
241	1698067	S.K.	-	-	-	-	-	-	-	Y	-	-	-	-	-	-	-	-	110
242	1696132	V.S.	Y	-	-	-	-	Y	Y	-	-	-	-	-	-	-	-	-	501
242	1648739	J.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140
243	1632765	R.K.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	68
244	1698359	B.D.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120

S No	MRD	NAME	HB	TLC	PLATELET	PH	PCO2	PO2	HCO3	SO2	LACTATE	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB	PH	HCO3	K	CA	MG	PO4	NA	UREA	CREATININE	BIL	SGOT	SGPT	ALP	TSP	ALB
193	1614889	M.K.	6.3	19.7	166	7.41	28	110	17.7	98	3.7	3.6	7.4	2.2	3.9	137	22	0.94	0.67	48	35	45	3.8	2.27	2	1	2	1	2	2	2	2	2	3	2	2	1	1
194	1609942	V.S.	9.6	32	489	7.41	50	20	31.7	33	1.9	4.05	9	2.8	3.2	136	14	0.7	1.54	49	60	277	7.2	3.29	2	3	2	2	3	2	2	2	2	3	3	3	3	2	1
195	1582678	S.D.	13.1	15.9	347	7.31	34	93	17.1	96	6.1	4.85	8.5	2.4	3.5	128	13	0.3	5.6	173	88	141	7.6	3.37	1	1	2	1	2	2	1	2	1	3	3	3	3	2	1
196	1614320	J.S.	12.2	15.71	198	7.55	43	104	37.6	99	3	6.5	8.9	2.4	3.6	140	34	1.12	0.81	133	80	62	5.6	3.48	3	3	3	2	2	2	2	2	2	3	3	2	1	1
197	1598436	S.	15	17.8	235	7.33	39	21	19	30	6.4	5.5	7.9	2.6	4	138	13	0.8	1.7	386	119	225	8.4	4.8	1	1	3	1	2	2	2	2	2	3	3	3	3	2	2
198	257508	M.K.	11.9	17.8	505	7.46	33	82	23.5	97	1.9	4.1	5.9	2.2	2.8	129	75	1.2	0.6	31	33	139	7.2	3.2	3	2	2	1	2	2	1	3	3	2	2	2	3	2	1
199	1616775	S.S.A	12	9.3	98	7.51	51	86	40.7	97	1.7	3.4	7.5	2	4.8	154	58	0.8	4	368	188	119	5.6	3	3	3	1	1	2	3	3	3	2	3	3	3	2	1	1
200	1616730	P.G.	7.4	6.6	120	7.45	38	98	21.9	95	1.2	4.7	8	1.8	3.4	131	42	0.8	2.9	236	302	36	7.2	4.1	3	1	2	1	2	2	1	2	2	3	3	3	1	2	2
201	27962	A.S.	7.5	7.59	110	7.42	36	96	23.4	98	1.3	4.3	8.9	2.56	3.7	125	39	0.92	7.7	92	42	116	6.2	2.37	2	2	2	2	2	2	1	2	2	3	3	3	2	1	1
202	1451743	H.S.M.	11.5	14.4	242	7.37	35	73	20.2	94	2.7	4.8	9.36	2.7	3.9	133	69	2.43	0.7	32	17	94	6.8	3.23	2	1	2	2	2	2	1	3	3	2	2	2	2	2	1
203	1611853	S.S	7.6	21.9	150	7.38	32	105	18.9	98	3.7	4	9.1	2.6	4.3	139	94	1.13	0.8	49	38	68	6.4	3.28	2	1	2	2	2	2	2	3	2	2	3	2	2	1	1
204	1438856	U.K.	8.6	9.9	118	7.44	22	108	14.9	98	4.3	4.6	8.2	2	3.6	121	66	2.15	11.56	88	4.6	95	6.3	2.87	2	1	2	1	2	2	1	3	3	3	3	2	2	1	1
205	1616014	P.C.	11.5	10	154	7.45	46	98	22.3	92	1.4	4.4	8.9	2	3.9	134	45	1.7	1.6	96	43	109	6.7	3.4	3	2	2	2	2	2	1	2	3	3	3	3	2	2	1
206	1612025	J.S.	12.4	10.4	434	7.42	36	98	21	95	0.4	4.3	9.2	2.6	4	132	34	1	0.9	51	22	115	7.2	4.1	2	1	2	2	2	2	1	2	2	2	3	2	2	2	2
207	1612075	R.D.	9.7	8.8	90	7.48	34	72	25.3	95	0.6	3	7.9	2.3	3.3	116	18	0.6	0.3	24	15	136	5.4	3.31	3	2	1	1	2	2	1	2	1	2	2	2	3	1	1
208	735295	N.D.	11.5	13.4	194	7.28	49	52	23	81	3.4	4	8.2	2.5	3.4	136	47	1.7	0.87	48	56	87	6.5	3.2	1	2	2	1	2	2	2	2	3	2	3	3	2	1	1
209	1336159	B.S.	13.1	14.1	120	7.41	42	83	26.6	96	1.3	4	8.9	2.56	2.8	138	44	1.3	0.6	21	16	73	7.2	5.2	2	3	2	2	2	2	2	2	3	2	2	2	2	2	3
210	1612065	H.S.	8.6	8.2	150	7.53	24	79	20.1	97	1.1	2.9	9.5	2.5	4.1	141	27	0.6	0.7	32	24	80	7	3.6	3	1	1	2	2	2	2	2	1	2	2	2	2	2	2
211	180340	J.K.	15.9	18.7	338	7.4	32	88	19.8	97	2.1	4.3	9.1	2.7	3.9	135	39	1	0.5	20	13	163	7.5	4.1	2	1	2	2	2	2	2	2	2	2	2	2	3	2	2
212	1388578	A.P.	18.1	6.7	116	7.42	25	89	22	96	1.8	3.5	8.9	2.1	2.7	138	13	0.7	0.7	48	59	75	6.7	3.9	2	2	2	2	2	2	2	2	2	2	3	3	2	2	2
213	869393	P.S.	13	15	232	7.37	40	89	23	96	1.8	4.1	8.7	2.6	4	130	23	0.7	0.78	36	23	78	6.6	3.4	2	2	2	2	2	2	1	2	2	2	2	2	2	2	1
214	58356	S.R.J	10.5	10.6	238	7.35	33	101	25.7	98	0.7	4.9	8.7	2.5	3.6	127	46	1.2	0.9	45	32	109	7.2	3.4	2	2	2	2	2	2	1	2	3	2	3	2	2	2	1
215	1616771	J.	8.6	11.8	210	7.32	38	121	20.3	98	3.4	5.1	8.9	2.9	3.4	132	50	1.7	0.8	49	38	98	6.4	3.3	1	1	3	2	3	2	1	3	3	2	3	2	2	1	1
216	1604066	A.K.	13.1	16.3	214	7.34	37	94	21	96	1.4	3.6	9.9	2.8	2.2	131	86	1.4	1.52	23	11	85	6.5	3.23	1	1	2	2	3	1	1	3	3	3	2	2	2	1	1
217	1284195	K.K.G.	10.3	3.5	108	7.29	47	89	18	93	2.3	4	9.2	2.8	6	136	51	4.6	0.9	46	56	72	6.8	3.2	1	1	2	2	3	3	2	3	3	2	3	3	2	2	1
218	1516533	R.K.	13.5	4.7	256	7.38	42	98	21.3	94	0.6	4.2	8.9	2	4.2	138	31	0.8	0.2	88	30	67	6.1	3.8	2	1	2	2	2	2	2	2	2	2	3	2	2	1	2
219	1507895	H.K.	11.5	6.3	183	7.41	44	85	23	96	1.2	4.1	9.8	1.6	4.8	138	26	0.7	0.39	38	22	70	6.6	4	2	2	2	2	1	3	2	2	2	2	2	2	2	2	2
220	160969	B.S.	14.1	9.2	200	7.39	45	96	21	92	1.3	4.6	8.8	2.8	4.5	136	30	1	0.6	21	29	60	7.2	4.4	2	1	2	2	3	3	2	2	2	2	2	2	2	2	2
221	1615282	M.S.	12.3	6.7	202	7.42	39	124	21.6	96	1.5	4	9.4	2.5	3.6	138	28	0.8	0.2	19	22	75	6.5	4.2	2	1	2	2	2	2	2	2	2	2	2	2	2	1	2
222	1614287	S.L.	9.7	14.5	150	7.36	37	345	20.9	100	2.9	7.1	9.2	2.3	6.3	146	119	6.1	1.9	4231	2026	940	5.6	3	2	1	3	2	2	3	3	3	3	3	3	3	3	3	1	1
223	1604415	M.L.J	16.9	18	702	7.39	46	174	27.8	100	1.7	3.8	8.3	2	3.6	134	54	1.3	0.4	20	14	103	7	4	2	3	2	1	2	2	1	3	3	2	2	2	2	2	2
224	161199	A.L.K.	12.9	8.2	270	7.36	43	87	25	95	1	5.1	9.2	2.57	4.8	138	21	0.8	0.5	53	29	61	6.5	3.8	2	2	3	2	2	3	2	2	2	3	2	2	1	2
225	1612797	V.B.	11.3	25	203	7.42	33	75	21.4	95	2.3	3	9.1	2.5	4.2	133	35	0.8	0.78	22	16	67	7.2	3.7	2	1	1	2	2	2	1	2	2	2	2	2	2	2	2
226	1611113	P.S.	6.1	18.9	272	7.47	36	97	22.4	96	1.8	4.1	8.9	2.5	3.6	134	67	1.3	0.8	109	92	102	7	4.1	3	2	2	2	2	2	1	3	3	2	3	3	2	2	2
227	1607769	S.S.	10.7	13.1	78	7.53	32	319	26.7	100	3.5	2.7	7.8	2.3	2.2	134	68	1	1.1	148	85	143	5	1.98	3	3	1	1	2	1	1	3	2	2	3	3	3	1	1
228	1612850	V.K.	14.6	8.6	207	7.44	34	96	23.7	100	1	4.5	9.8	2.6	4.2	142	50	1.3	1.2	115	62	60	6.8	3.6	2	2	2	2	2	2	2	3	3	3	3	3	2	2	2
229	145532	J.N.S	11.2	5	140	7.4	36	88	24	100	1.2	5.4	9.8	2	3.4	133	58	1.1	0.5	39	57	150	7	3.9	2	2	3	2	2	2	1	3	2	2	2	3	3	2	2
230	1489344	O.P.	13.4	10.3	416	7.48	30	96	22.3	98	1	4.5	9.6	2	3.3	138	38	0.9	0.7	15	17	87	7.5	4	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2
231	1610942	P.L.	13.1	24.3	165	7.45	27	122	22	99	0.4	4.7	9.5	2.3	3.5	143	45	1.1	1.15	31	36	69	5.3	3.45	3	2	2	2	2	2	2	2	2	2	2	2	2	1	1
232	16009973	A.K.V	15	9.3	180	7.39	41	98	21.7	100	1.3	3.7	9.9	2.4	3.9	138	22	0.6	0.52	157	149	119	7.4	4	2	1	2	2	2	2	2	2	1	2	3	3	2	2	2
233	1468451	M.K.	10.6	4.2	80	7.42	45	107	26	100	1	3.8	9	2.7	5	127	53	1.2	0.8	20	45	122	7	3.8	2	3	2	2	2	3	1	3	3	2	2	3	2	2	2
234	1547415	B.S.G	13.7	7.9	219	7.35	46	86	22	95	1.8	4.5	9.4	2.4	3.5	132	42	1.5	0.7	26	37	104	7.2	4.1	2	2	2	2	2	2	1	2	3	2	2	2	2	2	2
235	476777	G.S.	14.2	13.6	284	7.38	44	93	26	97	2.1	4.6	8.1	2.1	4.9	139	56	1.3	0.66	114	36	75	5.7	3.12	2	3	2	1	2	3	2	3	3	2	3	2	2	1	1
236	1610801	B.S.	7.3	16.2	256	7.47	22	75	16	96	1.2	5.2	7.8	2.1	6.1	131	162	7.4	0.3	122	40	114	6.6	2.9	3	1	3	1	2	3	1	3	3	2	3	2	2	2	1
237	1570112	J.S.	12.7	5.9	297	7.54	35	89	30	98	1.5	3.2	8.9	2.7	3.6	128	27	0.6	0.6	33	23	60	7.1	3	3	3	1	2	2	2	1	2	1	2	2	2	2	2	1
238	1613544	S.S.	13.9	7.3	271	7.45	38	90	23	100	1.2	3.6	9.2	2.5	3.9	127	18	0.8	0.9	45	47	89	6.8	3.2	3	2	2	2	2	2	1	2	2	2	3	3	2	2	1
239	450989	C.L.	12.8	7.7	243	7.46	31	313	22	100	1	4.2	4.18	2	4.1	139	35	1.1	0.9	19	19	56	6.6	3.8	3	2	2	1	2	2	2	2	2	2	2	2	2	2	2
240	1677376	R.K.N.	9.5	8.2	379	7.27	54	204	24.8	100	6.3	5.5	8.8	2.2	4.5	139	75	1.3	0.3	43	24	100	6.1	3.4	1	2	3	2	2	3	2	3	3	2	3	2	2	1	1
241	1698067	S.K.	12	4.9	403	7.35	46	92	24	93	1.8	4.3	9.2	2.3	3.8	135	40	1	0.4	42	21	98	7	3.5	2	2	2	2	2	2	2	2	2	2	3	2	2	2	2	2
242	1696132	V.S.	11.2	13	210	7.36	34	63	19	91	4.4	4.3	8.8	1.8	3.6	127	62	1.6	2	168	78	141	6.1	3.8	2	1	2	2	2	2	1	3	3	3	3	3	3	1	2
242	1648739	J.K.	13.7	14	178	7.34	32	98	21.7	92	0.8	4.5	9.5	1.7	3.6	141	29	0.6	0.2	123	2.6	144	6.9	4.4	1	1	2	2	2	2	2	2	1	2	3	2	3	2	2
243	1632765	R.K.	10.7	13.2	368	7.4	42	88	22.3	95	1.3	3.8	8.6	1.6	2.1	135	60	0.9	0.6	25	16	93	8.1	3.5	2	2	2	2	1	1	2	3	2	2	2	2	2	2	2
244	1698359	B.D.	11.5	5.5	80	7.45	33	86	23	97	0.6	3.9	10.3	1.8	3.8	141	28	0.5	0.9	19	14	140	7.5	4.2	3	2	2	3	2	2	2	2	1	2	2	2	3	2	2

S No	MRD	NAME	BLOOD CULTURE	LVEF	SPECIFIC TREATEMENT GIVEN FOR PROLONGED QTC T/T OF REVERSIBLE CAUSE	BETA BLOCKER	IV MGSO4	ISOPROTERENOL	IV XYLOCAINE	MEXILETINE	SYMPATHETIC DENERVATION	OVERDRIVE PACING	AICD	OTHERS	OUTCOMES OF TREATMENT SPECIFIC TO PROLONGED QTC BENEFIT ACHIEVED
193	1614889	M.K.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
194	1609942	V.S.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
195	1582678	S.D.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
196	1614320	J.S.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
197	1598436	S.	E.COLI	60	Y	Y	Y	-	-	-	-	-	-	-	Y
198	257508	M.K.	-	42	Y	-	Y	-	-	-	-	-	-	-	-
199	1616775	S.S.A	-	60	Y	-	-	-	-	-	-	-	-	-	Y
200	1616730	P.G.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
201	27962	A.S.	ACINETOBACTER	60	Y	-	-	-	-	-	-	-	-	-	-
202	1451743	H.S.M.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
203	1611853	S.S	CANDIDA	60	Y	-	-	-	-	-	-	-	-	-	Y
204	1438856	U.K.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
205	1616014	P.C.	-	60	Y	Y	Y	-	-	-	-	-	-	-	Y
206	1612025	J.S.	-	38	Y	-	Y	-	-	-	-	-	-	-	Y
207	1612075	R.D.	-	60	Y	Y	Y	-	-	-	-	-	-	-	-
208	735295	N.D.	-	15	Y	-	-	-	-	-	-	-	-	-	-
209	1336159	B.S.	-	45	Y	-	Y	-	-	-	-	-	-	-	Y
210	1612065	H.S.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
211	180340	J.K.	-	20	Y	-	Y	-	-	-	-	-	-	-	Y
212	1388578	A.P.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
213	869393	P.S.	-	60	Y	-	-	-	Y	-	-	-	Y	-	Y
214	58356	S.R.J	-	30	Y	-	-	-	-	-	-	-	-	-	Y
215	1616771	J.	-	25	Y	-	-	-	-	-	-	-	-	-	Y
216	1604066	A.K.	-	16	Y	-	Y	-	-	-	-	-	-	-	Y
217	1284195	K.K.G.	-	28	Y	Y	-	-	-	-	-	-	-	-	Y
218	1516533	R.K.	-	35	Y	Y	Y	-	-	-	-	-	-	-	-
219	1507895	H.K.	-	22	Y	Y	-	-	-	-	-	-	-	-	Y
220	160969	B.S.	-	48	Y	Y	-	-	-	-	-	-	-	-	Y
221	1615282	M.S.	-	60	Y	Y	-	-	-	-	-	-	-	-	Y
222	1614287	S.L.	-	28	Y	-	Y	-	Y	Y	-	-	-	-	Y
223	1604415	M.L.J	-	55	Y	Y	Y	-	-	-	-	-	-	-	Y
224	161199	A.L.K.	-	32	Y	-	Y	-	-	-	-	-	-	-	Y
225	1612797	V.B.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
226	1611113	P.S.	-	16	Y	-	Y	-	-	-	-	-	-	-	Y
227	1607769	S.S.	MRSA	60	Y	-	Y	-	-	-	-	-	-	-	Y
228	1612850	V.K.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
229	145532	J.N.S	-	22	Y	-	-	-	-	-	-	-	-	-	-
230	1489344	O.P.	-	35	Y	Y	Y	-	-	Y	-	-	-	-	-
231	1610942	P.L.	-	60	Y	-	Y	-	-	-	-	Y	-	-	-
232	16009973	A.K.V	-	44	Y	Y	-	-	-	-	-	-	-	-	Y
233	1468451	M.K.	-	60	Y	-	-	-	-	-	-	-	-	-	Y
234	1547415	B.S.G	-	24	Y	-	Y	-	-	-	-	-	Y	-	Y
235	476777	G.S.	-	18	Y	-	Y	-	-	-	-	-	-	-	Y
236	1610801	B.S.	-	26	Y	-	Y	-	-	-	-	-	-	-	Y
237	1570112	J.S.	-	38	Y	Y	-	-	-	-	-	-	-	-	Y
238	1613544	S.S.	-	34	Y	-	Y	-	-	-	-	-	-	-	-
239	450989	C.L.	-	20	Y	-	Y	-	Y	-	-	-	-	Y	-
240	1677376	R.K.N.	-	25	Y	-	Y	-	-	-	-	-	-	-	Y
241	1698067	S.K.	-	45	-	-	-	-	-	-	-	-	-	-	-
242	1696132	V.S.	-	44	Y	-	Y	-	-	-	-	Y	-	-	Y
242	1648739	J.K.	-	30	-	Y	Y	-	-	-	-	-	-	-	Y
243	1632765	R.K.	-	35	Y	-	Y	-	-	-	-	-	-	-	Y
244	1698359	B.D.	-	60	Y	-	Y	-	-	-	-	Y	-	-	Y

S No	MRD	NAME	QTC SHORTENED	SYNCOPE CONTROLLED	SEIZURE CONTROLLED	ARRYTHMIA CONTROLLED	DURATION OF ICU STAY	NO OF VT EPISODES	QTC UNCHANGED	QTC SHORTENED BY	QTC PROLONGED BY	-	-	-	DISCHARGED	DEATH	TREATMENT COMPLICATION
193	1614889	M.K.	Y	-	-	-	14	-	N	7	-	458	458	1	Y	N	-
194	1609942	V.S.	Y	-	-	-	17	-	N	207	-	330	330	0	N	Y	-
195	1582678	S.D.	Y	-	-	-	18	-	N	23	-	438	438	0	Y	N	-
196	1614320	J.S.	Y	-	-	-	15	-	N	24	-	454	454	1	Y	N	-
197	1598436	S.	Y	-	-	-	42	-	N	106	-	450	450	1	N	Y	-
198	257508	M.K.	-	-	-	-	8	-	N	-	64	467	531	1	Y	N	-
199	1616775	S.S.A	Y	-	-	-	13	-	N	14	-	483	483	1	Y	N	-
200	1616730	P.G.	Y	-	-	-	9	-	N	17	-	501	501	1	Y	N	-
201	27962	A.S.	-	-	-	-	12	-	N	-	104	450	554	1	Y	N	-
202	1451743	H.S.M.	Y	-	-	-	7	-	N	10	-	452	452	1	N	Y	-
203	1611853	S.S	Y	-	-	-	17	-	N	16	-	490	490	1	Y	N	-
204	1438856	U.K.	Y	-	-	-	8	-	N	31	-	473	473	1	Y	N	-
205	1616014	P.C.	Y	-	-	-	15	-	N	20	-	487	487	1	Y	N	-
206	1612025	J.S.	Y	-	-	-	2	-	N	34	-	440	440	0	Y	N	-
207	1612075	R.D.	-	-	-	-	3	-	N	-	58	462	520	1	Y	N	-
208	735295	N.D.	-	-	-	-	3	-	N	-	133	520	653	1	Y	N	-
209	1336159	B.S.	Y	-	-	-	2	-	N	11	-	435	435	0	Y	N	-
210	1612065	H.S.	Y	-	-	-	11	-	N	19	-	449	449	0	Y	N	-
211	180340	J.K.	Y	-	-	-	13	-	N	2	-	457	457	1	Y	N	-
212	1388578	A.P.	Y	Y	Y	-	3	-	N	8	-	441	441	0	Y	N	-
213	869393	P.S.	Y	-	-	-	2	1	N	14	-	504	504	1	Y	N	-
214	58356	S.R.J	Y	-	-	-	4	-	N	21	-	443	443	0	Y	N	-
215	1616771	J.	Y	-	-	-	7	-	N	11	-	478	478	1	Y	N	-
216	1604066	A.K.	Y	-	-	-	5	-	N	102	-	445	445	0	Y	N	-
217	1284195	K.K.G.	Y	-	-	-	2	-	N	36	-	459	459	1	Y	N	-
218	1516533	R.K.	-	-	-	-	7	-	N	-	17	454	471	1	Y	N	-
219	1507895	H.K.	Y	-	-	-	8	-	N	38	-	449	449	0	Y	N	-
220	160969	B.S.	Y	-	-	-	7	-	N	29	-	413	413	0	Y	N	-
221	1615282	M.S.	Y	-	-	-	6	-	N	20	-	431	431	0	Y	N	-
222	1614287	S.L.	Y	-	-	-	14	-	N	9	-	505	505	1	N	Y	-
223	1604415	M.L.J	Y	-	-	-	4	-	N	90	-	405	405	0	Y	N	-
224	161199	A.L.K.	Y	-	-	-	2	-	N	32	-	455	455	1	Y	N	-
225	1612797	V.B.	Y	-	-	-	5	-	N	19	-	452	452	1	Y	N	-
226	1611113	P.S.	Y	-	-	-	2	-	N	11	-	446	446	0	N	Y	-
227	1607769	S.S.	Y	-	-	-	12	-	N	47	-	516	516	1	Y	N	-
228	1612850	V.K.	Y	-	-	-	4	-	N	32	-	443	443	0	Y	N	-
229	145532	J.N.S	-	-	-	-	3	-	N	-	6	519	525	1	Y	N	-
230	1489344	O.P.	-	-	-	-	8	-	N	-	37	516	553	1	Y	N	-
231	1610942	P.L.	-	-	-	Y	4	-	N	-	32	476	508	1	Y	N	-
232	16009973	A.K.V	Y	-	-	-	6	-	N	32	-	432	432	0	Y	N	-
233	1468451	M.K.	Y	-	-	-	2	-	N	71	-	454	454	1	Y	N	-
234	1547415	B.S.G	Y	-	-	-	7	-	N	52	-	471	471	1	Y	N	-
235	476777	G.S.	Y	-	-	-	4	-	N	24	-	478	478	1	Y	N	-
236	1610801	B.S.	Y	-	-	-	9	-	N	19	-	461	461	1	Y	N	-
237	1570112	J.S.	Y	-	-	-	4	-	N	68	-	479	479	1	Y	N	-
238	1613544	S.S.	-	-	-	-	2	-	N	-	4	485	489	1	Y	N	-
239	450989	C.L.	-	-	-	-	7	2	Y	-	-	525	525	1	Y	N	-
240	1677376	R.K.N.	Y	-	-	-	8	1	N	28	-	469	469	1	Y	N	-
241	1698067	S.K.	-	-	-	-	3	-	N	-	-	463	463	1	N	N	-
242	1696132	V.S.	-	-	-	Y	11	-	N	-	32	551	583	1	Y	N	-
242	1648739	J.K.	Y	-	-	-	4	-	N	14	-	521	521	1	Y	N	-
243	1632765	R.K.	Y	-	-	-	7	-	N	61	-	483	483	1	Y	N	-
244	1698359	B.D.	-	-	-	Y	8	-	N	-	60	384	444	0	Y	N	-

Baba Farid University
of Health Sciences
Sadiq Road
Faridkot-151 203 (Pb). INDIA.
Phone : 01639-256232,256236
Tele/Fax : 01639-256235
Email – Thesisbfuhs@gmail.com

(76)

No. BFUHS/2K23p-TH/ 66 **Date** 1/1/24

The Principal
Dayanand Medical College & Hospital
Ludhiana

Subject:: Approval of Plan of Thesis.

This is to inform you that the Faculty of Medical Sciences in its meeting held on 25.09.2023 has approved the plan of thesis of **Keshav Sachdeva**, a student of your college for **DM Cardiology** along with the names of Supervisor/Co-Supervisor as under:-

Topic Plan of Thesis
Prevelance, clinical profile, and in-hospital outcomes in icu patients with prolonged qtc .

Supervisor	**Co-Supervisor:-**	**Co-Supervisor:-**
Dr. Naved Aslam	Dr. Abhishek Goyal	Dr. Parshotam Lal Gautam,
Professor	Assoc. Professor	Prof. & Head,
Dept. of Cardiology	Dept. of Cardiology,	Dept. of Critical Care Medicne

The student may submit the thesis in triplicate alongwith the plan in triplicate also, to the Controller of Examinations, BFUHS, Faridkot, at least six months before the commencement of theory examination, if he/she is otherwise eligible to take the examination. He /She may be directed to attach a photocopy of this letter with the forwarding letter while submitting thesis in the University along with the letter of approval of University for change of supervisor/Co-Supervisor, change of topic, if any.

Controller of Examinations

Note :

1. *If any discrepancy found regarding topic of thesis or Supervisor/Co-Supervisor, inform undersigned within one month after issue of this letter.*

PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc

THESIS PROPOSAL

FOR APPROVAL OF SUBJECT OF THESIS TO BE SUBMITTED

IN PARTIAL FULFILMENT OF THE REQUIREMENTS

FOR THE DEGREE OF

DOCTORATE OF MEDICINE

IN

CARDIOLOGY

OF THE

BABA FARID UNIVERSITY OF HEALTH SCIENCES
FARIDKOT

OCTOBER, 2022

DR. KESHAV SACHDEVA

DEPARTMENT OF CARDIOLOGY
DAYANAND MEDICAL COLLEGE & HOSPITAL
LUDHIANA

ABSTRACT OF PLAN OF THESIS

Title	PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc
For the degree of	DM CARDIOLOGY
Name of the candidate	Dr. Keshav Sachdeva
Supervisor	Dr. Naved Aslam, Professor, Department of Cardiology, Dmch Ludhiana.
Co-supervisors	Dr. Abhishek Goyal, Associate Professor, Department of Cardiology, Dmch Ludhiana. Dr. Parshotam Lal Gautam, Professor & Head, Department of Critical Care Medicine, Dmch Ludhiana.
Institution	Dayanand Medical College & Hospital, Ludhiana
University	Baba Farid University of Health Sciences, Faridkot

Introduction: QTc interval is affected by many factors and prolongation of same may have prognostic significance. A significant number of patients admitted in ICUs are acutely ill, have multiple comorbidities and are on medications, all of these factors might affect QTc interval and prognosis.

Aim of Study: To define prevalence, clinical profile and in hospital outcomes of patients with prolonged QTc.

Materials & Methods: Single-center, prospective, observational study will be carried out on ICU patients with different illnesses. Prolonged QTc will be defined as a QTc of ≥ 450 ms in men and ≥460 ms in women.

Clinical Significance: Little is known about the prevalence of QTc prolongation in nonselected ICU patients having a convergence of many potentially QTc prolonging medical conditions, electrolyte abnormalities, and medications. This study will help to find out the prevalence of prolonged QTc interval in ICU patients, factors predisposing it and prognostic significance in terms of duration of hospital stay, occurrence of ventricular tachycardia and hospital mortality.

Keywords: Electrocardiography, Torsades, Ventricular tachycardia, ICU, Prolonged QTc

(Signature)	(Signature)	(Signature)	(Signature)	(Signature)
Candidate	Co-Supervisor	Co-Supervisor	Supervisor	Principal

CERTIFICATE OF FACILITIES AVAILABLE

This is to certify that the facilities for work on the subject of thesis titled **"PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc"** exist in the Department of Cardiology, DMC&H, and Ludhiana and will be provided to the candidate. We will see that the data being included in the thesis is genuine and is collected by the candidate himself under our supervision and guidance.

Supervisor

Dr. Naved Aslam
Professor
Department of Cardiology
DMCH, Ludhiana

Co-Supervisors

Dr. Abhishek Goyal
Associate Professor
Department of Cardiology
DMCH,Ludhiana

Dr. Parshotam Lal Gautam
Professor
Department of Critical
Care medicine
DMCH,Ludhiana

Head of the Department

Dr. Gurpreet Singh Wander
Professor & Head
Department of Cardiology
DMCH, Ludhiana

Place : _____

Date : _____

APPROVAL PROFORMA
BY RESEARCH & ETHICAL COMMITTEE
DAYANAND MEDICAL COLLEGE & HOSPITAL, LUDHIANA

Name of candidate	DR. KESHAV SACHDEVA
Department	CARDIOLOGY
Topic of Thesis	PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc
Likely date of appearing in PG examination	May / June 2024
Date of enrollment	31st April, 2022
Name of Head of Department	DR. GURPREET SINGH WANDER
1) Supervisor **2) Co-Supervisors**	DR. NAVED ASLAM DR. ABHISHEK GOYAL DR. PARSHOTAM LAL GAUTAM
Signature of Members of Research Committee with Stamp	**Signature of Members of Ethics Committee with Stamp**
Dr. Harpreet Kaur (Professor & Head, Pathology)	Mr. R K Sharma (Legal Expert)
Dr. Jaspal Singh (Professor & Head, Surgery)	Dr. Ramit Mahajan (Associate Professor, Gastroenterology)
Dr. Dinesh Gupta (Professor & Head, Medicine)	Dr. Anu Sharma (Professor, Anatomy)
Dr. Sandeep Kaushal (Dean Academics & Professor & Head, Pharmacology)	Dr. Sandeep Kaushal (Dean Academics & Professor & Head, Pharmacology)
Dr. Gurpreet S Wander (Vice Principal)	Dr. Gurpreet S Wander (Vice Principal & Professor & Head, Cardiology)
	Dr. Gagandeep Singh (Secretary, Ethics Committee Professor & Head, Neurology)

Approved: Yes / No

Dr. Sandeep Puri
Chairperson
Research Committee

Chairperson
Research Committee

Approved: Yes / No

Prof. Arvind Malhotra
Chairperson
Ethics Committee

Chairperson
Ethics Committee

BABA FARID UNIVERSITY OF HEALTH SCIENCES, FARIDKOT

PROFORMA FOR REGISTRATION OF SUBJECT FOR DISSERTATION

1	NAME OF THE CANDIDATE AND ADDRESS	DR. KESHAV SACHDEVA R/O SACHDEVA HOSPITAL, WOOL MARKET, FAZILKA, 152123
2	NAME OF THE INSTITUTE	DAYANAND MEDICAL COLLEGE AND HOSPITAL LUDHIANA
3	COURSE OF STUDY AND SUBJECT	DM CARDIOLOGY
4	DATE OF ADMISSION OF COURSE	31/04/2022
5	TITLE OF THE TOPIC	PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc

6. BRIEF RESUME OF THE INTENDED WORK

6.1 NEED FOR THE STUDY

QTc interval on electrocardiography (ECG), is calculated from the beginning of Q wave to end of T wave. It is the measure of the duration of both cardiac depolarization and repolarization. Prolonged QTc interval can be a result of either a genetic or acquired conditions.[1-5] Many structural and functional factors affect myocardial repolarization resulting in QTc prolongation. There are many known demographic variables, comorbidities and biochemical abnormalities which have been found to be associated with prolonged QTc interval.[1-3]

Acquired causes include electrolyte abnormalities, sinus node dysfunction, high-grade atrioventricular block, myocardial ischemia and injury, medication use, etc. However, use of specific drugs is one of the important causes of acquired QTc prolongation. Various commonly prescribed cardiac and noncardiac medications can cause QTc prolongation.[4-5] QTc prolongation has been associated with much increased risk torsades de pointes (TdP), a potentially life-threatening cardiac arrhythmia and overall increased hospital mortality.[1-5]

There are a few studies carried out in the past to look for the factors associated with a prolonged QTc interval essentially in populations of patients with selected disease conditions.[6-12] However, there is scarce literature about the prevalence and determinants of QTc interval prolongation in patients admitted to the ICU. And the various available studies in ICU patients have shown very variable values of prevalences of LQTS of 24%[13], 46.6%[14], 27.9%[15], 39%[16], 61%[17] and 52%.[18] The prevalence of QTc prolongation is likely to be higher in patients admitted in this area because acutely ill patients often have more than one risk factors and receive multiple drug treatments.

QTc prolongation also has prognostic significance, and it is frequently overlooked parameter in ECG. This study is planned to find out the

prevalence, and prognostic significance of QTc prolongation in patients admitted to the ICU of a tertiary care hospital.

Apart from prevalence and prognostic significance, factors causing QTc prolongation will also be explored as by avoiding or correcting these factors, life-threatening arrhythmia might be prevented.

6.2 REVIEW OF LITERATURE

Critically ill patients are at increased risk of developing LQTS because they frequently receive pro-arrhythmic drugs, in addition to commonly having other risk factors for TdP, such as renal or hepatic impairment, electrolyte disturbances and bradyarrhythmias.[19]

A Scientific Statement from the American Heart Association (AHA) recommends that hospital patients should receive QT interval monitoring if certain conditions are present.[20] These AHA indications for QT interval monitoring include: patients who are receiving or have overdosed on a QT-prolonging drug, patients with cardiac rhythm disturbances causing severe bradycardia or long pauses, and patients with hypokalemia or hypomagnesemia. In a study conducted in an Intensive Care Unit (ICU), approximately 69% of critically ill patients had at least one of the three American Heart Association criteria for QT-interval monitoring.[13]

There are a few studies carried out in the past to look for the factors associated with a prolonged QTc interval essentially in populations of patients with selected disease conditions.

A study by Chugh SS et al.[6] showed that QTc prolongation is associated with five folds increased odds of sudden cardiac death (SCD). That QTc prolongation may be due to diabetes, drugs, or idiopathic.

A study by Cichoż-Lach H et al.[8] showed the association of prolonged QTc with live cirrhosis. However, prolonged QT and QTc intervals were not related to the severity of cirrhosis or to the presence of ascites. However another study by Day CP et al.[9] showed that QT interval prolongation occurs in some patients with alcoholic liver disease and is associated with an adverse prognosis, especially sudden cardiac death and they recommended that QT measurement should be included in the initial assessment of alcoholic patients, particularly in those considered for liver transplantation.

A study by Voiculescu M et al.[10] showed that despite the high incidence of QT prolongation in CRF patients (41.2%), short-term consequences are not as severe as those in cardiac patients. This was possibly explained by the different pathogenic mechanisms of arrhythmia in CRF when electrolytic disorders are the main cause for the development of arrhythmia.

A study by Kolo PM et al.[11] showed that QTc prolongation is a predictor of mortality in CHF and may be an important adjunct in risk stratification of patients with heart failure.

However, there is scarce literature about the prevalence and determinants of QTc interval prolongation in patients admitted to the ICU and the relation of QTc with multiple factors simultaneously have been very less studied.

Birda CL et al.[21] studied prevalence and prognostic significance of prolonged QTc interval in emergency medical patients and concluded that high prevalence of prolonged QTc interval was found in Indian emergency medical patients. However there was no difference in hospital mortality, though on subgroup analysis, patients with markedly prolonged QTc interval had significantly more episodes of in-hospital ventricular tachycardia and hospital mortality.

A study by Fernandes FM et al.[22] done in critically ill ICU patients showed that LQTS prevalence was 27.9 % and patients with mean age 61.3 years, myocardial infarction and bradycardia were the significant contributors.

George TK et al.[23] studied the association between a prolonged QTc interval and outcomes in patients in a medical Intensive Care Unit and concluded that prevalence of prolonged QTc was 30% and a large proportion 35 % was attributable to drugs. And patients with QTc prolongation had higher odds ratio for adverse outcomes.

6.3 AIM AND OBJECTIVE OF THE STUDY

1. To describe the clinical profile of patients with prolonged QTc in ICU settings.
2. To investigate the prevalence of LQTS in ICU patients.
3. To investigate the risk factors of LQTS in ICU patients.
4. To observe and assess predictors of the clinical outcomes during ICU stay of patients with prolonged QTc.

7. MATERIALS AND METHODS

Single-center, prospective, observational study carried out on patients with different illnesses recruited from medical, surgical and cardiac ICUs in Dayanand Medical College and Hospital, and Hero DMC Heart Institute, a tertiary care hospital in Ludhiana, Punjab.

7.1 SOURCE OF DATA

The study population will consist of consecutive patients meeting the inclusion criteria from medical, surgical and cardiac ICUs .

7.2 METHOD OF COLLECTION OF DATA

After admission to the ICU, detailed history of each patient including demographic data, clinical history and physical examination findings, past history of QTc interval prolongation, torsade de pointes (TdP), or sudden cardiac arrest, underlying and/or concomitant diseases, detailed drug history, main diagnostic categories leading to ICU admission will be recorded in a predesigned proforma. APACHE II score will be calculated for every patient. Each patient will be evaluated with chest X-ray, 12 lead ECG, arterial blood gas, hemogram, random blood sugar, serum electrolytes (potassium, sodium, calcium, magnesium, phosphate), renal function test (blood urea/creatinine), and liver function test. Prescription of medications associated with QTc interval prolongation during ICU admission will be recorded. Investigator will manually measure the RR and QT intervals from the 12-lead ECG done within 24 hour of ICU admission. Lead II or V5 will be used for QT measurement as it provides the closest approximation of the longest QT interval. Bazett's formula ($QTc = QT/\sqrt{RR}$) will be applied for correction of QT intervals for heart rate.[14] Even though there are many formulas for QT interval correction, we specifically have chosen this formula as most of the studies have used this formula. The U wave will not be included if it is distinct from and smaller than 50 percent of the T wave. Prolonged QTc will be defined as a QTc of ≥ 450 ms in men and ≥460 ms in women based on recommendations

from the American Heart Association and the American College of Cardiology Foundation. QTc interval of above 500 ms in either sex will be considered as markedly prolonged as this has been associated with significantly higher risk for torsade de pointes. At the end of the study, prevalence, clinical profile and in hospital outcomes of patients with prolonged QTc will be defined.

INCLUSION CRITERIA:

1. All ICU patients above 18 years of age admitted in medical, surgical and cardiac ICUs during a period of 6 months.

EXCLUSION CRITERIA:

1. Patients with tachyarrhythmias like permanent atrial fibrillation, QRS complex wide than >120 ms, or baseline ECG with unidentifiable T waves.

DURATION OF STUDY/NO. OF CASES:

6 Months. (January 2023 to June 2023.) ICU patients above 18 years of age admitted in medical, surgical and cardiac ICUs during a period of 6 months

OUTCOME

This study will help to find out the prevalence of prolonged QTc interval in ICU patients, factors predisposing it and prognostic significance in terms of duration of ICU stay, occurrence of ventricular tachycardia and hospital mortality.

STATISTICAL ANALYSIS: Data will be maintained on Microsoft excel sheet, and descriptive statistics will be used. The measurable data will be subjected to one sample Kolmogrov–Smirnov test for normality of the data. The measurement of central tendency and dispersion of data will be calculated by using mean or median and standard deviation or interquartile range (IQR) depending on the normality of data. Normally

distributed data will be presented by means and standard deviation whereas skewed data will be presented by median and IQR. Qualitative variables will be presented as number and percentage. Prevalence of prolonged QTc among patients with different illnesses will be calculated. Differences in various parameters between study subjects with or without QTc interval prolongation will be done using Student' s *t*-test for continuous variables with normal distribution and for nonnormally distributed, Mann–Whitney U-test will be used. Categorical variables will be compared using Chi-square test (or Fisher's exact tests). The values of $P < 0.05$ will be considered statistically significant.

7.3 DOES THE STUDY REQUIRE ANY INVESTIGATIONS OR INTERVENTIONS TO BE CONDUCTED ON PATIENTS OR OTHER HUMANS OR ANIMALS? IF SO, PLEASE DESCRIBE BRIEFLY.

No

7.4 HAS ETHICAL CLEARANCE BEEN OBTAINED FROM YOUR INSTITUTION IN CASE OF 7.3?

Yes, Attached herewith.

8. LIST OF REFERENCES

1. Khan IA. Long QT syndrome: Diagnosis and management. Am Heart J. 2002;143:7–14.
2. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115:2025–32.
3. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: A comprehensive review. Scientific World Journal. 2012;2012:212178
4. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: Recent advances. Curr Opin Cardiol. 2007;22:39–3
5. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–72.
6. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: The Oregon sudden unexpected death study. Circulation. 2009;119: 663–70.
7. Fukui S, Katoh H, Tsuzuki N, Ishihara S, Otani N, Ooigawa H, et al. Multivariate analysis of risk factors for QT prolongation following subarachnoid hemorrhage. Crit Care. 2003;7:R7–12.
8. Cichoż-Lach H, Tomaszewski M, Kowalik A, Lis E, Tomaszewski A, Lach T, et al. QT interval prolongation and QRS voltage reduction in patients with liver cirrhosis. Adv Clin Exp Med. 2015;24:615–22
9. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet. 1993;341:1423–8.
10. Voiculescu M, Ionescu C, Ismail G. Frequency and prognostic significance of QT prolongation in chronic renal failure patients. Rom J Intern Med. 2006;44:407–17
11. Kolo PM, Opadijo OG, Omotoso AB, Katibi IA, Balogun MO, Araoye MA. Prognostic significance of QT interval prolongation

in adult Nigerian with congestive heart failure. Niger J Clin Pract. 2008;11:336–41.

12. Purushothaman S, Salmani D, Prarthana KG, Bandelkar SM, Varghese S. Study of ECG changes and its relation to mortality in cases of cerebrovascular accidents. J Nat Sci Biol Med. 2014;5:434–6.
13. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Drew BJ. How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. J. Electrocardiol. 2010;43:572.
14. Ng TM, Olsen KM, McCartan MA, Speidel KM, Miller MA, Levit AV. Pharmacologic predictors of qtc prolongation and proarrhythmia in the adult medical Intensive Care Unit. Crit Care Med. 2004;32:A40.
15. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf. 2012;35:459–70.
16. Ng TM, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, et al. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother. 2008;42:475–82.
17. Ng TM, Olsen KM, McCartan MA, Puumala SE, Speidel KM, Miller MA, et al. Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors. J Pharm Pract. 2010;23:19–24.
18. Hoogstraaten E, Rijkenberg S, van der Voort PH. Corrected QT-interval prolongation and variability in intensive care patients. J Crit Care Med. 2014;29:835–9.
19. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality:

Results of the QT in Practice (QTIP) Study*. Crit Care Med. 2012;40:394–9.

20. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, et al. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation. 2004;110:2721-46.
21. Birda CL, Kumar S, Bhalla A, Sharma N, Kumari S. Prevalence and prognostic significance of prolonged QTc interval in emergency medical patients: A prospective observational study. Int J Crit Illn Inj Sci. 2018;8:28-35.
22. Fernandes FM, Silva EP, Martins RR, Oliveira AG. QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS One. 2018;13:e0199028.
23. George TK, Chase D, Peter JV, Satyendra S, Kavitha R, George LR, et al. Association between a prolonged corrected QT interval and outcomes in patients in a medical Intensive Care Unit. Indian J Crit Care Med. 2015;19:326-32.

PROFORMA

Serial no: Date:

1. MRD number
2. Name
3. Age/sex
4. Occupation
5. Religion
6. BP/PR
7. Religion
8. Marital status & consanguinity
9. Phone no.
10. Date of admission
11. Date of discharge
12. Temperature
13. APACHE II score _____
14. Diagnosis _____

_____

15. Co-morbidities:
    a. Hypertension
    b. Endocrine:
        i. Hypothyroidism
        ii. Hyperthyroidism
        iii. Diabetes mellitus type I

Signature of Candidate Signature of Supervisor

iv. Diabetes mellitus type II

v. Other

c. Neurologic

i. Hemorrhagic CVA

ii. Ischemic CVA

iii. Seizures

iv. Spinal cord involvement

v. Other

d. Pulmonary

i. Pneumonia

ii. COPD

iii. Pleural effusion

iv. Pneumothorax

v. Other

e. Cardiac

i. STEMI

ii. NSTEMI

iii. Unstable angina

Signature of Candidate

Signature of Supervisor

iv. Stable angina

v. Congenital heart disease

vi. Heart failure

vii. Arrythmia intermittent/sustained/no

1. AF
2. AFl
3. PSVT
4. VT
5. TDP
6. VPCs
7. Other

viii. Other

f. GI

i. CLD

ii. Hepatitis

iii. Acute liver failure

iv. Pancreatitis

v. SAIO

Signature of Candidate

Signature of Supervisor

vi. Cholecystitis

vii. Other

g. Nephro

i. AKI

ii. CKD

iii. Nephrotic syndrome

iv. Nephritic syndrome

v. Obstructive uropathy

vi. UTI

vii. Other

h. Sepsis

i. Infections

i. TB

ii. HIV

iii. Dengue

iv. Enteric

v. Malaria

vi. Leptospira

Signature of Candidate

Signature of Supervisor

vii. Scrub typhus

viii. COVID-19

ix. H1N1

x. Other

j. Malignancy

k. Surgical illness

i. GI surgery

ii. Orthopedic surgery

iii. Neurosurgery

iv. Urosurgery

v. OBG surgery

vi. ENT surgery

vii. Plastic surgery

viii. Trauma

ix. Other

l. Shock

16. History suggesting LQTS

a. History of documented VT yes/no

Signature of Candidate

Signature of Supervisor

b. Syncope yes/no

If yes- no. of episodes ____

precipitating factor_____

c. Seizure yes/no Type_____

d. Sudden cardiac arrest yes/no

If yes- Precipitating factor:

Exercise yes/no

Swimming yes/no

Sleep yes/no

Emotions yes/no

Auditory stimulus yes/no

e. Unexplained motor vehicle accidents yes/no

f. Unexplained drowning yes/no

g. Hearing loss yes/no

h. Periodic paralysis yes/no

i. Skeletal dysmorphism yes/no

j. Cognitive/behavioural issues yes/no

Signature of Candidate

Signature of Supervisor

k. Immune dysfunction yes/no

l. Autism yes/no

m. Others _____

17.Family history:

a. Premature sudden death in 1st degree relatives yes/no

(less than 40 year of age & autopsy negative)

b. Syncope yes/no

c. Consanguinity yes/no

d. Drowning yes/no

e. Death while driving yes/no

f. Seizures yes/no

g. Congenital deafness yes/no

h. Known long QT mutation yes/no

If yes- Type of mutation _____

Location of mutation _____

i. Relation with affected person _____

Signature of Candidate

Signature of Supervisor

18. Drugs with risk of QTc prolongation (with dose):

a. Anti-arrhythmics

i. Amiodarone yes/no

ii. Others _____

b. Antimicrobials:

i. Macrolides yes/no _____

ii. Fluoroquinolones yes/no _____

iii. Trimethoprim-sulphamethoxazole yes/no

iv. Clindamyicin yes/no

v. ATT yes/no _____

vi. Metronidazole yes/no

vii. Anti-malarial yes/no _____

viii. Antifungals yes/no _____

ix. Antivirals yes/no _____

c. Antipsychotics

i. Haloperidol yes/no

ii. Olanzapine yes/no

Signature of Candidate Signature of Supervisor

iii. Quetiapine yes/no

iv. Risperidone yes/no

v. Others yes/no _____

d. Antidepressants

i. Escitalopram yes/no

ii. Fluoxetine yes/no

iii. Sertraline yes/no

iv. Mirtazapine yes/no

v. Imipramine yes/no

vi. Others yes/no _____

e. Antihistamines

i. Diphenhydramine yes/no

ii. Hydroxyzine yes/no

iii. Other yes/no _____

f. Analgesics, anesthetic and sedative

i. Opioids yes/no _____

ii. Propofol yes/no

iii. Benzodiazepines yes/no _____

Signature of Candidate

Signature of Supervisor

g. Anti-neoplastic yes/no _____

h. Bronchodilators

i. Terbutaline yes/no

ii. Formetrol yes/no

iii. Indacaterol yes/no

iv. Salmetrol yes/no

v. Others yes/no _____

i. Diuretics

i. Furosemide yes/no

ii. Torsemide yes/no

iii. Metolazone yes/no

iv. Spironolactone yes/no

v. Others yes/no _____

j. GI drugs

i. Loperamide yes/no

ii. Ondansetron yes/no

iii. Granisetron yes/no

iv. Palonosetron yes/no

Signature of Candidate

Signature of Supervisor

x

v. Domperidone yes/no

vi. Metoclopramide yes/no

vii. Proton pump inhibitor yes/no

k. Drugs for BPH

i. Tamsulosin yes/no

ii. Alfuzosin yes/no

l. Cholinergic antagonists yes/no _____

m. Citrate (massive blood transfusion) yes/no

n. Cocaine yes/no

o. Ranolazine yes/no

p. Inotropes

i. Nor epinephrine yes/no

ii. Epinephrine yes/no

iii. Dopamine yes/no

iv. Dobutamine yes/no

v. Vasopressin yes/no

vi. Others yes/no _____

q. Others yes/no _____

Signature of Candidate

Signature of Supervisor

19. Other conditions predisposing to prolonged QTc

a. Electrolyte abnormaliy

i. Hypokalemia yes/no _____

ii. Hypomagnesemia yes/no _____

iii. Hypocalcemia yes/no _____

b. Cardiac conditions

i. Myocardial ischemia yes/no _____

ii. Myocarditis yes/no

iii. Marked bradycardia yes/no

iv. Stress cardiomyopathy yes/no

c. Endocrine disorders

i. Hypothyroidism yes/no

ii. Hyperparathyroidism yes/no

iii. Pheochromocytoma yes/no

iv. Hyperaldosteronism yes/no

d. Intracranial disorders

i. Subarachnoid hemorrhage yes/no

Signature of Candidate

Signature of Supervisor

ii. Thalamic hematoma yes/no

iii. Cerebrovascular accident yes/no _____

iv. Encephalitis yes/no

v. Head injury yes/no

e. Nutritional disorders

i. Anorexia nervosa yes/no

ii. Starvation yes/no

iii. Liquid protein diet yes/no

iv. H/o GI surgery yes/no _____

v. Celiac disease yes/no

f. Hypothermia yes/no

g. Others yes/no _____

20. Electrocardiographic features (at presentation):

a. Rate _____

b. Rhythm

i. Sinus rhythm yes/no

Signature of Candidate

Signature of Supervisor

ii. Atrial fibrillation yes/no

iii. Atrial flutter yes/no

iv. Ventricular tachycardia yes/no

v. PSVT yes/no

vi. Other _____

c. QRS duration _____

d. QT_C interval (Bazett) _____

e. T wave morphology _____

f. T wave alternans yes/no

g. U waves yes/no

h. AV block yes/no _____

i. ST elevation yes/no _____

j. ST depression yes/no _____

k. Torsades de pointes yes/no

l. LVH yes/no

m. RVH yes/no

n. Others _____

Signature of Candidate Signature of Supervisor

21.Investigations

a. RBS

b. CBC: Hb= TLC= Plt=

c. ABG: pH= pCO2= pO2= HCO3= SO2= Lac=

d. K= Ca= Mg= PO4= Na=

e. Deranged RFT yes/no

Urea= Cr=

f. Deranged LFT yes/no

Bil= SGOT= SGPT= ALP= TSP= Alb=

g. Blood culture done yes/no

If yes positive/negative _____

h. LVEF _____

i. Others yes/no _____

22. Specific treatment given for prolonged QTc yes/no

a. Treatment of reversible cause yes/no _____

b. Beta-blocker yes/no _____

Signature of Candidate

Signature of Supervisor

Dose=

c. IV MgSO4 yes/no Dose=

d. IV Isoproterenol yes/no Dose=

e. IV xylocaine yes/no Dose=

f. Mexiletine yes/no Dose=

g. Left cardiac sympathetic denervation yes/no

h. Overdrive pacing yes/no

i. AICD yes/no

If yes- No. appropriate shocks _____

No. of inappropriate shocks _____

j. Others yes/no _____

23. Outcomes of treatment specific to prolonged QTc:

a. Benefit achieved yes/no

b. QTc shortened yes/no By _____

c. Syncope controlled yes/no

Signature of Candidate

Signature of Supervisor

d. Seizures controlled yes/no

e. Arrythmia controlled yes/no

f. Others _____

24.Overall outcomes:

a. Duration of ICU stay _____ days

b. No. of VT episodes _____

c. QTc unchanged yes/no

d. QTc shortened yes/no By _____

e. QTc prolonged yes/no By _____

f. Discharged yes/no

g. Death yes/no

25.Treatment complication (if any):

Signature of Candidate

Signature of Supervisor

CERTIFICATE OF DEPARTMENTAL CLEARANCE

This is to certify that the plan of thesis entitled **"PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc"** has been discussed in the Department of Cardiology and approved by whole of the faculty of the department. The plan writing is satisfactory.

Supervisor

Dr. Naved Aslam
Professor
Department of Cardiology
DMCH, Ludhiana

Co-Supervisors

Dr. Abhishek Goyal
Associate Professor
Department of Cardiology
DMCH, Ludhiana

Dr. Parshotam Lal Gautam
Professor & Head
Department of Critical
Care Medicine
Dmch Ludhiana.

Head of the Department

Dr. Gurpreet Singh Wander
Professor & Head
Department of Cardiology
DMCH, Ludhiana

DAYANAND MEDICAL COLLEGE & HOSPITAL

LUDHIANA

Ref. No: DMCH/ Dated :

TO WHOM IT MAY CONCERN

Certified that the study entitled "**PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc**" involves only such investigations and / or treatment, which are relevant in the management of patients and has no extra cost implications to the patient.

Name of candidate: Dr. Keshav Sachdeva

Supervisor: Dr. Naved Aslam

Co-Supervisors: Dr. Abhishek Goyal

Dr. Parshotam Lal Gautam

Signature of candidate

Signature of Supervisor

DAYANAND MEDICAL COLLEGE & HOSPITAL,
LUDHIANA

Ref. No. DMCH/ Dated:

TO WHOM IT MAY CONCERN

I shall carry out the study **"PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc"** meticulously and shall maintain the records for 5 years after the submission of thesis and present them to any competent authority as and when required. The following documents will be preserved:

1. List of enrolled patients with identification details
2. Consent forms of all the enrolled patients
3. Proforma of each patient with verifiable details, individually signed by supervisor.

Dr. Keshav Sachdeva
D.M Resident
Dept. of Cardiology
DMC & Hospital, Ludhiana

CERTIFICATE

We hereby certify that the informed patient consent form and its translation and back translation to Hindi and Punjabi are accurate to the best of our knowledge and satisfaction.

Supervisor

Dr. Naved Aslam
Professor
Department of Cardiology
DMCH, Ludhiana

Co-Supervisors

Dr. Abhishek Goyal,
Associate Professor
Department of Cardiology
DMCH, Ludhiana

Dr. Parshotam Lal Gautam
Professor & Head
Department of Critical
Care Medicine
DMCH, Ludhiana

Dr. Keshav Sachdeva
D.M Resident
Dept. of Cardiology
DMC & Hospital, Ludhiana

INFORMED PATIENT CONSENT

Date: _____

I.....D/o, W/o, S/o.....
.....am willing to participate in the study **"PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc"** The procedure with its complications has been explained to me in local vernacular language. I have fully understood that no special tests and extra expenditure in any form, merely for the purpose of thesis is being carried out. I am free to opt out the study any time without assigning any reason.

.....
Signature of the Witness

.....
Signature of the patient

Name:

Signature of Candidate

Signature of Supervisor

मरीज अनुमति फार्म

तिथि _____

मैं _____ पत्नी/पुत्र/पुत्री _____

निवासी _____

इस शोधकार्य **"PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc"** में भाग लेने के लिए सहमत हूँ। मैं इस शोधकार्य में भाग लेने के लिए अपनी स्वेच्छा से तैयार हूँ। मैं पुष्टि करता/करती हूँ की यह स्वीकृति देने के लिए मुझे कोई आर्थिक प्रलोभन नहीं दिया गया और न ही दबाव डाला गया है। मुझे इस शोधकार्य का उद्देश्य स्पष्ट कर दिया गया है और मुझे यह विश्वास है की यह विज्ञान और मानवता के लाभ के लिए है। मुझे इस शोधकार्य में होने वाले जोखिम के बारे में समझा दिया गया है और मेरी समझ में यह जोखिम बहुत मामुली है।

मैं इस शोधकार्य में भाग लेने के सम्बन्ध में किसी भी समय अपनी अस्वीकृति व्यक्त कर सकता/सकती हूँ और मेरे अस्वीकृति व्यक्त करने का मेरे इलाज पर कोई प्रभाव नहीं पड़ेगा।

_____ _____

गवाह के हस्ताक्षर रोगी के हस्ताक्षर/अंगूठे का निशान

नाम: नाम:

_____

अन्वेषक के हस्ताक्षर

_____

विद्यार्थी के हस्ताक्षर

ਮਰੀਜ਼ ਰਜ਼ਾਮੰਦੀ ਫਾਰਮ

ਮਿਤੀ_____

ਮੈ_____ਪਤਨੀ/ਪੁੱਤਰ/ਪੁੱਤਰੀ_____

ਵਾਸੀ _____

"PREVELANCE, CLINICAL PROFILE, AND IN-HOSPITAL OUTCOMES IN ICU PATIENTS WITH PROLONGED QTc" ਤੇ ਚਲ ਰਹੀ ਖੋਜ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਲਈ ਰਜ਼ਾਮੰਦ ਹਾਂ। ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਲਈ ਮੈ ਆਪਣੀ ਮਰਜ਼ੀ ਨਾਲ ਤਿਆਰ ਹਾਂ। ਮੈ ਇਹ ਦਸਣਾ ਚਾਹੁੰਦਾ ਹਾਂ/ ਚਾਹੁੰਦੀ ਹਾਂ ਕੇ ਇਹ ਰਜ਼ਾਮੰਦੀ ਦੇਣ ਵਾਸਤੇ ਮੈਨੂ ਕਿਸੇ ਵੀ ਤਰਾਂ ਦਾ ਲੋਭ-ਲਾਲਚ ਨਹੀ ਦਿੱਤਾ ਗਿਆ ਅਤੇ ਨਾ ਹੀ ਕੋਈ ਦਬਾ ਪਾਇਆ ਗਿਆ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਦਾ ਮਨੋਰਥ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ ਅਤੇ ਮੈਨੂ ਇਹ ਭਰੋਸਾ ਦਵਾਇਆ ਗਿਆ ਹੈ ਕੇ ਇਹ ਖੋਜ ਵਿਗਿਆਨ ਅਤੇ ਮਾਨਵਤਾ ਦੀ ਭਲਾਈ ਲਈ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਵਿਚ ਹੋਣ ਵਾਲੇ ਖਤਰੇ ਬਾਰੇ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ ਅਤੇ ਮੈਨੂ ਇਹ ਯਕੀਨ ਹੈ ਕੇ ਇਹ ਖਤਰਾ ਬਹੁਤ ਮਾਮੂਲੀ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਦਾ ਢੰਗ – ਤਰੀਕਾ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ।

ਮੈ ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਬਾਰੇ ਆਪਣੀ ਰਜ਼ਾਮੰਦੀ ਕਿਸੇ ਵੀ ਸਮੇ ਵਾਪਸ ਲੈ ਸਕਦਾ ਹਾਂ/ ਸਕਦੀ ਹਾਂ ਅਤੇ ਮੇਰੀ ਰਜ਼ਾਮੰਦੀ ਵਾਪਸ ਲੈਣ ਦਾ ਮੇਰੇ ਇਲਾਜ ਤੇ ਕੋਈ ਅਸਰ ਨਹੀ ਹੋਵੇਗਾ।

_____
ਗਵਾਹ ਦੇ ਹਸਤਾਖਰ

ਮਿਤੀ_____

ਪਤਾ _____

_____
ਮਰੀਜ਼ ਦੇ ਹਸਤਾਖਰ

ਮਿਤੀ_____

ਪਤਾ _____

_____
ਨਿਰੀਖਕ ਦੇ ਹਸਤਾਖਰ

_____
ਸਿਖਿਆਰਥੀ ਦੇ ਹਸਤਾਖਰ